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Abstract 
 
Background: Healthcare associated infections (HCAI) pose a significant burden to health systems both 
within the UK and internationally. Surveillance is an essential component to any infection control 
programme, however traditional surveillance systems are time consuming and costly. Large amounts of 
electronic routine data are collected within the English NHS, yet these are not currently exploited for 
HCAI surveillance.  
Aim: To investigate whether routinely collected electronic hospital data can be exploited for HCAI 
surveillance within the NHS.  
Methods: This thesis made use of local linked electronic health data from Imperial College Healthcare 
NHS Trust, including information on patient admissions, discharges, diagnoses, procedures, laboratory 
tests, diagnostic imaging requests and traditional infection surveillance data.  To establish the evidence 
base on surveillance and risks of HCAI, two literature reviews were carried out. Based on these, three 
types of innovative surveillance tools were generated and assessed for their utility and applicability.  
Results: The key findings were firstly the emerging importance of automated and syndromic surveillance 
in infection surveillance, but the lack of investigation and application of these tools within the NHS. 
Syndromic surveillance of surgical site infections was successful in coronary artery bypass graft patients; 
however it was an inappropriate methodology for caesarean section patients. Automated case detection 
of healthcare associated urinary tract infections, based on electronic microbiology data, demonstrated 
similar rates of infection to those recorded during a point prevalence survey. Routine administrative 
data demonstrated mixed utility in the creation of simplified risk scores or infection, with poorly 
performing risk models of surgical site infections but reasonable model fit for HCA UTI. 
Conclusion: Whilst in principle routine administrative data can be used to generate novel surveillance 
tools for healthcare associated infections; in reality it is not yet practical within the IT infrastructure of 
the NHS.  
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Glossary of Terms 
 
Term Definition 
Syndromic Surveillance The detection, monitoring and follow up of infectious events based on a set of proxy indicators, derived from existing electronic data 
Syndromic algorithm A set of biological markers and proxy indicators of infection used to define an infectious event 
Traditional Surveillance All those data sources actively collected for the specific purpose of surveillance 
HPA SSI Surveillance data The data collected as part of the voluntary surgical site infection surveillance scheme run by the Health Protection Agency 
Cardiac Registry data The data collected by the Cardiothoracic surgeons and submitted to the national voluntary cardiac registry 
Caesarean surveillance data The data collected as part of an intervention study to reduce the incidence of surgical site infections 
Laboratory data The data from all of the laboratory departments 
Radiology data The data from all diagnostic imaging investigations 
Patient Administration 
System (PAS) data 
The data from the large administrative database, which goes on to form Hospital 
Episode Statistics data, containing information on admissions, diagnoses and 
discharges 
Patients Individuals admitted to Imperial College Healthcare NHS Trust 
Episode Period of care under a consultant (i.e. several episodes can make up one hospital admission) 
Spell Period in hospital from admission to discharge (i.e. one spell can be made up of several episodes) 
Sensitivity The proportion of true positives (i.e. the proportion of patients with an SSI that had a relevant code) 
Specificity The proportion of true negatives (i.e. the proportion of patients without an SSI that had no relevant codes) 
Positive Predictive Value The proportion of correctly identified positives (i.e. the proportion of patients with a relevant code to have an SSI) 
Negative Predictive Value The proportion of correctly identified negatives (i.e. the proportion of patients without a relevant code that do not have an SSI) 
Significant A p-value of >0.05 at a univariate analysis level 
Independent A p-value of >0.05 at a multivariate analysis level 
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Chapter 1: Introduction, Hypothesis, Aims, Objectives and Overview 
 
1.0 What are Healthcare Associated Infections? 
 
The topic of healthcare associated infections is vast, encompassing fields of study ranging from business 
and management, behaviour and innovation, microbiology and genetics to epidemiology and statistics. 
According to the US Centre for Disease Control (CDC) definition, healthcare associated infections (HCAI) 
are:  
 
“infections that patients acquire during the course of receiving treatment for other conditions within a 
healthcare setting”(1) 
 
This is the definition I have adopted for healthcare associated infections throughout the thesis. A key 
point to highlight in this definition of HCAI is that they are not just infections related to hospitals, but 
they are associated with any form of healthcare. This includes for example, antibiotic prescription, or 
presence of urinary catheters in nursing homes. Therefore defining infections as ‘healthcare associated’ 
is not always clear as the lines that distinguish between community and healthcare are blurred.   
Standard definitions for HCAI use a time element to classify infections as healthcare associated versus 
community acquired. If a patient has been in hospital for over 72 hours prior to their diagnosis, the 
infection is considered to be healthcare associated. Patients re-admitted to hospital within specified 
time periods of a previous hospital admission are also classified as healthcare associated, such as 30 
days for a Clostridium difficile infection (2). These standard thresholds and conditions were used 
throughout this thesis, although there is some discussion as to their appropriateness in subsequent 
chapters.  
Healthcare associated infections are categorised into conditions, however whilst certain infections form 
the majority of the burden, almost any infectious disease can be healthcare associated.  The most 
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common categories of HCAI are: urinary tract infections (UTI); surgical site infections (SSI); bloodstream 
infections (BSI); pneumonia as either hospital-acquired (HAP) or ventilator associated (VAP); skin and 
soft tissue infections (SST) and Clostridium difficile. This PhD focuses on both urinary tract infections and 
surgical site infections, coinciding with objectives set by the Health Protection Agency (HPA) for HCAI 
surveillance (3).  
 
1.0.1 Surgical Site Infections 
 
Surgical site infections (SSI) are those infections which occur as a result of surgery, at the site in which 
the operation occurred. SSI range greatly in their severity, with three categories of infection: superficial 
(or incisional), deep and organ space infections (Figure 1.0).  
 
Figure 1.0: Drawing demonstrating the classifications of SSI (4) 
 
 
All surgical procedures can result in the patient developing a surgical site infection; however surveillance 
of these infections is not universal across operation types and different surgeries carry varying levels of 
risk.  
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Currently the definitions used in the UK for SSI are based on those established by the CDC in the early 
1990’s (4). According to these definitions an SSI can be diagnosed using several criteria, from physical 
symptomology such as redness and swelling of the wound site, clinical judgement, and antibiotic 
prescription to confirmed microbiology (2). The standard definitions use a 30 day period in which an SSI 
can be diagnosed post-surgery in operations where no implant is inserted, and up to a year for those 
with an implant (2).    
 
1.0.2 Urinary tract Infections 
 
Urinary tract infections (UTI) are all those infections which occur within the urethra, kidneys and bladder 
(5). UTI are very common infections, both within a healthcare setting and in the community, affecting 
both men and women of all ages. Healthcare associated urinary tract infections (HCA UTI) are often 
linked to the patient being catheterised; this is referred to as catheter associated urinary tract infection.  
The definitions for HCA UTI used in the UK are those specified by the European Centre for Disease 
Control (ECDC). There are two types of UTI according to these standardised definitions, a 
microbiologically confirmed infection and those infections which are diagnosed solely on clinical 
symptomology (2). A third category is still present in the CDC definitions, for asymptomatic bacteriuria; 
this means that there are bacteria in the patients urine but they have no clinical symptoms of infection. 
In Europe these patients are no longer recorded as having a urinary tract infection, but instead as having 
contaminated or colonised urine (2).  
 
1.1 How Big is the Burden? 
 
Healthcare associated infections constitute a large burden both in terms of patient mortality and 
morbidity and as a strain on resources. Patients who develop HCAI have longer hospital stays, can 
require more intensive treatment and thus occupy spaces in the intensive care wards and in certain 
cases isolation precautions. The impacts of these infections are not limited to the UK or developed 
countries, but are a global problem.  
25 
 
1.1.1 NHS 
 
The most recent point prevalence survey in England was carried out in 2011. This survey found a 
prevalence of 6.5% in National Health Service (NHS) hospitals for all types of healthcare associated 
infections in the adult population and 5.4% in the paediatric population (3).  
This is a significant reduction to those prevalence figures reported by the three previous point 
prevalence surveys performed in England. In 1980 the prevalence was 9.2% (6), in 1993 it was 9.0% (7) 
and in 2006 it was 8.2% (8). There has been a general downward trend; however the most recent 
reduction of 1.7% is considerably large. The exclusion of asymptomatic bacteriuria may have falsely 
appeared as a reduction in infections and the differing methodologies between surveys may have 
skewed the comparisons. Several infection control programmes implemented by the NHS have been 
hailed as a success, supported by these numbers.  
This report found that surgical patients and those in the Intensive Care Unit (ICU) had the highest 
burden of infections, with rates of 8.0% and 23.4% respectively (3). Half of patients were recorded as 
having some form of invasive device, and the rate of urinary catheterisation has remained constant at 
18.8% from the 2006 survey. Interestingly though, almost half of those patients diagnosed with a UTI did 
not have a urinary catheter (3).  
Consistently across the different prevalence surveys in England, urinary tract infections have declined in 
prevalence, with the 2011 survey attributing 17.2% of HCAI to UTI. Surgical site infections on the other 
hand have increased from one survey to the next, with the most recent survey crediting 15.7% of HCAI 
to SSI (3).    
 
1.1.2 Internationally 
 
Healthcare associated infections are a global problem with the prevalence varying considerably across 
the world. In the developed world, the prevalence ranges from 12% in New Zealand to the very low 
numbers reported by the German national surveillance system of 3.6% (Figure 1.1). The UK places 
averagely in terms of rates of HCAI in developed countries. At the time of writing, the European-wide 
results from the point prevalence survey were not available, so a more recent comparison could not be 
made.   
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Figure 1.1: Rates of HCAI in high income countries, according to a literature review carried out by the WHO (9) 
 
A systematic review by the WHO found that information was lacking from most developing countries on 
the extent of this problem; countries from which data were available demonstrated that rates of HCAI in 
developing countries were generally high (Figure 1.2). 
Figure 1.2: Rates of HCAI in middle and low income countries, according to a literature review carried out by the 
WHO (9) 
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1.2 Why Routine Electronic Health Data? 
 
There is a wealth of data routinely collected and stored within the NHS, covering everything from 
patient admissions and laboratory results to estates and management (10). At present these data are 
not being exploited for healthcare associated infection surveillance, with current surveillance systems 
generally relying on active data collection. These traditional surveillance systems are time consuming, 
and thus costly to carry out meaning surveillance is only carried out on a few limited infections.  
The 2012 report from the Health Protection Agency relating to the European point prevalence survey 
highlighted the following areas as priorities (3): 
 Increased surveillance on surgical site infections, especially in surgical specialties where a high 
prevalence was detected 
 Development of standardised incidence surveillance methodology for pneumonia and catheter-
associated UTI 
Using routine electronic health data to address these priorities in the national healthcare associated 
infection surveillance agenda could demonstrate the potential for this data source to be exploited.  
 
1.3 The Purpose of Surveillance 
 
Surveillance is widely recognised as an essential component of infection prevention and control 
programmes, with several potential aims and intended outcomes. Solberg et al. describe three purposes 
of surveillance and emphasis that their competing purposes can conflict with one another 
(11).Therefore the objective of a surveillance programme needs to be clear in order to apply to correct 
methodology or approach. 
The three purposes are listed as improvement, accountability and research (11). In surveillance for 
improvement, the aim is to assess a process and provide measures of how it performs. This is a small, 
specific activity with the purpose of quality improvement to services. Surveillance for accountability on 
the other hand is results based, with the aim of allowing comparisons between outcomes and 
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monitoring trends over time. Finally, surveillance for research is intented to provide new insight, 
without necessarily any further intention than acquisition of knowledge(11).  
In this thesis the purpose of surveillance was accountability, according to Solberg et al’s categorisations. 
This implies a population level, instead of a patient level, approach was taken throughout the thesis. Key 
characteristics of this form of surveillance programme are large data sets, few outcome measure (i.e. 
infection or no infection) and generally complex processes for collection to ensure data validity (11). The 
final characteristic, of complex data collection, should not apply to systems based on routine electronic 
health data.     
 
1.4 The Study Context 
 
Healthcare associated infections in the UK have become highly visible in the media with the term 
‘superbug’ coined by several newspapers in relation to antibiotic resistant strains of bacteria found in 
hospitals. According to Washer and Joffe, there were 227 articles published by four Sunday papers1 over 
a 10 year period, which contained ‘MRSA’ (Methicillin Resistant Staphylococcus aureus) as their subject 
(12). This press coverage, including the reporting of outbreaks, investigations into the cleanliness of 
hospitals and exposures of poor patient safety practices has meant that HCAI have remained a political 
issue.  
Incorporated into the politics of the NHS is budget. As the current economic climate is enforcing 
austerity measures, the health budget has been protected; however in real terms this still means that 
savings need to be made. As HCAI were estimated to cost the NHS £1 billion every year in 2000 (13), 
reducing these infections in a cheap, effective and efficient manner is highly relevant in the current 
setting.  
This study utilises the hospital data from Imperial College Healthcare NHS Trust (ICHNT), one of the 
largest NHS Trusts in England. The Trust consists of five hospitals (Hammersmith, Charing Cross, St. 
Mary’s, Queen Charlotte’s, and the Western Eye Hospital) and was the first Academic Health Science 
Centre in the UK, aiming to increase partnership between healthcare research and implementation.  
There are 1,540 beds and the Trust treats approximately a million patients every year. The five hospitals 
                                                             
1 The four papers were: The Sunday Times, The Mail on Sunday, Sunday Observer and The Mirror.  
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have not historically been part of the same NHS Trust, with St. Mary’s hospital merging in 2007. This 
setting provides a complex organisational framework in which this study took place.   
ICHNT has not escaped the budget restrictions that have been seen across all public sector services. A 
significant cost saving budget has been implemented, with £45.6 million worth of improvements for 
2011/12 and further financial savings planned for the 2012/13 financial year (14). In this atmosphere of 
cost savings, there have been cuts to personnel and constraints on resources. However, a project 
relating to data warehousing was continued and this will hopefully in turn lead to cost savings.  
 
1.5 Hypothesis 
 
 Existing routine electronic hospital data can be used more effectively to create innovative surveillance 
tools for healthcare associated infections 
 
1.6 Aims and Objectives 
 
The overarching aim of this project was to determine whether routine electronic hospital data could be 
used for the surveillance of healthcare associated infections in an NHS setting.  In order to achieve this 
aim there were several objectives that were addressed throughout the duration of the project. The 
objectives were as follows: 
 To gain an understanding of what is already being used for healthcare associated infection 
surveillance both in the UK and internationally, with a specific interest in routine data and 
syndromic surveillance innovations   
 To apply identified risk factors and markers, taken from both national and international 
research, to local routinely collected hospital data 
 To identify the different data sources that are available for the project and determine their 
relative utility for research and infection surveillance 
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 To apply different surveillance methods, such as syndromic surveillance and risk monitoring, to 
routine electronic hospital data and assess their utility for healthcare associated infections 
within the NHS  
These objectives set out different aspects of study, and a combination of data analysis, literature review 
and statistical modelling was used in order to achieve them all. Each chapter states further specific aims 
and objectives which are relevant for that chapter.  
 
1.7 Thesis Overview 
 
This thesis consists of eight subsequent chapters. Each chapter is structured with a brief introduction, 
followed by an aim, methods, results and discussion section, with the exception of chapters two, four 
and nine.  
The thesis begins with three introductory chapters to set up the context for the study chapters. Chapter 
2 is a literature review on the past, present and future of healthcare associated infection surveillance. 
This provided context and an evidence base for the creation innovative surveillance tools in the analyses 
chapters. Chapter 3 is a systematic literature review on the risks for healthcare associated infections, 
with the creation of a hierarchy of risk and an initial assessment of the routine data for risk modelling. A 
paper relating to the hierarchy of risks of HCA UTI has been published in the Journal of Hospital Infection 
[Appendix 1] and this provided the evidence base for chapter 8. Chapter 4 presents the databases which 
were available for the project, highlighting the strengths and weaknesses of these different resources. 
This chapter serves as an introduction to the study chapters, putting the analyses into perspective.  A 
paper relating to the utility of data linkage for hospital epidemiology has been published in the Journal 
of Hospital Infection [Appendix 2].   
In chapters 5 to 8 (the study chapters) I then demonstrated the potential of existing electronic data to 
be used for surveillance in three distinct ways. Chapters 5 and 6 investigated the potential of routine 
data for syndromic surveillance tools of surgical site infections in coronary artery bypass graft (CABG) 
patients and caesarean section patients. A paper investigating the advantages of a streamlined, linked 
surveillance system for SSI following CABG, relating to chapter 5 has been submitted to the British 
Journal of Surgery [Appendix 3]. Chapter 7 assessed the potential for microbiology data to be exploited 
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for automated case detection of urinary tract infections in the general patient population.  Chapter 8 
looked at exploiting routine data for risk modelling and simplified risk scores. Finally, in chapter 9 I 
discuss the various limitations, challenges and insights from my PhD, with recommendations for further 
work and policy implications.    
This project is a unique opportunity as it uses well established theory, existing data sources in the NHS 
and collaboration with Imperial College Healthcare NHS Trust (ICHNT) to innovate methods of infection 
surveillance. Within the UK, this has not been done previously and the investigation of linked 
administrative data for automated surveillance and early alerts has the potential to reduce a serious 
problem within the NHS. 
 
Figure 1.3: PhD ‘road map’ 
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Chapter 2: The Past, Present and Future of Healthcare Associated Infection Surveillance 
 
 
Summary 
 
The first background chapter investigates surveillance of healthcare associated infections, looking at 
both the background and evolution of the current systems in place and emerging methodologies. It 
forms the basis for subsequent chapters, informing the types of surveillance tools that I investigated and 
acting as an evidence base for the utility of surveillance in healthcare associated infection control. The 
key themes of automated electronic surveillance and syndromic surveillance were discussed.  
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2.0 Introduction 
 
In the field of communicable diseases, surveillance has diverse uses and methods to aid in making 
decisions for control (15), from healthcare associated infection control, antibiotic resistance monitoring 
and reporting of notifiable diseases to bioterrorism alerts. As there are such a wide range of applications 
the definition of surveillance is broad, however the US CDC definition was used for this project:  
 
 “the ongoing and systematic collection, analysis, and interpretation of outcome-specific data for use in 
the planning, implementation, and evaluation of public health practice” (16) 
 
In terms of healthcare associated infections specifically, surveillance is the collection of information 
about these infections, the analysis of this data and feedback to the hospital staff and programme 
organizers. The aims of surveillance in general are: to establish valid estimates of incidence; identify 
trends in resistance and emerging pathogens; fast recognition of infections and outbreaks; aid in 
developing more efficient control activities and to assist collaborative research (17, 18). It has also been 
noted that certain factors need to be taken into account when developing surveillance, such as the 
flexibility to adjust to your patient population and taking local objectives into consideration in order to 
optimise the design (19-21).  
According to the World Health Organisation (WHO), surveillance is the highest priority activity for 
infection prevention and control within hospitals in Europe (22), thus establishing the current 
knowledge base in this field was essential for this project. This project focussed on routine 
administrative data and the way in which these can be better used for surveillance, along with 
investigating the application of syndromic surveillance for healthcare associated infections. This chapter 
outlined the evolution of surveillance for healthcare associated infections; described the current 
programmes of surveillance used both nationally and internationally, and looked specifically at examples 
of syndromic surveillance and surgical site infection surveillance. This allowed the current project to be 
put into context within the wider subject area of infection surveillance in HCAIs.  
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2.0.1 Aim and Objectives 
 
The aim of this chapter was to examine HCAI surveillance methods and national policies, both within the 
UK and internationally, and to identify emerging innovations. The objective was to determine what is 
currently used in surveillance, to ascertain what recent developments have been made and place this 
project in the context of the most recent evidence. 
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2.1 Method 
 
In order to address the aim of this chapter I performed a literature review using a structured search with 
the following methodology:  
 Search terms: surveillance, policy, technology and healthcare associated infection(several forms 
of this were used e.g. nosocomial and HCAI) 
 Databases searched: Medline, Web of Science 
 Inclusion: Any articles referring to surveillance methods and technologies in communicable 
diseases (innovations in surveillance did not necessarily need to be related to HCAIs).  
 Exclusion: Not in English; Abstracts only; Descriptive results of surveillance programmes (it was 
the method of surveillance and technologies which were of interest, not results or reports)  
In addition, I searched the websites of important organisations for relevant information, including the 
WHO, CDC, ECDC, HPA and the departments of health for countries that were identified as interesting or 
important in the literature review.   
I carried out a further search of Medline and Web of Science using the terms ‘syndromic surveillance’, 
‘automated surveillance’ and ‘electronic surveillance’ PLUS ‘hospital’ as the original search did not 
return many articles on these topics specifically. This was not a formal literature search as was done 
with the first search, but an ad hoc process, aiming to retrieve examples and not establish a 
comprehensive evidence base. Combinations of these extra terms and ‘surgical site infection’ and 
‘urinary tract infection’ specifically were also carried out.  
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2.2 Results and Discussion 
 
The original search returned 9,555 articles and 130 were eventually included for discussion. Over 2/3 of 
the articles were excluded for irrelevance, as the term surveillance can be related to several fields of 
study (e.g. social politics and engineering). For abstract and full text review, 348 articles were screened 
(Figure 2.0). At this stage most articles that were excluded were based on the descriptive results from 
surveillance programmes, which as stated earlier was not the purpose of this review. The methods for 
these surveillance papers were not screened, as most related to national programmes which I had 
already considered.  
 
 
Figure 2.0: Flow chart of article inclusion 
 
Search results:   9,555
Abstract and full text 
retrieval: 688
Abstract and full text 
review: 348
Total Included: 130 
Exclusion  due to not meeting criteria: 218
Descriptive results: 95
Modelling: 15
Case Definitions: 13
Abstracts: 25
Other: 70
Exclusion due to foreign language: 181 Exclusion due to availability: 159
(most were not found due to 
incomplete/incorrect reference)
Exclusion due to duplication: 2,327 Exclusion due to irrelevance: 6,538
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There were no matching articles returned from the urinary tract infection and surgical site infection 
specific searches. The only article that was retrieved when ‘syndromic surveillance’ and ‘healthcare 
associated infection’ was searched was written by our own research group (Appendix 2 (10)).   
The searches produced a wide variety of articles, based on different aspects of surveillance for 
healthcare associated infections. The results of the review will be presented under different sub 
headings, beginning with the historical context of surveillance, then the current forms of surveillance, 
followed by the specific examples of surgical site infections and electronic, automated and syndromic 
surveillance for infectious diseases. 
 
2.2.1 Historical Context of HCAI Surveillance 
 
The use of surveillance in disease control programmes has been a recommended practice since the late 
1950s (23), with the establishment of control activities encouraged in response to Staphylococcal 
epidemics appearing in hospitals (24). In the late 1960’s, four major benefits were identified as resulting 
from surveillance: pathogen identification; endemic rates of infection determined; epidemic 
identification and the Hawthorne effect2 (25). At this stage the recognition that using a specialist, 
assigned to infection control activities was also appreciated (25, 26), with the role of the ‘infection 
control sister’ adopted in the UK (23).  
By the late 1970’s the American ‘National Nosocomial Infection Surveillance’ (NNIS) programme had 
been established by the CDC (23), and reports on surveillance methods were being published. For 
example, Feldman et al. reported the use of antibiotic prescribing as a surveillance proxy for infection 
(27); the state of Virginia described the effect of education on its recently established state-wide 
surveillance scheme (28) and the ‘Kardex’3 system was evaluated (26). 
However, whilst surveillance programmes were being established, especially in the USA, the true value 
of surveillance had not been quantified and thus reluctance to allocate resources contributed to a slow 
                                                             
2 The Hawthorne effect is the reactionary change in behaviours observed when people are aware they are being 
evaluated or studied. In this case it refers to health care workers practicing better control activities if they are 
aware surveillance is taking place. 
3 The ‘Kardex’ system is based on the nurses’ patient information cards, instead of doing full patient chart reviews.  
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uptake (29). Hence the decision to conduct a national study in the USA into the effect of surveillance on 
rates of healthcare associated infections.  
The ‘Study on the Efficacy of Nosocomial Infection Control’ (SENIC) was a seminal moment in HCAI 
surveillance, as it was the first study to demonstrate that surveillance activities have a direct impact on 
reducing rates of healthcare associated infections. The principle of the study was based on there being 
two types of risks, intrinsic and extrinsic and SENIC was based on surveillance of extrinsic factors (30). 
This study found that hospitals using surveillance could reduce infections by 32% (17). The highest 
reduction was achieved with a full time infection control nurse for every 250 beds, resulting in 38% 
fewer UTIs (31). However, between 1976 and 1983 the number of infections that were prevented out of 
the potential 32%, was only 6% - 9% (17). 
The main conclusions from this study, which have gone on to provide the scientific evidence base for 
many infection control surveillance programmes since, are multiple and include: 
 The cut off of having 250 beds per infection control nurses was confirmed in this study as it was 
compared to 400 bed threshold and found to be more appropriate (32).  
 Hospitals starting with high rates of infections decreased whereas those with low rates to begin 
with demonstrated a tendency to increase (32).  
o This is likely to represent ‘regression to the mean’, so reductions in rates following the 
commencement of surveillance need to be interpreted with caution 
 The four main criteria needed in a surveillance programme are: balance between intensive 
surveillance and background control; IC nurse for every 250 beds; trained member of 
epidemiology staff in every hospital; SSI rates to be fed back to the surgeons (17).  
 Changes in staffing to allow for more dedicated infection control activities led to more infections 
being found (32) 
However, just because the evidence presented by SENIC suggested the potential for great reductions in 
infection rates, this study could not make recommendations on what the most effective programme 
should be (33). It also used targeted patient groups to perform surveillance on, which curiously did not 
include neonates (24), suggesting that this often quoted figure of 32% reduction is not universally 
applicable. After SENIC, the development of surveillance systems had solid scientific backing, however 
reluctance to instigate national policies was fuelled by shortages of infection control nurses, slow 
consensus, lack of technology uptake and considerable costs (34, 35).  
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As national and local programmes were created, case definitions became an important aspect of 
surveillance. The definitions produced by the CDC up to this point were little changed and used by most 
surveillance schemes (36). The stringent criteria of these definitions, the time consuming methods of 
hand written prevalence reports and the non-continuous nature of this traditional surveillance led to the 
development of computer based systems. In the 1980’s articles began appearing, outlining methodology 
and validation of computer or laboratory based systems (37-39).  For example, Courcol et al. developed 
a system that tracked outbreaks in the ICU utilising antibiotic susceptibility data, to produce an 
automated report every third day for the infection control team (39).  
The next steps in the evolution of HCAI surveillance were to address the concerns surrounding the use of 
computer systems, such as the quality and usage of available data (23). Then the development of 
electronic methods and the creation of systems that allow for comparisons between institutions and 
countries. These developments are still underway in infection surveillance, with varying levels of 
successful implementation. 
 
2.2.2 Current Traditional Surveillance of HCAI 
 
Current HCAI Surveillance in the UK 
 
In the UK, surveillance of healthcare associated infections has been carried out on a voluntary basis 
since 1977 (40, 41). Currently the ‘Nosocomial Infection National Surveillance Scheme’ has both 
voluntary and mandatory dimensions. The system used to be paper based, with the results of these 
reports disseminated quarterly; surveillance schemes in England now have web-based reporting and 
publicly available reports (to a Trust level) are on the internet weekly (42). The public dissemination of 
surveillance results has been debated, with questions arising around the benefits and appropriateness 
(43). The UK is one of a limited number of countries that has instigated public reporting, in contrast with 
the German system which keeps institutions individual rates confidential.  
An electronic web-based system for the enhanced mandatory reporting of MRSA and MSSA has been in 
place since 2006 with mandatory reporting initiated in 2001 (40). The method of surveillance at the 
national level in England is based on laboratory reports, with local data feeding into regional centres and 
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then to a national centre. In the voluntary system only clinically significant cases had laboratory reports 
sent, but in the mandatory reporting system it is all microbiologically positive cases (40). Since 1989, all 
reports were required to come with an antimicrobial susceptibility report (41).  A general issue that has 
been noted with the mandatory system, despite its obvious advantages, is that the data do not contain 
demographic or clinical information, restricting the amount of analysis that can be done (41).  
As well as MRSA surveillance, England has mandatory reporting of Clostridium difficile cases and surgical 
site infections following orthopaedic procedures. A study by Morgan et al. presented the results from 
the pilot study of mandatory SSI reporting. It demonstrated that surveillance in orthopaedic surgery can 
be continuous and sustainable, encouraging a national programme and integration within the local 
hospital systems (44). Post-discharge surveillance, which will be discussed in more detail further on, is 
not universal in SSI surveillance and has several methods for data collection. The use of a postal 
questionnaire method for this surveillance has been recommended, and could feasibly be implemented 
within the NHS (45).   
SSI surveillance is an example of condition based surveillance; conversely, MRSA bacteraemia 
surveillance, and now E. coli bacteraemias, are examples of a targeted organism based approach. This 
second approach is good for monitoring changes in a specific organism, for a specific infection. However 
single organisms can cause several different infections and many organisms cause specific infections, 
thus this surveillance gives a very narrow view of what is happening in hospitals (46). Surveillance of 
infectious diarrhoea in hospitals is an area which has largely not been investigated, with the exception of 
C. difficile (47), again showing the difference in surveillance approaches of organism versus condition. 
 
 
Current HCAI Surveillance Internationally 
 
The American surveillance system, originally the National Nosocomial Infection Surveillance (NNIS) and 
now named the National Healthcare Safety Network (NHSN), has been a pillar of surveillance 
incorporating features such as standard definitions, confidential reporting and validation studies (48). 
The programme originally consisted of a hospital-wide surveillance strategy, but this was amended to 
allow for a targeted, high risk focussed surveillance. It was found that the larger hospitals changed to 
targeted surveillance in this system more than smaller hospitals, potentially explained by resource 
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allocation and time burden (49). As this is a long standing surveillance system, the figures and statistics it 
produces are widely quoted in the literature; however a study by Emori et al. highlighted that the rates 
reported are not necessarily accurate, as the sensitivity (especially for UTIs) can be low, thus comparison 
and interpretation should be done with caution (50). 
In Europe the ‘Hospitals in Europe Link for Infection Control through Surveillance’ (HELICS) was set up, 
based on the American system to try and harmonise the surveillance that were being set up around 
Europe (51). As there has not historically been any uniform method for surveillance in Europe, 
comparisons between countries have been difficult and often the data are misinterpreted (52). 
Currently HELICS has been incorporated into the wider ‘Improving Patient Safety in Europe’ (IPSE) 
programme run through the ‘European Centre for Disease Control’ (ECDC) (51).  
Despite the fact that the majority of surveillance schemes in Europe are based on CDC definitions, the 
variability in other factors, such as training of data collectors and diagnostic techniques, means that a 
uniform method of surveillance was necessary for comparisons to be made. For example, in Germany 
only around 50% of the patient population have samples taken for microbiological confirmation of 
infection, a rate that will differ greatly from other countries (52).  
Currently most European surveillance systems do not have public reporting, remaining with anonymous, 
confidential reporting and individual feedback. Few countries do not follow this trend, England being 
one of them; on the other hand a court ruling in the Netherlands ruled that PREZIES data remain 
anonymous (51). The French system has an element of public reporting, focusing on process based 
measures, and its 2009 – 2012 plans is to move all medical records onto an electronic system to enhance 
their current surveillance capability (53).  
The Spanish system was launched in 1990 in response to media coverage of MRSA and Aspergillus 
outbreaks in their hospitals. It has successfully demonstrated a decline in infection rates, using several 
methods including daily lab reports, annual prevalence estimates and targeted SSI surveillance (54). The 
variety of methodologies used within one country, let alone across Europe and globally, highlights the 
issue of within and cross country benchmarking.   
In an attempt to harmonise prevalence figures across Europe, the European Centre for Disease Control 
(ECDC) co-ordinated a European Point Prevalence Survey (PPS). In 2011 this surveillance activity was 
started, using a standardised methodology for comparable results (2). However, these surveys are time 
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consuming to collect and collate and costly to implement on a regular basis, with the European wide 
results still not published at the time of writing (September 2012).  
 
Surgical Site Infection Surveillance 
 
In this project, I focus on surgical site infections and a large number of papers found by this overarching 
review were related to the surveillance of SSI. There are several SSI specific issues in surveillance such as 
post-discharge surveillance, case definitions, surgeon feedback and pooled versus targeted rates (55). It 
has been shown that between 19% - 65% of SSI can occur after a patient has been discharge from the 
hospital (56). Combining this with the drive to have shorter hospital stays and an increasing volume of 
ambulatory surgery, the role of post-discharge surveillance increases (56, 57). Several studies, using 
various methods, demonstrated that post-discharge surveillance can be incorporated into programmes 
and show beneficial effects (57, 58).  
Royal Hobarth Hospital in Australia provides a good example of continuous active surveillance being 
effective at demonstrating reduced infection rates during the period of surveillance. A programme was 
in place since the 1980’s and was interrupted for a 15 month period, during which the levels of SSI 
returned to those that were recorded pre-surveillance (59). Whether the increase in infections which 
occurred in the absence of surveillance was attributable to the disruption of the programme is not clear, 
however it does demonstrate the utility of surveillance for quality assurance and accountability. An issue 
remains in post-discharge surveillance concerning the follow-up period. The current definitions state a 
30 day follow up for most surgeries and up to year for those surgeries with an implant (60). However, 
there is little evidence to support this time range cut off (56).  
An interesting development in elective surgeries in the UK is the collection of Patient Reported Outcome 
Measures (PROMS). This data set contains information on patients’ quality of life and general health 
both prior to and post-surgery; the post-surgical data are collected using a postal questionnaire (61). 
The reply rate has been reported as 72% (62), with older patients from higher socioeconomic 
backgrounds having the highest return rate (63). PROMS are of interest, as it could be exploited for SSI 
surveillance; if a measure for SSI was included in the questionnaires sent to patients, a self-reported 
infection rate could be passively generated.  
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Secondly, there is an argument for the classification of SSI in post-discharge surveillance to be simplified 
for the purpose of surveillance. A change from the widely used “organ space”, “deep” or “superficial” 
classification, to simply “treated in the community” or “re-admitted” has been proposed as a more 
practical method (64). However, the universal adoption of the CDC definitions of SSI is currently the 
recommended approach (55) and represents a potential block.  
The way in which the surveillance data are collected and interpreted can lead to different results, as the 
data can be pooled for all surgeries or targeted at specific procedures; both methods have advantages 
and disadvantages (65). As SSI surveillance has been shown to be effective, the next evolution in this 
field is to converge emerging systems, using the optimal method for easily interpreted comparable 
results (66). The use of electronic data for case detection would allow SSI surveillance to become 
cheaper and more sensitive (67); it also presents the opportunity to survey procedures that are 
currently not considered high risk, at little to no extra cost (68).  
 
2.2.3 Innovations in Infection Surveillance 
 
Innovations for the surveillance of HCAI, moving away from the traditional manual case finding structure 
of many surveillance programmes, began with the setting up of Hospital Information Systems (HIS). The 
use of these data systems had been limited up till the paper published by Mertens et al. in 1994, with 
only one case of a fully functioning system reported (discussed further on) (69). However, during the 
1990’s the call for increased use of computer technology was being addressed and their utility well 
recognised, as they result in reduced cost and man-power, combined with the ability to merge different 
datasets and create alerts (70, 71). 
An example of a simple computer system developed in the early 1990’s was an MRSA alert system, 
linked to the microbiology test results, that provided an alert when an MRSA carrier was re-admitted or 
a positive test result was received (70).  Another example of a simple computerised solution is the 
universal use of a spread sheet set up to determine standardised rates of infection within the Japanese 
health system; its benefits are simplicity, ease of use, timely electronic reporting and comparability (72). 
Another early innovation was the creation of specific HCAI surveillance computer software, an early 
example being the development of NosoCom (73). A key element in the success of this task was to make 
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it user-friendly to both the data collectors, analysers and implementers as the programme needs to be 
accessible to all three types of personnel (69, 74).  
However, concerns with computerising surveillance lay in the quality of data that are available, as the 
surveillance system can only do so much without good reliable data (71). A study comparing surveillance 
done by a computer system to that done the traditional manual method, found that the reliability of the 
computer system could be as high as 94-99% accurate (71). This meant that the computer system could 
identify up to 99% of the records which the traditional surveillance system had found, indicating that 
computer technology was an appropriate tool for surveillance. 
 
Automated and Electronic Surveillance 
 
As computer technology has advanced and data storing, warehousing and linking capabilities have 
improved, the field of electronic and automated surveillance has exploded. It has been proposed as a 
potential replacement or enhancement of the traditional prevalence studies due to its timeliness and 
reduction of resource requirement (75-77). For example, Italy recently created an electronic-record 
web-based UTI surveillance system using HELICS methodology (78). Automated surveillance is the 
process of using ‘interrelated’ databases (for example laboratory data, medical records, and antibiotic 
prescribing) and turning it into ‘information’. This can be done using several methods, such as data 
mining, automated control charts, syndromic surveillance (which will be discussed further on) and 
cluster detection to produce a wide range of outputs, such as alerts and infection reports (79, 80).  
As these sources of data are being used more and more frequently, with many countries and hospitals 
converting to electronic medical records, the resources that could be saved makes it a natural 
progression in HCAI surveillance (81). Issues remain with this method however, such as: differing data at 
various sites making solutions un-scalable; not all desirable data are readily available in existing data 
sources; the current case definitions cannot always be met (82) and supportive technology needing to 
be created (e.g. novel statistical methods and software) (83).  
As surveillance of HCAI is seen as necessary for a good infection control system, having automated 
surveillance that reduces the resources spent and time allocated is generally regarded as beneficial (82, 
84). Beyond this, is the use of artificial intelligence solutions, such as expert system programming (using 
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predetermined rules to reach an outcome), in the prediction and pre-emptive detection of HCAIs in real-
time (85). An expert system based on the probability of infection for the detection of VAP was created 
and shown to be a successful use of this method (86). The element of real-time updates is very 
attractive in a surveillance system, as automated programmes have been established that have time 
delays (87), delaying outbreak detection.  
However, just because a system is more effective at providing timely alerts concerning infections does 
not necessarily mean this will be translated into clinical practice (88). At this juncture, further innovation 
may be needed, such as was seen at Johns Hopkins, where alerts were sent directly to Personal Digital 
Assistants (PDAs) used by nurses in charge of patients at risk of UTIs (89).  One of the major concerns 
with electronic surveillance systems is that they are based in the most part on microbiology data, and 
not clinical information (77), as many HIS do not contain electronic medical records. This means that the 
definitions of infection are greatly simplified and the distinction between colonisation and infection 
cannot always be made (76). For the future of electronic and automated surveillance, further work is 
needed on the appropriate use of routine data and accuracy of definitions (75). 
There are several examples of electronic surveillance systems that have been successfully implemented 
for diagnosing HCAI, for surgical site infections (90), C. difficile (91), and urinary tract infections (92). One 
particular case study is discussed further detail, as an example of a comprehensive electronic 
surveillance system for healthcare associated infections (Box 1).  
 
Box 1: Case Study of Salt Lake City, Utah 
In Salt Lake City, Utah, by the early 1990’s an electronic surveillance system had been implemented, 
using linked existing hospital data about adult patients to produce alerts and reminders about antibiotic 
prescribing at the patient’s bedside (93). The system is set up, using the programme ‘HELP’, which 
performs data linkage and automated reminders (94); however this system was only applicable to adult 
patients. Building on the ‘HELP’ system, the ‘Computerised Infectious Disease Monitor’, applied 
principles of paediatric infection surveillance to this electronic automated surveillance programme (93);  
the system was successfully implemented for paediatric patients. This is an example of surveillance that 
uses routinely collected data, links it together within a computer system and then outputs to the 
patient’s bedside, in a manner that supports clinical decisions, both in adult and paediatric populations.  
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Syndromic Surveillance 
 
Syndromic surveillance is a term that has been used increasingly in relation to infection surveillance over 
the last decade. The definition of syndromic surveillance I will be using for this project is based on that 
specified by the Triple-S project (which will be discussed further on):  
 
‘a real-time (or close to real-time) system of collecting, interpreting and circulating routine data for the 
monitoring and early identification of out-breaks, public health threats and abnormal trends’ (95) 
 
Whilst most definitions of syndromic surveillance focus on the use of rapid, routine, electronic systems 
specifically for outbreaks or bioterrorism alerts, I am using syndromic surveillance in this project to 
identify infectious events. Key characteristics of syndromic surveillance, which distinguish it from 
traditional surveillance or electronic case finding, include the use of automated routine data and the 
lack of a laboratory diagnosis. Instead, clinical signs or proxy indicators of infection, such as having a test 
ordered (96), are used to generate case algorithms (the ‘syndromes’). These aim to have a high 
sensitivity and positive predictive value (95). 
Syndromic surveillance was pioneered and implemented as a tool for state-wide bioterrorism 
surveillance (97), stimulated by the anthrax letters in the USA in 2001 (98, 99). Since the development of 
these systems for bioterrorism, the majority of work using syndromic surveillance have been designed 
using accident and emergency department data, regarding the early identification of influenza and 
respiratory infection outbreaks in the USA (100-102). However, systems have also been implemented in 
Canada (103-105), Australia (106-108), Taiwan (109), China (110) and Italy (111). Other successful 
applications of syndromic surveillance based on accident and emergency department data have been 
major events monitoring, the effects of heat waves (112, 113) and cardiovascular events, such as heart 
attacks (114).  
In Europe the Triple-S (Syndromic Surveillance Survey) programme was launched in 2010 to create an 
inventory of the different syndromic surveillance projects in Europe, with a view to generate 
standardised guidelines (95). In England specifically, data from the NHS direct service has been used to 
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create syndromic surveillance for norovirus, using the key term of ‘vomiting’ logged in calls from the 
community setting; this could be used to anticipate outbreaks in hospitals (115). However, no examples 
exist of syndromic surveillance in the UK using routine hospital data, with the nearest exception being 
work carried out at Imperial College Healthcare NHS Trust. In their use of antibiotic prevalence surveys 
were used alongside electronic radiology and laboratory data to identify HCAI (116). The reason I use 
the term ‘nearest’ for this work is that it is still reliant on paper collection of information on antibiotic 
prescriptions, which under the definition I am adopting is not true syndromic surveillance. 
The most common data source utilised in syndromic surveillance to date is accident and emergency 
department data, which in the USA (where the majority of studies have been carried out) are called 
‘chief complaints’ data and contain the symptomology of the presenting patient. Other sources that 
have been used are prescription data, routine laboratory tests, discharge diagnosis codes (117-121) and 
even patients’ self-reported diagnoses (122).  
The success of these types of surveillance systems can be hindered by several issues such as the 
interoperability between databases and lack of or incomplete information (123). As with all surveillance, 
the effectiveness and utility is only as good as the information available. The existing literature base 
presents a confusing picture of the data quality and hence the accuracy of current syndromic 
surveillance systems. Positive predictive values have ranged from 5.3% to 100% (114, 124-126) for 
different syndromes in different settings. However, a poor PPV and sensitivity does not necessarily 
mean the system is performing badly, as it depends on the purpose of the surveillance system. For 
example a system to detect post-transfusion injury, based on a specific laboratory test had a PPV of only 
26% despite the test it was based on being clinically accurate (118).  
Another aspect of the successful implementation of a surveillance system is the participation and 
understanding of different parties, such as healthcare providers, healthcare workers, managers and 
government departments. A study on the uptake of syndromic surveillance found that the healthcare 
workers were the least likely to take advantage of the information generated (127). One study noted 
that during the influenza season, the accuracy of the ICD-10 coding used to create the syndromic case 
definitions improved (128). The effects of health worker perception both of specific syndromes and the 
awareness of surveillance may have significant impacts on the performance of the syndromic 
surveillance system.  
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On the other hand, benefits to syndromic surveillance systems are commonly cited as time efficiency 
and cost effectiveness; Hope et al. demonstrated that their syndromic system for pneumonia provided a 
four day head-start in recognising an outbreak, compared to clinician recognition (129). This highlights 
the benefit of early detection that can be obtained using syndromic surveillance systems. In terms of 
cost effectiveness, one study demonstrated no extra cost to the healthcare staff (130), whereas another 
study estimated the cost of running a syndromic system in Boston to be almost $120,000 for 18 months 
(131), which is relatively expensive. 
An interesting aspect of syndromic surveillance is it’s applications in the community as well as the 
hospital setting. Examples of applying the models geographically have shown the potential for 
monitoring health events and their spread, based on the simple modelling of fever (132) or influenza like 
illnesses (133). There are even moves to enhance the use of pre-hospital electronic data, such as that 
captured by the emergency services. This could include details from the scene of an accident or the 
drugs administered in the ambulance, beginning surveillance before a patient even arrives at hospital 
(134). For hospitals this could allow for better planning and the potential to reduce the spread of 
infections (like norovirus) within the healthcare environment.   
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2.3 Conclusion 
 
Surveillance has been regarded as necessary for infection control programmes since the 1970’s and has 
gone through several stages of innovation, from scientific validation and programme creation to 
international collaboratives and artificial intelligence. Current trends in surveillance for HCAI are the 
better use of routine data and improving automated systems for monitoring diagnoses and improving 
clinical outcomes. This chapter has highlighted the work already undergoing in developing automated, 
electronic surveillance systems and the use of syndromic surveillance, demonstrating that this work is 
lacking from England and pertaining to healthcare associated infections specifically. This project sits at 
the heart of these advances, aiming to use routinely collected, linked data to generate surveillance tools 
for healthcare associated infection, including real time syndromic surveillance.  
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Chapter 3: Risks of Healthcare Associated Infections 
 
 
Summary 
 
The second of the background chapters, this chapter presents a systematic literature review of the risks 
of developing a healthcare associated infection. With a particular focus on urinary tract infections and 
surgical site infections, I generated a hierarchy of risks for these infections, quantifying the relative 
importance of different risk factors. This forms the evidence base for the risk modelling analyses carried 
out in chapter 8.   
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3.0 Introduction 
 
As presented in chapter 2, surveillance has the potential to reduce healthcare associated infections and 
one methodology for enhancing surveillance is the use of risk scores and predictive modelling.  
Risks can generally be split into two categories, intrinsic and extrinsic. Intrinsic risks relate to 
characteristics of the patient which predisposes them to infection, while extrinsic risks are those posed 
by the environment they are exposed to, such as being catheterised (135). Surveillance tends to focus 
on extrinsic risks, as they are perceived as preventable or minimisable, with best practice and guidelines 
aimed at reducing the potential negative effects of extrinsic risks. However, individual patient risk scores 
are also employed in healthcare to stratify the likelihood of a patient’s intrinsic risks causing them to 
develop an HCAI.  
A good example of this is the use of case-mix adjustment in surveillance. In order to allow for more 
accurate comparison of infection rates between hospitals, a patient’s intrinsic risk can be taken into 
account (136, 137). For example, take two hospitals, one which receives older, sicker patients, and a 
second which generally receives young patients with fewer comorbidities. The first hospital could be 
expected to have higher rates of HCAI as their patients are more vulnerable, so adjusting for this will 
enable a fairer comparison of hospital performance.  
Both of these approaches provide potential for innovating reactive and real-time surveillance tools. 
Identifying high risk patients on admission to hospital could help with setting a patient pathway to 
minimise risk. Monitoring extrinsic risks can help to highlight breaches in best practice and assess 
whether interventions are being successful. Both these approaches could aid with early detection of 
infections or potential outbreaks, allowing for active and reactive surveillance systems. 
In order to implement or develop such surveillance tools, the first step is to determine the existing 
evidence base and investigate the electronic health data available for the best predictors of infection.    
 
 
 
52 
 
3.0.1 Aim and Objectives 
 
The aim of this chapter was to identify, assess and apply previously established risks of healthcare 
associated infections. 
This aim contains three aspects, firstly the identification of predictors of HCAI, which I addressed by 
performing a systematic literature review. The second part was to assess the strength of association 
between the risks and contracting an infection, providing an indication of the relative importance of the 
different risks.  Finally, applying the risks within the local hospital data available for this project, and 
hence determining their utility for innovative surveillance tools.  
A second more general objective for this chapter was to re-examine the current presumptions about 
HCAI risks and to gain a full understanding of current knowledge and practice in HCAI predictive 
modelling. However, this review did not cover any assessment of risk adjusted surveillance models, or 
the validity of these risk models.  
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3.1 Method 
 
3.1.1 Systematic Review 
 
To address the aim of this chapter I carried out a systematic literature review, using the methodology 
below. Cochrane was included to assess whether or not a comprehensive literature review on HCAI risk 
factors had previously been undertaken. 
 Search terms: risk and ‘healthcare associated infection’(several forms of this were used e.g. 
nosocomial and HCAI) 
 Databases searched: EMBASE, PubMed/MEDLINE, Web of Science, and Cochrane 
The inclusion criteria I used were:  
 Original research papers in English  
 Clear and reasonable study designs  
 Demonstrated statistical analysis, with reported odds ratios, relative risks or hazard ratios, and 
p-values  
 Clearly stated how HCAI ‘cases’ were diagnosed, either based on published definitions (e.g. CDC) 
or  positive microbiology, antibiotic prescription and clinical data  
 ‘Controls’ clearly defined as not diagnosed with the HCAI of interest  
 All study participants have been exposed to ‘healthcare’, defined as either a hospital admission 
for 72 hours or longer, or re-admissions with prior exposure to healthcare.  
However, this search did not return a sufficient number or relevant papers (only 3 papers about C. 
difficile were identified), so the search terms were expanded to include the following: UTI or ‘urinary 
tract infection’ or ‘Bloodstream infection’ or bacteraemia or SSI or ‘Surgical site infection’ or VAP or HAP 
or ‘ventilator associated pneumonia’ or ‘hospital acquired pneumonia’ or ‘Clostridium difficile’ or ‘C. 
difficile’.  
Those studies investigating risk factors for acquiring an antimicrobial resistant infection versus an 
antimicrobial susceptible infection were excluded as the controls did not meet the inclusion criteria.  
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Risk factors that were associated with an HCAI (p-value <0.05) at the univariate and multivariate level 
were selected for further investigation, and were defined as ‘significant’ risks. A risk factor was 
considered ‘independent’ when its associated p-value was <0.05 at the multivariate analysis level.  
 
3.1.2 Population attributable risks 
 
In order to assess the relative importance of the independent risk factors, Population Attributable Risk 
percentages (PAR%) were calculated for the risks relating to surgical site infections and urinary tract 
infections, using the pooled data from all the studies. A meta-analysis was not carried out, as this review 
was not aiming to assess one treatment or exposure, which is traditionally what meta-analyses are used 
for. This method is generally recommended as the results are weighted according to the power of the 
studies they came from; pooling on the other hand does not take this into account (138). Despite the 
potential for results from a pooled analysis to vary compared to those from a formal meta-analysis 
(139), I decided to use this methodology. I only intended the PAR% to act as a guide and this method 
was less intensive. It has also been used previously for ranking risk factors and within a literature review 
(140-142). PAR% is defined as:  
 
“The portion of the incidence of a disease in the population (exposed and non-exposed) that is due to 
exposure. It is the incidence of a disease in the population that would be eliminated if exposure were 
eliminated.” (143) 
 
If the risk factor would be removed from the population, the infection incidence would be reduced by 
the PAR% value. In cases where the PAR% is negative, the risk factor would instead be protective against 
infection. The following formula was used to calculate the PAR%: 
 
PAR% = (It – Iu) / It x 100 
where It = (a+c) / (a+b+c+d) 
and Iu = c / (c+d) 
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 Case Control 
Exposed a b 
Unexposed c d 
 
In this formula It is the incidence of HCAI in the total population and Iu is the incidence of HCAI in the 
unexposed population. The incidence values were calculated by extracting the number of HCAI ‘cases’ 
and ‘controls’ that were exposed and unexposed to each categorical risk factor, and for which published 
data were available. In those studies where raw data were not published but odds ratios and the 
population sizes of the exposed and unexposed were reported, a methodology described by Pietrantojn 
was used to extract the raw numbers (144). This is demonstrated in Box 2. The numbers from all the 
papers to include each particular risk factor were combined and the PAR% and 95% confidence intervals 
were calculated. A worked example is presented in Box 3. 
The studies which used point prevalence survey methods were excluded from the PAR% calculations as 
this study design is inappropriate for the methodology. Variables relating to the type of surgery carried 
out were not included as I was not interested in ranking the inherent risks specific to different surgical 
procedures.  
The purpose of pooling the data from the different papers and calculating the PAR% for all the risk 
variables was to provide a guide on the relative importance of different risks. As pooling data have 
several issues, the subsequent hierarchies of risks must be interpreted and utilised with caution, acting 
solely as a guide.  
 
3.1.3 Identifying risk factors in local data  
 
Then to assess the utility of the data available in this project for risk modelling in the routine electronic 
hospital data, I searched the local data for the identified significant risk factors for SSI and HCA UTI. 
Keyword searches of the ICD-10 codes were performed, using the World Health Organisation (WHO) 
online search tool. ICD-10 codes identified from any included studies were also utilised. The process was 
repeated with operation and procedure codes (OPCS) and the laboratory codes used at Imperial College 
Healthcare NHS Trust.  
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Box 2: Method used to extract raw numbers from odds ratios 
A paper published in the Journal ‘Statistics in Medicine’ presents a method for extracting the raw 
counts of exposed and unexposed, cases and controls. The method requires odds ratios and their 
corresponding confidence intervals and the total number of exposed and unexposed patients. 
The method is based on estimating the standard error from the confidence intervals, and using 
the quadratic equation to calculate number of exposed and unexposed cases.  
 Case Control  
Exposed a b m1 
Unexposed c d m2 
 
The standard error is estimated using the following formula: 
 
Which is then imputed into the following equations, to give the values of a and c:  
 
 
 
The values of a and c can then be used to calculate b and d 
[UL: upper limit of the confidence interval; LL: lower limit of the confidence interval; Z1-x/2: 1.96 for a 
confidence interval of 95%; OR: Odds ratio; m1: total exposed population; m2: total unexposed population; 
Se2ln(OR): estimated standard error] 
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Box 3: Worked example of a PAR% calculation 
Using the example of having surgery as a risk for HCA UTI, six studies included this in their 
analyses. Adding the data from all the papers together gave the following numbers of exposed 
and unexposed, cases and controls: 
 Case Control 
Exposed 350 4,628 
Un-exposed 564 3,399 
 
PAR% = (It – Iu) / It x 100 
where It = (a+c) / (a+b+c+d) 
and Iu = c / (c+d) 
So for surgery, putting the numbers into the formulas gives the following incidence’s and PAR%: 
It = (350 + 564) / 8941 = 0.102226 
Iu = 564 / 3,963 = 0.142316 
PAR% = (0.102226 – 0.142316) / 0.102226 x 100 
PAR% = -39.22% 
Then the 95% confidence intervals were calculated, using the standard error: 
SE = √(PAR%*-(100-PAR%)/total patient population) = 0.781441 
UL = PAR% + (1.96 x SE) = -37.69% 
LL = PAR% - (1.96 x SE) = -40.75% 
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3.2 Results 
 
A total of 69,613 papers were returned from the searches (Table 3.0). Most papers were found in the 
general HCAI search (39%), followed by the bloodstream infection specific search (25%) and the least for 
the C. difficile (5%) specific search.  
 
Table 3.0: Summary of the search results by conditions and database 
Search Term PubMed Cochrane MedLine Embase Web of Science TOTAL 
HCAI 7,585 373 368 275 18, 204 26,805 
UTI 2209 1 1046 607 698 4,561 
C. difficile 861 16 828 598 946 3,249 
Pneumonia 1,984 32 2,261 1,971 2,437 8,685 
SSI 2,649 8 2,046 1,658 2,853 9,214 
Bloodstream 7,073 15 3,794 3,140 3,077 17,099 
TOTAL:  69,613 
 
 
The majority of papers were excluded as duplicates or for being unrelated, leaving 2,174 articles with 
relevant titles. Almost half of those with relevant titles were then removed for not being in English or 
electronically available (most of which were published prior to 1990). This resulted in 1,181 papers for 
abstract and full text review, of which 340 met the study criteria (Figure 3.0). 
Of the 340 papers which met the study inclusion criteria, 33% related to surgical site infections and only 
7% related to HCA urinary tract infections, the two HCAIs that I investigated in further detail in this 
thesis (Table 3.1).  
 
Table 3.1: Summary of the papers meeting the study criteria 
Type of HCAI Number of Papers Number of Independent Risks 
General 32 63 
Pneumonia 59 115 
Surgical site Infection 115 95 
Bloodstream 81 124 
C. difficile 29 41 
Urinary Tract Infection 23 43 
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The results for surgical site infections and HCA urinary tract infections are presented in detail (with 
PAR% calculations), with an overview of the results for the remaining HCAIs, followed by an assessment 
of what independent risk factors could be found within the local electronic hospital data. 
Figure 3.0: Flow diagram of article inclusion  
 
  
3.2.1 Surgical Site Infections 
 
A total of 115 papers were included, with none of these studies investigating neonates and only 8 (7%) 
researching risks of SSI in paediatric patient populations (Table 3.2). Two papers were based on point 
prevalence surveys (and these will not contribute to the subsequent PAR% calculations) (145, 146). Most 
of the papers were cohort studies with 71 papers (62%); the remaining studies used either a case-
control method (29%) or were based on surveillance data (8%). Distinguishing between cohort and 
surveillance methods was not clear cut for many of the papers; I classified papers as cohort studies 
unless a surveillance method was clearly stated.  
All search results: 
69,613
Relevant titles: 
2,174
Abstract review: 
1,181
UTI: 23 C. difficile: 29 Pneumonia: 59 SSI: 115 BSI: 81 General: 32
Excluded for not meeting study criteria: 837
No statistics: Descriptive & surveillance (261); 
Education trial (2); Modelling (29) : 292
Not original papers: Abstract (20); Audit (2); 
Case report (6);  Comment (2); Editorial (6); 
Guidelines (2); Letter (35); Protocol (1); Info  
sheet (16); Review (136); News (1) : 227
Cases/Controls not appropriate: Clinical trial 
(50); Predictive risks, mortality, resistance (251); 
Colonisation (9); Recurrence (8): 318
Excluded due to foreign language: 420 Excluded due to availability:  573
Excluded due to duplication or 
irrelevance: 67,439
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Table 3.2: Summary of the articles included for Surgical Site Infections from the systematic literature review 
Study design Surgical population Country Study Size (SSI/total) Data source (electronic) First author (year) 
Case control Cardiac (paed) USA 19/92 Study Allpress (2004) 
Case control General USA 150/381 Surveillance Anderson (2008) 
Case control Spinal USA 13/60 Medical records Apisarnthanarak (2003) 
Case control Cardiac (paed) Israel 47/151 Study Ben-Ami (2008) 
Case control Breast USA 18/45 Surgical log Bertin (1998) 
Case control Oncology USA 29/87 Surveillance Chemaly (2010) 
Case control Orthopaedics Holland 197/11309 Surveillance De Boer (1999) 
Case control Laminectomy USA 41/123 Study Friedman (2007) 
Case control General USA 300/600 Medical records Haridas (2008) 
Case control Transplant (paeds) USA 25/77 Surveillance Hollenbeak (2003) 
Case control Cardiac (paeds) USA 40/160 Study Holzmanm-Pazgal (2008) 
Case control Colon Japan 187/801 Study Imai (2008) 
Case control General India 135/1125 Study Joyce (2009) 
Case control General USA 196/563 Study Kaye (2001) 
Case control Elderly USA 569/589 Study Kaye (2006) 
Case control Orthopaedics USA 169/340 Medical records Lee (2006) 
Case control Spinal (paeds) USA 44/176 Medical records Linam (2009) 
Case control Spinal USA 104/3894 Surveillance Maragakis (2009) 
Case control Kidney Brazil 120/240 Study Menezes (2008) 
Case control Oncology Japan 60/285 Study Miki (2006) 
Case control Knee Canada 22/88 Study Minnema (2004) 
Case control Cardiac (paeds) Canada 38/1117 Study Nateghian (2004) 
Case control Caesarean USA 81/391 Electronic records Olsen (2008) 
Case control Breast USA 63/341 Electronic records Olsen (2008) 
Case control Orthopaedics USA 46 /273 Electronic records Olsen (2008) 
Case control Breast USA 15/60 Study Rey (2005) 
Case control General USA 39/711 Surveillance Talbot (2004) 
Case control Breast Mexico 77/280 Surveillance Vilar-Compte (2004) 
Case control Oncology Mexico 313/626 Surveillance Vilar-Compte (2000) 
Case control Ambulatory Mexico 38/1350 Surveillance Vilar-Compte (2001) 
Case control Breast Mexico 50/260 Study Vilar-Compte (2008) 
Case control Breast Mexico 438/2338 Study Vilar-Compte (2009) 
Case control Cardiac Finland 172/884 Study Vuorisalo (1998) 
Cohort Pancreas Japan 38/265 Study Ambiru (2008) 
Cohort Transplant Spain 107/1222 Administrative data (e) Asensio (2008) 
Cohort General France 14851/948664 National surveillance Astagneau (2009) 
Cohort General France 1333/38973 Study Astagneau (2001) 
Cohort Knee Israel 10/181 Medical records Babkin (2007) 
Cohort Cardiac India 116/615 Study Bhatia (2003) 
Cohort Digestive Brazil 224/6892 Surveillance Biscione (2007) 
Cohort Spinal USA 24/256 Surveillance Blam (2003) 
Cohort Digestive Brazil 33/81 Medical records Breigeiron (2008) 
Cohort General Russia 138/1453 Medical records Brown (2007) 
Cohort Cardiac USA 322/3878 Study Bundy (2006) 
Cohort Paediatric Spain -/3646* Study Casanova (2006) 
Cohort Cholecysectomy Taiwan 3/277 Study Chang (2006) 
Cohort Spinal USA 26/195 Medical records Chen (2009) 
Cohort General USA 38131/12861108 Claims data (e) Daneman (2009) 
Cohort General Brazil 149/608 Study De Oliveira (2006) 
Cohort Spinal Japan 8/113 Study Demura (2009) 
Cohort General Italy 76/1281 Surveillance Di Leo (2009) 
Cohort Plastics Italy 85/2804 Study Drapeau (2007) 
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Cohort Breast Brazil 60/354 Study Felippe (2007) 
Cohort General Italy 154/2972 Administrative data (e) Fiorio (2006) 
Cohort Cardiac  Australia 259/4633 Laboratory data Friedman (2007) 
Cohort Neurology USA 7/114 Surveillance Gibbs (2004) 
Cohort Trauma Spain 212/5320 Study Herruzo-Cabrera (2004) 
Cohort Digestive USA 126/1446 Study Hiyama (2006) 
Cohort General Goa 35/114 Study Kamat (2008) 
Cohort Spinal Lebanon 27/81 Study Kanafani (2006) 
Cohort General Thailand 26/2139 Study Kasatpibal (2006) 
Cohort Maternal USA 59/765 Study Killian (2001) 
Cohort Oncology Japan 23/405 Study Kobayashi (2009) 
Cohort Cardiac Canada 342/11508 Study Kohli (2003) 
Cohort Cardiac France 38/1268 Surveillance Lepelletier (2005) 
Cohort Neurology France 35/844 Study Lietard (2008) 
Cohort General Spain 254/2237 Study Lizan-Garcia (1997) 
Cohort Oncology Brazil 100/258 Study Lofti (2008) 
Cohort Orthopaedics Serbia 63/277 Study Makimovic (2008) 
Cohort General USA 162/5031 Surveillance Malone (2002) 
Cohort Rectal Canada 27/149 Medical records McConnell (2009) 
Cohort Neurology USA 9/32 Medical records McGovern (2003) 
Cohort Cardiac (paeds) USA 10/202 Medical records Mehta (2000) 
Cohort General Spain 81/1540 Surveillance Molina-Cabriani (2008) 
Cohort Cardiac Spain 23/467 Study Munoz (2008) 
Cohort General Thailand 192/4437 Study Narong (2003) 
Cohort General Vietnam 76/697 Study Nguyen (2001) 
Cohort Head & Neck Japan 21/209 Medical records Ogihara (2009) 
Cohort Hepatic Japan 22/152 Study Okabayashi (2009) 
Cohort Liver USA 76/680 Medical records Park (2009) 
Cohort Kidney Brazil 29/119 Medical records Perdiz (2009) 
Cohort Spinal USA 132/3174 Administrative data (e) Pull Ter Gunne (2009) 
Cohort Arthoplasty UK 363/16291 Surveillance Ridgeway (2005) 
Cohort Appendicitis Switzerland 176/2468 Surveillance Romy (2008) 
Cohort General Switzerland 290/6103 Study Rosenthal (2009) 
Cohort General Greece 129/2420 Study Roumbelaki (2008) 
Cohort General Pakistan 60/460 Study Sangrassi (2008) 
Cohort Cardiac USA 86/3452 Surveillance Sharma (2009) 
Cohort General Bolivia 45/372 Study Soleto (2003) 
Cohort Urinary Japan 34/104 Study Takeyama (2005) 
Cohort General Taiwan 134/2809 Study Tang (2001) 
Cohort Orthopaedics Vietnam 73/582 Study Thu (2005) 
Cohort General Turkey 222/1572 Surveillance Topaloglu (2008) 
Cohort General USA 39/863 Medical records Torres (2006) 
Cohort Caesarean Taiwan 95/969 Study Tran (2000) 
Cohort Rectal Japan 27/192 Study Uchino (2010) 
Cohort Rectal Japan 71/562 Study Uchino (2009) 
Cohort General Spain 314/2795 Study Vazquez-Aragon (2003) 
Cohort Spinal USA 752/24774 Surveillance Veeravagu (2009) 
Cohort Oncology Brazil 317/1205 Surveillance Velasco (1998) 
Cohort General USA 71/586 Medical records Waisbren (2010) 
Cohort General Japan 146/941 Study Watanabe (2008) 
Cohort Orthopaedics Japan 15/2423 Study Yano (2009) 
Cohort General Japan 115/2663 Study Yoshida (2006) 
Prevalence General Greece 49/1093 Study Gikas (2004) 
Prevalence General Vietnam 56/391 Study Sohn (2002) 
Surveillance General Italy 29/305 Study Drapeau (2009)  
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Surveillance Coronary USA 310/4474 NNIS surveillance Harrington (2004) 
Surveillance Caesarean Scotland 80/715 National surveillance Johnson (2006) 
Surveillance Caesarean Saudi Arabia  20/735 Study Mah (2001) 
Surveillance General Italy 241/4665 Study Petrosillo (2008) 
Surveillance Abdominal Kosovo 27/253 Study Raka (2007) 
Surveillance Abdominal Iran 139/802 Audit Ravazi (2005) 
Surveillance Groin Scotland 140/2665 Medical records Taylor (2004) 
Surveillance Caesarean UK 745/5563 Study Ward (2008) 
*This number was not provided by the paper and could not be derived from the information given. NNIS: National Nosocomial 
Infection Surveillance 
 
Of the 115 papers, only four (3%) were based in the UK, of which two were specifically in Scotland (147-
150). The majority of the studies were performed in high income settings, namely the USA (30%) and 
Japan (10%). Twenty two studies (19%) were based in developing countries, including Iran, Bolivia and 
Vietnam. There was a wide range of surgical specialties investigated, however almost a third (29%) of 
the papers were related to unspecified surgeries or investigated the whole surgical population (which 
have been classified as ‘general’ in Table 3.2). There were fourteen papers regarding cardiovascular 
surgeries and five relating to caesarean sections, the two surgeries I focus on in this project.  
The type of data which the studies used was also investigated and only four of the 115 studies included 
had used electronic data. None of these four studies were in caesarean section or CABG patient groups, 
nor were they based in the UK.  
A total of 344 risk factors were investigated (excluding those that related to technical aspects of the 
specific surgeries). Of these 95 (27%) different variables were found to be independent predictors of 
surgical site infection (Table 3.3). Table 3.3 (and the subsequent PAR%) does not present the surgery 
specific features and risk factors, however the CABG and caesarean section specific features are 
presented in Table 3.5.  
Of the risks found to be independent predictors of SSI, 40 (43%) were found independent by more than 
one study and 35 (36%) were only investigated by one paper. The risk factors found significant by the 
most papers were diabetes, high BMI or being obese, a higher American Society of Anaesthesiologists 
score (ASA), a prolonged pre-operative length of stay, being an emergency admission and the length of 
the surgery. These are a mixture of intrinsic and extrinsic risk factors, with diabetes and obesity being 
intrinsic to the patient, but pre-operative length of stay being extrinsically determined.  
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Table 3.3: Number of studies which found  each risk factor significant in univariate and multivariate analysis 
Risk Factors 
Significant in Univariate analysis 
 (% of the total number of studies to 
investigate the risk) 
Significant in Multivariate analysis 
 (% of the total number of studies to 
investigate the risk / Odds Ratio range) 
Demographics, Scores and Comorbidities 
Sex (unspecified) 3 (3) (151-153) 1 (1 / 1.54) (153) 
Male 9 (10) (146, 154-160) 4 (4 / 1.26 – 2.3) (154, 155, 157, 160) 
Female 5 (6) (161-165) 5 (6 / 1.36 – 7.77) (161-165) 
Age (continuous) 27 (30) (147, 149-152, 157, 160, 161, 163, 165-182) 8 (9 / 0.63 – 1.66) (147, 149, 150, 156, 165, 167, 172, 177)  
<1 month 1 (100) (166) 1 (100 / 8.5) (166) 
>45 years 2 (100) (183, 184) 1 (50 / 3.74) (183) 
>50 years 7 (100) (154, 185-190) 4 (57 / 2.6 – 4.4 ; 2.66 RR) (185, 186, 189, 190) 
>58 years 1 (100) (191) 1 (100 / 1.8) (191) 
>65 years 4 (100) (179, 192-194) 3 (75 / 3.4 – 4.7) (179, 192, 194) 
 >70 years 2 (100) (151, 195) 1 (50 / 2.408) (151) 
 >75 1 (50) (194) 1 (50 / 6.0) (194) 
Daily wage living 1 (100) (183) 1 (100 / 4.39) (183) 
Rural residence 1 (50) (196) 1 (50 / 1.28) (196) 
ASA score (continuous) 40 (62) 
(147, 152, 153, 155-157, 160, 166-169, 171, 173, 176, 
178, 180, 187, 192, 193, 197-217) 
22 (34 / 1.55 – 9.7) (147, 153-155, 157, 160, 171, 180, 192, 
197-199, 203, 205, 207, 209-213, 216, 217) 
NNIS score (>1) 13 (65) (148, 158, 171, 184, 192, 195, 199, 206, 218-222) 5 (25 / 3.34 – 6.7) (148, 192, 195, 221, 222) 
Chronic disease score 1 (100) (207) 1 (100 / - ) (207) 
Comorbidity (unspecified) 3 (100) (159, 223, 224) 2 (67 / 2.8 – 13.8) (159, 224) 
Weight loss (>10%) 3 (75) (154, 217, 225) 2 (50 / 2.14) (217, 225)  
Obesity 
36 (84) (149, 151, 159, 162-164, 171, 174, 177, 180, 186, 187, 
191, 197, 202, 206, 208, 213, 219, 222, 223, 226-231) (200, 232, 233) 
(150, 165, 185, 193, 200, 234) 
29 (67 / 1.05 – 13.82) (149, 159, 162-164, 171, 177, 180, 
187, 191, 197, 208, 213, 219, 222, 226-228, 230, 231) (232, 233) (151) 
(150, 165, 193, 201, 202, 234) 
Underlying malignancy 3 (25) (159, 175, 223) 1 (8 /13.778)  (159) 
Smoking 5 (17) (173, 200, 206, 217, 235) 4 (13 / 1.19 – 2.96) (173, 206, 217, 235)  
Alcoholism 2 (22) (196, 236) 1 (11 / 1.11) (196) 
Diabetes mellitus 
30 (47) (151, 155, 158, 162-165, 170, 173, 177, 182, 183, 190, 
191, 193, 196, 201, 204, 206, 209, 214, 217, 222, 225, 227, 231-233, 
237) 
22 (34 / 1.1 – 21.48 ; 1.6 – 4.1 RR) (158, 162-165, 
170, 177, 183, 193, 196, 201, 204, 214, 217, 222, 225, 227, 229, 231-
233, 237) 
Pre-operative anaemia 1 (100) (225) 1 (100 / no odds) (225) 
Post-operative anaemia 1 (100) (225) 1 (100 / no odds) (225) 
Congestive heart failure 5 (63) (165, 196, 202, 208, 236) 2 (25 / 1.08 – 2.75) (165, 196) 
Cyanotic heart disease 2 (100) (167, 169) 1 (50 / 4.93) (167) 
Lung disease 2 (67) (196, 223) 1 (33 / 1.08) (196) 
COPD 5 (45) (158, 162, 202, 208, 218) 4 (36 / 1.66 – 2.52) (158, 208, 218, 236)  
HIV/AIDS 1 (100) (222) 1 (100 / 13.9) (222) 
Renal impairment 2(100) (165, 177) 1 (50 / 3.31) (165) 
Liver disease 2 (40) (196, 202) 1 (20 / 1.32) (196) 
Chronic glomerulonephritis 1 (100) (228) 1 (100 / 40.91) (228) 
Pre-transplant diabetes 1 (100) (228) 1 (100 / 5.84) (228) 
Progressive cancer 1 (100) (238) 1 (100 / 4.66) (238) 
Neoplasm 2 (67) (172, 196) 2 (67 / 1.09 – 1.69) (172, 196) 
Disseminated cancer 1 (100) (217) 1 (100 / 1.83) (217) 
Hepatitis C infection 1 (50) (184) 1 (50 / 2.7) (184) 
Chlorioamnionitis 1 (100) (213) 1 (100 / 10.6) (213) 
Pre-eclampsia 1 (100) (213) 1 (100 / 2.3) (213) 
Nulliparity 1 (100) (213) 1 (100 / 1.8) (213) 
Functional dependence  2 (100) (202, 217) 2 (100 / 1.36 – 3.97) (202, 217) 
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Inflammatory Bowel Syndrome 1 (100) (211) 1 (100 / 2.593) (211) 
Ascites 1 (33) (225) 1 (33 / no odds) (225) 
Antibiotics and Drug Therapy 
Radiation therapy 8 (67) (154, 158, 187, 190, 191, 200, 204, 239) 7 (58 / 2.1 – 20.35) (154, 158, 187, 190, 191, 200, 204) 
Chemoradiation 5 (100) (187, 190, 191, 200, 240) 5 (100 / 2.3 – 4.1) (187, 190, 191, 200, 240) 
Immunosuppressive  2 (50) (233, 241) 1 (25 / 2.7) (233) 
Local Anaesthetic 1 (100) (200) 1 (100 / 0.4) (200) 
Prednisolone 1 (100) (212) 1 (100 / 3.33) (212) 
Vasopressor intra-operative 1 (100) (242) 1 (100 / 3.14) (242) 
Antibiotic prophylaxis  19 (51) 
(148, 152, 154, 167, 172, 197-201, 215, 219, 224, 234, 
235, 238, 243-245)  
10 (27 / 0.22 – 20.5) (148, 154, 172, 199-201, 219, 235, 238, 
243)  
Cephalosporin 1 (100) (226) 1 (100 / 0.2) (226) 
Clindamycin 1 (50) (197) 1 (50 / 6.2) (197) 
Admission and Stay 
Private insurance 1 (100) (208) 1 (100 / 0.29) (208) 
University teaching hospital 1 (100) (226) 1 (100 / 2.7)(226) 
Prior Surgery admission 1 (50) (236) 1 (50 / 2.4) (236) 
Admission from healthcare  1 (100) (246) 1 (100 / 4.35) (246) 
Use of home care 1 (100) (196) 1 (100 / 1.2) (196) 
ICU admission 3 (100) (170, 172, 199) 3 (100 / 2.2 - 5.35) (170, 172, 199) 
Number of diagnoses 1 (50) (224) 1 (50 / 2.77) (224) 
Prior trauma 1 (25) (196) 1 (25 / 2.06) (196) 
Emergency admission 16 (41) 
(146, 152, 156, 157, 160, 164, 171, 180, 181, 192, 193, 
195, 198, 219, 221, 223) 
11 (28 / 0.57 – 3.38) (156, 157, 164, 171, 172, 192, 193, 
195, 198, 221, 223) 
Trauma surgery 3 (75) (146, 147, 156) 3 (75 / 1.87 – 5.36) (146, 147, 156) 
Day care surgery (protective) 2 (100) (158, 192) 1 (50 / no odds) (192) 
Pre-operative stay 21 (58) 
(145, 152-154, 166-168, 172, 181, 192, 194, 195, 211, 
214, 215, 221, 222, 224, 238, 243, 247) 
10 (28 / 1.06 – 1.73) (145, 153, 172, 192, 195, 211, 221, 
243) (194, 222) 
Post-operative ICU stay 3 (75) (168, 175, 238) 1 (25 / 12.98) (175) 
Biomarkers and Clinical Feature 
Intraoperative temperature 1 (50) (248) 1 (50 / 1.33) (248) 
Hypothermia 1 (50) (197) 1 (50 / 0.29) (197) 
PaO2/FiO2 1 (50) 
(180) 1 (50 / 12.0) (180) 
Blood glucose (high / poor) 6 (40) (190, 201, 220, 230, 232, 249) 5 (33 / 1.2 – 6.6) (190, 201, 220, 230, 249) 
Sliding scale glucose control 1 (100) (230) 1 (100 / 1.2)(230) 
Postoperative haematocrit 1 (100) (225) 1 (100 / 0.92) (225) 
Hypoalbuminemia 4 (31) (155, 161, 176, 236) 1 (8 / 1.8) (236) 
Blood transfusion 13 (50) 
(159, 169, 179, 180, 193, 200, 201, 214, 217, 220, 233, 
242, 248) 5 (19 / 1.4 – 3.4) 
(179, 200, 214, 217, 248) 
Mean blood loss 9 (50) (149, 159, 179, 213, 223, 230, 231, 237, 240) 7 (39 / 1.03 – 4.4) (149, 179, 213, 223, 230, 231, 240) 
Mean volume transfused 2 (50) (155, 241) 2 (50 / 2.0 – 6.2) (155, 241) 
International normalised ratio 1 (100) (250) 1 (100 / 2.4) (250) 
White blood cell count 2 (50) (161, 167) 1 (25 / 1.28) (161) 
Operative Features 
High risk surgery 1 (100) (234) 1 (100 / 1.72) (234) 
Surgeon 6 (67) (155, 156, 170, 173, 201, 250) 3 (33 / 2.2 – 6.65) (155, 156, 201) 
Surgery on a Monday 1 (100) (169) 1 (100 / 5.6) (169) 
Multiple surgeons / contacts 2 (100) (196, 209) 2 (100 / 1.004 – 1.28) (196, 209) 
Number of operations 6 (75) (169)#(156, 192, 194, 199, 204) 2 (25 / 1.9) (192, 199) 
Re-operation 10 (77) (160, 170, 180, 228, 229, 238, 242, 246, 251, 252) 5 (38 / 4.2 – 156 ; 3.1 RR) (160, 170, 228, 242, 251)  
Length of surgery  37 (59) 
(147-149, 153-156, 159, 161, 165, 166, 170, 172, 175, 
176, 178, 181, 188, 189, 191, 196, 206, 210, 217, 228, 231, 233-236, 
18 (29 / 1.003 – 14.88) (147, 153, 154, 156, 159, 161, 165, 
166, 172, 191, 196, 210, 217, 231, 234, 236, 244, 245) 
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240, 245, 250, 253-256) 
T-time (>75%) 13 (76) 
(151, 157, 160, 173, 180, 192, 199, 201, 202, 207, 208, 
215, 219) 7 (41 / 1.98 – 4.7) 
(157, 160, 173, 180, 192, 199, 202) 
>35 mins 1 (100) (186) 1 (100 / 2.4) (186) 
>1 hour 2 (100) (152, 216) 2 (100 / 1.81 ; 3.29 RR) (152, 216) 
>2 hours 3 (75) (198, 224, 227) 2 (50 / 1.6 – 2.1) (198, 224)  
>8 hours 1 (100) (151) 1 (100 / 15.271) (151) 
Operative Delay  2 (67) (155, 175) 1 (33 / 8.18) (175) 
Non-laparoscopic 1 (50) (234) 1 (50 / 2.4) (234) 
Cervical level 1 (50) (201) 1 (50 / 0.3) (201) 
Posterior approach 3 (75) (180, 201, 231) 1 (25 / 3.5) (180)  
Anterior approach 1 (100) (231) 1 (100 / 0.264) (231) 
Non-endoscopic surgery 1 (100) (221) 1 (100 / no odds) (221) 
Hair removal - Razor 2 (50) (180, 209) 2 (50 / 2.77 – 3.6) (180, 209) 
Other / prior infection 11 (61) (154, 169, 173, 194, 206, 213, 216, 236, 243, 248, 249) 5 (28 / 1.53 – 16.5) (249) (169, 173, 213, 231, 248) 
Colonisation 3 (75) (185, 205, 229) 3 (75 / 2.5 – 11.0) (185, 205, 229) 
Wound class  (continuous) 20 (95) 
(145, 155, 160, 171-173, 176, 178, 181, 188, 202, 206, 
215, 219, 223, 224, 240, 243, 247, 248) 8 (38 / 2.28 – 7.9) 
(145, 160, 173, 202, 223, 224, 240, 243) 
Clean-contaminated 6 (33) (153, 171, 210, 216, 224, 234) 6 (33 / 1.66 – 7.51) (153, 171, 172, 210, 216, 224) 
Contaminated 10 (45)  (153, 154, 156, 157, 194, 208-210, 216, 224, 234) 10 (45 / 1.95 – 5.96) (153-155, 157, 172, 208-210, 216, 224) 
Dirty 15 (71) 
(146, 153, 154, 156, 157, 171, 194, 198, 208-210, 216, 
224, 234, 257) 
13 (62 / 2.92 – 26.84) (146, 153, 154, 157, 171, 172, 198, 
208-210, 216, 224, 257) 
Invasive Devices 
Central venous catheter 3 (75) (145, 224, 243) 2 (50 / 2.44 – 4.46) (145, 224) 
Duration of CVC 2 (50) (166, 167) 1 (25 / 1.15) (167) 
Peripheral catheter 2 (100) (224, 243) 1 (50 / 11.8) (224) 
Urinary catheter 2 (50) (153, 224) 2 (50 / 1.04 – 2.78) (153, 224) 
Mechanical ventilation 2 (50) (145, 224) 1 (25 / 3.01) (242) 
External fixation 1 (100) (198) 1 (100 /2.9)  (198) 
Surgical drain 12 (67) 
(154, 155, 158, 188, 191, 195, 206, 215, 216, 227, 250, 
254) 5 (28 / 1.6 – 7.0) 
(155, 158, 195, 216, 250) 
Drain duration  5 (71) (187, 201, 209, 227, 247) 2 (29 / 1.84 – 2.9) (187, 227) 
Multiple ducts 1 (50) (187) 1 (50 / 3.7) (187) 
Pre-operative intubation 1 (100) (242) 1 (100 / 3.01) (242) 
Frequency of glove change 1 (100) (223) 1 (100 / 3.01)(223) 
Instrumentation 1 (33) (180) 1 (33 / 2.5) (180) 
ASA: American Society of Anaesthesiologists score; NNIS: National Nosocomial Infection Surveillance score; COPD: Chronic 
Obstructive Pulmonary Disease; ICU: Intensive Care Unit; CVC: Central venous Catheter; T-time: the 75th percentile of the 
duration of a surgery used to indicate a long versus short surgery; PaO2 / FiO2: index to characterize the acute respiratory 
distress syndrome. 
 
The data on numbers of cases, controls, exposed and unexposed patients was extracted from 98 of the 
115 (85%) papers relating to SSI for the calculation of PAR%. Of these, the raw numbers were given in 79 
of the papers, two papers had the data in text form and nine required manipulation of the data 
presented. I used the method presented in Box 2, to extract the raw numbers from the odds ratio and 
related confidence intervals for eight papers. The subsequent results of the PAR% calculations for 
independent risk factors are shown in Table 3.4.                                                                                                                                         
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  Table 3.4: Summary of PAR% for independent risks of SSI and their availability in local administrative hospital data  
Risk factor PAR% (95% CI) Total patients 
Prevalence in 
the exposed 
Prevalence in the 
unexposed 
Number of 
Studies 
Available 
locally Data source 
Sliding scale glucose control 100 (100, 100) 152 18% 0.0% 1 N - 
Colonization 72.9 (71.3, 74.6) 2792 18% 0.7% 2 Y LIMS 
Postoperative anaemia 71.1  (69.8, 72.3) 5031 4.9% 0.9% 1 Y LIMS 
Age >45 42.4 (40.0, 44.9) 1544 20% 7.4% 3 Y PAS 
Posterior surgical approach 42.4 (35.7, 49.1) 208 58% 29% 1 Y OPCS 
One or more glove change 39.6  (36.5, 42.7) 941 18% 9.4% 1 N - 
Surgical drain: duration 38.8  (37.4, 40.2) 4784 15% 4.0% 2 N - 
Trauma with motor accident 37.4 (33.5, 41.3) 582 22% 7.9% 1 Y PAS/ICD10 
Age < 1 month 36.3 (26.5, 46.1) 92 56% 13% 1 Y PAS 
FiO2 < 50% 34.0 (27.5, 40.4) 208 67% 33% 1 N LIMS? 
Abdominal level approach 33.5 (31.1, 35.8) 1540 5.3% 3.1% 1 Y OPCS 
Lumbar-sacral level of surgery 31.5 (25.2, 37.8) 208 59% 34% 1 Y OPCS 
NNIS >1  31.3 (30.6, 31.9) 19578 8.7% 3.5% 9 N - 
Postoperative ICU stay 30.9 (29.1, 32.6) 2654 22% 5.2% 4 Y PAS/OPCS 
ASA >2 30.5 (29.8, 31.2) 17630 9.0% 5.1% 14 N - 
Cyanotic heart disease 25.8 (21.5, 30.2) 393 41% 20.% 3 Y ICD10 
Central venous catheter 23.6 (22.3, 25.0) 3765 44% 6.2% 2 N - 
Blood transfusion 23.2 (22.5, 24.0) 11557 15% 7.8% 15 N - 
Prior surgery (any) 23.1 (22.1, 24.1) 7386 37% 11% 11 Y PAS/OPCS 
Surgical drain 23.0 (22.2, 23.7) 11560 23% 12% 19 N - 
General anaesthetic 23.0 (22.2, 23.8) 9951 12% 8.2% 9 N - 
Hepatitis C virus 22.3 (19.3, 25.4) 710 9.7% 5.7% 2 Y ICD10/LIMS 
Instrumentation 22.2 (21.7, 22.7) 25414 6.3% 2.8% 3 Y OPCS 
Incorrect antibiotics 22.2 (20.5, 24.0) 2138 17% 6.4% 3 N - 
ASA >3 21.8 (21.7, 21.9) 1035547 4.4% 1.6% 40 N - 
Urinary catheter 21.3 (20.0, 22.6) 3942 42% 6.4% 3 Y ICD10/OPCS 
Surgical duration (t-time) 20.9 (20.8, 21.0) 968187 3.2% 1.3% 13 Y Surveillance 
International Normalised Ratio >3 20.0 (11.6, 28.4) 88 39% 20% 1 Y LIMS 
Surgery on Monday 19.4 (13.3, 25.5) 160 45% 20% 1 Y PAS/OPCS 
Functional dependence 18.6 (18.2, 19.1) 26652 19% 5.0% 4 N - 
Wound class >3 18.4 (18.3, 18.4) 1004946 5.9% 1.5% 30 Y Surveillance 
Obese 17.9 (17.2, 18.5) 14799 24% 12% 16 Y Surveillance 
Ascites 17.8 (16.8, 18.8) 5788 16% 3.7% 3 Y ICD10 
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Surgical duration (prolonged) 17.7 (15.8, 19.5) 1581 48% 25% 4 Y Surveillance 
Age >75 years 17.6 (17.0, 18.2) 14606 6.8% 2.9% 5 Y PAS 
NNIS >2 17.6 (17.5, 17.7) 981968 6.7% 1.4% 5 N - 
External fixation 17.4 (14.3, 20.4) 582 31% 10% 1 Y OPCS 
Preoperative stay (all) 17.2 (17.1, 17.3) 1042607 4.1% 1.5% 19 Y PAS/OPCS 
Preoperative stay (> day) 17.2 (17.1, 17.3) 1042520 4.1% 1.5% 18 Y PAS/OPCS 
Obesity (all) 16.4 (16.1, 16.8) 41794 15% 8.2% 35 Y Surveillance 
Chemoradiation 16.2 (14.7, 17.6) 2434 30% 22% 4 N - 
Cancer  16.0 (15.6, 16.5) 26535 20% 3.3% 8 Y ICD10 
Age (all) 15.4 (15.4, 15.5) 1101651 2.5% 1.7% 41 Y PAS 
Age >65 years 15.4 (15.3, 15.5) 1019775 2.1% 1.4% 7 Y PAS 
BMI >30 14.5 (14.1, 14.9) 25894 9.5% 5.3% 15 Y Surveillance 
Surgical duration (all) 14.3 (14.0, 14.5) 75637 8.5% 4.1% 20 Y Surveillance 
Re-operation 14.1 (13.4, 14.7) 10002 49% 15% 10 Y PAS/OPCS 
Wound class >2 14.0 (13.6, 14.4) 27818 19% 5.7% 9 Y Surveillance 
Renal insufficiency 12.6 (11.5, 13.7) 3452 7.9% 2.2% 1 Y Icd10 
Age >60 years 12.2 (11.8, 12.7) 20279 11% 7.0% 9 Y PAS 
Radiotherapy 11.6 (10.7, 12.5) 5061 29% 9.1% 8 N - 
Mechanical ventilation 11.1 (10.2, 12.1) 4445 27% 7.7% 3 N - 
Peripheral catheter 11.1 (10.1, 12.1) 3646 52% 6.2% 1 N - 
Age >50 years 10.9 (10.6, 11.3) 30480 4.5% 3.7% 7 Y PAS 
Anaemia 10.8 (10.2, 11.5) 7840 5.1% 3.4% 2 Y ICD10/LIMS 
Comorbidity (unspecified) 10.8 (9.21, 12.4) 1449 24% 12% 3 Y ICD10 
Serum glucose (high) 10.0 (9.05, 11.0) 3470 38% 27% 9 N - 
Preoperative shaving 10.0 (7.33, 12.7) 485 48% 31% 2 N - 
Emergency surgery 9.87 (9.81, 9.92) 1070860 3.0% 1.7% 34 Y PAS 
Vasopressors 9.81 (7.57, 12.0) 680 24% 10% 1 N - 
Multiple surgeries 9.26 (8.58, 9.95) 6935 8.7% 3.7% 3 Y PAS/OPCS 
Multiple procedures 9.17 (9.11, 9.23) 917866 2.8% 1.4% 6 Y PAS/OPCS 
Daily wage labourer 9.15 (7.47, 10.8) 1125 18% 11% 1 N - 
Preoperative stay >2 weeks 9.10 (8.48, 9.71) 8462 18% 7.9% 4 Y PAS/OPCS 
COPD 8.54 (7.96, 9.12) 8872 29% 16% 8 Y ICD10 
Weight loss 8.15 (7.86, 8.44) 33818 9.5% 3.4% 4 N - 
Other/prior infection 8.15 (7.90, 8.39) 46621 16% 5.2% 19 Y PAS/LIMS/ICD10 
Preoperative stay >1 week 7.95 (7.42, 8.49) 9863 18% 9.2% 8 Y PAS/OPCS 
Preoperative ICU stay 7.75 (6.70, 8.80) 2494 36% 12% 3 Y PAS/OPCS 
68 
 
Admission from healthcare 7.35 (4.58, 10.1) 340 81% 46% 1 Y PAS 
Intraoperative transfusion 5.21 (4.93, 5.48) 24977 6.4% 3.0% 3 N - 
HIV infection  5.15 (4.40, 5.91) 3277 13% 5.3% 2 Y ICD10/LIMS 
Immunosuppressive 3.82 (3.51, 4.13) 15087 14% 6.3% 6 N - 
Trauma 3.43 (3.38, 3.48) 489237 22% 12% 5 Y PAS 
Number of diagnoses 3.26 (2.69, 3.84) 3646 12% 6.7% 1 Y ICD10 
Rural residence 3.24 (3.19, 3.29) 469724 11% 8.6% 2 N - 
Diabetes 2.55 (2.50, 2.59) 548649 5.2% 4.5% 53 Y ICD10 
NNIS >3 2.27 (1.78, 2.76) 3563 17% 6.2% 2 N - 
Private insurance 1.80 (1.52, 2.09) 8549 16% 15% 7 Y PAS 
Malignancy 1.71 (1.67, 1.74) 477711 4.4% 4.1% 12 N - 
Lung disease 1.46 (1.43, 1.50) 473099 7.2% 6.7% 3 Y ICD10 
Congestive heart failure 0.74 (0.72, 0.77) 475817 10% 9.2% 8 Y ICD10 
Liver disease 0.33 (0.31, 0.35) 473697 14% 11% 5 Y ICD10 
Alcohol use 0.13 (0.12, 0.14) 494985 11% 10% 5 Y ICD10 
Albumin >3/4 -0.85 (-0.11, -0.58) 4715 13% 13% 6 Y LIMS 
Smoking -6.40 (-6.64, -6.17) 48110 5.3% 6.3% 21 Y ICD10 
Endoscopic surgery -9.93 (-6.76, -6.27) 45622 2.3% 3.8% 4 Y OPCS 
Cervical level approach -10.7 (-11.6, -8.23) 1453 17% 23% 4 Y OPCS 
Day case surgery -10.7 (-10.8, -10.6) 965190 0.7% 1.8% 7 Y PAS 
Female gender -11.9 (-12.0, -11.8) 1125899 1.9% 2.4% 64 Y PAS 
Subcutaneous suture -12.1 (-14.4, -9.7) 941 8.5% 17% 1 N - 
Local anaesthetic -12.7 (-16.8, -8.6) 325 9.7% 20% 1 N - 
Antibiotics (excl. incorrect) -16.4 (-16.7, -16.1) 60709 7.2% 9.1% 37 N - 
Laparoscopic -42.6 (-43.9, -41.4) 14252 3.5% 10% 7 Y OPCS 
Prophylaxis -69.5 (-70.6, -68.4) 40242 7.0% 14% 21 Y Surveillance 
PAR%: Population Attributable Risk percentage; LIMS: Laboratory Information Management System; OPCS: Operation and Procedure Codes; PAS: Patient Administration System; 
ICD-10: International Classification of Diseases version 10; NNIS: National Nosocomial Infection Surveillance score; ICU: Intensive Care Unit; COPD: Chronic Obstructive Pulmonary 
Disease; BMI: Body Mass Index; ASA: American Society of Anaesthesiologist score; FiO2: Fraction of inspired oxygen 
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Of the 95 independent risks for SSI, two thirds had a PAR% calculated and of these, 11 (17%) were 
protective, with correct prophylaxis having the lowest PAR% of -69.5%. Sliding scale glucose control 
had the highest PAR%, at 100%. However this was based on one study where all the patients who 
developed an SSI had had sliding scale glucose control; this result should not be extrapolated to 
other patient populations as it does not indicate that all SSI within all patient groups would be 
prevented by stopping sliding scale glucose control. Instead it means that in this patient group, this 
risk factor was universal to all the patients who developed an infection  Other risks with a high PAR% 
were being over 45 years old or under 1 month old, colonisation and duration of surgical drain 
insertion, all of which would be expected risks.  
When all the studies were combined, female gender was considered protective (-11.9%), despite 
several papers having found female gender to be a risk for infection. The risks that were found 
significant by the most papers had varying PAR%, with diabetes for example only having a PAR% of 
2.55% despite being one of the most commonly cited risks for SSI. These are both examples of the 
negatives of pooling data, as it discounts the effect of different patient populations, and in this case 
surgical populations. When considering length of surgery and obesity, using the paper’s own cut offs 
or definitions, obesity had a PAR% of 16.4% and duration of surgery had a PAR% of 14.3%.  
There were several papers pertaining specifically to caesarean section and coronary artery bypass 
graft procedures. The independent risks relating to these specific surgical procedures and their 
associated PAR% (calculated using just those relevant papers) are presented in Table 3.5. None of 
the risks investigated for caesarean section and CABG procedures were protective against SSI. The 
highest PAR% was associated with using internal mammary artery in CABG patients and staple use in 
the closure of caesarean sections. Diabetes was a risk in both surgeries, with the PAR% being higher 
in both than was seen in the general calculation, especially for CABG (24.3%).  
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Table 3.5: Summary of PAR% for independent risks of SSI and their availability in local administrative hospital data for caesarean and CABG procedures 
Risk factor PAR% (95% CI) Total patients Prevalence in the exposed 
Prevalence in the 
unexposed 
Number of 
Studies Available locally Data source 
Coronary Artery Bypass Graft 
Internal mammary artery 57.4 (55.8, 58.9) 3836 2.7% 0.8% 1 Y OPCS 
Obesity 29.1 (27.6, 30.5) 3809 4.3% 2.1% 2 Y Surveillance 
Diabetes 24.3 (23.5, 25.1) 11921 5.9% 2.8% 3 Y ICD-10 
Renal disease 9.84 (8.88, 10.8) 3709 8.0% 2.6% 2 Y ICD-10 
Re-operation 8.48 (7.60, 9.36) 3836 7.5% 1.8% 1 Y ICD-10/OPCS 
Female 5.15 (4.68, 5.63) 8442 4.8% 4.1% 3 Y PAS 
Congestive heart failure 3.42 (2.84, 4.00) 3809 3.4% 2.8% 2 Y ICD-10 
Immunosuppressive 2.13 (1.82, 2.45) 8085 7.7% 4.2% 2 N - 
Caesarean section 
Staple use 48.0 (45.0, 50.9) 1103 17% 7.6% 2 N - 
Labour (active) 33.7 (30.7, 37.1) 765 9.5% 5.1% 1 N - 
Nulliparity 24.8 (22.0, 27.5) 969 8.0% 4.6% 1 N - 
Labour (induced) 22.1 (18.0, 26.2) 391 27% 16% 1 N - 
Obesity 18.9 (16.0, 21.8) 715 20% 9.1% 1 Y Surveillance 
Labour >12 hours 12.1 (8.86, 15.3) 391 31% 18% 1 N - 
Prenatal care (<7 visits) 10.5 (8.29, 12.6) 765 22% 6.9% 1 N - 
Preeclampsia 6.15 (4.64, 7.66) 969 16% 7.5% 1 Y ICD-10 
Diabetes 6.10 (5.38, 6.82) 4227 5.0% 3.8% 2 Y ICD-10 
Other HAI 5.61 (4.16, 7.06) 969 26% 2.0% 1 Y LIMS/ICD-10 
Chorioamnionitis 5.56 (4.11, 7.00) 969 26% 3.2% 1 Y ICD-10 
PAR%: Population Attributable Risk Percentages; OPCS: Operation and Procedure Codes; ICD-10: International Classification of Diseases version 10; PAS: Patient Administration 
System; LIMS: Laboratory Information Management System; HAI: Healthcare Associated Infection 
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3.2.2 Urinary Tract Infections 
 
Of the 23 papers included for healthcare associated urinary tract infections, three papers were case-
control studies, 13 were cohort studies, and six were surveillance and prevalence studies, and one 
paper used data derived from a large randomised control trial database (Table 3.6).  
 
Table 3.6: Summary of the studies identified for Urinary Tract Infections from the systematic literature review 
Study design Patient population Country 
Study Size 
(HCA UTI/total) Data source (electronic) Reference (year) 
Case control General Saudi Arabia 206/824 Patient records  Al-Helali (2004) 
Case control Hip Sweden 101/435 Patient records  Hedstrom (1999) 
Case control General UK 136/4869 Study / Surveillance  Nguyen (1999) 
Cohort Paediatric India 69/287 Study  Brindha (2011) 
Cohort Transplant Brazil 73/163 Study  Dantas (2006) 
Cohort Spinal Spain -/128* Study  DeRuz (2000) 
Cohort General Australia 69/3308 Study / Patient records  Graves (2007) 
Cohort Orthopaedic Spain 74/5320 Study Herruzo-Cabrera (2001) 
Cohort ICU Canada 105/1981 Linked records (e)  Laupland (2002) 
Cohort ICU Canada 356/4465 Linked records (e)  Laupland (2005) 
Cohort ICU France 53/553 Study Leone (2003) 
Cohort Stroke USA 84/663 CASPR registry Ovbiagele (2006) 
Cohort Paediatric USA 188/311 Patient records  Traxel (2009) 
Cohort Surgery Spain 314/2795 Patient records  Vazquez-Aragon (2003) 
Cohort General USA 97/747 Study  Larsen (1986) 
Cohort ICU France 42/137 Study  Tissot (2001) 
Prevalence General UK 1269/75694 Prevalence survey Humphreys (2008) 
Prevalence General Germany 218/14966 Prevalence survey Kampf (1997) 
Prevalence General Israel 177/668 Patient records  Mnatzaganian (2005) 
RCT General USA 134/1458 Study Platt (1986) 
Surveillance ICU USA 20/126 Patient records Rosser (1999) 
Surveillance General Egypt 161/757 Study  Talaat (2010) 
Surveillance ICU France 241/2539 Surveillance Vanhems (2008) 
*This paper reported the incidence /100 person-days and did provide enough information to calculate the number of 
patients with an HCA UTI. HCA UTI: Healthcare Associated Urinary Tract Infection; ICU: Intensive care Unit; CASPR: 
California Acute Stroke Pilot Registry; RCT: Randomised Control Trial 
 
 
The majority of the studies were performed in high income settings, of which two were based in the 
UK. Three studies were undertaken in the middle income countries of Brazil, India, and Egypt. Two 
studies considered paediatric populations, with the remaining 21 papers investigating adult 
populations, including patients from general wards; ICU patients; surgical patients; stroke patients;  
orthopaedic patients; hip fracture admissions; spinal injury patients; and renal transplant patients. 
Two of the papers used electronic health data to carry out the studies, both of which were relatively 
large studies in Canada.  
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Table 3.7: Number of studies which found  each risk factor significant in univariate and multivariate analysis 
Risk Factors 
Significant in Univariate analysis 
 (% of the total number of 
studies to investigate the risk) 
Significant in Multivariate analysis 
 (% of the total number of studies to 
investigate the risk / Odds ratio range) 
Demographics, Scores and Co-morbidities 
Sex (female) 13 (65) (258-270) 11 (55 / 1.47 – 5.1 ; 1.58 – 1.9 HR) (258-263, 265, 267-270) 
Age (continuous)  5 (28) (263, 268, 269, 271, 272) 2 (11 / 7.14 ; 1.01 HR) (263, 268) 
Acute Physiology Score (12)  1 (100) (263) 1 (100 / 1.03 HR) (263) 
ASA score (>2)  1 (100) (153) 1 (100 / 2.13) (153) 
ASA score (>3) 1 (100) (267) 1 (100 / 3.2) (267) 
Functional Independence Score (<74)   1 (100) (272) 1 (100 / 9.96) (272) 
Underlying debilitation  1 (100) (273) 1 (100 / 3.11) (273) 
Diabetes mellitus  4 (50) (258, 261, 264, 273) 2 (25 / 2.3 – 6.27) (258, 273) 
Some assistance with daily tasks 1 (100) (261) 1 (100 / 2.58) (261) 
Neurologic disease  1 (50) (261) 1 (50 / 2.59) (261) 
Unresolved spinal injury  1 (100) (261) 1 (100 / 4.07) (261) 
Previous stroke  2 (100) (261, 269) 2 (100 / 1.51 - 1.94) (261, 269) 
Unconsciousness 1 (100) (268) 1 (100 / 2.96) (268) 
Antibiotics 
Prior antibiotics 1 (50) (270) 1 (50 / 0.06) (270) 
Systemic antibiotic with catheter  1 (100) (258) 1 (100 / 22.4) (258) 
Systemic antibiotic pre-catheter  1 (100) (258) 1 (100 / 2.3) (258) 
Antibiotics on admission  1 (100) (265) 1 (100 / 0.61 HR) (265) 
Admissions, Stay and Operations 
Prior surgery 1 (100) (268) 1 (100 / 2.01) (268) 
Intra-hospital transfer 1 (100) (261) 1 (100 / 2.9) (261) 
Hospital size (<200 beds) 1 (100) (268) 1 (100 / 0.37) (268) 
Elective admission 1 (100) (259) 1 (100 / 2.72) (259) 
General surgery 2 (25) (259, 263) 1 (13 / 0.64 HR) (263) 
Orthopaedics (fracture ad) 1 (50) (261) 1 (50 / 3.34) (261) 
Nursery ICU 1 (100) (273) 1 (100 / 2.73) (273) 
Burn ICU 1 (100) (273) 1 (100 / 3.05) (273) 
ICU admission 1 (100) (263) 1 (100 / 2.46 HR) (263) 
Length of stay in the ICU 5 (100) (260, 262, 264, 266, 271) 1 (20 / 1.09) (260) 
Pre-operative length of stay (>4 days) 1 (100) (274) 1 (100 / 4.53) (274) 
Length of stay 9 (100) (259-261, 266, 271-275) 5 ( 56 / 1.09 – 8.29) (259, 261, 272, 273, 275) 
Serum creatinine  1(100)  (258) 1 (100 / 2.1) (258) 
Wound class: Clean-contaminated 1 (50) (153) 1 (50 / 3.42) (153) 
Wound class: Dirty  1 (100) (153) 1 (100 / 2.96) (153) 
Deceased kidney donor  1 (100) (275) 1 (100 / 3.64) (275) 
Change of Immunosuppressant  1 (100) (275) 1 (100 / 17.04) (275) 
Pre-op recurrent UTI  1 (100) (276)# 1 (100 / 2.2) (276)# 
Bladder dysfunction  1 (100) (276)# 1 (100 / 3.3) (276)# 
Vesicoureteral reflux 1 (100) (272) 1 (100 / 22.86) (272) 
Invasive Devices 
Invasive procedure  2 (100) (272, 277) 1 (50 / 2.62) (272) 
Indication for catheterisation 1 (100) (258) 1 (100 / 2.0) (258) 
Urinary catheter 5 (83) (153, 261, 274, 277, 278) 2 (67 / 1.05 – 5.16) (153, 261) 
Duration of urinary catheter  8 (89) (258, 262, 264, 270, 271, 273-275) 5 (56 / 1.07 – 26.5) (258, 270, 273-275) 
Number of catheters: >2  1 (100) (273) 1 (100 / 4.56) (273) 
Urinemeter drainage  1 (100) (258) 1 (100 / 2.0) (258) 
Colonisation of drainage bag 1 (100) (258) 1 (100 / 3.8) (258) 
Pre-connected and sealed junction  1 (100) (258) 1 (100 / 3.0) (258) 
Transurethral catheter 1 (100) (259) 1 (100 / 4.52) (259) 
Cervical level  1 (100) (272) 1 (100 / 2.99) (272) 
Intermittent catheterisation  1 (100) (259) 1 (100 / 3.85) (259) 
ASA: American Society of Anaesthesiologists score; ICU: Intensive Care Unit; UTI: Urinary tract Infection; HR: Hazard Ratio 
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A total of 143 risk factors were assessed by the different studies, of which 96 (68%) risks were found 
significant and 43 were found to be independent risk factors for HCA UTI; six studies did not perform 
a multivariate analysis. Table 3.7 summarises the risks found to be independent. 
Of the independent risk factors, 29 were only included by one study. Among the remaining 14 risk 
factors that were assessed by multiple studies, half were found significant by more than one of the 
studies in which it was included (female sex; increasing age; diabetes mellitus; length of hospital 
stay; prior stroke; urinary catheter; and duration of urinary catheter). Female sex was included in all 
the papers for analysis and was found significant in 65% of the studies. A quarter of the independent 
risk factors were associated with urinary catheter use and associated catheter management, 
including colonisation of the drainage bag, having multiple catheters and having intermittent 
catheterisation.    
Raw data, for calculating PAR%, were directly extracted from 14 studies, whilst odds ratios were 
used to calculate the raw data values from four studies. Two studies did not publish sufficient data 
to enable PAR% calculations, and three papers were not included as these were prevalence studies. 
Thus, 18 of the 23 papers included contributed data to the PAR% calculations. A total of 35 
significant risk factors for HCA UTI had PAR% values estimated, of which 26 were also independent 
risk factors. The remaining 17 independent risk factors did not have sufficient data for calculation 
(Table 3.8). 
From the 35 risk factors for which PAR% were calculated, functional independence (measured as the 
level of assistance required with daily living tasks) was found to have a non-significant PAR% (1.47, 
95% CI -0.62, 3.55) despite being identified as an independent predictor of HCA UTI. The remaining 
34 significant risk factors were stratified into a hierarchy, with the risk factor with the highest PAR%, 
of 79.34% [95% CI: 78.18, 80.50], being urinary catheterisation. Five risk factors demonstrated 
protective properties from the calculated PAR%, and these included creatinine level <1 mg/dL (-
1.42%), neurological disease (-3.51%), surgical rather than medical admission (-39.22%), antibiotic 
therapy (-57.47%) and non-elective admission (-62.71%).  
Of the 96 significant risk factors for HCA UTI, 41% were located within the administrative hospital 
data stored within ICHNT, and 24 of these had PAR% calculated. A total of 28 (65%) of the 43 
independent risk factors were located in the local hospital data with 18 of these having associated 
PAR%. All the risk factors identified by multiple studies as independent predictors of HCA UTI (except 
duration of urinary catheterisation), were found within the local hospital data. These risks were: age, 
female sex, diabetes, prior stroke, length of stay and urinary catheter. 
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Table 3.8: Summary of PAR% for significant risk factors of HCA UTI and their availability within local hospital data  
Risk factor PAR% (95% CI) Total patients Prevalence in the exposed 
Prevalence in 
the unexposed 
Number of 
Studies 
Available 
locally Data source 
Urinary Catheter 79.34 (78.18, 80.50) 4,652 8.1% 0.6% 2 Y PAS/LIMS 
Transurethral catheterisation 52.41 (48.21, 56.60) 544 49% 12% 1 N - 
Positive meatal culture 36.88 (33.42, 40.34) 747 4.5% 1.5% 1 Y LIMS 
ASA score >2 32.69 (31.07, 34.31) 3,229 7.0% 2.9% 2 N - 
Stroke 27.62 (26.39, 28.86) 5,028 10% 2.2% 2 Y ICD-10 
Urine meter drainage 26.00 (23.74, 28.22) 1,474 21% 6.8% 1 N - 
Disconnection of collection junction 25.63 (23.40, 27.86) 1,474 16% 6.9% 1 N - 
Bladder dysfunction 25.13 (20.31, 29.96) 311 23% 8.9% 1 Y ICD-10 
Length of stay >10 days 24.92 (21.28, 28.55) 544 33% 19% 1 Y PAS 
Urinary catheter duration >6days 23.29 (21.13, 25.45) 1,474 27% 7.1% 1 N - 
Female Sex 23.00 (22.51, 23.44) 31,408 6.4% 4.1% 16 Y PAS 
Hypertension 21.85 (18.71, 25.00) 663 14% 9.9% 1 Y ICD-10 
Dead kidney donor 19.32 (13.26, 25.38) 163 84% 54% 1 Y OPCS 
Colonisation of drainage bag 15.69 (13.83, 17.54) 1,474 43% 7.8% 1 Y LIMS 
Drainage bag change 14.43 (12.64, 16.23) 1,474 17% 7.9% 1 N - 
Intermittent catheterisation 13.25 (10.40, 16.10) 544 61% 22% 1 Y Audit 
Atrial fibrillation 12.79 (10.25, 15.34) 663 19% 11% 1 N - 
Age >60 years 11.83 (10.91, 12.76) 4,674 5.6% 4.4% 2 Y ICD-10 
Age >50 years 11.70 (10.36, 13.04) 2,221 7.2% 6.1% 2 Y ICD-10 
Prior UTI in current hospitalisation 10.37 (8.82, 11.93) 1,474 17% 8.3% 1 Y ICD-10 / LIMS 
Diabetes 9.56 (8.89, 10.22) 7,522 11% 6.7% 6 Y ICD-10 
ASA score >3 9.54 (6.78, 12.30) 435 29% 21% 1 N - 
Prior indwelling catheter 8.35 (6.94, 9.77) 1,470 25% 8.4% 1 N - 
Age >65 years 6.42 (5.12, 7.72) 1,368 27% 23% 2 Y ICD-10 
Bag-outlet tube error 5.72 (4.54, 6.91) 1,474 22% 8.7% 1 N - 
Other malignancy 4.24 (2.54, 5.93) 544 32% 24% 1 Y ICD-10 
Bladder instrumentation 3.62 (3.07, 4.17) 4,365 3.2% 1.6% 1 Y OPCS 
Unresolved spinal injury 3.54 (2.99, 4.09) 4,365 9.7% 1.6% 1 Y ICD-10 
Central venous catheter 2.07 (0.87, 3.27) 544 46% 24% 1 Y OPCS 
Creatinine <1 mg/dL -1.42 (-2.03, -0.81) 1,474 9.0% 9.4% 1 Y LIMS 
Neurological disease -3.51 (-5.28, -1.75) 449 13% 17% 2 Y ICD-10 
Surgery (vs. medical) -39.22 (-40.75, -37.69) 8,941 7.0% 14% 6 Y PAS 
Antibiotics -57.47 (-60.18, -54.75) 4,724 10% 19% 6 Y Audit 
Non-elective admission -62.71 (-71.20, -54.22) 544 17% 41% 1 Y PAS 
PAR%: Population Attributable Risk Percentages; ASA: American Society of Anaesthesiologists score; PAS: Patient Administration System; LIMS: Laboratory 
Information Management System; ICD-10: International Classification of Diseases version 10; OPCS: Operation and Procedure Codes 
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3.2.3 Summary of the risks of the remaining HCAI 
 
A summary of those risks identified as independent by more than one study for pneumonia, C. 
difficile and bloodstream infections are summarised in Table 3.9. 
 
General HCAI 
 
A total of 32 papers were included under the term ‘general’. This category represents those studies 
which did not distinguish between the types of HCAI, but evaluated risks against all healthcare 
associated infections. Several of these papers looked specifically at the risk of infection from one 
organism. Of these papers 26% (9) were based on neonatal patient groups and 9% (3) on paediatric 
patient groups. This was a high proportion of papers dedicated to neonates compared to the other 
HCAI that were investigated, although paediatric studies were still disappointingly few.  
63 variables were found to be independent risk factors, with 15 of these identified by multiple 
papers (Table 3.9). These were: age; birth weight; increasing McCabe and Jackson scores; COPD; 
maternal illness; being a surgical admission; central venous catheter (CVC); total parenteral feeding 
(TPN); mechanical ventilation (MV) and the duration of ventilation; length of stay in the ICU and in 
total; blood transfusion. Of this list of risk factors only the first six are intrinsic to the patient, the 
remaining risks are external factors related to healthcare.  
Two interesting variables that were included in these papers and found to increase the risk of an 
HCAI, but were not seen in any condition specific studies were Kangaroo mother care and diagnostic 
imaging. ‘Kangaroo mother care’ was included in a study investigating the risks for MRSA infection in 
neonates in Japan (279); the principle of ‘Kangaroo Mother care’ is to promote the health and well-
being of infants through skin to skin contact between pre-term babies and their mother or 
healthcare staff (280). The WHO recommends this strategy, providing evidence that it does not harm 
the neonates, contradicting this study (279). The use of diagnostic imaging being an independent risk 
factor for paediatric HCAIs was discussed in the article by Cavalcante et al. and they concluded that 
environmental contamination of the imaging equipment as the explanation (281). However an 
alternative explanation could be that diagnostic imaging acted as a proxy for infection diagnosis in 
these patients.  
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Table 3.9: Summary of the risk factors found to be independent by more than one paper 
Risk Factor General HCAI Bloodstream Infection Pneumonia C. difficile 
Demographics, Scores and Comorbidities 
Male sex   4 (282-285)  
Female sex  1 (286)  2 (287, 288) 
Young Age 2 (281, 289) 4 (290-293)   
Old Age 1 (294) 5 (295-299) 4 (300-303) 8 (287, 304-310) 
Low birth weight 2 (279, 311) 5 (292, 312-315)   
ASA score 1 (316) 2 (153, 317) 1 (153)  
APACHE II score 1 (318) 3 (319-321) 6 (322-327)  
NNIS score 1 (328) 2 (317, 329) 1 (330)  
Charlson score 1 (331) 1 (332) 1 (333)  
McCabe score 2 (294, 334)    
Horns Index    2 (307, 335) 
Underlying malignancy  3 (336-338)   
Number of comorbidities  3 (329, 339, 340)   
Obesity 1(341)  1(330)  
Low weight/loss  1(342) 1(303)  
Diabetes  5 (319, 321, 343-345)   
Anaemia 1(316) 2(338, 346)   
Cardio vascular diseases  2(338, 347) 2(284, 348)  
Renal failure 1(349) 3(350-352) 2(300, 353) 3 (288, 310, 354) 
Acute respiratory distress 1(355) 2(319, 356) 3*(357-359)  
COPD 2(316, 360) 2(338, 344) 5(303, 324, 330, 358, 361)  
Immunosuppressed  4(340, 356, 362, 363)   
Maternal illness 2(311, 364)    
Cancer   1(365) 1 (306) 
CNS disorder   2(302, 366)  
Coma  1(329) 5(326, 348, 367-369)  
Genetic syndrome  1#(370) 1(371)  
Burns  1(286)   
Previous ulcer 1(372)  1(366)  
Admission and Stay 
ICU admission 3(294, 316, 334)   1 (308) 
Pre-operative length of stay  1(153) 1(153)  
Length of stay in the ICU 3(353, 373, 374) 3(345, 375, 376) 4(353, 368, 377, 378) 1 (310) 
Total length of stay 3(281, 294, 379) 5(296, 297, 350, 363, 380) 1(369) 3 (309, 381, 382) 
Transport out of ICU  1(383) 1(285)  
Emergency / trauma 1(334) 3(321, 376, 384) 1(385)  
Surgical admission 2(355, 386) 4(153, 337, 387, 388) 3(300, 301, 303)  
Duration of surgery 1(316) 2 (153, 347)   
Medical admission  1(339) 1(358)  
Prior admission 1(389) 1(336) 3(301, 348, 390) 2 (288, 306) 
Prior infection  12(296, 340, 350, 362, 363, 376, 
388, 391-395) 
3*(358, 365, 396) 4 (288, 304, 309, 397) 
Colonisation 1(279) 5(286, 362, 375, 384, 387) 4(378, 398-400)  
Antibiotics and Drug Therapy 
Sedative 1(355)  3(283, 323, 367)  
Steroid therapy 1#(289) 2#(339, 342) 1(401)  
Antacids   3(302, 402, 403) 1 (382) 
Proton Pump Inhibitors    4 (288, 306, 354, 404) 
Sucralfate   2(403, 405) 1 (406) 
H2 Blockers 1(289) 1(407) 3(368, 402, 403) 2 (306, 404) 
Antibiotic treatment   2(282, 408) 1 (397) 
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Length of Antibiotic 1(360)   2 (287, 308) 
Prior antibiotic  4(296, 342, 356, 375) 6 (300, 361, 378, 409-411)  
Number of antibiotics   1(412) 1 (413) 
Carbapenems 1(389) 1(414)   
Quinolones 1(389)  1(415) 4 (309, 397, 416, 417) 
Flouroquinolones  1(332)  2 (306, 418) 
Penicillins  1(332)  3 (307, 382, 418) 
Cephalosporins  2(414, 419) 2(403, 415) 9 (305-307, 309, 382, 
417, 418, 420, 421) 
Metronidazole  1(419)  1 (304) 
Glycopeptides  2(291, 419)  2 (304, 306) 
Beta lactams  1(332)  2 (309, 421) 
Macrolides    3 (309, 382, 420) 
Lincosamides    3 (304, 309, 381) 
Invasive Devices 
Invasive devices  2(337, 356)   
No. of invasive devices 1(422) 2(383, 423) 1(402)  
Intravenous catheter  3(336, 337, 424)   
Central Venous Catheter 
(CVC) 
7 (294, 311, 316, 334, 364, 
425, 426) 
13(153, 297, 313, 339, 342, 350, 
363, 375, 380, 427-430) 
1(323)  
Duration of CVC 1(374) 10(291, 299, 320, 347, 374, 391, 
394, 407, 431, 432) 
1#(433)  
Multiple lumen  3(351, 393, 434)   
Peripheral catheter 1(294) 2(314, 435)   
Arterial catheter  3(370, 383, 436)   
Umbilical catheter  2(427, 437) 1(357)  
Jugular catheter  2(432, 434)   
Urinary catheter 2(294, 316) 5 (336, 345, 414, 430, 436)   
Nasogastric tube 1(316)  4(326, 367, 368, 390) 3 (308, 382, 397) 
Total Parenteral Nutrition 
(TPN) 
5(311, 353, 364, 379, 425) 11(290, 313, 314, 329, 350, 351, 
387, 393, 437, 438) 
2(283, 353)  
Duration of TPN  5(292, 388, 439-441)   
Enteral nutrition   5(283, 369, 376, 385, 409) 1 (416) 
Mechanical ventilation 8(311, 316, 364, 374, 422, 
425, 426, 442) 
1*(313) 5(153, 282, 330, 358, 390) 1 (306) 
Duration of ventilation 4(289, 318, 374, 443) 2*(374, 395) 14(283, 301, 324, 325, 365, 
366, 401, 412, 433, 444, 445) 
 
Tracheotomy   10(285, 326, 367, 368, 376, 
400, 402, 412, 446) 
 
Re-intubation   8(285, 301, 333, 366, 367, 371, 
402, 444) 
 
Haemodialysis  2(299, 388)   
Bronchoscopy   3(376, 409, 445)  
Aspiration   5(300, 358, 398, 408)  
Biomarkers and Clinical Features 
Blood transfusion 3(281, 289, 316) 5 (339, 363, 370, 388, 435) 5 (283, 301, 327, 333, 447) 1 (287) 
Fresh Frozen Plasma   2(327, 447)  
Body temperature  2(297, 394)   
Albumin  4 (317, 363, 432, 436)  3 (304, 306, 404) 
White Blood Cell count  2(298, 448)  3 (304, 404, 406) 
Neutrophil count  5(297, 339, 340, 448, 449)   
ICU: Intensive Care Unit; COPD: Chronic Obstructive Pulmonary Disease; ASA: American Society of Anaesthesiologists 
score; APACHE II: Acute Physiology and Chronic Health Evaluation II; NNIS: National Nosocomial Infection Surveillance 
Score 
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Three classes of antibiotics were found to be significantly associated with an increase in risk: 
carbapenems; aminoglycosides and quinolones (318, 389), with carbapenems and quinolones also 
being found significant in studies investigating other HCAI. However, only a few papers included 
antibiotic risk factors and no two papers looking at general HCAI found the same antibiotic to be a 
risk. This can be explained by the varied bacteria causing infections and the local resistant patterns 
in the study location. This area was under explored in terms of general HCAIs, with only 1/3 of the 
papers including any sort of antibiotic variable (including prophylaxis or prior therapy).  
 
Bloodstream Infections 
 
The second highest number of papers was included for bloodstream infections (BSI), after surgical 
site infections, with 81 papers investigating the risks of developing BSI meeting the study criteria. Of 
these papers, 39 (48%) were investigating patients in an intensive care setting, of which eight were 
specifically paediatric and sixteen specifically neonatal intensive cares. A quarter of papers were 
related to the general patient population. Only four studies were set in developing countries, a 
comparatively small number when contrasting with the papers included for SSI.  
A total of 124 risk factors were found to be significant in the 81 papers which was the largest 
number of risk factors for any of the conditions. Of these risk factors, 49 of the 124 were found to be 
independently significant by more than one paper; these included: diabetes; increasing age; TPN and 
CVC presence and it’s duration of insertion. All of these risk factors were to be expected, especially 
the relationship between various catheters and BSI, as often healthcare associated BSI are referred 
to as ‘catheter related BSI’. Urinary catheters were also found to be a risk for BSI in several papers, 
as untreated or complicated urinary tract infections can develop into bloodstream infections.  
 
Pneumonia 
 
In the category of pneumonia, which mainly refers to ventilator associated pneumonia (VAP), 59 
papers met the search criteria. Of these five (8%) related to neonatal patients and the same number 
referred to paediatric populations. Two studies investigated ‘hospital acquired pneumonia’ (HAP) 
instead of VAP (302, 445).  
 79 
 
A total of 33 variables were found independently significant by more than one study, of the 115 risk 
factors that were found independent. In total 11 were intrinsic to the patient or their condition, and 
are as follows: male gender; age; APACHE II score; SOFA score; acute respiratory distress; COPD; 
impaired consciousness; CNS disorder; coma; trauma leading to an emergency surgery. These are all 
related to the patient and cannot be altered by the form of healthcare provided. COPD and a high 
APACHE II score were the most frequently identified risks in this group.  
The factors related to healthcare with the most significant identifications as risks were: prior 
antibiotic therapy; mechanical ventilation and its duration; re-intubation and tracheotomy. These all 
had five or more papers identify them as independent predictors of VAP or HAP. The presence of 
mechanical ventilation was not included by most studies as the entire patient population had been 
ventilated. The duration for which the patient is ventilated on the other hand was included by 
several studies and 39% of the papers for VAP found it significant to at least a univariate level 
(corresponding to 89% of those studies which included it as a risk factor).  
Only two of the variables that were found as risk factors were slightly unusual. Firstly male gender, 
contradicting what is seen for other conditions such as UTI, and secondly, the use of non-invasive 
ventilation, which was considered by Mastropierro et al. (445). This is a little unexpected as invasive 
ventilation was also compared and that too was found significant, suggesting it may not be the 
invasive nature of ventilation that poses the risk.  
 
C. difficile 
 
29 papers relating to C. difficile infections met the study criteria, and 23 of these (79%) were in the 
general patient population. Half of the studies were carried out in the USA, and none were based in 
developing countries. A total of 41 risk factors were found to independent, of which 17 (41%) were 
related to antibiotic exposure.  
In this literature review, cephalosporins were identified most frequently as a significant risk factor 
for healthcare associated C. difficile. The way in which antibiotics react in the gut with C. difficile can 
be broken down into three broad categories: minimal interaction with the natural gut micro flora; 
interaction with some micro-flora, but not C. difficile; effective against C. difficile (450). The second 
type of interaction is the most dangerous as a risk of infection, as this allows C. difficile an 
opportunity to flourish in the intestinal system, thus antibiotics that have this action spectrum are 
the ones which put a patient at risk of infection.  
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Eleven papers included diabetes in their analyses but none found it to be a significant risk of C. 
difficile infection. Female gender was associated with increased infection risk, similar to UTI, 
however this was only seen in two studies (287, 288). In the study by Dial et al. the cases and 
controls were matched on antibiotic class, ward and age, but not sex (288).  Crabtree et al. matched 
cases and controls on day of surgery and institution, and in the discussion stated that finding female 
sex to be a risk factor came as a surprise (287). Whilst no explanation is obvious, especially as only 
two of the 25 studies which used this is a risk variable found female sex to be significant at either 
univariate or multivariate analysis, it is possible that anomalies in the data could be the explanation.   
Increasing age was found significant to a multivariate level by 28% of the papers that included it is a 
risk variable (287, 304-310).  The youngest age category found to be independently significant was 
50 – 79 years (310), whereas over 40 years of age was found to be significant at a univariate level by 
McFarland et al (307).  
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3.3 Discussion 
 
The aim of this chapter was to identify the scientific evidence base on risk factors for HCAI, 
specifically HCA UTI and SSI, and quantify their potential utility in the available administrative 
hospital data. This forms a base of information for the project going forward and helps to establish 
the value of this data source for developing automated risk models. There were 340 papers that met 
the study inclusion criteria, of which 115 related to risks for SSI and 23 related to risks for HCA UTI.  
 
3.3.1 Surgical Site Infections 
 
Most papers were found relating to SSI than any other type HCAI in this review, despite SSI only 
accounting for 15.7% of HCAI in the UK (451). In this review, 34% of papers related to risks for SSI; a 
reason for the high numbers is the number of different surgical procedures that were investigated, 
with different surgeries having different risks. Of the 95 independent risk factors, two thirds were 
located within the routine administrative data.  
Interesting risk factors were identified for surgical site infections, firstly gender, as both male and 
female genders were found to be risks for developing SSI. However this could be due to the different 
papers looking at different surgery types.  
Secondly was the risk one paper found of having surgery on a Monday; this was the risk with the 
highest odds ratio found by this study, however they noted that they had no explanation for this 
finding (169). A possible explanation of this result could be the surgeon time table, as they did not 
account for the surgeon in their model, or the difference in cleaning rota on the weekend having a 
knock on effect on a Monday.   
Another interesting risk to be identified was that of being a daily wage worker, in a developing 
country setting (India) (183) and conversely private insurance in the USA being protective. These 
touch upon the idea of wealth and social status having an impact on the likelihood of developing 
infections and was widely un-investigated by the papers included.  
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3.3.2 Urinary Tract Infections 
 
As UTIs are reported to cause 17.2% of HCAIs in the UK (3), there were fewer papers than expected 
relating to HCA UTI, with only 7% of the papers included in this review relating to urinary tract 
infections. The systematic literature review returned 23 relevant studies, with 96 significant and 43 
independent risks of HCA UTI. Of the independent risk factors, 65% were located within the local 
administrative hospital databases.  
The finding that female sex, increasing age, diabetes, length of stay, urinary catheters and prior 
stroke are all significant risks factors of acquiring HCA UTI was anticipated; the fact that these risk 
factors have been found to be independent predictors of HCA UTI suggests that the search 
methodology was robust.  
Although some of the other risk factors found to be strong risks or protectors in the PAR% 
calculations were contradictory or questionable. For example, non-elective and surgical admissions 
were both found to be protective against HCA UTI, but surgical patients generally constitute elective 
admissions. In this case, the population for non-elective admissions was small with only one study 
contributing to the calculation, suggesting this association may be specific to that particular study 
population and the paper itself questioned the finding (259). Similarly, neurological disease was 
found to be protective (-3.51%), whereas having had a stroke was associated with the fifth highest 
PAR% (27.62%). In this instance, the population for neurological disease PAR% calculation was 
limited. However, there is the potential for local policies and patient case mix to distort the reported 
associations and result in some unexpected PAR%. As stated in the methods, the PAR% need to be 
interpreted with caution and this has been confirmed by some of the results seen here.  
 
3.3.3 General Risks 
 
When considering all the HCAI, there were some overarching themes as well as interesting 
discoveries. The risk factors found to be common to all the conditions can be categorised into four 
themes: increasing age; prior hospital admissions; antibiotic therapy and invasive devices. For 
invasive devices, such as peripheral or urinary catheters, it is not surprising that they are associated 
with the increased risk in all the different types of HCAI, as invasive devices allow a portal of entry 
for pathogens. Antibiotics can act as a protective factor, e.g. surgical prophylaxis, or aid the 
pathogen in becoming infectious as with C. difficile. Being exposed to hospitals increases the 
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likelihood of exposure to pathogens and as patients get older they can be exposed to healthcare 
more and have a higher number of comorbidities.  
An interesting result was the relative lack of papers seen throughout that related to the paediatric 
and neonatal patient populations. With the exception of C. difficile, where patients under the age of 
two do not develop this infection, neonates are generally seen as vulnerable patients. Overall, 8.8% 
of the included studies looked at neonatal populations, of which none were investigating SSI or HCA 
UTI.  
Secondly, certain risks generally perceived as being important, namely obesity, diabetes and invasive 
devices, were not necessarily found to be risks for all infections. For example, obesity, which has 
been identified as a risk factor for surgical site infections, was not researched specifically as a risk 
factor for HCA UTI. In fact, other than for SSI, it was found significant by only one other paper 
relating to ventilator associated pneumonia. BMI or obesity was included in 43 of the papers 
investigating SSI, whereas only 11 of the 225 other papers not looking at SSI had considered BMI or 
obesity in their models. This is something that needs further study, as being overweight is commonly 
considered as a risk for infections, not limited to SSI. On the other hand, being underweight, or 
having undergone recent weight loss was only investigated by six studies, but of these four found it 
to be an independent risk. This could have implications for patient management, such as requiring 
patients to lose weight prior to operations or procedures.  
Diabetes was included by over a third of the papers included in this review (133), however of the 29 
papers that found it to be an independent risk, 22 were investigating SSI. Again, this commonly 
accepted risk factor was limited in its significance in HCAI other than SSI, and in this instance having 
poor intra-operative blood glucose was also found significant. As only one study distinguished 
between a patient having Type 1 (insulin dependent or juvenile diabetes) or Type 2 (non-insulin 
dependent) diabetes, the relationship between this comorbidity and infection is not totally clear.     
The lack of papers relating to workforce factors, such as staffing levels on the ward was surprising, 
with the sole paper out of 340 which investigated staffing levels only using univariate analysis. The 
ratio of nurses to patients or the levels of hand hygiene compliance have been linked to infection 
rates (452), so the lack of consideration for these variables was a considerable oversight. At ICNHT 
some of this information is available electronically in the form of human resources databases and 
the recording of staff sickness and absences.  
Out of the 340 papers that were included in this review, 3.5% were based in the UK. This was fewer 
than expected, with the most papers from any one country being in the USA, followed by Canada 
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and Japan. Only six of the 138 (4%) papers included for SSI and HCA UTI reported that they had used 
electronic or automated data for their study, of which two were carried out in Canada, two in the 
USA, one in Italy and another in Spain; none of those studies from the UK utilised electronic health 
data. Most of the studies for these HCAI had collected the data specifically for their study, 
highlighting the novelty of using electronic automated data for risk modelling.  
 
3.3.4 Limitations 
 
There were several limitations that I need to highlight in this chapter, starting with the term of 
‘systematic literature review’. This term generally applies to studies that have been validated by a 
second reviewer, which in this case did not happen as I was the sole reviewer. However, I have 
termed it systematic as the inclusion criteria and search strategy were discussed with my supervisors 
and agreed upon, and I followed a clear methodical approach to minimise the potential for reviewer 
bias.   
In extracting and amalgamating the risk factors, and creating comprehensive tables of those risks 
factors investigated, those found significant and subsequently independent, I encountered problems 
in trying to group risk factors together. The different study settings, designs and populations, and 
diversity in local practices (such as antibiotic prescribing policies) might have masked the relevance 
and importance of certain risk factors. Different papers used various terms to describe the same or 
similar risks and condensing these into comprehensible risks and grouping the different variables 
posed challenges. This was particularly apparent for the risks that fell under the ‘biochemical 
markers and clinical features’ heading, as several papers did not report units or give quantifications. I 
made the decision to exclude these variables from any PAR% calculations, but kept them for the 
calculation of the number of significant and independent risks.  
Publication bias is defined as the likelihood of ‘positive’ results being more likely to be published by 
journals (453).  In this review, the effect of having a bias towards positive results would be to over-
inflate the significance and PAR% of a risk factor, or exaggerate its protective properties. Although 
some papers demonstrated that no risk factors could be identified for the prediction of HCAIs, the 
majority did show positive associations. Funnel plots are generally used to assess the effect of 
publication bias; however this was not done as it was inappropriate for the review question.  
Another aspect to bias in reporting positive results is that the likelihood of publishing in English 
increases, known as language bias (454). My inclusion criteria for this review specified papers 
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published in English only, and this could have introduced language bias into the review; however 
only 0.6% of the overall papers were excluded for being in a foreign language.  
The use of PAR% was appropriate for the purpose of stratifying the different risk variables, however 
there were two limitations regarding this aspect of the methodology. Firstly, only categorical 
variables could be included in the calculations. This meant that not all the data published in the 
papers could be taken advantage of for the PAR% calculations, and hence some of the values may be 
over or under-estimated compared to the true population value. The risk factors in which this was 
notable were age, BMI and risk scores, often analysed as continuous variables and not considered as 
categorical.  
The second limitation was the lack of comprehensive use across all the appropriate papers. The 
reason for this was the lack of information provided by the papers themselves, and several papers 
only reported numbers for those variables they found significant. This would have introduced bias 
into the PAR% calculations; in order to avoid this bias I could have chosen to include only those 
papers which published full raw data for all the variables they considered. I decided against this as it 
would have restricted the number of variables I could investigate and have biased the results in a 
different way. As the PAR% calculations were intended as a guide, not a concrete hierarchy, this 
methodology despite its limitations still fulfilled its purpose.  
Finally, when determining what independent variables were available in the local routine electronic 
hospital data, there were certain limitations in the terms and codes employed in recording 
healthcare data. For example, there are no specific codes for risk factors such as ‘underlying 
debilitation’ and ‘indication for catheterisation’, so these could not be directly extracted from the 
local data. Conversely, risk factors might be recorded under a specific code or term within the local 
hospital databases but these might not necessarily be accurate. For example, the keyword search for 
‘unconscious’ returned the ICD-10 code for ‘coma, unspecified’, which might not correspond to the 
clinical notes of a patient being unconscious during their admission. Similarly, the risk factor of 
‘meatal colonisation’ for HCA UTI for example, does not necessarily relate to the code identified for a 
meatal swab in the laboratory data. When determining whether a code or variable for one of the 
identified risk factors for SSI or HCA UTI were available locally, if a code was found in a keyword 
search then it was included, regardless of the potential misinterpretation.  
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3.4 Conclusion 
 
This chapter has demonstrated the wide use of predictive risk modelling for healthcare associated 
infections. However, it has also highlighted the lack of studies carried out in the NHS and the 
relatively rare exploitation of routine hospital data for these analyses. Using PAR% allowed for a 
guide to the relative importance of the different risks of SSI and HCA UTI; then investigating the data 
available in the routine hospital databases has demonstrated that many of the variables with 
significant PAR% could be found electronically.  This chapter has provided the knowledge base for 
me to exploit the existing hospital data for the risk modelling that was carried out in chapter 8.  
  
 87 
 
Chapter 4: Potential Data Sources for Developing Healthcare Associated Infection Surveillance Tools  
 
 
Summary  
 
This is the last of the background chapters, and is an overview of the various data sources which are 
collected and stored at ICHNT. This chapter describes the data types, their inherent advantages and 
disadvantages and specific features of the local data. This chapter acts as the rationale for the 
subsequent data analyses chapters.  
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4.0 Introduction 
 
Information technology (IT) within the NHS has developed in an ad hoc fashion, with different Trusts 
using disparate systems, varying database structures within single trusts and duplication of data 
sources at a local as well as national level. With over 750 databases located at ICHNT alone, there 
are a multitude of potential data sources that could have been used in this project (10).   
Recently, the NHS National Programme for IT (NPfIT), a project initiated in 2002, was dismantled due 
to the conclusion that it was unfit to deliver a modern IT service for the NHS (455). The objective of 
the programme was to improve and homogenise data across the NHS. The intention was to create a 
national data warehouse for patient data that linked primary and secondary care information, and 
introduced a standardised database system across English trusts. Although the project had fulfilled 
some of its objectives, such as the ‘Choose and Book’ system, the National Audit Office concluded 
that the programme did not deliver value for money and was unlikely to fulfil the remaining aims 
(456).  
At a local level, several IT projects are currently being both discussed and implemented, the most 
significant in this case being the creation of a data warehouse (10). This data warehouse will 
eventually house all routine data from Imperial College Healthcare NHS Trust, allowing patient data 
to be linked from multiple existing databases. This project is currently underway, meaning that there 
was no comprehensive linked data available for this project. Applications of this data warehouse 
include audit and surveillance, as well as the opportunity to use it for research; in the case of this 
project the intention would be that any tools created for surveillance could be applied in the linked 
data warehouse. Patient records have been made fully electronic in other settings, meaning all the 
information recorded during a patient stay would be available for automated analysis. In the 
absence of such a system at ICNHT, research and innovative surveillance tools must be founded on a 
combination of data resources. 
This chapter introduces the potential data sources currently established within the NHS 
environment, including all those being utilised by this project. Methodologies of collection and 
current uses for the data, and a discussion of the advantages and disadvantages associated with this 
data type are presented, followed by an overall discussion on administrative and surveillance data in 
relation to this project.  
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4.0.1 Aim and Objectives 
 
The aim of this chapter was to provide a comprehensive overview of the data used in the 
subsequent analyses to provide context for the ensuing analysis chapters. The objectives were to 
explore the strengths and weaknesses of the different data sources and to outline those potential 
data sources which were not used during this project, as well as those that are.  
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4.1 Data Sources at ICHNT 
 
The seven different data sources I used in this project are diverse in their methods of collection and 
storage, purpose and target audience, along with the nature of the data itself. The data sources are 
as follows: Patient Administrative System data (PAS); Laboratory data; Radiology data; Point 
Prevalence Survey data; HPA SSI surveillance data relating to CABG patients; Cardiothoracic Surgeon 
Registry data, and caesarean SSI surveillance data which was based on an intervention study. 
However, as stated previously there are over 750 databases at ICHNT, most of which were not used 
in this project, although they potentially contained a vast amount of relevant data for developing 
innovative surveillance tools. Reasons for not utilising these data include ethical restrictions on the 
study, lack of time to collate and analyse all the potential data sources and therefore the relative 
precedence of certain data types over others.  
 
4.1.1 Routine Administrative Hospital Data 
 
Routine administrative data refers to the databases within the hospital that contain information 
which is collected and stored as routine practice in the day to day running of the hospital. This 
covers information including patient admissions and discharges, the laboratory test results obtained 
from patients during their stay, information on staff sickness and logistics, estates and finances. 
These data are collected and stored without the purpose of research in mind; as such, their 
information architecture in constructed with operations rather than research in mind and the data 
may not contain all the desired relevant information. The main administrative data sources are 
described below, starting with those I have used. 
 
Patient Administration System 
 
The Patient Administration System data contains information on patient admissions, discharge 
diagnoses and procedures (457). The data are stored as patient episodes - an episode being a period 
of hospital stay under one consultants care - and this system feeds into the national Hospital Episode 
Statistics (HES) dataset. The HES dataset combines administrative data from hospitals nationwide 
and is used widely for research purposes, having undergone a standardised anonymisation and 
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cleaning process.  The PAS data used in this project has not undergone the cleaning process that it 
does for HES, so the results found in this study will not necessarily correspond to those reported 
when using Imperial College Healthcare NHS Trust’s HES data.  
HES were established in the late 1980’s and data are available from 1989 onwards, although the 
data are not consistent during this time period (457). Currently all procedure codes are stored as 
Operation and Procedure Codes (OPCS) version 4.4, introduced in 2008, and all diagnostic codes are 
recorded using the International Classification of Diseases version 10 (ICD-10), introduced in 1995.  
PAS forms the backbone of the electronic administrative data; since all the patients admitted to 
hospital should have a record; this is likely to be the only system within the hospitals that should 
contain a comprehensive list of admitted patients. However, difficulties lie within the unique 
identification of a patient, as different hospitals at ICHNT assign different patient identifiers. 
Furthermore a patient who is re-admitted to the same hospital may not be given the same ID on 
each occasion if they cannot be matched to their previous admission. This means that a patient 
cannot always be tracked through the PAS system or from one hospital to another.   
This database relies heavily on coding systems for storing large amounts of patient information, 
where ICD-10 and OPCS codes form a substantial portion of the data. Whilst these coding systems 
are standardised, with guidelines published on the correct use of codes to assign for conditions, as 
well as instructions on the types of conditions that should be coded for, there remain issues with the 
accuracy of this information (458, 459). One of the reasons for inaccuracies is the quality of the 
patients’ paper notes, from which the codes are derived, as details may be hard to decipher and 
information may be misrepresented or omitted. Secondly, clinical coders are non-clinical members 
of staff in the NHS and as such, there can be discrepancies in understanding about the information 
recorded on patient charts. This can make coding standards across key diagnoses difficult to 
maintain; this could be especially problematic when more than one code, or several non-specific 
codes are needed to describe a particular diagnosis.  
Studies focussing on the accuracy of clinical coding have varied greatly in their conclusions as to the 
validity of using ICD-10 codes (458). However, the vast volume of data available in this medium 
makes it worth investigating for surveillance purposes.  
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Laboratory Data 
 
At ICHNT there is one central laboratory which processes all laboratory samples from the five 
hospitals. The merging of these hospital laboratories took place as recently as 2010, and as such 
there are still two IT systems operating simultaneously in the one laboratory. In this project, the 
entire laboratory data were taken from the Mysis database system, which does not included any 
data from St. Mary’s hospital. The laboratory data contains information from the six different 
departments within the pathology department, storing data on the tests requested and results 
obtained. I used data from three of the six departments, all of which are described below, along with 
the tests considered relevant for analysis in this project (Table 4.0). 
 
Microbiology 
 
This department looks solely at cultures for pathogens, including routine MRSA screens which make 
up the majority of the workload. This department is crucial for this project as many of the HCAI 
definitions rely on positive microbiology for a diagnosis to be made, especially in the case HCA UTI. 
However, I identified an issue in the completeness of archived microbiology tests that was not 
present in the other laboratory departments’ data.  
As the dataset produced by the laboratory department is so vast, after six months the data are 
transferred from a live system onto a backup system where it is archived. However, due to the 
nature of the data structure, there are often several ‘result’ records for a single microbiology culture, 
each containing distinct parts of the result. For example, in urine cultures it is routine to report not 
only the organism but the number of colonies, as this is crucial in distinguishing between normal 
colonising flora in the urine and an infection. I found that when the data were being transferred to 
the backup system, only one ‘result’ record was being kept for each test and the others falsely 
discarded as duplicates, rendering the results incomplete.  
As a consequence of this incompleteness, the microbiology data dating back to 2009 and 2010 were 
used in a binary format for this project, with the existence of the record rather than the result itself 
being considered for the analysis. The ‘live’ system however contains complete results for each 
microbiology culture and six months of data from the live system was also exploited for this project.  
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Clinical Biochemistry 
This department processes all tests relating to the chemical makeup of bodily fluids, such as blood 
and urine. In addition the tests to monitor the levels of drugs in the system (i.e. alcohol, poisoning 
and antibiotic levels) are processed through this department. The main workload is routine blood 
tests, such as liver functions tests, bone profiles, C-reactive protein (CRP), urea and electrolytes and 
this project will be investigating these routine tests as potential markers of infection (Table 4.0).  
 
Haematology 
The haematology department is used for blood tests regarding clotting, blood counts and 
transfusions, but also more specialised tests such as malarial screening. The main workload for this 
department is full blood counts, which are performed routinely in many patients; these tests were 
also investigated in this project as potential markers of infection.   
 
Cell pathology 
This laboratory department includes cytopathology, histopathology, and electron microscopy and 
mortuary services and these diagnostic tests are generally concerned with cancer diagnostics (e.g. 
smear tests are processed through this department). This project will not be utilising data from this 
department, as it is not directly relevant in diagnosing HCAIs.  
 
Immunology 
The main work in this department relates to histocompatibility, immune-genetic and autoimmunity 
testing and monitoring immunity and immunodeficiency. These tests are used to determine 
allergies, certain forms of autoimmune disorders and the presence of antibodies for a selection of 
infections such as Hepatitis, HIV and measles. Despite antibody testing being relevant for diagnosing 
certain infectious diseases, the types of infection being investigated in this project will not have 
antibody tests carried out e.g. an E. coli UTI, therefore this department’s data were not  used in this 
project.  
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Virology / Mycology 
This department processes all virology and fungal samples. These data are stored separately to the 
rest of the laboratory data, with only a small sample of the virology information available in the main 
laboratory data extracts available for this project. Again, the types of infections being modelled by 
this project are generally bacterial however detailed virology and mycology data could not be 
investigated.  
  
Radiology Data 
 
Information on diagnostic imaging exams are stored in two formats, on two different systems, one 
as the request information and the second as the images themselves. In this project I used the data 
on requests and not the image data or the reports detailing the findings of the exam. The reason for 
this was that the radiology department could not provide general extracts from the system 
containing images and reports, as it is only able to export using single patient ID look ups. Also, the 
results of the diagnostic imaging investigations are presented as free text reports. In the absence of 
standardised terminology guidelines within the Trust, keyword searches for specific outcomes and 
results would have been laborious to develop, with any number of ways to describe a particular 
result.  
The data associated with radiology requests include the date of investigation, the type of exam 
performed (e.g. ultrasound or x-ray) and the body location of the exam. It also stores information on 
the specialty of the patient and the consultant in charge of ordering the investigations. This project 
used data from 2010 – 2011; however the data from 2009 was not available as it was stored on a 
different database system. The legacy system’s archives had not yet been harmonised onto one 
system and extracts were reportedly difficult to produce.  
 
Pharmacy Data 
 
Information on antibiotic and drug therapy at Imperial College Healthcare NHS Trust is still stored in 
paper format, with records on antibiotic prescribing for patients digitalised only during biannual 
audits. However, treatment with certain antibiotics (amikacin, gentamycin and vancomycin) can be 
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determined from the blood level tests carried out as routine when treated with these specific 
antibiotics. 
 A long term plan for ICHNT is to implement electronic prescribing records; however in their absence 
antibiotic data were limited for this project. Other studies, including one at Imperial Trust, have 
shown the utility of antibiotic prescription as a proxy indicator for infections (116, 460); the lack of 
this information in an electronic format was a limitation for this project.  
 
Accident and Emergency Data 
 
Data are collected when patients arrive at the accident and emergency (A&E) department and 
stored in the ‘Symphony’ database. This data source has substantial potential in infection 
surveillance as many re-admission cases are likely to be admitted through the A&E department, and 
‘Symphony’ has a re-admission variable. It has potential for use in syndromic surveillance, and many 
of the syndromic surveillance systems established to date are based on A&E data (117, 461).  
However, there were issues with the A&E data, which meant I was unable to exploit this database 
for this project. Firstly, this data system uses a different patient ID to other hospital systems as 
patients are assigned a temporary hospital number; this quirk of the ICNHT IT systems means that 
accident and emergency data are hard to harmonise with the rest of the data. Secondly, due to the 
provision of the database system by an external company there were some difficulties in accessing 
the back end of the Symphony database within the time frame of this thesis.  
 
Theatre Data 
 
Information about surgeries is collected in the ‘TheatreMan’ database; this system is a management 
tool for planning and monitoring surgical activities. Access to this data system would have been 
desirable for this project; however delays in other aspects of the data access process meant that this 
database was not prioritised for linkage in this project. This database has the potential to be 
exploited for infection surveillance in the future as it could have information stored on risks and 
predictors of surgical site infections not routinely captured anywhere else.  
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Estates and Finances Data 
 
Administrative data also covers that information collected and stored by non-clinical departments, 
such as estates and finances. These data are not being used in this project, as it was not considered a 
priority for linkage and acquisition. In the future when these databases are integrated into the linked 
data warehouse there is potential to use it to monitor changes in infections according to building 
works, opening and closing of wards and modelling changes in the products supply chain, such as 
switching types of alcohol gels.   
 
Staff Absence Data 
 
Information on staff absence is collected by two different systems at ICHNT, a specific database for 
staff illness and the overall human resources (HR) database, resulting in duplication in this area of 
administrative data. The former data source contains information on the number of staff absences, 
the reason for absences, staff grade and ward in which they work. The NHS is the largest employer in 
the UK and one of the largest worldwide, and the quantity of comprehensive data collected 
regarding their health, presents a significant opportunity to carry out research on this cohort of 
people.  
These data are being investigated for their potential in generating early warning alerts for outbreaks 
based on the levels of infections circulating in the community by a member of my research group,  
hence I am not using it in this project (462). This data source has great tangential potential in 
developing surveillance systems for healthcare associated infections, for example in patient to staff 
ratios on the wards, as well as for mapping infection transmissions from the community to the 
hospital.  
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Table 4.0: Definitions of biological markers of infection and their interactions (463-465) 
Marker Definition / Mechanism of action Normal range* 
Indications for increased 
levels 
Indications for decreased 
levels 
Status in Subsequent 
Analyses 
C-reactive 
protein 
An acute phase protein produced by the liver in 
response to inflammatory cytokines. Acts as a 
pattern recognition receptor, binding to exposed 
phosphocholine motifs to initiate complement 
cascades and further immunological response 
0 – 10 mg/L 
Acute inflammation, e.g. 
bacterial infection; 
burns; late pregnancy 
(mild increase) 
- Significant 
White Blood 
Cell count 
Major component of the immune system, protecting 
the body against foreign substances and producing 
antibodies  
4.0 – 11.0 
x109/L 
Infection; allergic 
reaction; acute 
inflammation (see 
specific WBC types) 
Chemotherapy; specific 
infections (see specific 
WBC types) 
Significant 
Eosinophils 
Type of white blood cell which responds to 
inflammation and helminthic infections. They 
release chemical mediators following activation, 
which are toxic to parasite and host tissues 
0.0 – 0.4 
x109/L 
Allergic reactions; 
parasitic infections; 
vascular disease 
Cushing’s syndrome; 
steroid use Significant 
Basophils 
Type of white blood cell, Involved in inflammatory 
and allergic reactions, specifically releasing heparin 
and histamines  
0.0 – 0.1 
x109/L 
Inflammation, generally 
from allergic reactions Pregnancy; acute infection Significant 
Lymphocytes 
Type of white blood cell involved in cell killing 
through the release of cytotoxic granules, producing 
antibodies and cytokines. They also produce 
memory cells, allowing more rapid response to 
familiar pathogens 
1.0 – 3.5 
x109/L 
Viral infections; 
ulcerative colitis; 
lymphatic leukaemia 
Chemotherapy; congestive 
heart failure; malignancy; 
certain infections (e.g. 
AIDS) 
Not significant 
Monocytes 
Type of white blood cell, which responds to 
inflammation and differentiate into macrophages 
and dendritic cells for phagocytosis, cytokine 
production and antigen presentation  
0.3 – 1.0 
x109/L 
Acute infection; 
autoimmune disorders 
Arthritis; prednisone 
treatment Not significant 
Neutrophils Type of white blood cell which responds to 
inflammation, migrating to sites of infection or 2.0 – 7.5 
Acute inflammation and 
infections; haemorrhage; 
Ineffective cell production 
in certain infections (viral); 
Not significant 
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injury, amplifying the inflammatory reactions by 
releasing cytokines. They directly attack micro-
organisms through phagocytosis  
x109/L stress; obstetric labour severe renal injury 
Band 
neutrophils 
Immature neutrophils with an unsegmented 
nucleus. When there are more of these immature 
cells present than mature segmented cells, this is 
termed ‘left shift’ 
0.0 – 0.7 
x109/L 
Acute infection 
(bacterial); severe 
anaemia; leukaemia 
Certain infections (viral); 
ineffective cell production n/a 
Fibrinogen 
An acute-phase protein. Exposure of cells containing 
tissue factor initiates a cascade system for clotting in 
which fibrinogen is the precursor to fibrin (involved 
in clot formation) 
1.5 – 4.0 g/L 
Pregnancy; 
cardiovascular disease; 
inflammation 
DIC (several causes 
including: cancers, pre-
eclampsia; trauma, gram-
negative sepsis) 
Significant 
Platelets 
Produced in blood cell formation, budding off from 
megakaryocytes. They are activated when damage 
to endothelial cells exposes them to the 
bloodstream 
120 – 400 
x109/L 
Wound repair; 
Inflammation (injury, 
infection & surgery); 
malignancy; anaemia or 
haemorrhage 
Renal insufficiency; 
toxaemia of pregnancy; 
septicaemia and blood 
loss 
Significant 
International 
Normalised 
Ratio 
This ratio represents a patient’s prothombin time 
(time for plasma to clot) divided by the normal or 
‘control’ prothombin time. High INR indicates a high 
chance of bleeding and a low INR indicates a high 
chance of clots  
0.9 – 1.1 
(ratio) 
Warfarin treatment; DIC; 
vitamin K deficiency; 
liver failure 
- n/a 
Erythrocyte 
Sedimentation 
Rate 
The rate at which red blood cells settle out of 
suspension in blood plasma. When increased levels 
of pro-sedimentation factors are present in the 
blood (e.g. fibrinogen), clumps will form, increasing 
the rate of sedimentation. This generally reflects an 
inflammatory response 
0 – 12 mm/hr 
Infections (including 
bacterial & acute 
hepatitis); following 
open heart surgery; 
pregnancy (from the 3rd 
month onwards) 
Congestive heart failure; 
sickle cell anaemia n/a 
Procalcitonin 
A peptide precursor of the hormone calcitonin.  It 
responds to inflammation (especially bacterial 
infection), produced by cells throughout the body, 
<10 pg/mL 
Neuroendocrine 
tumours; bacterial 
infections; trauma; 
- n/a 
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which lack the capability to convert procalcitonin to 
calcitonin. Therefore high levels indicate an 
inflammatory reaction 
sepsis 
Haematocrit 
The percentage volume of red blood cells in blood. 
Red blood cells are one component of blood and 
their expected volume can increase or decrease for 
several reasons 
37 – 52 % 
Relative increase in 
dehydration; COPD; 
shock  
Haemorrhage; anaemia 
(chronic or acute); 
pregnancy 
n/a 
Albumin 
This is the main blood plasma protein, principally 
formed in the liver. It is responsible for transport of 
large organic anions and maintaining osmotic 
pressure 
33 – 47 g/L 
Relative increase in 
dehydration; IV albumin 
infusion 
Chronic infections can 
cause impaired synthesis; 
trauma and infection can 
increase albumin 
breakdown; pregnancy 
Not significant 
Creatinine 
This waste product (the breakdown product of 
creatine phosphate) is filtered out of blood by the 
kidneys, therefore levels in urine and blood can 
indicate glomerular filtration rate 
60 – 125 
µmol/L 
Severe kidney 
impairment (ingestion of 
roast meat which 
contains creatinine); 
muscle disease 
Pregnancy Not significant 
*Unless otherwise stated this is the standard reference ranged used by the Imperial College Healthcare NHS Trust laboratory. Those markers with ‘n/a’ in the ‘included in 
subsequent analyses’ meant there was insufficient data for investigation or in the case of procalcitonin and neutrophil banding, these tests are not carried out at ICHNT. 
DIC: disseminated intravascular coagulation 
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4.1.2 Active Surveillance Data 
 
In contrast with the routine administrative data already described, active surveillance data (or 
traditional surveillance) are collected with the express purpose of reporting the incidence or 
prevalence of infections, monitoring processes and events and to provide information on trends and 
patterns over time. This type of data requires purposeful collection, storage and reporting of 
information for a specific purpose, beyond that which is carried out routinely.  
As discussed in chapter 2, surveillance of HCAIs in the UK can be mandatory or voluntary and at 
ICHNT both forms of surveillance are carried out in relation to different healthcare associated 
infections. There are several methods for carrying out surveillance, with continuous, one off surveys 
and periodic surveillance all forming part of an active surveillance approach.  
 
Point Prevalence Survey Data 
 
The fourth European point prevalence survey (PPS) on HCAIs and the first point prevalence surveys 
on antimicrobial use and quality indicators were performed in 2011/2012 in the UK. These collected 
information on infection rates, types, and causative organisms, antibiotic prescribing and invasive 
devices. The European Centre for Disease Control (ECDC) prevalence survey was carried out at 
Imperial College Healthcare NHS Trust in September 2011 and was performed at the Charing Cross 
Hospital site only, over a period of three weeks.  Prior prevalence surveys have taken place in the 
UK, in 2006 a prevalence rate of 8.2% was reported and a prevalence survey on antimicrobials 
undertaken in 2009 showed a prescription rate of 27.8% (451). Using a standardised European 
survey allows for cross-country comparisons, as well as comparisons between infection rates within 
the UK.  
A standardised methodology was used across all participating hospitals and has been published (2). 
Briefly, all wards were included in the study with the exception of day cases and long term care 
facilities. The patients included in the study comprised any patient present on the ward at 8am on 
the day of the audit, even if the patient had already been audited in a different ward and these 
patients formed the denominator. Patients with an HCAI according to the standard definitions on 
the day of the survey made up the numerator. In the case of any dispute about an infection being 
present, or the classification of the infection, it was discussed between the IPC nurses and a 
conclusion was made at the time of survey.  Data collection and organisation was led by the 
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pharmacy team and the infection prevention and control (IPC) nurses, with any one ward being 
surveyed simultaneously by a senior and junior IPC nurse and an antimicrobial pharmacist.  I took 
part in data collection for all but two wards and was solely responsible for all the data entry in this 
study; this allowed me to have immediate access to the data for analysis.  
Alongside this prevalence survey, I designed an additional local form (Appendix 4) to capture data on 
risk factors, building on prior research performed at this trust in developing syndromic surveillance 
(116, 460). The purpose of the extra data collection was to investigate risk factors in the population 
and allow for validation of the PAS data. The selection of those risk factors to be included in the 
additional form consisted of several inputs; firstly, those that were found to be important predictors 
from the established literature (chapter 3); secondly, those that were available within existing 
administrative hospital data. Finally those variables that would not take a lot of time or effort for the 
nurses / pharmacists to collect were prioritised, as determined in discussions with the lead IPC nurse 
and antimicrobial pharmacist.   
Data collection for the IPC nurses took 56 hours with three people participating in the collection 
(with the exception of two days) and pharmacy data took 23 hours to collect. In addition data entry 
took 21 hours, incorporating time for re-entry subsequent to an error in the standardised ECDC 
software. In total 100 hours were dedicated to the collection and entry of the data for the PPS at 
Charing Cross Hospital. Using the antimicrobial information, alongside electronic microbiology and 
radiology information produced a dataset that was both sensitive and specific for identifying cases of 
HCAI (116, 460), suggesting the same information collected in the PPS could have been determined 
in a quarter of the time (the 23 hours for pharmacy data collection).    
The overall prevalence rate of 8.8% found by the PPS at Charing Cross hospital was similar to that 
found by the previous PPS performed in the UK, as was the rate of antimicrobial prescription. Other 
countries have also reported similar rates in the last few years, such as a healthcare associated 
infection rate of 8.7% in Canada (466) and 8.5% in Finland (467).  
Most of the information gathered during this point prevalence survey was available electronically in 
local databases and considering the amount of time spent organising, collecting and entering data, 
there is likely to be a more efficient way to produce this information. In addition, point prevalence 
surveys, unless preformed on a regular basis, provide little information other than an isolated 
snapshot. It does not provide any context on the patients; as noted on the data collection ward 
rounds, several patients were known to the IPC nurses as having had infections but on the day were 
no longer HCAI positive. This meant that any sort of risk analysis performed utilising these data 
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would likely be skewed, as the distinction between the ‘controls’ and ‘cases’ was not necessarily a 
true one.  Therefore these data were only used is descriptive analyses throughout this project.  
Another issue that became clear in the data collection was that despite the HCAI definitions being 
standardised and strict, the patient notes on the other hand often did not provide sufficient 
information to make a confident decision on a diagnosis.  There were two aspects to this issue with 
the patient notes, firstly a lack of information in the notes, relating to vital dates and clinical or 
diagnostic information. The second regarded misdiagnosis within the notes.  I encountered several 
examples of patients diagnosed with ‘hospital acquired pneumonia’ in their notes, but these patients 
failed to meet the ECDC definitions, for example only having been admitted   for one day before 
being classified as a HAP case (and having had no recent hospital exposure).  
  
Voluntary HPA SSI Surveillance Data 
 
The infection prevention and control nurses and lead cardiac nurse at Hammersmith Hospital carry 
out surveillance for surgical site infections following CABG procedures; this initiative started in 
January 2011.  This is a voluntary surveillance activity using standard methodology set out by the 
HPA (468), with the purpose of detecting and reporting post-CABG surgical site infections that occur 
within 30 days of the surgery.  
Surveillance rounds are carried out once weekly by an IPC nurse and the lead cardiac nurse. All 
patients on the cardiac post-surgery ward, cardiac ICU and general cardiac ward that had undergone 
CABG surgery are physically reviewed where possible and their patient charts interrogated for the 
relevant information. The information is submitted to the HPA on a quarterly basis, where it is 
cleaned and reported back to the Trust, this process usually taking another two to three months.  
The patients with surgical site infections identified by the HPA SSI surveillance were used as the ‘gold 
standard’ during analyses in this project, as in theory these patients have met the strict definitions 
for a SSI set out by the HPA protocol. However, there are certain issues that need to be raised with 
this data source which need to be kept in mind during the analyses. Firstly, it is possible that the 
surveillance missed patients, and failed to identify patients with infections. Surveillance was not 
carried out every day, and given the standard patient pathway of a five day post-operative stay, it is 
likely that patients were missed from the surveillance. Take for illustrative purposes the example of 
a patient undergoing an operation on a Wednesday - the day on which surveillance rounds are 
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carried out. If this patient were to be in surgery when the nurses came to collect the data, the 
patient record would not be on the ward, preventing the completion of a form for that patient. If the 
patient is then discharged five days later (on a Monday) with a red, sore, inflamed wound and a 
prescription for antibiotics, again no data would be collected on the next surveillance round. It is 
possible that this patient had a SSI developing on discharge and would have met the conditions for a 
SSI under the surveillance definitions; but in this case not only would no infection be recorded but 
the patient would not be captured at all.  
The second problem with the HPA SSI surveillance data is that discussed previously in Section 4.1.0 
pertaining to PAS data. The patient notes themselves may not be detailed enough to make a 
confident diagnosis. Combined with the fact that often the wounds cannot be physically examined as 
they are covered in dressings or the patient is not on the ward, means that SSI may not always be 
diagnosed by the surveillance ward round. I saw an example of this on the surveillance round I 
attended – a patient had been re-admitted with a deep SSI according to the IPC nursing staff, but the 
patient notes had the reason for re-admission as pneumonia and antibiotics had been prescribed 
accordingly. In this case, the IPC nurses had examined the patient themselves and could clearly 
identify a wound infection; however, in a situation where a physical examination isn’t possible the 
surveillance would have misreported no infection.  
Thirdly, the criteria for diagnosing a SSI according to the HPA protocol raises questions, as a 
physician diagnosis or antibiotic prescription are sufficient to diagnose an infection. This means that 
surgical site infection diagnoses can be subjective, as they depend on the tendencies of the 
surgeons. Surgeon behaviour in diagnosing SSI could lead to either an over or under-diagnosis of SSI 
in the CABG patients and the subjectivity introduces uncertainty into the quality of this dataset.  
Despite these limitations in the surveillance data, this type of surveillance has the added value of 
post-discharge follow-up. This means that the patients are contacted at 30 days post-surgery and 
asked to complete a questionnaire in an attempt to diagnose any infections that have developed 
whilst in the community. This is an aspect of SSI surveillance that electronic surveillance based on 
administrative hospital data could not capture without linkage to primary care records. This form of 
surveillance is the best indication of the incidence of SSI amongst CABG patients that is available at 
ICNHT and will be used as the best representation of infections in this project.  
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Mandatory HCAI Surveillance Data 
 
Mandatory surveillance has been implemented in the UK for several years for a select group of 
healthcare associated infections. The infections covered by this surveillance requirement are C. 
difficile, MRSA bacteraemias and more recently E. coli and MSSA bacteraemias, and SSI following 
orthopaedic procedures, all of which are collected and reported by ICHNT. These data are publicly 
reported for all Trusts and are available online for anyone to access. 
Despite the long running datasets from multiple trusts, I am not investigating these infections. The 
grounds for this are that this reporting system is already in process and the emphasis of this project 
on the development of cheap, efficient electronic surveillance tools that can target a wide range of 
infections. As infection rates are high in surgery types not covered by mandatory surveillance, such 
as the CABG patients, it makes this group of patients a more effective focus. Similarly the numbers of 
HCA UTI are far higher than MRSA bloodstream infections (3), and the reduction in morbidity 
associated to HCA UTI could be hugely beneficial.  
 
Safety Thermometer Data 
 
The Safety Thermometer was an initiative launched at the beginning of 2011, with the intention of 
monitoring indicators of patient care by nurses. The measures chosen for collection include pressure 
ulcers, catheter associated urinary tract infections and deep vein thrombosis, as these are all 
considered to be conditions that are preventable through effective nursing care.  This is the only 
national initiative to include surveillance of catheter associated urinary tract infections (469).  
This would have been  an excellent data source for my project, providing ‘cases’ of CA-UTI to model 
the administrative data against, however the safety thermometer was only launched  at ICNHT in 
July 2012, making it too late to exploit.  
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4.1.3 National Cardiothoracic Registry Data 
 
In the UK there are several national registries which cover a wide range of diseases, surgery types 
and patient populations, for example:  the national lung cancer audit; paediatric intensive care and 
the sentinel stroke report. This small example of national registries demonstrates the diversity of 
these data sources. For this project I am specifically interested in the Adult Cardiac Surgery Registry 
(ACSR), as it contains information relating to CABG patients.  
The ACSR was created in 1977 as a voluntary reporting system for hospitals to contribute data on 
cardiac surgeries by Sir Terence English and Dr Alan Bailey (470). The registry has been receiving data 
from participating NHS hospitals continuously since then and is under the control of The Health and 
Social Care Information Centre (HSCIC) and the Society of Cardiothoracic Surgeons of Great Britain 
and Ireland (471). The data are held by the cardiac surgeons, who are responsible for collecting and 
submitting the data, and the information covers operation details, the patients’ underlying 
conditions, and operative outcomes including mortality and re-operation (472).  
This data source has several advantages, firstly the duration for which it has been in use, and the 
detail of the variables which are collected. A large advantage of this data set, as with surveillance 
data routinely collected in the hospitals by the infection prevention and control teams, is that it does 
not rely on the interpretation of patient records by a coding team. The data collection forms are 
completed by the cardiac surgeons, and so the reliability of the data can be assumed to be high, 
especially on the details of the operations which they have performed. However, completeness of 
the data may be questionable as collection is voluntary and the diligence with which data are 
collected and submitted between different surgeons can be expected to vary.  
A major disadvantage for this project is that whilst surgical outcomes are recorded by this registry, 
post-operative infection is only recorded if the patient needs a re-operation for debridement of the 
wound or if they have a deep sternal wound infection. As surgical site infections can be considered a 
negative outcome for surgeons, the reliability of this variable may be questionable.  
These data are generated and stored locally by the cardiac surgeons prior submission to the national 
dataset. For this project, working in collaboration with the local data lead for the cardiac registry 
data, I obtained an extract containing data on CABG surgeries from January to September 2011. Data 
on surgeon specific details were not permitted for this project; this is sensitive information and due 
to the voluntary self-reported nature of this data source the surgeons did not authorise the release 
of this aspect of the data.  
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4.1.4 Intervention Study Data  
 
Studies are conducted frequently in the NHS either to assess interventions or investigate explicit 
clinical hypotheses and these studies will generally collect very specific data. These studies form 
another source of data that could be used not only for the original purpose of the study, but also for 
developing surveillance. Conversely, there is great potential for these studies to use routine data 
rather than expressly collecting all the information needed for each study; this would save time and 
money, thereby allowing for more detailed studies to be carried out.  
In this project, study data from an intervention among caesarean section patients was used (473). 
This study was carried out by the showcase hospitals; showcase hospitals are a group of eight trusts 
that have been selected to pioneer new technologies and innovations to control healthcare 
associated infections. The intervention being assessed by this particular study was to compare the 
incidence of surgical site infections after caesarean sections between patients that had a 2% 
chlorhexidine gluconate (CHG) antiseptic wipe used before surgery and those that did not.  
The cloths being tested are packaged in such a way as to provide easy-to-apply antiseptic, with the 
protocol indicating that patients are to be given the cloths to disinfect themselves prior to surgery. 
The study was based on a rationale that a 40% reduction in SSI could be achieved by using this form 
of pre-surgical preparation, added to the fact that rates of SSI in caesarean operations have been 
reported as over 10% (150). Whilst this is similar data to the surgical site infection surveillance data 
that the HPA collects, it does not adhere to the standard HPA protocol.  
The study protocol had several limitations; firstly, there was no standardised follow-up period during 
which the patients were required to be reviewed. In the standardised HPA surgical site infection 
surveillance scheme, patients are followed up for 30 days, the commonly accepted period during 
which an infection attributable to the surgery could develop. In this protocol it was left to the 
discretion of the community midwife to discharge the women from care and at this point the follow 
up ended. This could have affected the number of SSI detected, as those women that appeared to be 
recovering well and discharged could then go on to develop an infection.  
The second issue was that following up all the patients was not straightforward as many caesarean 
sections are emergencies and the hospital to which the patient is admitted may not be their local 
hospital. This can lead to a situation where the community midwife and the GP that are responsible 
for the post-discharge assessments may not be known to the hospital. Similarly this could mean that 
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re-admissions related to SSI could be to other Trusts, and would thus not be picked up by this 
surveillance.  
Finally, the study was being led by the showcase hospitals, but the majority of data collection 
regarding infections was being carried out in the community. This is likely to lead to confusion in 
data collection, submission and management, which could result in incomplete data and missing 
patients. That is why, whilst I used this study as the ‘gold standard’ for SSI cases in the caesarean 
section analyses, these limitations must be kept in mind during the analysis.  
 
Table 4.1: Summary of the Advantages and Disadvantages of Different Data Sources 
Data Type Advantages Disadvantages 
Point Prevalence 
Data 
 Comprehensive list of infections & 
specialties covered 
 Rigorous methodology 
 Comparable across sites in the UK and 
the EU 
 Antimicrobials included  
 Labour and resource intensive 
 Rare 
 Does not capture time / no follow up 
 Does not allow attribution to be 
determined 
Routine 
Administrative Data 
 Cheap, efficient and timely for research 
use 
 Continuous data supply, with 
retrospective capacity 
 Passive and active systems are possible 
 Accuracy and completeness of the data 
are questionable 
 Complex structures and processes 
 
HPA SSI surveillance 
data 
 Thorough follow up of patients (30 day 
SSI follow up performed) 
 Rigorous, standardised methodology 
used – HPA protocol 
 Continuous cohort of patients  
 Time consuming 
 Labour intensive 
 Small patient population and no 
generalizability 
National Registry 
data 
 Long duration of data collection 
 Detailed information, not necessarily 
captured elsewhere 
 Filled in by the surgeons, does not rely 
upon coding standards 
 Is very specific, so does not cover the 
majority of surgeries or patient 
populations 
 Depends on surgeon dedication for 
maintenance and data collection 
Mandatory HCAI 
surveillance data 
 
 Consistent methodology across all UK 
Trusts 
 Regular data updates and published 
rates 
 Rigorous methodology 
 Limited number of infections 
 No demographic or risk factor 
information 
 Time consuming and resource intensive 
Intervention Studies 
 Can include information not found 
elsewhere 
 Detailed and specific information 
 Specific to a particular question being 
researched 
 Issues in data ownership for the study 
 Sporadic and generally short 
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4.2 Data Governance  
 
Ethical approval was granted to CIPM by the St. Mary’s National Research Ethics Committee (REC) 
for the project “developing and utilising surveillance schemes including novel uses of existing 
databases to enhance surveillance capability of healthcare-associated infections (HCAI)” allowing the 
use of anonymised NHS data (REC reference number: 09/H0712/85 – Appendix 5).  
All the data used in this project was done so with ethical approval and the permission of those that 
manage the different datasets. In the case of the ECDC prevalence survey, I also contributed to the 
collection and entry of data. All parties were made aware of the project and a data management 
protocol was agreed upon for the correct handling, storage, management and interpretation of the 
data used. A summary of the data sources used in this project are presented in Table 4.2. 
 
Table 4.2: Summary of the Data Sources being used by this Study 
Database name Responsibility Data contained and used 
HPA SSI surveillance data IPC nurses / HPA CABG surgery follow up for surgical site infections 
Cardiac Registry data Cardiothoracic surgeons CABG surgery risk factors, patient demographics and surgical details 
ECDC PPS data IPC nurses / CIPM Point prevalence survey on HCAIs, antimicrobials and invasive devices 
Caesarean surveillance 
data IPC / HPA 
Caesarean section surgery follow up for 
surgical site infections 
Radiology data Radiology department (CPG 6) Diagnostic imaging investigation requests and investigation type 
Laboratory data Pathology department (CPG 6) Microbiology, haematology and clinical biochemistry test requests and results 
PAS data Imperial NHS IT department Patient admissions, demographics, diagnosis and procedure codes 
 
The data were stored on an NHS server within the NHS system, encrypted and anonymised by the 
CIPM Database Manager. All the data underwent a one way encryption process and then different 
records linked via the unique CIPM patient identifier produced for each patient. This was done using 
a SHA256 hash algorithm, devised by the CIPM database manager. This encryption process was 
based on a set of patient identifiers (date of birth, hospital number and NHS number) and these 
identifiers were subsequently removed from the data. The data were then uploaded to a secure 
remote server held and managed by Imperial College central IT, accessed by CIPM researchers 
through a secure network connection. This process, which was all in compliance with the ethics 
approval received for this project, allowed for different anonymised databases to be linked whilst 
encrypted.  
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Figure 4.0: Schematic of the data sources used in this project 
  
 
 Research Database 
Inpatient data, pathology, diagnosis and procedure data & 
surveillance data 
Anonymisation and Encryption Process 
 
SSI Surveillance data 
(Coronary artery bypass 
graft patients) 
Point Prevalence Survey 
ECDC  
(HCAI, antimicrobials and 
invasive devices) 
HCAI Surveillance 
schemes  
 
Administrative Data  
Laboratory Data 
(Microbiology, 
haematology and clinical 
biochemistry) 
Patient Administration 
System 
(Demographics, 
admissions, discharges, 
OPCS and ICD10 codes) 
Radiology Data 
(Diagnostic imaging 
requests) 
 
Caesarean surveillance 
(SAGE 2% chlorhexidine 
gluconate wipes 
intervention study) 
 
National Registry  
Cardiac Registry Data 
(Surgical details, cardiac 
history and risk factor & re-
operation for wound 
debridement) 
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4.3 Discussion 
 
The process of obtaining and preparing data for use in this study has produced several interesting 
findings, as well as highlighting the huge potential that the data stored at Imperial College 
Healthcare NHS Trust has for research and surveillance. The issues in the individual databases and 
potential limitations of the different data types have been discussed. In summary, no single data 
source contains all the relevant information for infection surveillance and each data type in turn has 
its own limitations. As a result, it is necessary to try and reduce the potential for the inherent flaws 
in the data to affect the analyses and exploit the inherent advantages that certain data pose.  
The main advantage of exploiting routine administrative data instead of implementing active 
surveillance programmes for every infection is the time and money that could be saved. On the 
other hand, the main advantage of using active surveillance is that it is focussed and targeted on the 
desired outcome. The overall aim of this project was to investigate the better use of routine data for 
surveillance, and thus investigating whether the trade-off in data accuracy for the time and money 
and larger applicability provided by using these types of data was considered worthwhile.  
This prospect is supported by the argument that in fact the ‘gold standard’ surveillance data are not 
as perfect as would be desired either, and so if the expensive, time consuming data are not suitably 
accurate and complete then it is sensible to investigate using administrative data in its place. 
Reasons to suspect the surveillance data of being imperfect are so far in this thesis based on the 
experiences I had when participating in data collection for both the HPA SSI surveillance and for the 
ECDC PPS, and further arguments will be made for this in subsequent chapters. In further chapters it 
should be kept in consideration that although the traditional surveillance sources is being used as 
the ‘gold standard’, this study by no means consider them to be perfect.  
Similarly, it has been well documented that administrative data, specifically coding in ICD-10 and 
OPCS is inaccurate (458, 474). The first issue has been presented anecdotally already in this chapter 
with coding only ever able to reflect the conditions in the patient’s medical records. Where clinical 
notes are confusing, lack vital information and in some cases have outright inaccuracies, the clinical 
coding must consequently have missing and incorrect information. Conversely, summarising a whole 
patient episode of care into a limited number of codes (20 in HES and 14 in the local extracts used 
for this project), when it can take up to three or four to describe a single condition and certain 
conditions should always be recorded (475), makes the job of accurately assigning ICD-10 codes very 
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difficult. In this project, the PAS data will be used with caution in making concrete diagnoses, as it is 
clear that the presence of a certain code does not necessarily reflect the clinical situation.  
An aspect of the active surveillance data which the routine administrative data will not have and is 
unlikely to be capable of in the near future is post discharge surveillance. In the instance of surgical 
site infections this is a critical flaw of any electronically developed system for surveillance, as a large 
proportion of these infections are diagnosed in the community (56).  
One of the main issues encountered at this stage concerns data management, in obtaining, storing 
and structuring such a large quantity of data. The most obvious obstacle at this stage was the 
seemingly simple task of identifying a patient, and being able to distinguish this person as the same 
patient across multiple admissions and between the Imperial College Healthcare NHS Trust hospitals. 
It was decided to use NHS number as the primary patient identifier, as this should remain constant 
throughout a person’s life from admission to admission. However, only about 70% of patients at 
ICNHT had an NHS number assigned; in the absence of the NHS number, a combination of local 
hospital number and date of birth were used to create the CIPM ID’s.  
Where different databases recorded these identifiers differently, the SHA256 hash code anonymises 
them differently; hence most of the linkages were carried out prior to anonymisation by the CIPM 
database manager. However, in the absence of a comprehensively used and consistent patient 
identifier, it must be accepted that not all the linkages were accurate, and some records may have 
been lost for this reason at various stages of the analyses.  
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4.4 Conclusion 
 
There is a huge amount of information stored within the NHS, whether or not it was purposefully 
collected for research and surveillance, which could be investigated for its utility in developing 
innovative surveillance tools. However, it is clear that no one data source is without flaws, with each 
trading time and effort in its collection with the potential quality of information. This project’s aim 
was to demonstrate the utility of administrative data for performing surveillance and therefore 
leading to improved patient outcomes. It thereby seeks the optimal balance between reliability of 
the data and efficient sustainable tools needs to be considered during the subsequent analyses. 
Given that aim, it was those data sources that are routine, preferably report in real time and have a 
high level of data quality that were preferentially exploited, which in this context consist primarily of 
radiology, laboratory and patient administration system data.   
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Chapter 5: Syndromic Surveillance of Surgical Site Infections following Coronary Artery Bypass Graft  
 
 
Summary  
 
The first of the analyses chapters, this chapter investigates the potential of routine data for creating 
syndromic surveillance of surgical site infections in patients undergoing coronary artery bypass graft 
procedures. The different data sources pertaining to this patient group were compared, investigating 
the quality of currently implemented traditional surveillance schemes. Syndromic definitions of 
surgical site infections were compared with diagnostic codes and their potential to enhance 
surveillance considered.   
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5.0 Introduction 
 
A coronary artery bypass graft (CABG) is a surgical procedure used to treat coronary artery disease; 
this is done by taking vein or artery from another part of the body (generally from the leg) and 
grafting it to the coronary artery (476). This allows blood vessels to the heart which have suffered 
from narrowing (stenosis) or damage to be bypassed, providing improved blood flow to the heart. 
Several grafts can be performed in one operation, depending on the level of disease. This surgery 
involves an incision both in the patient’s leg (where the veins are harvested from) and to the 
sternum, where the chest is opened, and patients can suffer from SSI at either incision site.   
The first CABG surgery was performed in 1960, and currently in the UK approximately 28,000 CABG 
procedures are carried out annually making it one of the most common operative procedures (472). 
The demographic of patients is skewed towards men, and the average age of patients undergoing 
this surgery in the UK is 61 years old (477). This patient population has a high proportion 
comorbidities, such as diabetes, underlying renal and chronic airway diseases, compared to the 
general population (477). 
As previously described in chapter 4, several data sources are collected relating to cardiac surgery 
patients, and specifically pertaining to CABG patients, which is partly why I am focussing on this 
particular patient group.  The second reason, explaining why surveillance has been conducted in this 
patient group at ICHNT, is the high prevalence of surgical site infections locally. This suggests that an 
investigation into the utility of the data sources being collected would be beneficial for infection 
control in this surgical group both locally and nationally. Previous studies have shown prevalence of 
surgical site infections post-CABG surgery ranging from 0.49% - 18.8% (163, 478-480), however these 
have tended to look predominantly at inpatient populations or sternal wounds only.  
In England, the surveillance of SSI following CABG procedures is voluntary, as part of the HPA 
surgical site infection surveillance scheme. This programme uses standardised definitions of surgical 
site infections, based on either clinical or microbiological diagnosis. The HPA reported SSI rate from 
their 2010/11 report was 4.4% (481). The HPA data demonstrates that rate of SSI in CABG patients 
from 2006 to present has been static, despite the number of Trusts submitting data gradually 
increasing and therefore surveillance becoming more widespread (481). As less invasive 
interventions for coronary artery disease have become first line treatments form coronary artery 
diseases, those patients undergoing CABG procedures are likely to be higher risk or have a more 
severe condition (482); they could therefore be more vulnerable to infection.   
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The UK is not alone in having a long running, widely used cardiac registry and national initiatives for 
surgical site infection surveillance. The National Cardiovascular Data Registry (NCDR) in the USA has 
been established since 1997 (www.ncdr.com), considerably shorter than the UK register maintained 
by the Society for Cardiothoracic Surgeons since 1977 (www.ic.nhs.uk). According to Taylor (483), 
Sweden and the UK are the only two countries worldwide where all centres report to a national 
cardiology registry. The Swedish register is now completely electronic and has been linked to other 
national data sources, allowing for long term patient follow-up (483). This registry, like that in the 
UK, collects data on post-operative complications and specifically re-operation for mediastinitis (484, 
485).   
Despite submission of to the National Cardiac Registry being near complete, it has been 
acknowledged that reporting of post-operative complications can have up to 15% missing data (470). 
For this reason, having electronic methods for identifying SSI that could be implemented on a 
national basis, would be hugely beneficial for reliable, consistent and complete reporting of SSI after 
CABG surgery. To my knowledge integrating SSI surveillance data with cardiac registry data and 
administrative hospital data has not been done previously, allowing a unique opportunity to 
investigate these data sources for SSI surveillance.  
Syndromic surveillance, whilst widely adopted in infectious disease surveillance, is still a relatively 
new tool in healthcare associated infection surveillance and has not yet been applied to surgical site 
infections. Several studies have investigated the use of biological markers of infection for the early 
detection of post-surgical infectious complications (486-488). The markers which have been 
successfully used or investigated for surgical site infections include c-reactive protein (CRP), white 
blood cell count (WBC), procalcitonin (PCT) and erythrocyte sedimentation rate (ESR) (489, 490). 
Multiple data sources and the potential for markers and investigations to be exploited for syndromic 
surveillance, make coronary artery bypass graft patients an ideal group for exploration in this 
project. 
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5.0.1 Aims and Objectives 
 
This chapter has two aims, the first to investigate the data sources available for coronary artery 
bypass graft surgery patients and assess their utility for surveillance for surgical site infections. The 
second aim was to utilise administrative hospital data to develop syndromic surveillance of SSI 
following CABG procedures.  
The objectives for the chapter were to understand the data sources currently collected, including 
their methodology, quality and utility for efficient streamlined surveillance; this included 
investigating how they overlap (including duplications and discrepancies) and complement each 
other.   
The next objective was to gain an understanding of the effect of surgery and infections on biological 
markers, particularly looking at threshold values. Based on this, the next objective was to develop 
syndromic algorithms for surgical site infections, taking into account these identified marker 
patterns and assess how practical these algorithms could be for surveillance.  
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5.1 Methods 
 
Stata SE 11 and Microsoft Excel were used for all analyses and graphs and a p-value of <0.05 was 
considered statistically significant in all analyses throughout the analyses chapters (chapter 5 – 
chapter 8), unless otherwise stated.  All linkages and anonymisation (based on NHS number, hospital 
number and date of birth) were performed on NHS servers by the CIPM Database Manager, in 
accordance with the project’s ethics approval, throughout the thesis. 
 
5.1.1 Data Linkage, Cleaning and Management 
 
Before any analyses could begin, data needed to be linked, cleaned and formatted into a usable 
form for analysis. The databases used for this chapter and the time periods in which they were used 
are shown in Table 5.0. The cleaning processes described apply to all possible years of data and 
databases, unless clearly stated otherwise.  
 
Table 5.0: Overview of the data sources used in chapter 5 
2009 2010 2011 
PAS 
Laboratory 
PAS 
Laboratory 
Radiology 
PAS 
Laboratory (Jan - June only) 
Radiology (Jan - June only) 
Cardiac Registry 
HPA SSI Surveillance 
 
A direct linkage of HPA SSI surveillance and cardiac registry data to the specific spell of the CABG 
procedure in the PAS data was attempted; however, this was unsuccessful as the dates of admission 
recorded in the HPA SSI surveillance and cardiac registry data were not accurate enough for 
deterministic linkages. Instead linking the HPA SSI surveillance and cardiac registry data to PAS was 
not restricted by date, meaning all potential patient episodes within PAS for a CABG patient were 
linked.  
A cleaning process to remove any irrelevant episodes for each patient was then carried out. Relevant 
episodes for each patient consisted of the CABG operation episode and any subsequent episodes 
starting within 30 days of the surgery. All other episodes were then removed; the derived variables 
for this process are described in Table 5.1.  
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Table 5.1: Definition of the derived variables used to determine relevant patient episodes 
Derived Variable Definition 
Operation episode 
Binary variable indicating the episode in which the CABG procedure took place; 
generated using the date of operation, date of episode start and date of episode 
end 
30 day post-CABG Date variable indicating the date 30 days after the CABG procedure took place; generated using the date of operation variable 
Re-admission 
Binary variable indicating whether the episode was during a re-admission or not; 
generated using date of admission, date of discharge, district spell number 
(administrative variable acting as a unique admission identifier) and operation 
episode 
 
I received the data in a ‘long’ format, meaning there were several records for one patient, several for 
each spell and several for each laboratory request. To simplify the subsequent methodology the data 
were re-shaped into a ‘wide’ format resulting in one record per patient. This single patient record 
included all the diagnosis codes for relevant episodes, all radiology and microbiology requests and 
routine blood test results.  
For the radiology, microbiology, clinical biochemistry and haematology data all test requests and 
results (where appropriate) performed within 35 days of the CABG procedure were investigated. 
This is five days longer than the standardised follow up period for SSI following this surgery type. The 
reason for keeping tests beyond the standard 30 days was to take into account the inaccuracies that 
may be present in the recording of dates in the routine data, as well as allowing for a trend to be 
seen if an infection was diagnosed on day 30 post-surgery.  
Microbiology requests were categorised by culture type, such as wound culture or blood culture. A 
binary variable was generated for each culture type on each day post-CABG, with a one indicating a 
culture request and a zero indicating no culture request on that day. A continuous variable was then 
generated for each culture type, indicating the total number of culture requests in the 35 days 
following the CABG procedure. The same process was used for radiology requests.  
For the haematology and clinical biochemistry tests, which had results, both pre-operative and post-
operative tests were investigated. In order to create the pre-operative baseline value for each 
patient, all results available during the 12 days prior to the CABG surgery were averaged into a single 
continuous value for each patient. This acted as a reference, as the patient was presumed to not 
have a surgical site infection or changing levels due to the trauma of surgery. Similar to the method 
used for microbiology requests, a daily post-operative variable was generated for each clinical 
biochemistry and haematology test. These variables were continuous. A count variable was 
generated for each test type, indicating the number of times this test had been requested for each 
patient post-operatively.  
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5.1.2 Descriptive Analysis of HPA SSI Surveillance and Cardiac Registry data 
 
I used three data sources for this analysis: the cardiac registry, the HPA SSI surveillance data and 
PAS. For patient’s that had not linked according to the standard protocol, their date of admission, 
date of surgery and gender were investigated to ensure these patients were individual patients. The 
data extracts covered all coronary artery bypass graft surgery carried out between the 1st January 
2011 and 31st December 2011 at Hammersmith Hospital. I carried out a descriptive analysis of the 
data recorded by the HPA SSI surveillance and cardiac registry. 
 
5.1.3 Extracting CABG Patients from the Administrative Data 
 
In order to compare the information stored by the cardiac registry and HPA SSI surveillance data, 
with that available in the PAS data, all the CABG patients needed to be extracted from this dataset. 
This process was carried out in all the PAS data, including 2009 and 2010.  
CABG patients were defined using OPCS codes, using those codes defined by the HPA surveillance 
protocol for CABG patients (468) (Table 5.2). There are 14 procedure variables within PAS which can 
be assigned during an episode, and one ‘main procedure code’. All of these variables were 
considered when identifying the relevant CABG patients.   
 
Table 5.2: OPCS code categories for coronary artery bypass graft procedures  
OPCS code(s) OPCS code translation 
K40.1 – K40.9 Saphenous vein graft replacement of coronary artery (one – four arteries) 
K41.1 – K41.9 Other auto graft replacement of coronary artery (one – four arteries) 
K43.1 – K43.9 Prosthetic replacement of coronary artery (one – four arteries) 
K44.1 Replacement of coronary arteries using multiple methods 
K44.2 Revision of replacement of coronary artery 
K44.8 Other specified other replacement of coronary artery 
K44.9 Unspecified other replacement of coronary artery 
K45.1 Double anastomosis of mammary arteries to coronary arteries 
K45.2 Double anastomosis of thoracic arteries to coronary arteries not elsewhere classified 
K45.3 Anastomosis of mammary artery to left anterior descending coronary artery 
K45.4 Anastomosis of mammary artery to coronary artery not elsewhere classified 
K45.5 Anastomosis of thoracic artery to coronary artery not elsewhere classified 
K45.6 Revision of connection of thoracic artery to coronary artery 
K45.8 Other specified connection of thoracic artery to coronary artery 
K45.9 Unspecified connection of thoracic artery to coronary artery 
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The number of procedures and the rate of infection, along with the demographic makeup of the 
CABG patient population extracted were compared to the HPA SSI surveillance and cardiac registry 
patients, to assess the similarities and differences. Within this patient group patients with SSI 
(‘cases’) were defined using ICD-10 codes. The remaining patients, who had undergone a CABG 
procedure but did not have any relevant ICD-10 codes for infection, were defined as ‘controls’.   
To compare the PAS data to the HPA SSI surveillance and cardiac registry data in terms of surgical 
site infections specifically, the ICD-10 codes for identifying SSI needed to be established. I searched 
for relevant codes in three ways: 
 a keyword search of the ICD-10 codes  
 any codes that had been used in the published literature 
 codes specified by a communication with the Coding Clinic [Appendix 6] 
 
Table 5.3: ICD-10 codes identified as relevant for diagnosing surgical site infections 
ICD-10 
Code ICD-10 code Translation 
Method of 
Identification 
M861 Other acute osteomyelitis, site unspecified L (491) 
M862 Sub-acute osteomyelitis, site unspecified L (491) 
M869 Osteomyelitis, unspecified L (491) 
L022 Cutaneous abscess, furnacle and carbuncle of trunk L (491) 
L029 Cutaneous abscess, furnacle and carbuncle, unspecified L (491) 
L033 Cellulitis of trunk L (491) 
L039 Cellulitis, unspecified L (491) 
T813* Disruption of operation wound, not elsewhere classified CC, L, KW (491) 
T814 Infection following a procedure, not elsewhere classified CC, L, KW (491-495) 
T826 Infection and inflammatory reaction due to cardiac valve prosthesis CC, L (491, 495) 
T827 Infection and inflammatory reaction due to other cardiac/vascular device, implant/graft CC, L 
(491, 495) 
T845 Infection and inflammatory reaction due to internal joint prosthesis CC, L (491, 492, 494, 495) 
T846 Infection and inflammatory reaction due to internal fixation device (any site) CC, L (491, 492, 495) 
T847 Infection and inflammatory reaction due to internal orthopaedic prosthesis device / implant / graft CC, L 
(491, 492, 495) 
T857 Infection and inflammatory reaction due to other internal prosthetic device / implant/graft CC, L 
(491, 492, 495) 
Y83* 
Surgical operation and other surgical procedures as the cause of abnormal 
reaction of the patient, or of later complication, without misadventure as the 
time of procedure 
CC, L (491, 494) 
Y840* Cardiac catheterisation, as the cause of abnormal reaction of the patient or of later complication CC 
*These are to be used in combination with the following ICD-10 codes: B95 (streptococcus & staphylococcus as the 
cause of diseases classified to other chapters); B96 (Other specified bacterial agents as the cause of diseases 
classified to other chapters); B97 (Viral agents as the cause of diseases classified to other chapters). 
CC: coding clinic; L: established literature; KW: keyword search of ICD-10 codes 
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The ICD-10 codes that I identified as potentially relevant are presented in Table 5.3. A specific ICD-10 
code for nosocomial conditions (Y95) was also identified, which can be used in conjunction with 
other codes to indicate that the infection was healthcare associated. 
Binary variables were created for all the potential ICD-10 codes, with any diagnostic code within a 
post-operative episode starting in the 30 days following CABG surgery being considered. Several of 
the codes were not found locally, including: M861, M862, L022, L029, L033, L039, T826, T845, T846, 
T847, T857 and Y840.  
 
5.1.4 Comparing Administrative and Surveillance Data 
 
All the diagnostic ICD-10 codes identified as relevant were then compared to the surveillance SSI (i.e. 
all those patients with an SSI diagnosed by either the HPA SSI surveillance or cardiac registry). They 
were investigated as individual codes and in combinations. The calculation of sensitivities, 
specificities, positive predictive value (PPV) and negative predictive values (NPV) was carried out 
using the ‘diagt’ command. This command provided the following desired outputs: sensitivity, 
specificity, PPV, NPV and the area under the ROC curve (AUC), along with the corresponding 95% 
confidence intervals. 
For this analysis, only ‘inpatient surgical site infections’ were considered from the cardiac registry 
and HPA SSI surveillance data. Inpatient SSI consists of all those infections diagnosed in the patient’s 
surgical admission or upon re-admission; this excludes those self-reported infections and those 
diagnosed through post-discharge surveillance.  The reason for only using these cases when 
investigating the sensitivity of diagnostic codes was that there would not be any ICD-10 codes 
relating to events that occur outside of the hospital. Therefore, including infections diagnosed in the 
community would introduce a bias against the ICD-10 code method of diagnosing SSI. 
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5.1.5 Creating Syndromic Algorithms of SSI  
 
The second aim for this chapter was to develop syndromic algorithms of surgical site infections 
following CABG surgery. I addressed this aim by creating the syndromic algorithms using inpatient 
SSI, from the HPA SSI surveillance and cardiac registry datasets.  
The syndromic algorithms were developed using electronic diagnostic data, which consisted of 
radiology, clinical biochemistry, haematology and microbiology department data. The data for this 
analysis dated from January – June 2011. The first stages of analysis were to: describe how biological 
markers of infection change due to surgery, both in those with infections and for the whole patient 
population; justify the markers that were used for developing syndromic surveillance algorithms and 
the thresholds that were applied; investigate diagnostic test requests (i.e. wound cultures and x-
rays) as proxies of infection.  
In order to determine the routine blood tests performed on CABG patients, both prior to and post-
surgery, I looked at the number of each test (e.g. CRP or full blood count) sent to the laboratory. I 
then selected specific markers from the routine panels of tests for further investigation in relation to 
identifying surgical site infections. The choice of specific markers was based on scientific principles 
(e.g. white blood count), having a published evidence base (e.g. CRP), and having been identified as 
significant by the systematic literature review in chapter 3 (e.g. INR).  
A mean pre-operative value for each patient was generated for any routine tests. This provided an 
individual base-line for each patient (for those who had any pre-operative tests). For each post-
operative day (up to 35 days) a variable for each marker was created, as well as a patient average for 
post-surgery values. Based on the marker thresholds of infection that were decided upon, daily 
binary variables for each marker were also created to indicate a test result exceeding the threshold 
values. Variables for the number of times a marker exceeded a set threshold value were generated. 
Setting up the haematology and clinical biochemistry in these three different ways allowed diverse 
approaches to be taken when generating the syndromic case algorithms.  
Several graphical and statistical methods were used to set marker thresholds for infections and 
investigate the trends in these markers; these are summarised in Table 5.4. Basic summary statistics 
and t-tests were carried out to compare the pre and post-operative averages for the markers in 
patients with and without surgical site infections. Based on the results of the trend graphs, simple 
statistics and established literature, threshold values in the markers which indicate an SSI were 
defined and daily binary variables for each relevant marker were generated.  
 123 
 
Table 5.4: Summary of graphs and analyses employed to develop syndromic algorithms of SSI 
Graph / Analysis Description / Comment Stata Command 
Line graph of median 
values 
Median daily values of the infected and uninfected patients 
were plotted to investigate patterns in markers over time. 
Medians were used instead of means to reduce the effects of 
extreme values 
(Excel) 
Box and Whisker plots 
The mean and interquartile range of markers in the infected 
and uninfected patients, pre and post-operatively were plotted 
as box and whisker plots.  
Boxplot 
Scatter graph with 
moving average 
A random sample of uninfected patients and all of the infected 
patients were plotted as a scatter graph, with the moving 
average calculated. 
Lowess 
ROC curves 
Receiver Operating Characteristic curves (which plots the 
sensitivity against the specificity) were plotted to compare the 
performance of different markers and proxies of infection 
Roctab / 
Roccomp 
Timeline plots 
Daily occurrences of markers exceeding the threshold values 
and proxies of infection were plotted for each infected patient 
to observe patterns over time 
(Excel) 
Sensitivity and 
specificity 
Calculations of sensitivities, specificities, positive predictive 
values, negative predictive values and the area under the ROC 
curve for different markers, proxy indicators of infection and 
ICD-10 codes were carried out 
Diagt 
T-tests A statistical test to compare the means of the Marker values between the infected and uninfected patients Ttest 
 
The standard patient pathway for a CABG patient includes two chest x-rays post-surgery; one to 
check the chest drain and one for its removal. Hence two chest x-rays should be standard for all 
patients. A variable was created for the number of chest x-rays carried out, as well as any further 
diagnostic imaging examinations. The full microbiology results were not available for these analyses, 
so microbiology data were used as a binary variable indicating if there was a request for a culture, 
namely wound cultures. The daily binary culture requests and the number of wound cultures 
requested post-CABG were investigated for a relationship to the inpatient SSI patients.  
The binary variables that I had generated based on the marker thresholds, diagnostic imaging 
investigations and culture requests were investigated for their sensitivity, specificity, PPV and NPV as 
individual variables, as well as in combination. This command compares the variable containing the 
real status of the patient (inpatient SSI) with the ‘diagnostic’ variable (i.e. the syndromic algorithm). 
The optimal syndromic algorithms for detecting SSI were chosen based on the area under the 
receiver operating characteristic curve (AUC) value, or ‘c-statistic’. The balance between sensitivity 
and specificity was also considered, attempting to find the most ‘true cases’ without sacrificing 
accuracy.  
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5.1.6 Applying the Syndromic Algorithms in Administrative Data 
 
Using ‘cases’ and ‘controls’ as defined (section 5.1.) by ICD-10 codes (Table 5.3), all those CABG 
patients in the PAS data from January 2009 – December 2010 were used to investigate the 
syndromic algorithms performed in the administrative data.  A sensitivity analysis was then carried 
out, using the patients defined as having an SSI according to the ICD-10 codes as the ‘gold standard’ 
to which the syndromic algorithms were compared.  
 Variables for other typical healthcare associated infections (pneumonia, C. difficile, bloodstream and 
urinary tract infections) were created using ICD-10 codes (Table 5.5). These codes were identified 
from a keyword search of the ICD-10 codes using the online WHO search tool and codes used by 
published articles. A binary variable indicating any other infection diagnosis was created, to take into 
account how other infections may be skewing the relationship between markers of infection and 
surgical site infections. Requests for non-wound cultures (e.g. urine cultures) were also taken into 
account when investigating the potential effect of non-surgical site infections on infection markers.  
 
Table 5.5: ICD-10 codes used to define a non-SSI healthcare associated infection 
Infection 
type ICD-10 code ICD-10 code translation 
UTI N10 Acute tubule-interstitial nephritis 
UTI N11 Chronic tubulo-interstitial nephritis 
UTI N12 Tubulo-interstitial nephritis, not specified as acute or chronic 
UTI N15 Other renal tubule-interstitial diseases 
UTI N30 Cystitis 
UTI N34 Urethritis and urethral syndrome 
UTI N390 Urinary tract infection, site not specified 
C. difficile A047 Enterocolitis due to C. difficile 
BSI A40 Streptococcal sepsis 
BSI A41 Other sepsis 
Pneumonia J12 Viral pneumonia 
Pneumonia J13 Pneumonia due to Streptococcus pneumoniae 
Pneumonia J14 Pneumonia due to Haemophilus influenzae 
Pneumonia J15 Bacterial pneumonia, not elsewhere classified 
Pneumonia J16 Pneumonia due to other infectious organisms, not elsewhere classified 
Pneumonia J17 Pneumonia in diseases classified elsewhere 
Pneumonia J18 Pneumonia, organism unspecified 
Sepsis A49 Bacterial infection of unspecified site 
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Figure 5.0: Summary of the methodological steps in chapter 5 
 
  
PAS, Laboratory, Radiology, Cardiac Registry, and 
HPA SSI surveillance databases (2009 – 2011) 
Data linkage and cleaning  
PAS, Cardiac Registry and HPA SSI surveillance 
(Jan – Dec 2011) 
Descriptive analysis of the data collected by the 
HPA SSI surveillance and cardiac registry  
Cardiac registry, HPA SSI surveillance, 
Laboratory and Radiology databases (Jan – Jun 
2011) 
Syndromic algorithm development, 
investigating marker patterns and infection 
thresholds 
PAS, Laboratory and Radiology databases (Jan 
2009 – Dec 2010) 
Comparison of syndromic algorithms for SSI with 
ICD-10 codes 
PAS, Cardiac Registry and HPA SSI surveillance 
(Jan – Dec 2011) 
Assessing ICD-10 codes for identifying SSI 
diagnosed by the HPA SSI surveillance and 
cardiac registry and comparing these with the 
caesarean surveillance data 
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5.2 Results 
 
5.2.1 Descriptive Analysis of HPA SSI Surveillance and Cardiac Registry data 
 
There were 618 patients recorded as having a CABG procedure by the HPA SSI surveillance and 
cardiac registry data. Of these, 473 (77%) patients contained data from both the HPA SSI surveillance 
and cardiac registry datasets (Figure 5.1).  
 
Figure 5.1: Venn diagram showing the number of patients recorded by the cardiac registry and HPA SSI 
surveillance databases in 2011 
 
 
Basic demographic data of age and gender are recorded by both the HPA SSI surveillance and cardiac 
registry, with some discrepancies between the two datasets. Twenty patients were recorded in the 
HPA SSI surveillance data as male but these patients were female in the cardiac registry data. 
However the gender distribution was similar in the two datasets with 81% of patients from HPA SSI 
surveillance data and 77% from the cardiac registry data being male. Patient age (or date of birth) is 
also recorded by both datasets with the eldest patient being 93 and the youngest 28, with an 
average age of 65; 93% of patients were over 50 years of age.  
The average total length of stay for patients undergoing CABG surgery was 13 days, with the longest 
stay being 136 days. The majority of patients stayed for more than a week, with only a third of 
patients staying a week or less. The average length of stay pre-operation was 3 days with the longest 
pre-operative stay being almost seven weeks. The median post-operative stay was a week, which is 
consistent with the CABG patient pathway, which has a standard five day stay after the surgery. Of 
Cardiac Registry: 
61
[Total: 534]
HPA SSI Surveillance:
84
[Total: 557]
473 
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the patients recorded as having surgical site infections, the average post-operative length of stay 
was 17 days, a third longer than those without infections.  
 
Comorbidities and Risk Factors 
 
The cardiac registry collects a wealth of information relating to the patient’s cardiac history, risks 
and comorbidities; the HPA SSI surveillance data on the other hand only collects BMI and ASA score 
as part of the patients’ comorbidities or risks. BMI was collected by both schemes; however 7% of 
patients had missing data for this variable of which most were patients captured by HPA SSI 
surveillance only. The data from both datasets was combined to make an average BMI value for each 
patient, taking into account any discrepancies, however there were no large differences. A fifth of 
patients undergoing CABG surgery had a healthy BMI, with the majority of patients being classified 
as overweight or obese (Figure 5.2). 
 
Figure 5.2: Number of patients undergoing CABG surgery according to BMI 
 
 
A summary of the risks and comorbidities recorded by the cardiac registry are presented in Table 
5.6. Renal deficiencies prior to surgery were noted for 28 patients (5%), with 14 patients receiving 
dialysis for chronic renal failure and seven suffering from acute renal failure. Almost three times 
more patients had underlying pulmonary issues than renal, with the types of pulmonary 
comorbidities demonstrated in Figure 5.3.   
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Table 5.6: Summary of the comorbidities and risks recorded by the 
cardiac registry 
Variable % of patients 
Diabetes: Insulin therapy 
                  Oral therapy 
                  Diet controlled 
9% 
27% 
11% 
Smoking: Current 
                  Previous 
15% 
49% 
Hypertension 92% 
Pulmonary hypertension 4% 
Neurological dysfunction 8% 
 
Several clinical scores were recorded in the registry data, measuring the extent of heart failure (New 
York Heart Association score: NYHA score), severity of angina (Canadian Cardiovascular society 
score: CCS score) and two multi-factorial scores: the complex CABG Bayes score and the EuroScore.  
The majority of patients (61%) had a NYHA score of two, indicating mild symptoms and slight 
limitation to ordinary activities), 20% experienced a marked limitation to normal activity (score of 
three) and 6% a severe limitation (score of four). A similar pattern was seen with the CCS score, with 
50% of the patients having a slight limitation, with angina only during vigorous activity (score of 
two), 22% had a score of three and 10% a score of four. The American Society of Anaesthesiologist’s, 
recorded by the HPA SSI surveillance, is a measure of physical well-being.  88% of patients had a 
score of three which indicates the patient has a severe systemic disease; 6% had an ASA score of 
four which means it is a constant threat to their life. Only six patients had an ASA score of one, 
meaning they are considered in good health. 
 
Figure 5.3: Pulmonary comorbidities among CABG patients 
 
Asthma COAD/emphysema
COAD/emphysema/asthma COPD
Pneumonia Pulmonary oedema
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The patient’s history of cardiac interventions was recorded by the cardiac registry and nine patients 
had had a prior CABG procedure. Percutaneous coronary interventions (PCI) had been performed on 
121 patients (23%). Most had been carried out on a prior admission (20%), some dating back to 
2002, with only eight PCIs carried out within 24 hours of the current CABG surgery. Cardiac 
catheterisation had been performed in 86% of the patients, with the oldest date of catheterisation 
reported as February 2010.  
A large proportion of the patients undergoing CABG surgery have had previous myocardial 
infarctions, with 9% of patients suffering two or more previous myocardial infarctions and 38% 
having only one. Most of those patients that had suffered previous myocardial infarctions had them 
between 1 – 90 days before the CABG surgery and only 12 patients were reported as having had one 
during the day before surgery. Left main stem disease was present in a quarter of patients, and 69% 
of patients had coronary disease in three of their vessels.  
The heart rhythm of patients was normal sinus rhythm for 91% of those undergoing CABG surgery. 
Irregular heart rhythms were recorded as atrial fibrillation (5%), heart block (1%), bradycardia and 
tachycardia (1%) and one patient had a pacemaker rhythm. Several physiological measurements 
could be recorded (e.g. systolic pressure and ejection fraction); however in this local registry extract 
the recording of these was incomplete and sporadic. Only pre-operative creatinine values were 
consistently recorded across all quarters of data, with an average of 103 (μmol/l) in this patient 
group (within the normal expected range). The ejection fraction, a measure of the volume of blood 
pumped out of the heart with each beat, was split into categories of good, fair and poor. The 
majority of patients (80%) had a good ejection fraction value and only 4% had a poor value.   
 
Pre-operative features 
 
The cardiac registry records details of the patient’s condition prior to surgery, for example noting 
whether the patients were ventilated (1%). It records administration of different substances; 
however the recording of these variables was not consistent throughout the year, resulting in mostly 
missing data. The exception to this was intravenous inotrope support, which was relatively rare 
occurring in only five patients, and the administration of nitrates which was slightly more common 
with 31 patients having nitrates pre-operatively. The HPA SSI surveillance data recorded information 
on pre-operative antimicrobial prophylaxis. All but two patients were recorded as having received 
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antibiotics as part of the trusts policy for surgical prophylaxis, indicating a breach of protocol in 
these two patients (0.4%).  
 
Operative Features 
 
Both data sources collected information regarding the surgery, with the cardiac registry data being 
far more comprehensive. Details regarding the surgeons were not permitted on the extract I 
received from the cardiac registry, however based on the HPA SSI surveillance data 14% of 
operations had a second surgeon recorded and all these surgeons were of a consultant level grade.  
 
Figure 5.4: Box and whisker plot of length of surgery in CABG patients 
 
 
The duration of operation was recorded by both data sources; however the times reported by the 
cardiac registry appeared to be inconsistent with the expected durations for CABG surgery. The 
cardiac registry had a median surgical duration of 780 minutes (13 hours), whereas the t-time 
(indicating a long surgery) generally used for CABG is >300 minutes. The guidelines for the cardiac 
registry data specify that the start time of the operation is when the first incision is made, however it 
does not specify when the end should be recorded. It was unclear whether they are measuring a 
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different duration and the data dictionary I used did not specify this variable.  The surveillance data 
on the other had followed the expected times for this category of operations (Figure 5.4). The 
shortest surgery was 95 minutes and the longest lasted 633 minutes, with the majority (76%) sitting 
in the 180-300 minute group.  
According to the cardiac registry data, just over half (53%) of the procedures were classified as 
urgent, 4% as emergency and 43% as elective procedures. Three procedures were classified as 
salvage operations (meaning cardiopulmonary resuscitation was needed prior to reaching the 
operating theatre).The HPA SSI surveillance data recorded this information as either elective or 
emergency, with 98% of the surgery falling in the elective category, suggesting this includes ‘urgent’ 
procedures. A discrepancy was seen with two of the emergency procedures according to the HPA SSI 
surveillance data, actually being classified as elective by the cardiac registry. The HPA SSI surveillance 
data however does classify surgery as trauma in a separate variable, with only seven patients 
considered trauma patients.  
Cardiac registry specific variables included details of intra-aortic balloon pumps (IABP), grafts, bypass 
details and the type of myocardial protection used. IABP were used pre-operatively for 28 patients, 
intra-operatively for four patients and post-operatively for two; the reason for IABP (either 
prophylactic, for unstable angina or haemodynamic instability) was only recorded for 59% of those 
who received IABP. The number of grafts and anastomoses (an artificial connection between two 
blood vessels) put in place during the CABG procedure was recorded, along with the amount of time 
the patient spent on bypass or with a cross clamp (Table 5.7).  
 
Table 5.7: Summary of continuous operative variables collected by the cardiac registry 
Variable Average Minimum Maximum Number of records 
Distal coronary artery anastomoses 2.7 0 6 533 
Arterial grafts 0.9 0 2 533 
Venous grafts 1.8 0 5 533 
Bypass time (min)1 67.7 0 291 510 
Cross clamp time (min) 32.2 0 183 508 
1 The value of 988 minutes was removed as this exceeds the longest surgical duration and was presumed to be 
a data error. The mean bypass time including this value was 83.8 minutes  
 
Myocardial protection was cardioplegic (the intentional stopping of the heart) in 61% of procedures 
and non-cardioplegic in the remaining 39% of the CABG performed. The methods of non-
cardioplegic protection are not recorded for 40% of patients, however the most frequent method 
reported was ‘beating without a cross clamp’ (off-pump surgery).  All but one of the procedures 
using cardioplegia protection were antegrade and intermittent. 
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Post-operative features 
 
According to the HPA SSI surveillance data, 61 of the 557 patients that they followed up in 2011 
developed an SSI (11%). Taking into consideration the whole CABG population (i.e. including those 
patients only recorded by the cardiac registry data as well), the incidence ranged from 14.6% in the 
first quarter to 8.2% in the final quarter of 2011. One patient had more than one SSI reported, a 72 
year old female diagnosed upon readmission. The first infection was a deep infection of the donor 
site and the second an organ space infection of the bone (osteomyelitis) located at the chest 
incision.  
Of the infections recorded by the HPA SSI surveillance data 29 were self-reported by the patients 
following discharge from hospital, making the incidence of ‘inpatient infection’ (i.e. excluding those 
infections diagnosed in the community) 6 per 100 coronary artery bypass graft procedures.  
 
Figure 5.5: Venn diagram showing the number of patients with a surgical site infection recorded by the 
cardiac registry and HPA SSI surveillance databases in 2011 
 
 
Of the 61 HPA SSI surveillance surgical site infections, 69% had the type of infection recorded (Table 
5.8). Most infections were superficial (52%), followed by deep infections (31%) and the remaining 
17% were organ space infections. The organ space infections were mostly bone infections 
(osteomyelitis) with one infection of the mediastinum detected. Of the two possible incision sites, 
chest or donor site, more infections occurred at the chest incision (57%). All of the infections with an 
associated organism were diagnosed during the surgical admission. One deep infection, at the chest 
incision, had two organisms recorded, an Enterococcus and a Pseudomonas species.  
Cardiac Registry: 
5
[Total: 15]
HPA SSI Surveillance:
51 (29 post-discharge)
[Total: 61]
10 
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Table 5.8: Summary of the surgical site infections detected by the HPA SSI surveillance 
Infection Type (n) Method of detection Causative organisms % identified by the cardiac registry 
Superficial (22) 
Current admission: 9 
Re-admission: 3 
Post-discharge: 10 
E. aerogenes 
CNS 
Coliform (unspecified) 
14% 
Deep (13) 
Current admission: 7 
Re-admission: 5 
Post-discharge: 1 
CNS (x2) 
Pseudomonas (unspecified) 
Enterococcus (unspecified) 
31% 
Organ space (7) 
Current admission: 6 
Re-admission: 1 
Post-discharge: 0 
CNS 
E.coli 43% 
Unspecified (18) Post-discharge: 18 - - 
 
Post discharge questionnaires (PDQs) were carried out in 64% of patients followed up by the HPA SSI 
surveillance, with only two patients failing to complete the questionnaire. Six patients were still at 
Hammersmith Hospital at the end of the 30 day post-surgical follow up period, with four of these 
patients having had an SSI. The average time between surgery and SSI diagnosis was 16 days, with 
the shortest time between operation and infection diagnosis being 2 days. The longest period was 
35 days, with three infections technically falling outside of the standardised definitions for a surgical 
site infection.      
The cardiac registry on the other hand recorded 15 cases of surgical site infection, seven of which 
were recorded in the third quarter of data collection, giving an incidence ranging from 1% (4th 
quarter) to 4.1% (3rd quarter). The cardiac registry also collects information relating to other post-
operative complications, not just SSI. Post-operative neurological complications occurred in 1% of 
operations, transient strokes were recorded in three patients and one case of paraplegia in a 49 year 
old male was reported. New renal issues occurred in 5% of patients after surgery.  
Both the HPA SSI surveillance and cardiac registry recorded re-operation, with 28 and 16 patients 
having recorded re-operations, respectively. Cardiac registry data notes the reason for re-operation, 
and this was recorded for three of the four quarters of data collected in 2011. Reasons for re-
operation were bleeding, deep infection in need of debridement or to re-suture. Twelve patients 
(2%) were recorded as having died following their CABG surgery within the follow up period of the 
HPA SSI surveillance and cardiac registry data, one of which had an SSI.   
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5.2.2 Comparing ICD-10 Codes and Inpatient SSI 
 
The results of comparing ICD-10 codes with those surgical site infections recorded by the HPA SSI 
surveillance and cardiac registry are presented, followed by a description of those CABG patients 
extracted from the PAS data in 2009 and 2010. The results from the sensitivity analyses to determine 
the optimal set of ICD-10 codes for diagnosing SSI in the routine data are presented in Table 5.9.  
 
Table 5.9: Comparison of ICD-10 codes for identifying SSI with the ‘inpatient SSI’ 
Code Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
M869 0 99.8 (99, 100) 0 94.3 (92.1, 96) 0.50 
Y95 11.4 (3.2, 26.7) 97.5 (95.9, 98.6) 22.2 (6.41, 47.6) 94.7 (92.5, 96.3) 0.55 (0.49, 0.60) 
T813 8.57 (1.8, 23.1) 99.8 (99, 100) 75 (19.4, 99.4) 94.6 (92.5, 96.3) 0.54 (0.50, 0.59) 
T813 + org 2.86 (0.07, 14.9) 100 (99.3, 100) 100 (2.5, 100) 94.3 992.1, 96) 0.51 (0.49, 0.54) 
T814 37.1 (21.5, 55.1) 97.3 (95.6, 98.5) 46.4 (27.5, 66.1) 96.1 (94.2, 97.6) 0.67 (0.59, 0.75) 
T826 0 99.8 (99, 100) 0 94 (91.8, 95.8) 0.50 
T827 28.6 (14.6, 46.3) 99.1 (97.9, 99.7) 66.7 (38.4, 88.2) 95.7 (93.7, 97.2) 0.64 (0.56, 0.71) 
Y83 37.1 (21.5, 55.1) 91.1 (88.5, 93.3) 20.6 (11.5, 32.7) 95.9 (93.8, 97.4) 0.64 (0.56, 0.72) 
Y83 + org 11.4 (3.2, 26.7) 98.8 (97.5, 99.5) 36.4 (10.9, 69.2) 94.7 (92.6, 96.4) 0.55 (0.50, 0.61) 
T813 / T814 45.7 (28.8, 63.4) 97.2 (95.4, 98.4) 50 (31.9, 68.1) 96.6 (94.8, 98) 0.71 (0.63, 0.80) 
T813 / T827 37.1 (21.5, 55.1) 98.9 (97.7, 99.6) 68.4 (43.4, 87.4) 96.2 (94.3, 97.6) 0.68 (0.60, 0.76) 
T814 / T827 65.7 (47.8, 80.9) 96.4 (94.5, 97.8) 53.5 (37.7, 68.8) 97.8 (96.3, 98.9) 0.81 (0.73, 0.89) 
T813 / 14 / 27 76.5 (58.8, 89.3) 96.3 (94.4, 97.7) 55.3 (40.1, 69.8) 98.5 (97.2, 99.4) 0.86 (0.79, 0.94) 
T813 / 14 / 27 / Y83 74.3 (56.7, 87.5) 89.2 (86.3, 91.3) 29.9 (20.5, 40.6) 98.2 (96.3, 99.2) 0.82 (0.74, 0.89) 
T813 / 14 / 27 / Y83 + org 76.5 (58.8, 89.3) 95.6 (93.5, 97.1) 51 (36.6, 65.2) 98.5 (97.1, 99.4) 0.86 (0.79, 0.93) 
T813+org /14 / 27 / Y83+org 68.6 (50.7, 83.1) 95.9 (93.9, 97.4) 51.1 (36.1, 65.9) 98 (96.5, 99) 0.82 (0.74, 0.90) 
Any code + Any B95, 6, 7 34.3 (19.1, 52.2) 98 (96.5, 99) 52.2 (30.6, 73.2) 96 (94.1, 97.4) 0.66 (0.58, 0.74) 
A ‘+’ indicates both codes were present and a ‘/’ indicates either code was present. Org: organism code (B95, B96 or B97); 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
The ICD-10 codes M869 and T826 were both present in only one patient, however these were 
patients that had not been diagnosed as having an SSI by either the HPA SSI surveillance or cardiac 
registry. T813, which was only meant to be used in combination with a pathogen code, had a 
reduced sensitivity when this rule was adhered to than when it was used in isolation.  
The best ICD-10 code combination for correctly identifying the inpatient SSI was: T813, T814 and 
T827. This had a sensitivity of 76.5% indicating that just over three quarters of those patients with an 
SSI were identified and a PPV of 55.3%, showing that over half the patients with these codes did in 
fact have an inpatient SSI. The specificity of 96.3% indicates that only 4% of patients were false 
positives and the NPV of 98.5% shows that almost all patients without any codes did not have an SSI. 
The area under the Receiver Operating Characteristic (ROC) curve was 0.86 using these codes to 
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identify cases. The number of patients with an SSI and without and whether they have a relevant 
code or not for this code combination is shown Table 5.10.  
 
Table 5.10: Number of patients with and without inpatient SSI according to the presence of 
ICD-10 codes T813, T814 or T827 
 No Inpatient SSI Inpatient SSI Total 
No Relevant ICD-10 Code 542 9 551 
Relevant ICD-10 Code 21 26 47 
Total 563 35 598 
 
A similar range of results was obtained when adding in the presence of the Y83 plus an organism 
code. This addition reduced the specificity and positive predictive value slightly, but the AUC 
remained the same. The number of patients according to presence of ICD-10 code and SSI are 
presented in Table 5.11 for this code combination.  
 
Table 5.11: Number of patients with and without inpatient SSI according to the presence of 
ICD-10 codes T813, T814, T827 or Y83 + organism code 
 No Inpatient SSI Inpatient SSI Total 
No Relevant Code 538 9 547 
Relevant Code 25 26 51 
Total 563 35 598 
 
For those patients that were reported as having an inpatient SSI, but did not have any relevant ICD-
10 codes, I searched their diagnoses codes. Five of these patients were recoded as having superficial 
infections and two as having deep infections, and two of these patients were also recorded as having 
an SSI by both the cardiac registry and the HPA SSI surveillance.  
Two of the patients had codes indicating that there had been complications relating to their surgery, 
the deep infection patient having a haemorrhage complicating the procedure (T810) with pleural 
effusion (J90X). The other patient had a code for a mechanical complication of their vascular dialysis 
catheter (T824). Neither of these patients could be identified as SSI cases based on these codes 
alone. The remaining patients only had codes relating to their heart disease and comorbidities, 
suggesting that a quarter of patients which were identified by the HPA SSI surveillance and cardiac  
registry as having SSI could not be recognised with ICD-10 codes.    
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Based on these analyses, I decided to use the following set of codes to extract ‘cases’ of surgical site 
infections from the PAS data: 
 
Any of the following codes: T813, T814, T827, Y83 + organism 
 
5.2.3 Comparing Administrative and Surveillance Data 
 
All patients with CABG operations taking place between January 2009 and December 2010 were 
selected from the PAS data. In 2009 there were 446 patients with a CABG surgery performed 
according to the PAS data, corresponding to 472 admissions. Of these 24 patients were re-admitted 
to hospital within 30 days of their CABG surgery, of which two patients were day case admissions. A 
total of 515 episodes of care were recorded for the 446 patients, an average of 1.2 episodes per 
patient, with the most episodes being four for a single patient and three in one admission.  
In 2010 648 patients had a CABG surgery carried out according to the PAS data, accounting for 753 
episodes of care and 688 admissions, with 40 patients being re-admitted. There was an average of 
1.2 episodes of care per patients, with four being the highest number of episodes within 30 days of a 
CABG. Two patients had extensive missing data and were therefore removed, to give 646 patients 
from 2010.  Combining the two years gives 1,092 patients, of which 5.9% were re-admitted within 30 
days of their surgery.  
During 2011, 617 patients were recorded as having had CABG surgery according to the HPA SSI 
surveillance and cardiac registry data. When the HPA SSI surveillance and cardiac registry data were 
linked to the PAS data 19 (3.1%) patients did not link, reducing the patient population to 598. The 
most patients were picked up by the PAS data, followed by the HPA SSI surveillance and finally the 
cardiac registry database (Figure 5.8).  
A summary of patient demographics for 2009 – 2011 is presented in Table 5.12. The SSI prevalence 
using ICD-10 codes was 7.5% in 2009 – 2010. The average length of stay for this cohort was 12 days, 
similar to that seen in the HPA SSI surveillance and cardiac registry patients. 43% of patients stayed 
for a week or less, and 81% of patients stayed for 2 weeks or less, with the longest length of stay for 
being 171 days. The number of CABG procedures recorded in the PAS data was highest in 2010, with 
almost a quarter more procedures than in 2009.   
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Table 5.12: Comparison of CABG patients in 2009 – 2010 with those identified by traditional 
data sources 
Comparison variables 2009 2010 
Linked PAS, HPA SSI 
surveillance & cardiac 
registry 
Number of patients 446 646 598 
Sex distribution (F:M) 1 : 3.7 1 : 3.9 1 : 3.3 
Average age 67.1 66.8 66.1 
Age range 30 - 88 28 - 89 28 - 95  
SSI patients (incidence) 34 (7.6%) 48 (7.4%) 34 (5.7%) 
 
The demographic makeup of the CABG cohort was similar to that reported by the HPA SSI 
surveillance and cardiac registry data, with 79% of patients being male and 65% of patients aged 
between 60 – 80 years old (Figure 5.6). 
 
Figure 5.6: Number of patients from the PAS data (2009-2010) according to age group and SSI 
 
 
All three data sources contained information relating to surgical site infections, but with varying 
degrees of detail. A total of 61 SSI were diagnosed by the HPA SSI surveillance data in 2011, of which 
30 were inpatient infections. This is compared to the 16 infections recorded by cardiac registry data 
and 51 from the ICD-10 codes (Figure 5.9).   
The variables collected by all three data sources can be split into themes, with varying levels of detail 
associated to the different data sources (Table 5.13). 
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Table 5.13: Summary of the variables collected by  the HPA SSI surveillance, cardiac registry and PAS 
Variables collected HPA Surveillance  
Cardiac 
Registry  PAS* 
Patient Information (identifiers, age and sex) +++ +++ +++ 
Patient History (risks, co-morbidities & operative history) + +++ +++ 
Pre-operative features (drug administration & support) + ++ + 
Operative features (surgeons, type, duration & technical details)  ++ +++ + 
Post-operative complications (SSI, stroke, renal complication, death) ++ ++ ++ 
+ Less than 25% of the potential variables collected by all the databases; ++ Between 25 – 75% of the potential 
variables collected by all the databases; +++ Over 75% of the potential variables collected by all the databases 
*The information available from PAS is not necessarily stored as specific variables but could be generated, such as prior 
surgery or post-operative stroke. 
 
The cardiac registry data had a sensitivity and specificity of 16.4% and 99.1%, for identifying the 
inpatient SSI diagnosed by the surveillance data. However, the sensitivity increased to 43% and the 
specificity changed to 98% when considering organ space infection only, indicating the registry data 
were more sensitive to picking up more severe infections.  Interestingly, not all those infections 
picked up by the cardiac registry data were also diagnosed within the HPA SSI surveillance data. Five 
SSI were diagnosed by the cardiac registry, of which four were also associated with ICD-10 codes, 
however they were not diagnosed by the HPA SSI surveillance.  Of these four SSI, three were within 
patients that had been captured by all three databases.  
 
 
 
 
HPA Surveillance 
Data: 11
[Total 557]
PAS Data 
[Total 598]
Cardiac Registry 
Data: 8
[Total 534]
HPA Surveillance 
Data: 6
[Total 30]
PAS Data: 26 
[Total 51]
Cardiac Registry 
Data: 1
[Total 16]
Figure 5.7: Number of patients recorded as 
having a CABG in 2011 
Figure 5.8: Number of patients recorded as 
having an SSI following CABG. The HPA SSI 
surveillance infections were only those 
diagnosed on re-admission or surgical 
admission. The denominator was 617. 
473 
52 
72 
9 
13 
4 
2 
Total: 617 Total: 61 
1 
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The cases derived from the ICD-10 codes were plotted using a Statistical Process Control (SPC) chart, 
from the beginning of 2009 (Figure 5.9). The monthly rate of infections did not exceed the control 
limits at any stage, nor was the running mean adjusted.  
 
Figure 5.9: Statistical Process Control Chart for SSI diagnosed by ICD-10 codes 
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5.2.4 Creating Syndromic Algorithms of SSI  
 
When the HPA SSI surveillance and cardiac registry data were linked to the laboratory, radiology and 
PAS data, 3% of patients would not link. Only those patients lacking PAS information were excluded 
at this stage, as it could not be determined if not having radiology data for example was a linkage 
error or the patient simply not having an x-ray. The six months of data (from January to June 2011) 
being used contained 303 patients and all had laboratory, radiology, PAS, HPA SSI surveillance and 
cardiac registry data. Firstly the results from investigating the clinical biochemistry and 
haematological markers are presented, followed by radiology requests and microbiology requests, 
then combinations of these.   
The highest number of episodes to occur in one patient was nine, with an average of two episodes 
per patient (including the operative episode). A re-admission was recorded for 38 patients, 21% of 
which had an SSI, according to the HPA SSI surveillance and cardiac registry. There were 20 patients 
with an inpatient surgical site infection, on which the syndromic algorithms were created. There 
were six patients with no corresponding laboratory data. In the following results, ‘infected’ refers to 
those patients with an inpatient SSI and ‘uninfected’ to those without an inpatient SSI.  
  
Haematology and Clinical biochemistry 
 
The markers that were investigated for their association with a wound infection were: white blood 
cell count (WBC), and specifically eosinophils, basophils, lymphocytes and neutrophils, the 
international normalised ratio (INR), and erythrocyte sedimentation rate (ESR), platelets, fibrinogen, 
creatinine, haematocrit, serum albumin and C - reactive protein (CRP). The results of a comparison 
of these tests between inpatient SSI patients (20) and uninfected patients (283) are presented in 
Table 5.14.  
The basophil count was converted to a binary variable, of ‘0’ and ‘over 0’ when determining if there 
was a difference between patients with and without an inpatient SSI. This was done as the number 
range was too narrow for any meaningful comparison (reference range 0.0 – 0.1 x109/L). At this 
stage, ESR was not investigated further as the test was not performed frequently enough to be used 
effectively (only 11 patients had a post-operative ESR performed and none were carried out pre-
operatively). One of the patients with a post-operative ESR test had an inpatient surgical site 
infection; therefore the requests were not correlated with infection.  
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Table 5.14: Summary of Routine Blood Tests Being Investigated for Developing Syndromic Surveillance 
 Pre CABG Post CABG 
Marker Inpatient SSI No Inpatient SSI Inpatient  SSI No Inpatient  SSI 
C-reactive Protein 
(0 – 10 mg/L) 
0.30 – 113.1 (range) 
9.60 (mean) 
3.25 (median) 
100% (patients) 
0.20 – 164.71 
9.46 
3.25 
89% 
44.34 – 198.38 
110.95 
103.66 
100% 
5.58 – 268.07 
115.97 
112.5 
98% 
Full White Blood 
Cell Count 
(4 – 11 x109/L) 
5.05 – 13.10 
7.97 
7.73 
100% 
3.25 – 13.00 
7.60 
7.50 
93% 
7.76 – 13.38 
9.83 
9.43 
100% 
4.63 – 21.81 
10.02 
9.72 
98% 
Lymphocytes 
(1.0 – 3.5 x109/L) 
0.9 – 3.7 
2.27 
2.20 
100% 
0.40 – 4.6 
2.02 
1.93 
94% 
0.70 – 2.56 
1.53 
1.39 
100% 
0.37 – 2.91 
1.37 
1.29 
98% 
Neutrophils 
(2.0 – 7.5 x109/L) 
3.05 – 8.30 
4.79 
4.77 
100% 
1.50 – 10.15 
4.73 
4.75 
94% 
5.07 – 9.82 
7.20 
7.03 
100% 
3.57 – 18.18 
7.64 
7.51 
98% 
Basophils* 
(0.0 – 0.1 x109/L) 
0 – 0.1  
0.01 
0.0 
100%  
0 – 0.1  
0.01 
0.0 
96% 
0 – 0.06 
0.015 
0.004 
100% 
0 – 0.05 
0.004 
0.0 
98% 
Eosinophils** 
(0.0 – 0.4 x109/L) 
0.03 – 0.60 
0.27 
0.25 
100% 
0 – 1.05 
0.22 
0.20 
96% 
0.10 – 0.94 
0.26 
0.18 
100% 
0 – 0.72 
0.17 
0.14 
98% 
Platelets* 
(120 – 400 x109/L) 
163.8 – 450.0 
251.69 
248.4 
100% 
70.64 – 586.51 
231.52 
220.67 
93% 
205.0 – 599.17 
375.43 
371.70 
100% 
55.11 – 566.07 
223.12 
204.10 
98% 
Fibrinogen** 
(1.5 – 4.0 g/L) 
2.01 – 5.09 
3.36 
3.24 
90% 
1.82 – 7.23 
3.49 
3.38 
93% 
3.9 – 6.88 
5.18 
5.24 
100% 
1.53 – 8.27 
4.60 
4.50 
98% 
International 
Normalised Ratio 
(0.9 – 1.1 ratio) 
1.0 – 1.20 
1.07 
1.05 
50% 
0.90 – 3.00 
1.09 
1.00 
37% 
1.05 – 2.27 
1.28 
1.14 
100% 
0.95 – 3.10 
1.22 
1.15 
84% 
Creatinine 
(60 – 125 µmol/L) 
59.0 – 145.5 
85.75 
80.0 
100% 
53.0 – 1001.2 
106.83 
85.99 
95% 
52.50 – 230.91 
93.68 
76.99 
100% 
48.25 – 651.14 
105.49 
84.50 
98% 
Haematocrit 
(0.42 – 0.52 %) 
0.28 – 0.46 
0.39 
0.39 
100% 
0.28 – 0.53 
0.40 
0.40 
94% 
0.27 – 0.34 
0.30 
0.30 
100% 
0.24 – 0.40 
0.30 
0.30 
98% 
Serum Albumin 
(33 – 47 g/L) 
31.00 – 41.67 
36.86 
37.38 
100% 
23.54 – 46.00 
36.80 
37.00 
93% 
20.71 – 31.5 
25.70 
26.16 
100% 
15.6 – 32.63 
24.44 
24.50 
98% 
*Significant in a t-test comparing the average post-operative values between infected and uninfected patients, 
with a p-value <0.0001 
** Significant in a t-test comparing the average post-operative values between infected and uninfected patients, 
with a p-value <0.05 
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I used t-tests to compare the mean pre-operative and post-operative values for each potential 
biological marker of infection. This showed four markers to be statistically significantly different 
between the infected and uninfected patients, in the post-operative values. These markers were: 
eosinophils, basophils, platelets and fibrinogen. CRP and WBC analysed in this way were not 
statistically significant, despite being found by previous studies as good indicators of infection. There 
were no significant differences between the pre-operative means for the markers in the infected and 
uninfected patients. 
The next step was to determine patterns in the biological markers of infection after surgery and to 
compare those with an inpatient SSI to those with no recorded inpatient SSI. This was to see if there 
were any distinctive patterns due to both surgery and surgical site infection.   
The medians of the infected and uninfected patient groups were graphed over time; the median was 
used as opposed to the mean as this reduces the influence of any extremes on the overall pattern. 
Box plots were drawn for pre and post-operative levels in the two patient populations, and in some 
cases these graphs were also plotted by severity of surgical site infection. Graphs for markers that 
were not found to be good indicators of infection at this stage of the analysis are in Appendix 7; 
these included: albumin, creatinine, lymphocytes, neutrophils, haematocrit and INR.  
 
Starting with C - reactive protein, the median CRP values for patients with and without inpatient SSI, 
and the scatter plot with the moving average (Figure 5.10 and Figure 5.11) both show that there is a 
distinct increase in CRP following surgery, peaking on post-operative days 3 – 5.  
There was a statistically significant difference between the CRP levels at day 4 between the infected 
and uninfected patients, with the patients with inpatient SSI having a higher peak post-operation (p-
value: 0.02; mean infected: 201 mg/L; mean uninfected: 164 mg/L). Those patients with an inpatient 
SSI continued to have raised CRP levels 5 days post-CABG, with distinctive peaks in the median 
values occurring throughout the post-operative period. The moving average, based on the 20 
infected and 20 randomly selected uninfected patients, however shows the uninfected patients also 
have fluctuating CRP levels.   
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Figure 5.10: Median CRP following CABG procedures, according to SSI status 
 
 
Figure 5.11: Scatter plot of CRP following CABG procedures in a sample of patients, according to SSI status 
 
 
However, when the infections were broken down into severity (superficial, deep and organ space), it 
was clear that the patients with organ space infections have dramatically increased CRP levels with 
peaks occurring throughout the follow up period (Figure 5.12 and 5.13). The average post-operative 
CRP level for this group of patients was almost a third higher than those patients without an 
inpatient SSI. Interestingly, the patients with deep infections appear to follow the same pattern as 
those patients with no inpatient SSI, showing no discernable post-operative peaks in CRP levels.   
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Figure 5.12: Box plot of CRP levels following CABG procedures, according to severity of SSI 
 
 
Figure 5.13: Median CRP following CABG procedure, according to type of surgical site infection 
 
 
The white blood cell counts were slightly elevated for a significant period after CABG surgery before 
levelling back to the pre-operative average (Figure 5.14 and.5.15). However, the elevation remained 
mostly within the ‘normal’ range, with few peaks surpassing the upper limit of 11 WBC x109/L. The 
scatter plot demonstrated slightly better than the daily medians that those patients with inpatient 
SSI had levels which exceeded the upper normal limit consistently for two weeks following surgery. 
However, there was no dramatic post-CABG response in WBC due to the trauma of surgery.  
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Figure 5.14: Median white blood cell count following CABG procedures, according to SSI status 
 
 
Figure 5.15: Scatter plot of WBC following CABG procedures in a sample of patients, according to SSI status 
 
 
For eosinophils there were clear peaks associated with patients that had a superficial SSI; deep and 
organ space infections on the other hand had a pattern that did not differ from those patients with 
no surgical site infections (Figure 5.16). There was a slight depression in median eosinophil levels 
immediately following surgery, however all the daily median values remained within in the normal 
range, with the exception of superficial infection patients.  
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Figure 5.16: Median eosinophil count following CABG procedures, according to SSI severity 
 
 
The basophil levels, both the pre and post-operation appeared to be raised in those patients with 
inpatient SSI, despite only the post-operative difference being statistically significant (Figure 5.17). 
However, plotting the median values showed no distinctive effect of surgery on the levels of 
basophils, and peaks were observed for both superficial and deep infections.   
 
Figure 5.17: Box plot of basophil levels pre and post CABG procedures, according to SSI status 
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The platelet levels were significantly different between those infected and uninfected patients 
following CABG procedures, demonstrated by Figures 5.18 and 5.19. When the daily median values 
were plotted (Figure 5.20), it can be seen that from a week post-CABG the platelet levels are 
consistently higher in the infected patients than the uninfected patients. The elevated levels 
observed in the inpatient SSI patients were almost constantly exceeding the upper normal limit from 
day 10 post-CABG onwards. There was a slight suppression in both the infected and uninfected 
individuals immediately following surgery, however this stayed within the normal reference range.  
 
Figure 5.18: Box plot of platelet levels pre and post CABG procedures, according to SSI status 
 
 
Figure 5.19: Median platelet count following CABG procedures, according to SSI status 
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When the median daily values were split into infection severity, there was no stand out differences 
between the infection types (Figure 5.20). Although in this instance the organ space infections, if 
anything appear to be lower than in the superficial or deep infection individuals.  All infection types 
had values exceeding the upper normal threshold, suggesting this is could be a good general marker 
for SSI.  
 
Figure 5.20: Median platelet count following CABG procedures, according to SSI severity 
 
 
Finally, fibrinogen levels decreased immediately following surgery, followed by a sharp increase 
peaking at post-operative days 4 – 6 (Figure 5.21 and 5.22). After this peak both the SSI and non-SSI 
patients’ fibrinogen levels slowly normalise, although the infected patients consistently had higher 
fibrinogen levels than those uninfected patients. The upper normal threshold on 4g/L appears to be 
too low in this patient population to distinguish between uninfected and infected patients, however 
a threshold of 5g/L would be more appropriate based on these data and population group.  
 
Figure 5.21: Median fibrinogen count following CABG procedures, according to SSI status 
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Figure 5.22: Scatter plot of fibrinogen following CABG procedures in a sample of patients, according to SSI 
status 
 
 
The markers that were found to be indicative of a surgical site infection were CRP, platelets, 
fibrinogen, eosinophils and basophils based on the simple graphical analyses and t-tests to compare 
the average pre and post-operative values between infected and uninfected patients. The marker 
thresholds to indicate ‘infected’ and ‘uninfected’ patients were either set or validated (in 
comparison to those used as standard by ICHNT laboratory). The markers and their thresholds which 
were investigated further are summarised in Table 5.15.  
 
Table 5.15: Marker thresholds indicative of SSI following CABG 
Marker Threshold for ‘Infection’ 
C-reactive Protein 
>50mg/L after day 7 post-surgery 
>100mg/L after day 7 post-surgery 
Platelets >400 x109/L any day post-surgery 
Fibrinogen >5 g/L after day 7 post-surgery 
WBC >11 x109/L any day post-surgery 
Basophils >0 x109/L any day post-surgery 
Eosinophils >0.4 x109/L any day post-surgery 
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Two thresholds were used for CRP; the lower threshold of >50 mg/L was suggested as appropriate 
for defining infections in a personal communication with a haematologist at ICHNT. The higher 
threshold (>100 mg/L) was chosen based on the initial analyses in this chapter.  
The number of times a patient was recorded as having a marker exceed the threshold value was 
plotted as a ROC curve (Figure 5.23).  Based on the AUC values, platelets (0.92) and fibrinogen (0.89) 
were the best performing biological markers for identifying a patient with an inpatient SSI. This was 
followed by CRP level over 50 mg/L, which performed better in this patient group than the higher 
threshold of over 100 mg/L. Eosinophils was the poorest performing marker for detecting inpatient 
surgical site infections, with an AUC of 0.58.  
 
Figure 5.23: ROC curve of the number of times a marker exceeds the threshold value in determining 
inpatient SSI 
 
 
The sensitivities, specificities, positive predictive values and negative predictive values for the 
different makers when investigated in isolation and the number of times they exceeded the set 
thresholds are presented in Table 5.16. Very high sensitivities were achieved using certain markers, 
namely platelets, fibrinogen and white blood cells, all of which detected 95% of inpatient SSI 
patients when investigating a single occurrence of the marker exceeding the threshold value. 
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However, several patients without SSI were also identified as having results over the thresholds, 
meaning the PPV (8.68% - 19.4%) and specificities (29.1% - 72%) were not very high.  
The two thresholds for CRP found that whilst the higher threshold was more discerning (sensitivity 
80.5%), it only had a sensitivity of 60%. The lower threshold on the other hand had a higher 
sensitivity of 80%, but the specificity reduced to 66%. Despite being statistically significant, when 
investigated for their potential in differentiating infected and uninfected patients, both basophils 
and eosinophils performed poorly. Basophils had a higher sensitivity (55%) than eosinophils (40%), 
however both these markers had relatively high specificities.  
 
Table 5.16: Sensitivity analyses of different markers in detecting inpatient SSI 
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Any occurrence of C-reactive protein >50mg/L after 7 days post-CABG 
One or more occurrence 80 (56.3, 94.3) 66 (60.1, 71.5) 14.3 (8.39, 22.2) 97.9 (94.7, 99.4) 0.73 (0.64, 0.82) 
Two or more occurrences 70 (45.7, 88.1) 75.5 (70.1, 80.4) 16.9 (9.54, 26.7) 97.3 (94.1, 99) 0.73 (0.62, 0.83) 
Three or more occurrences 70 (45.7, 88.1) 82.6 (77.7, 86.9) 22.2 (12.7, 34.5) 97.5 (94.6, 99.1) 0.76 (0.66, 0.87) 
Four or more occurrences 65 (40.8, 84.6) 86.9 (82.4, 90.6) 26 (14.6, 40.3) 97.2 (94.4, 98.9) 0.76 (0.65, 0.87) 
Any occurrence of C-reactive protein >100 mg/L after 7 days post-CABG 
One or more occurrence 60 (36.1, 80.9) 80.5 (75.4, 85) 17.9 (9.61, 29.2) 96.6 (93.4, 98.5) 0.70 (0.59, 0.82) 
Two or more occurrences 55 (31.5, 76.9) 88.7 (84.4, 92.1) 25.6 (13.5, 41.2) 96.5 (93.5, 98.4) 0.72 (0.61, 0.83) 
Three or more occurrences 55 (31.5, 76.9) 92.6 (88.8, 95.3) 34.4 (18.6, 53.2) 96.7 (93.8, 98.5) 0.74 (0.63, 0.85) 
Four or more occurrences 40 (19.1, 63.9) 94.3 (90.9, 96.7) 33.3 (15.6, 55.3) 95.7 (92.6, 97.7) 0.67 (0.56, 0.78) 
Any occurrence of Platelets >400 x109/L any day post-CABG 
One or more occurrence 95 (75.1, 99.9) 72 (66.4, 77.1) 19.4 (12.1, 28.6) 99.5 (97.3, 100) 0.84 (0.78, 0.89) 
Two or more occurrences 90 (68.3, 98.8) 80.9 (75.8, 85.3) 25 (15.5, 36.6) 99.1 (96.9, 99.9) 0.85 (0.78, 0.93) 
Three or more occurrences 80 (56.3, 94.3) 86.5 (82, 90.3) 29.6 (18, 43.6) 98.4 (95.9, 99.6) 0.83 (0.74, 0.93) 
Four or more occurrences 75 (50.9, 91.3) 89.7 (85.6, 93) 34.1 (20.5, 49.9) 98.1 (95.5, 99.4) 0.82 (0.73, 0.92) 
Any occurrence of Fibrinogen >5 g/L after 7 days post-CABG 
One or more occurrence 95 (75.1, 99.9) 61.7 (55.8, 67.4) 15 (9.25, 22.4) 99.4 (96.9, 100) 0.78 (0.73, 0.84) 
Two or more occurrences 85 (62.1, 96.8) 79.4 (74.2, 84) 22.7 (13.8, 33.8) 98.7 (96.2, 99.7) 0.82 (0.74, 0.91) 
Three or more occurrences 70 (45.7, 88.1) 86.5 (82, 90.3) 26.9 (15.6, 41) 97.6 (94.8, 99.1) 0.78 (0.68, 0.89) 
Four or more occurrences 60 (36.1, 80.9) 91.8 (88, 94.8) 34.3 (19.1, 52.2) 97 (94.2, 98.7) 0.76 (0.65, 0.87) 
Any occurrence of White blood cell count >11 x109/L  any day post-CABG 
One or more occurrence 95 (75.1, 99.9) 29.1 (23.8, 34.8) 8.68 (5.3, 13.2) 98.8 (93.5, 100) 0.62 (0.57, 0.68) 
Two or more occurrences 80 (56.3, 94.3) 48.2 (42.3, 54.2) 9.88 (5.75, 15.5) 97.1 (92.8, 99.2) 0.64 (0.55, 0.74) 
Three or more occurrences 70 (45.7, 88.1) 61 (55, 66.7) 11.3 (6.31, 18.2) 96.6 (92.8, 98.8) 0.66 (0.55, 0.76) 
Four or more occurrences 60 (36.1, 80.9) 71.3 (65.6, 76.5) 12.9 (6.85, 21.5) 96.2 (92.6, 98.3) 0.66 (0.54, 0.77) 
Any occurrence of Basophils >0 x109/L  any day post-CABG 
One or more occurrence 55 (31.5, 76.9) 75.5 (70.1, 80.4) 13.8 (7.07, 23.3) 95.9 (92.4, 98.1) 0.65 (0.54, 0.77) 
Two or more occurrences 35 (15.4, 59.2) 92.6 (88.8, 95.3) 25 (10.7, 44.9) 95.3 (92, 97.4) 0.64 (0.53, 0.75) 
Three or more occurrences 25 (8.66, 49.1) 97.2 (94.5, 98.8) 38.5 (13.9, 68.4) 94.8 (91.6, 97.1) 0.61 (0.51, 0.71) 
Four or more occurrences 25 (8.66, 49.1) 98.2 (95.9, 99.4) 50 (18.7, 81.3) 94.9 (91.7, 97.1) 0.62 (0.52, 0.71) 
Any occurrence of Eosinophils >0.4 x109/L  any day post-CABG 
One or more occurrence 40 (19.1, 63.9) 74.8 (69.3, 79.8) 10.1 (4.47, 19) 94.6 (90.8, 97.2) 0.57 (0.46, 0.69) 
Two or more occurrences 25 (8.66, 49.1) 84.4 (79.6, 88.4) 10.2 (3.4, 22.2) 94.1 (90.4, 96.6) 0.55 (0.45, 0.65) 
Three or more occurrences 20 (5.73, 43.7) 87.9 (83.6, 91.5) 10.5 (2.94, 24.8) 93.9 (90.3, 96.5) 0.54 (0.45, 0.63) 
Four or more occurrences 20 (5.73, 43.7) 92.2 (88.4, 95) 15.4 (4.36, 34.9) 94.2 (90.8, 96.7) 0.56 (0.47, 0.65) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
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The best AUC was 0.85, for having two or more occurrences of platelets over the 400 mg/L 
threshold. In general, the AUC values increased when more occurrences of the marker exceeding the 
threshold value were investigated, despite the sensitivities decreasing; the exceptions were 
basophils and eosinophils. 
Combinations of the biological markers of infection were tested against the inpatient SSI to 
determine whether combinations improved the sensitivity and specificities. These are presented in 
Table 5.17. At this stage eosinophils and basophils were not included, as the highest possible 
sensitivity when using these markers in any combination would be 40% and 55%, respectively.  
When markers were combined, the AUC values as a whole were improved. The highest AUC value 
was associated with a combination of one or more occurrences of white blood cell count, platelets 
and fibrinogen all exceeding the threshold levels (AUC: 0.87; 95% CI: 0.79 – 0.94); however the PPV 
was still relatively low at 27.3%. This indicates that using this combination of markers alone will not 
be able to distinguish between patients with and without SSI, despite identifying 90% of those 
patients with an inpatient SSI. The PPV values improved when two or more occurrences of platelets 
and fibrinogen exceeding the threshold values and any occurrence of WBC were used, with a PPV of 
37.2%. In this combination the AUC remained high (0.86) but the sensitivity dropped to 80%.  
 
Table 5.17: Sensitivity analyses of combinations of markers in detecting inpatient SSI 
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
CRP >50 + Platelets 80 (56.3, 94.3) 83.7 (78.8, 87.8) 25.8 (15.5, 38.5) 98.3 (95.8, 99.5) 0.82 (0.73, 0.91) 
CRP >50 + Fibrinogen 75 (50.9, 91.3) 73.4 (67.8, 78.5) 16.7 (9.64, 26) 97.6 (94.6, 99.2) 0.74 (0.64, 0.84) 
CRP >50 + WBC 75 (50.9, 91.3) 71.3 (65.6, 76.5) 15.6 (9.02, 24.5) 97.6 (94.4, 99.2) 0.73 (0.63, 0.83) 
CRP >100 + Platelets 60 (36.1, 80.9) 90.4 (86.4, 93.6) 30.8 (17, 47.6) 97 (94.1, 98.7) 0.75 (0.64, 0.86) 
CRP >100 + Fibrinogen 55 (31.5, 76.9) 84 (79.2, 88.1) 19.6 (10.2, 32.4) 96.3 (93.2, 98.3) 0.70 (0.58, 0.81) 
CRP >100 + WBC 55 (31.5, 76.9) 84 (79.2, 88.1) 19.6 (10.2, 32.4) 96.3 (93.2, 98.3) 0.70 (0.58, 0.81) 
Platelets + Fibrinogen 90 (68.3, 98.8) 81.2 (76.1, 85.6) 25.4 (15.8, 37.1) 99.1 (96.9, 99.9) 0.86 (0.79, 0.93) 
Platelets + WBC 90 (68.3, 98.8) 76.2 (70.8, 81.1) 21.2 (13.1, 31.4) 99.1 (96.7, 99.9) 0.83 (0.76, 0.90) 
Fibrinogen + WBC 95 (75.1, 99.9) 70.9 (65.2, 76.2) 18.8 (11.7, 27.8) 99.5 (97.3, 100) 0.83 (0.77, 0.89) 
CRP >50 + Platelets + 
Fibrinogen 75 (50.9, 91.3) 85.5 (80.8, 89.4) 26.8 (15.8, 40.3) 98 (95.3, 99.3) 0.80 (0.70, 0.90) 
WBC + Platelets + 
Fibrinogen 90 (68.3, 98.8) 83 (78.1, 87.2) 27.3 (17, 39.6) 99.2 (97, 99.9) 0.87 (0.79, 0.94) 
CRP >50 + Platelets + 
Fibrinogen + WBC 75 (50.9, 91.3) 86.9 (82.4, 90.6) 28.8 (17.1, 43.1) 98 (95.4, 99.3) 0.81 (0.71, 0.91) 
>2 Platelets + >2 
Fibrinogen + WBC 80 (56.3, 94.3) 91.1 (87.2, 94.2) 39 (24.2, 55.5) 98.5 (96.1, 99.6) 0.86 (76.4, 0.95) 
>2 Platelets + >2 
Fibrinogen 80 (56.3, 94.3) 90.4 (86.4, 93.6) 37.2 (23, 53.3) 98.5 (96.1, 99.6) 0.85 (0.76, 0.94) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
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All of these reported sensitivities, specificities, PPVs and NPVs were based on the whole inpatient SSI 
population SSI; however the graphs previously plotted indicated that organ space infections and 
superficial infections have differing marker patterns. Therefore different combinations of markers 
may have better powers of detecting different severities of infection. The same process was carried 
out for organ space infections. Deep and superficial infections were classified together as a separate 
patient group for investigation (Table 5.18). 
 
Table 5.18: Sensitivity analyses of combinations of markers in detecting inpatient SSI of differing severity 
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Specifically for Organ Space Surgical Site Infections 
CRP >50 100 (47.8, 100) 65.8 (60, 71.4) 4.95 (1.63, 11.2) 100 (98, 100) 0.83 (0.80, 0.86) 
CRP>100 100 (47.8, 100) 80.4 (75.3, 84.9) 8.33 (2.76, 18.4) 100 (98.4, 100) 0.90 (0.88, 0.93) 
Platelets >400 100 (47.8, 100) 71.9 (66.2, 77.1) 5.95 (1.96, 13.3) 100 (98.2, 100) 0.86 (0.83, 0.89) 
Fibrinogen >5 80 (28.4, 99.5) 61.6 (55.6, 67.3) 3.57 (0.98, 8.89) 99.4 (96.8, 100) 0.71 (0.51, 0.91) 
WBC >11 80 (28.4, 99.5) 28.8 (23.6, 34.5) 1.96 (0.54, 4.94) 98.8 (93.4, 100) 0.54 (0.35, 0.74) 
>2 CRP >100 100 (47.8, 100) 88.9 (84.3, 92.1) 13.5 (4.54, 28.8) 100 (98.5, 100) 0.94 (0.92, 0.96) 
>3 CRP >100 100 (47.8, 100) 92.5 (88.8, 95.3) 19.2 (6.55, 39.4) 100 (98.6, 100) 0.96 (0.95, 0.98) 
>4 CRP >100 80 (28.4, 99.5) 94.3 (90.9, 96.7) 20 (5.73, 43.7) 99.6 (97.9, 100) 0.87 (0.68, 1.00) 
>2 CRP >100 + Platelets 100 (47.8, 100) 93.6 (90.1, 96.2) 21.7 (7.46, 43.7) 100 (98.6, 100) 0.97 (0.95, 0.98) 
>2 CRP >100 + Platelets + 
Fibrinogen 80 (28.4, 99.5) 94.3 (90.9, 96.7) 20 (5.73, 43.7) 99.6 (97.9, 100) 0.87 (0.68, 1.00) 
Specifically for Superficial & Deep  Surgical Site Infections 
CRP >50 68.8 (41.3, 89) 65.8 (60, 71.4) 10.3 (5.24, 17.7) 97.4 (94, 99.1) 0.67 (0.55, 0.79) 
CRP>100 43.8 (19.8, 70.1) 80.4 (75.3, 84.9) 11.3 (4.66, 21.9) 96.2 (92.9, 98.2) 0.62 (0.49, 0.75) 
Platelets >400 87.5 (61.7, 98.4) 71.9 (66.2, 77.1) 15.1 (8.48, 24) 99 (96.5, 99.9) 0.80 (0.71, 0.89) 
Fibrinogen >5 93.8 (69.8, 99.8) 61.6 (55.6, 67.3) 12.2 (6.99, 19.3) 99.4 (96.8, 100) 0.78 (0.71, 0.84) 
WBC >11 93.8 (69.8, 99.8) 28.8 (23.6, 34.5) 6.98 (3.96, 11.2) 98.8 (93.4, 100) 0.61 (0.55, 0.68) 
>2 Fibrinogen  81.3 (54.4, 96) 79.4 (74.2, 83.9) 18.3 (10.1, 29.3) 98.7 (96.2, 99.7) 0.80 (0.70, 0.91) 
>3 Fibrinogen 62.5 (24.5, 91.5) 86.5 (81.9, 90.2) 20.8 (10.5, 35) 97.6 (94.8, 99.1) 0.75 (0.62, 0.87) 
>2 WBC 75 (47.6, 92.7) 48 (42.1, 54.1) 7.59 (3.99, 12.9) 97.1 (92.8, 99.2) 0.62 (0.50, 0.73) 
>3 WBC 62.5 (35.4, 84.8) 60.9 (54.9, 66.6) 8.33 (4.07, 14.8) 96.6 (92,8, 98.7) 0.62 (0.49, 0.74) 
Platelets+Fibrinogen+WBC 87.5 (61.7, 98.4) 82.9 (78, 87.1) 22.6 (12.9, 35) 99.1 (97, 99.9) 0.85 (0.77, 0.94) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
The best marker combinations differed between the organ space infections and superficial and deep 
infections. The optimal combination of codes remained the same in the superficial and deep group 
(using WBC, platelets and fibrinogen) as it was when investigating the entire inpatient SSI 
population. Organ space infections were best identified using the combination of two CRP values 
exceeding the 100mg/L threshold and at least one occurrence of platelets exceeding 400x109/L. This 
combination of markers identified all the possible cases of organ space infections and had an AUC of 
0.97. The PPV was still low at only 21.7%, meaning that almost 4/5ths of those patients identified 
with this code combination did not have an inpatient organ space infection.  
 154 
 
Radiology Data 
 
A total of 1,367 diagnostic imaging investigations were requested for the CABG patients within 35 
days of their surgery. The majority of the diagnostic imaging investigation requests were made 
within five days of surgery (68%), as would be expected from the standard five day post-operative 
stay.  
One fluoroscopy investigation was requested in this patient group; angiograms and MRIs were also 
rare with only three and one investigation requested, respectively. These investigation types were 
not investigated further as proxy indicators of infection. Almost 90% of the diagnostic investigations 
were x-rays of which 98% were chest x-rays. Each patient had an average of 3.9 x-rays during their 
post-operative stay, with the most in a single patient being 31 x-rays in the 35 days following 
surgery. 24 patients had no x-ray requests, indicating a breach in the standardised patient pathway 
and 60% of patients had more than two x-rays.  
 
Figure 5.24: Number of post-CABG diagnostic imaging requests, according to SSI status 
 
 
Looking at the number of investigations requested for x-rays, ultrasounds and CTs, there was a 
difference between patients with and without inpatient surgical site infections, with the mean for 
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patients with SSI being 6 x-rays and the mean for those without being 3.8 (Figure 5.24). The same 
was true of ultrasounds and CT investigations, with the mean number of requests in both changing, 
from no exams to one exam between infected and uninfected patients. All of these differences were 
statistically significant when analysed individually; however when they were regressed together, 
only the number of CT investigations remained significant (OR: 3.19; CI: 1.49, 6.85; p-value: 0.003).  
 
Table 5.19: Sensitivity analyses of combinations of diagnostic imaging requests in detecting inpatient SSI  
Infection Proxy Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Ultrasound any  35 (15.4, 59.2) 83 (78.1, 87.2) 12.7 (5.27, 24.5) 94.8 (91.2, 97.2) 0.59 (0.48, 0.70) 
CT any 45 (23.1, 68.5) 91.9 (88.1, 94.8) 28.1 (13.7, 46.7) 95.9 992.9, 98) 0.68 (0.57, 0.80) 
>1 Ultrasound 10 (1.23, 31.7) 95.4 (92.3, 97.5) 13.3 (1.66, 40.5) 93.8 (90.3, 96.3) 0.53 (0.46, 0.60) 
>1 CT  20 (5.73, 43.7) 97.9 (95.4, 99.2) 40 (12.2, 73.8) 94.5 (91.3, 96.8) 0.59 (0.50, 0.68) 
Ultrasound any / 
CT any 55 (31.5, 76.9) 79.5 (74.3, 84.1) 15.9 (8.24, 26.7) 96.2 (92.8, 98.2) 0.67 (0.56, 0.79) 
X-rays occurring over the expected number in the patient pathway 
>2 x-rays 85 (62.1, 96.8) 41.3 (35.5, 47.3) 9.29 (5.51, 14.5) 97.5 (92.9, 99.5) 0.63 (0.55, 0.72) 
>3 x-rays 70 (45.7, 88.1) 67.8 (62.1, 73.3) 13.3 (7.49, 21.4) 97 (93.5, 98.9) 0.69 (0.58, 080) 
>4 x-rays 55 (31.5, 76.9) 79.9 (74.7, 84.4) 16.2 (8.36, 27.1) 96.2 (92.9, 98.2) 0.67 (0.56, 0.79) 
>5 x-rays 35 (15.4, 59.2) 88.7 (84.4, 92.1) 17.9 (7.54, 33.5) 95.1 (91.7, 97.4) 0.62 (0.51, 0.73) 
>6 x-rays 30 (11.9, 54.3) 91.5 (87.6, 94.5) 20 (7.71, 38.6) 94.9 (91.5, 97.2) 0.61 (0.50, 0.71) 
Any diagnostic imaging examinations occurring over 5 days post CABG 
Ultrasound any 25 (8.66, 49.1) 92.2 (88.5, 95.1) 18.5 (6.3, 38.1) 94.6 (91.2, 96.9) 0.59 (0.49, 0.69) 
CT any 40 (19.1, 63.9) 94.7 (91.4, 97) 34.8 (16.4, 57.3) 95.7 (92,6, 97.8) 0.67 (0.56, 0.78) 
X-ray any 75 (50.9, 91.3) 77 (71.7, 81.8) 18.8 (10.9, 29) 97.8 (94.8, 99.3) 0.76 (0.66, 0.86) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver 
operating characteristic curve; CT: computer tomography scan 
 
The results of the sensitivity analysis for the diagnostic imaging requests are in Table 5.19. When the 
sensitivities, specificities, positive predictive values and negative predictive values were calculated 
for inpatient surgical site infections, the area under the ROC curves as well as the sensitivities and 
specificities were not as good as those achieved using the biological markers of infection.  
As CT exams were relatively rare, with only 10% of the patients having one requested, the sensitivity 
could be expected to be low (45%), but with the PPV also remained low (28.1%), this indicates that 
using the presence of a CT exam as a proxy for infection not only doesn’t identify over half the 
patients with infections, but only a quarter of those with CT exams had infections (Table 5.20).  
 
Table 5.20: Number of patients with a CT exam request according to infection status   
 No inpatient SSI Inpatient SSI Total 
No CT exam 260 11 271 
Any CT exam 23 9 32 
Total 283 20 303 
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The code combination with the highest AUC was the occurrence of any x-ray after 5 days post-CABG 
(AUC 0.76). The reasoning for testing the code in this way was to focus on the patients having 
diagnostic imaging investigation requests outside of the expected patient pathway. The PPV of this 
code combination was low (18.8%), however as chest x-rays are likely to be used to diagnose or 
investigate multiple post-operative complications (e.g. VAP), this could be expected.  
The requests so far were taking all types of x-rays, ultrasounds and CT’s into account, regardless of 
the body location. When only those exams that could be considered relevant to diagnosing an 
inpatient SSI following CABG were taken into consideration (i.e. chest and leg locations) there was 
no change to the results for x-rays, as only two x-rays were not of the chest or thorax. For ultrasound 
requests this actually reduced the sensitivity to 30% (11.9, 54.3) from 35% and the AUC reduced to 
0.58 from 0.59. For CT exams, using ‘relevant’ exams increased the PPV and specificity to 40.9% and 
95.4% from 28.1% and 91.9%; the AUC increased to 0.70, compared to 0.68 when all possible CT 
exams were included. 
Diagnostic imaging data in isolation did not prove as good for distinguishing infected patients from 
uninfected patients as the biological markers. The two proxy indicators of SSI that were investigated 
in further analysis were having a relevant CT request and any x-ray requested after 5 days post-
surgery.  
 
Microbiology 
 
Of the 303 patients, 24 patients (8%) had no microbiology culture requests during their post-
operative stay. The most cultures to be performed on one patient were 90 and the average number 
was five cultures (of which on average two were MRSA screening cultures). There was a threefold 
difference in the average number of cultures carried out for inpatient SSI patients (15) and 
uninfected patients (4.4). A summary of the number of patients with different culture requests is 
presented in Table 5.21.  
Patients with inpatient SSI diagnoses had relatively high proportions of non-wound cultures 
requested; however wound cultures are the most relevant culture for diagnosing an SSI. The number 
of wound cultures requested was plotted as a ROC curve against inpatient SSI. This relationship had 
an AUC of 0.88, demonstrating that it was a good predictor of inpatient SSI (Figure 5.25).  
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Table 5.21: Summary of culture requests in CABG patients 
Culture Type Number of patients Range 
Number of patients 
with SSI 
Bodily Fluid 11 0 - 1 3 
Blood 92 0 - 11 11 
C. difficile 33 0 - 17 4 
Faecal  29 0 - 11 3 
Fungal 13 0 - 4 4 
Sputum 63 0 - 13 9 
MRSA screen 267 0 - 12 17 
TB 10 0 - 5 2 
Urine 87 0 - 12 11 
Wound  113 0 - 18 19 
Tissue 15 0 - 2 8 
  
Figure 5.25: ROC curve of the number of wound culture requests in determining inpatient SSI 
 
 
The sensitivity analyses for wound culture requests as a proxy for inpatient SSI infection are shown 
in Table 5.22. 
 
Table 5.22: Sensitivity analyses of wound culture requests in detecting inpatient SSI 
Infection Proxy Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) Area under ROC 
Any wound culture 95 (75.1, 99.9) 66.8 (61, 72.2) 16.8 (10.4, 25) 99.5 (97.1, 100) 0.81 (0.75, 0.87) 
>1 wound culture 95 (75.1, 99.9) 84.1 (79.3, 88.2) 29.7 (18.9, 42.4) 99.6 (97.7, 100) 0.90 (0.84, 0.95) 
>2 wound cultures 90 (68.3, 98.8) 92.2 (88.5, 95.1) 45 (29.3, 61.5) 99.2 (97.3, 99.9) 0.91 (0.84, 0.98) 
>3 wound cultures 80 (56.3, 94.3) 95.1 (91.8, 97.3) 53.3 (34.3, 71.7) 98.5 (96.3, 99.6) 0.88 (0.78, 0.97) 
>4 wound cultures 65 (40.8, 84.6) 96.1 (93.2, 98) 54.2 (32.8, 74.4) 97.5 (94.9, 99) 0.81 (0.70, 0.91) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
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Having three or more wound cultures, irrespective of their result had the best balanced set of 
results, with a sensitivity of 90% and specificity of 92.2% and an AUC value of 0.91. However, the 
PPV was below 50%, lower than the best set of results using PAS data only. The number of patients 
that were correctly and incorrectly identified using three or more wound culture requests is shown 
in Table 5.23. 
 
Table 5.23: Number of patients with two or more wound culture request according to 
infection status   
 No inpatient SSI Inpatient SSI Total 
Less than 2 cultures 261 2 263 
2 or more cultures 22 18 40 
Total 283 20 303 
 
 
Clinical biochemistry, Haematology, Microbiology and Radiology Data 
 
Whilst some of the potential markers and proxies for infection have had varying success, the next 
step was to see whether combining them would achieve better sensitivities and specificities (Table 
5.24). 
The highest sensitivity out of all the combinations of markers and proxies that were investigated was 
95%; this was achieved when any occurrence of platelets exceeding the threshold of 400 x109/L and 
up to two wound culture requests. This combination of platelets and wound cultures also had the 
highest AUC value (0.94), however the positive predictive value was relatively low (47.5%).  
Instead, the combination which included any occurrence of WBC and fibrinogen exceeding the 
threshold values retained a high sensitivity (90%) and AUC (0.92) and had a higher positive predictive 
value of 51.4%. This was the best balance between identifying as many inpatient surgical site 
infections, while not detecting too many false positives.   
Using the diagnostic imaging requests to act as proxies for infection reduced the specificities and 
positive predictive values. This would have been expected seeing as lots of patients without 
inpatient surgical site infections have diagnostic imaging requests.  
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Table 5.24: Sensitivity analyses of markers and proxies of infection in detecting inpatient SSI 
Infection proxies and 
markers Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) Area under ROC 
One or more wound culture 
CRP > 50 80 (56.3, 94.3) 82.8 (77.8, 87.1) 25.4 (15.3, 37.9) 98.3 (95.6, 99.5) 0.81 (0.72, 0.91) 
CRP > 100 60 (36.1, 80.9) 89.7 (85.5, 93.1) 30 (16.6, 46.5) 96.8 (93.9, 98.6) 0.75 (0.64, 0.86) 
Fibrinogen >5 90 (68.3, 98.8) 83.5 (78.6, 87.7) 28.6 (17.9, 41.3) 99.1 (96.9, 99.9) 0.87 (0.80, 0.94) 
Platelets >400 95 (75.1, 99,9) 87.2 (82.6, 90.9) 35.2 (22.7, 49.4) 99.6 (97.7, 100) 0.91 (0.86, 0.96) 
WBC > 11 90 (68.3, 98.8) 72.9 (67.2, 78.1) 19.6 (12, 29.1) 99 (96.5, 99.9) 0.81 (0.74, 0.89) 
Relevant CT exam 45 (23.1, 68.5) 96.8 (94, 98.5) 50 (26, 74) 96.1 (93.2, 98.1) 0.71 (0.60, 0.82) 
Any X-ray (after 5 days) 75 (50.9, 91.3) 88.3 (84, 91.8) 31.3 (18.7, 46.3) 98 (95.5, 99.4) 0.82 (0.72, 0.92) 
Two or more  wound cultures 
CRP > 50 80 (56.3, 94.3) 88.6 (84.3, 92.2) 34 (20.9, 49.3) 98.4 (95.9, 99.6) 0.84 (0.75, 0.94) 
CRP > 100 60 (36.1, 80.9) 93.4 (89.8, 96) 40 (22.7, 59.4) 97 (94.1, 98.7) 0.77 (0.66, 0.88) 
Fibrinogen >5 90 (68.3, 98.8) 89.7 (85.5, 93.1) 39.1 (25.1, 54.6) 99.2 (97.1, 99.9) 0.90 (0.83, 0.97) 
Platelets >400 95 (75.1, 99,9) 92.3 (88.5, 95.2) 47.5 (31.5, 63.9) 99.6 (97.8, 100) 0.94 (0.89, 0.99) 
WBC > 11 90 (68.3, 98.8) 85.3 (80.6, 89.3) 31 (19.5, 44.5) 99.1 (97, 99.9) 0.88 (0.81, 0.95) 
Relevant CT exam 45 (23.1, 68.5) 97.2 (94.5, 98.8) 52.9 (27.8, 77) 96.2 (93.2, 98.1) 0.71 (0.60, 0.82) 
Any X-ray (after 5 days) 75 (50.9, 91.3) 91.9 (88.1, 94.8) 39.5 (24, 56.6) 98.1 (95.7, 99.4) 0.83 (0.74, 0.93) 
CRP >50 + Platelets + 
Fibrinogen 75 (50.9, 91.3) 94.5 (91.1, 96.9) 50 (31.3, 68.7) 98.1 (95.6, 99.4) 0.85 (0.75, 0.95) 
WBC + Platelets + 
Fibrinogen 90 (68.3, 98.8) 93.8 (90.2, 96.3) 51.4 (34, 68.6) 99.2 (97.2, 99.9) 0.92 (0.85, 0.99) 
CRP >50 + Platelets + 
Fibrinogen + WBC 75 (50.9, 91.3) 94.9 (91.5, 97.2) 51.7 (32.5, 70.6) 98.1 (95.6, 99.4) 0.85 (0.75, 0.95) 
>2 Platelets + >2 
Fibrinogen + WBC 80 (56.3, 94.3) 96.3 (93.4, 98.2) 61.5 (40.6, 79.8) 98.5 (96.2, 99.6) 0.88 (0.79, 0.97) 
>2 Platelets + >2 
Fibrinogen 80 (56.3, 94.3) 96 (92.9, 98) 59.3 (38.8, 77.6) 98.5 (96.2, 99.6) 0.88 (0.79, 0.97) 
Two or more wound cultures OR three or more  X-rays OR any relevant CT exam 
CRP > 50 80 (56.3, 94.3) 78.8 (73.4, 83.5) 21.6 (12.9, 32.7) 98.2 (95.4, 99.5) 0.79 (0.70, 0.89) 
CRP > 100 60 (36.1, 80.9) 87.9 (83.4, 91.5) 26.7 (14.6, 41.9) 96.8 (93.7, 98.6) 0.74 (0.63, 0.85) 
Fibrinogen >5 90 (68.3, 98.8) 80.2 (75, 84.8) 25 (15.5, 36.6) 99.1 (96.8, 99.9) 0.85 (0.78, 0.92) 
Platelets >400 95 (75.1, 99.9) 87.5 (83, 91.2) 35.8 (23.1, 50.2) 99.6 (97.7, 100) 0.91 (86, 0.97) 
WBC > 11 90 (68.3, 98.8) 72.2 (66.4, 77.4) 19.1 (11.8, 28.6) 99 (96.4, 99.9) 0.81 (0.74, 0.88) 
CRP >50 + Platelets + 
Fibrinogen 75 (50.9, 91.3) 90.8 (86.8, 94) 37.5 (22.7, 54.2) 98 (95.4, 99.4) 0.83 (0.73, 0.93) 
WBC + Platelets + 
Fibrinogen 90 (68.3, 98.8) 90.8 (86.8, 94) 41.9 (27, 57.9) 99.2 (97.1, 99.9) 0.90 (0.84, 0.97) 
CRP >50 + Platelets + 
Fibrinogen + WBC 75 (5.9, 91.3) 91.6 (87.6, 94.6) 39.5 (24, 56.6) 98 (95.5, 99.4) 0.83 (0.73, 0.93) 
>2 Platelets + >2 
Fibrinogen + WBC 80 (56.3, 94.3) 94.1 (90.7, 96.6) 50 (31.9, 68.1) 98.5 (96.1, 99.6) 0.87 (0.78, 0.96) 
>2 Platelets + >2 
Fibrinogen 80 (56.3, 94.3) 93.4 (89.8, 96) 47.1 (29.8, 64.9) 98.5 (96.1, 99.6) 0.87 (0.78, 0.96) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve; CRP: c-reactive protein; WBC: white blood cell count; CT: computer tomography scan 
 
The same was then investigated for organ space and superficial and deep infections to see whether 
it was better to have separate algorithms for detecting the severity of SSI. The results are presented 
in Table 5.25. This demonstrated the accuracy with which organ space infections could be identified 
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using a syndromic algorithm; the AUC using a combination of markers and proxies was 0.99, with a 
sensitivity of 100% and a specificity of 98.5%.  
 
Table 5.25: Sensitivity analyses of markers and proxies of infection in detecting inpatient SSI of differing severity 
Infection proxies and 
markers Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Specifically for Organ Space Surgical Site Infections 
>2 CRP >100 + Platelets + >3 
wound cultures 100 (39.8, 100) 98.5 (96.3, 99.6) 50 (15.7, 84.3) 100 (98.6, 100) 0.99 (0.99, 1.00) 
>2 CRP >100 + Platelets + >4 
wound cultures 100 (39.8, 100) 98.9 (96.8, 99.8) 57.1 (18.4, 90.1) 100 (98.6, 100) 0.99 (0.99, 1.00) 
Specifically for Superficial & Deep  Surgical Site Infections 
Platelets + Fibrinogen + WBC 
+ >2 wound cultures 87.5 (61.7, 98.4) 93.8 (90.2, 96.3) 45.2 (27.3, 64) 99.2 (97.2, 99.9) 0.91 (0.82. 0.99) 
Platelets + Fibrinogen + WBC 
+ >3 wound cultures 68.8 (41.3, 89) 97.8 (95.3, 99.2) 64.7 (38.3, 85.9) 98.2 (95.8, 99.4) 0.83 (0.72, 0.95) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve; CRP: c-reactive protein; WBC: white blood cell count; CT: computer tomography scan 
 
These analyses led to two different syndromic algorithms for detecting inpatient SSI, one relating 
specifically to organ space infections and another to all surgical site infections (termed ‘general SSI’). 
The proposed algorithms are as follows: 
 
General SSI 
Any occurrence of WBC >11 x109/L PLUS any occurrence of Platelets >400 x109/L PLUS any occurrence 
of Fibrinogen >5 g/L PLUS two or more wound culture requests 
 
Organ Space SSI  
Two or more occurrences of CRP >100 mg/L PLUS any occurrence of Platelets > 400 x109/L PLUS three 
or more wound culture requests 
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Time to Diagnosis 
 
To assess the utility of these syndromic algorithms in practice, I investigated their potential for early 
SSI detection, compared to the surveillance, by looking at the time to diagnosis. The HPA SSI 
surveillance collects information on the date of infection onset and this was used to make a 
comparison, as this indicates the clinical diagnosis. Three patients classified as having inpatient SSI 
did not have a date of onset for the infection recorded; therefore 17 patients were investigated for 
their time to diagnosis. I plotted out of the days on which any markers exceeded the set threshold 
values and the days on which a wound culture was requested for each patient; this is essentially a 
time-line, allowing patterns of markers to be visualised over time in a patient (Figure 5.26, 5.27 and 
5.28).  
 All CRP and fibrinogen results exceeding the threshold value prior to day seven post-CABG have not 
been plotted, to account for the post-operative peaks in these markers due to the trauma of surgery.  
 
 
Of the six patients with superficial surgical site infections, two were diagnosed upon re-admission 
and all but one was related to the chest incision. Using the general syndromic algorithm, two of the 
six patients were diagnosed earlier than they had been clinically (patients 1 and 2). The average time 
to diagnosis for a superficial SSI in this patient cohort was 12 days according to the clinical 
information. Using the syndromic algorithm, this increased to 14 days (Figure 5.26).  
Patient 3, who was diagnosed upon re-admission, displayed several markers of infection prior to 
their initial discharge. However no clinical diagnosis was implied at that time and this patient had the 
longest time to diagnosis both clinically and using the general syndromic algorithm for surgical site 
infections.  
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Figure 5.26: Time lines of superficial SSI diagnosis using proxies and markers of infection 
Vertical line indicates the day on which the general SSI algorithm would have diagnosed the infection 
1 (RED) = CRP >50mg/L; 2 (ORANGE) = CRP >100mg/L; 3 (YELLOW) = Platelets >400 x109/L; 4 (GREEN) = 
Fibrinogen >5g/L; 5 (BLUE) = WBC >11 x109/L; 6 (PURPLE) = any wound culture 
 
 
 
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 1: surgical admission; chest incision; diagnosed day 12 
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 2: surgical admission; chest incision; diagnosed day 12 
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 3: re-admission; chest incision; diagnosed day 24 
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 4: surgical admission; donor site; diagnosed day 8
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 5: re-admission; chest incision; diagnosed day 11
1
2
3
4
5
6
0 5 10 15 20 25 30 35
Patient 6: surgical admission; chest incision; diagnosed day 6
 163 
 
Figure 5.27: Time lines of deep SSI diagnosis using proxies and markers of infection 
Vertical line indicates the day on which the general SSI algorithm would have diagnosed the infection 
1 (RED) = CRP >50mg/L; 2 (ORANGE) = CRP >100mg/L; 3 (YELLOW) = Platelets >400 x109/L; 4 (GREEN) = 
Fibrinogen >5g/L; 5 (BLUE) = WBC >11 x109/L; 6 (PURPLE) = any wound culture 
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Of the eight patients with deep surgical site infections, three were diagnosed upon re-admission and 
six were related to the chest incision (Figure 5.27). Using the syndromic algorithm, none of the 
patients were diagnosed earlier than the clinical diagnosis. The average time till diagnosis of a 
superficial SSI in this patient cohort was 10 days according to the surveillance data. Using the 
syndromic algorithm, this increases to 14 days. Patient 12 did not meet the criteria of the syndromic 
definition of an SSI as they had no WBC or fibrinogen levels above the set thresholds, therefore a 
diagnosis would never have been made. 
 
Of the three patients with organ space infections which had a clinical date of SSI diagnosis, all were 
diagnosed during the surgical admission. Using the general syndromic algorithm (solid line), all 
patients were diagnosed after the clinical diagnosis had been made (Figure 5.28). Using the organ 
space specific algorithm did not improve this. The average time till diagnosis of an organ space SSI in 
this patient cohort was 13 days according to the clinical date of diagnosis. Using the general 
syndromic algorithm or the organ space algorithm, this increases to 17 days.  
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Figure 5.28: Time lines of organ space SSI diagnosis using proxies and markers of infection 
The SOLID vertical line indicates the day on which the general SSI algorithm would have diagnosed the 
infection and the DASHED line to the day on which the organ space algorithm would have diagnosed infection 
1 (RED) = CRP >50mg/L; 2 (ORANGE) = CRP >100mg/L; 3 (YELLOW) = Platelets >400 x109/L; 4 (GREEN) = 
Fibrinogen >5g/L; 5 (BLUE) = WBC >11 x109/L; 6 (PURPLE) = any wound culture 
 
 
 
When investigating time till diagnosis, the algorithm for general SSI did not generally reduce this 
measure. I adjusted the syndromic algorithm criteria to be the presence of any three of the markers 
or proxies. When doing this, 116 patients were identified by the adjusted algorithm with a sensitivity 
of 95% (75.1%, 99.9%), a specificity of 65.7% (59.9%, 71.2%), a PPV of 16.4% (10.2%, 24.4%) and a 
NPV of 99.5% (97.1%, 100%). The AUC for this algorithm was 0.80 (0.75, 0.86), so it performs 
relatively well still, despite identifying more false positives than the original general SSI algorithm.  
Using this adjusted algorithm, superficial infections took an average of 7 days to diagnose, deep 
infections an average of 12 days, and organ space infections an average of 8 days. Overall this meant 
SSI were diagnosed 3 days sooner by the adjusted general SSI algorithm than they were clinically, 
with the exception of deep surgical site infections.   
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5.2.4 Applying the Syndromic Algorithms in Administrative Data 
 
The syndromic SSI algorithms were then tested against the PAS and pathology data from 2009 - 
2010. The purpose of this stage was to investigate the potential for retrospective use of pathology 
data in syndromic surveillance. Non-SSI ICD-10 infection codes were also investigated during this 
analysis to determine the effect of having a different post-operative infection on how the syndromic 
algorithms perform.   
Results from the univariate analysis using a logistic regression of the marker thresholds defined by 
the prior analyses are presented in Table 5.26. I looked at both the number of times the patient had 
a marker exceed the threshold value or the number of wound culture requests, and as a binary.  
 
Table 5.26: Univariate analysis of infection markers and proxies and SSI defined using ICD-10 codes 
Markers and proxies treated as continuous (number of times it exceeds the threshold / number of requests) 
Variable Odds Ratio Standard Error P-value Confidence interval 
Wound culture 1.71 0.12 0.000 1.50, 1.95 
CRP >50 mg/L 1.26 0.04 0.000 1.19, 1.34 
CRP >100 mg/L 1.40 0.07 0.000 1.27, 1.55 
Fibrinogen >5 g/L 1.31 0.05 0.000 1.22, 1.41 
WBC >11 x 109/L 1.12 0.03 0.000 1.06, 1.19 
Platelets >400 x 109/L 1.38 0.06 0.000 1.26, 1.52 
Markers and proxies treated as  binary variables 
Wound culture 8.74 2.13 0.000 5.42, 14.1 
CRP >50 mg/L 5.94 1.42 0.000 3.72, 9.48 
CRP >100 mg/L 8.76 2.15 0.000 5.42, 14.2 
Fibrinogen >5 g/L 5.33 1.27 0.000 3.35, 8.50 
WBC >11 x 109/L 1.69 0.42 0.033 1.04, 2.73 
Platelets >400 x 109/L 5.21 1.26 0.000 3.24, 8.35 
WBC: white blood cell count; CRP: c-reactive protein 
 
This analysis demonstrated that having any wound culture requests or CRP result exceeding 100 
mg/L in the 35 days following CABG surgery, both increased the odds of the patient having an ICD-10 
code a  surgical site infection by 8.7 times. The marker with the weakest (although still statistically 
significant) relationship to having a positive SSI diagnosis according to diagnosis codes was white 
blood count.  
The sensitivity, specificity, PPV and NPV comparing SSI defined by ICD-10 codes and SSI defined by 
the syndromic algorithms are presented in Table 5.27.  
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Table 5.27: Sensitivity analysis of syndromic algorithms for SSI in detecting patients with ICD-10 codes for SSI 
Syndromic algorithm Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
General Algorithm 30.5 (20.8, 41.6) 98.1 (97.1, 98.9) 56.8 (41, 71.7) 94.6 (93, 95.9) 0.64 (0.59, 0.69) 
Organ Space Algorithm 17.1 (9.66, 27) 99.5 (98.8, 99.8) 73.7 (48.8, 90.9) 93.7 (92, 95) 0.58 (0.54, 0.62) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
The syndromic algorithms did not perform as well as they did against the inpatient SSI on which they 
were created, however this would be expected. The organ space algorithm detected 19 cases (1.7%) 
and the general algorithm detected 44 cases (4%). The organ space infections are a similar rate to 
that seen in the HPA SSI surveillance and cardiac registry; however the general algorithm detected 
fewer cases than expected.  
ROC curves of the number of wound culture requests and the number of times the different markers 
exceeded the threshold values demonstrate a relationship with the SSI identified using ICD-10 codes 
(Figure 5.29 and 5.30).  
 
Figure 5.29: ROC curve for the number of wound culture requests against the ICD-10 cases 
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Figure 5.30: ROC curve of ICD-10 cases and the frequency a marker exceeds the threshold 
 
 
It was found that 56 (5%) of the 1,092 CABG patients in 2009 – 2010 had a non-SSI infection post-
surgery, as classified by ICD-10 codes, of which 5 patients had more than one other infection. Of the 
patients with codes for other infections, 12 (21%) also had SSI codes. Half the patients within this 
cohort (564) had a microbiology culture request, of which 342 (31%) patients had a culture other 
than a wound culture or MRSA screen.   
The different biological markers of infection were graphed according to infection status, including 
SSI, other infection and no infection. This was to try and see whether taking the patients with non-
SSI infections out of the uninfected patient group there would be a more obvious difference in the 
patterns seen in the markers.  
 The graphs showed little difference between the three groups (Figure 5.31, 5.32, 5.33 and 5.34). 
However an interesting observation was that the median platelet levels for the patients with other 
infections was generally lower than both the SSI and no infection patients. Also, CRP remained 
slightly higher still for the SSI patients than the other two patient groups.  
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Figure 5.31: Median fibrinogen levels after CABG surgery, according to SSI and other infection status 
 
Figure 5.32: Median platelet levels after CABG surgery, according to SSI and other infection status 
 
Figure 5.33: Median white blood cell count after CABG surgery, according to SSI and other infection status 
 
Figure 5.34: Median CRP levels after CABG surgery, according to SSI and other infection status 
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5.3 Discussion 
 
The surgical site infections reported by the HPA SSI surveillance and the cardiac registry, during 2011 
demonstrated a high burden of infection in this patient group at ICHNT, with an incidence of 10.4 
infections /100 coronary artery bypass graft procedures. If all the SSI diagnosed within the PAS data 
using ICD-10 codes are also considered, the maximum possible incidence was 14.6 SSI / 100 CABG 
procedures; the equivalent of approximately 7.5 cases a month. However, in investigating the data 
sources for CABG patients, several important issues need to be raised regarding not only the number 
of SSI that were reported but also the denominator of patients undergoing CABG. Three major 
components of data quality (coverage, completeness and validity) are discussed, followed by 
positive findings and recommendations. This is followed by a discussion relating to the use of 
markers and proxies of infection from the routine electronic data, to aid surveillance and their 
potential in clinical support.  
 
5.3.1 Comparison of Data Sources 
 
Coverage 
 
Coverage refers to both the numbers of true CABG patients that were picked up by the various 
databases and the scope of variables captured. In general, there was a good level of linkage between 
PAS and the HPA SSI surveillance and cardiac registry databases. Only 3.2% of records from the 
cardiac registry and HPA SSI surveillance data did not link to the PAS data, compared to the poor 
linkage between the cardiac registry and HPA SSI surveillance. There are several reasons why records 
which truly relate to the same patient may not have linked with PAS. The most likely being 
incorrectly recorded and entered data in the HPA SSI surveillance or cardiac registry data, such as 
mistyping the hospital number or date of birth. The second explanation could be the issue of some 
patients having multiple hospital numbers, meaning that a single patient would not be uniquely 
identified. However, it is also a possibility that in this case study the PAS database simply does not 
capture all the patients admitted to the hospital.  
Conversely, the likelihood of a patient from the HPA SSI surveillance or cardiac registry being 
incorrectly linked to a different patient’s information, whilst possible was highly implausible in this 
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cohort of patients. All the PAS records that linked to the HPA SSI surveillance and cardiac registry 
records had operation codes for CABG surgery and the dates fell within the correct time period, 
making an incorrect linkage unlikely.  
The fact that the cardiac registry had recorded the fewest patients of the three data sources was 
surprising. The National Cardiac Registry has published reports claiming 100% reporting in the UK, 
referring to the number of centres that submit data (470).  However, the aim is to have all patients 
undergoing CABG included in this register so a local finding of the register capturing only 86.5% of 
patients was cause for investigation.  
A wide range of variables are collected by the HPA SSI surveillance and cardiac registry schemes, 
many of which not only overlap with each other, but also overlap with the administrative electronic 
data routinely collected within the hospital. These duplications of variables relate to demographic 
information, surgical features and infection information. The cardiac registry had the most 
comprehensive coverage of variables relating to CABG patients, with extensive data collection on 
patient comorbidities, risk factors and operative features. The PAS data on the other hand stores a 
vast amount of data but it is not always specific and needs to be manipulated to extract the relevant 
information. The HPA SSI surveillance database is relatively meagre in terms of risks and operative 
details. Where it excels however is in the detail collected regarding surgical site infections; this level 
of information was not available in any other databases, with information such as the severity of 
infection, method of diagnosis and post-discharge follow-up.  
 
Completeness  
 
Completeness is the level to which the variables are filled in, addressing the issue of missing data. 
The cardiac registry had several variables with sporadic data collection, such as pre-operative drug 
administration. Some of these variables were completed in full for one or two specific quarters but 
in other variables there was no clear pattern for the missing data. A level of missing data was also 
seen in the HPA SSI surveillance data, for example body mass index. However the completeness of 
the HPA SSI surveillance database was high compared to the cardiac registry data. PAS had the best 
level of completeness, with very little missing information in completed patient admissions.  
For variables such as laboratory test results or body mass index, it is plausible that these measures 
were difficult to obtain or were not performed. However, for variables such as receiving pre-
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operative nitrates, this information should have been recorded for all patients in their drug charts or 
patient notes, demonstrating either poor note keeping or poor data collection.  
 
Validity 
 
Validity refers to the quality of the data that is captured, essentially whether or not the information 
recorded is in fact correct or not. As I did not perform any validation of the data (such as clinical 
chart reviews), I could not make any comment about which the true values were when discrepancies 
were observed. An exception to this was the length of surgery variable collected by the HPA SSI 
surveillance and cardiac registry; in this case it was clear that the cardiac registry variable was either 
collecting a different parameter or was incorrect.  
In some of the variables that were double reported, such as patient sex, there were discrepancies 
between the HPA SSI surveillance and cardiac registry. Some level of error is expected when data 
collection is in a paper format and then manually entered into a database, which has no routine 
validation protocol. The HPA SSI surveillance data were collected by the infection prevention and 
control (IPC) nurses and the cardiac registry data were collected by the cardiac surgeons. It may be 
that these two groups of data collectors were obtaining their information from disparate sources, 
such as patient notes or direct observation. Having a mechanism to make these data sources directly 
comparable on a regular basis (and not just for specific research questions as is the case here) could 
allow for some understanding of where the errors are arising.  
For this project specifically, the disagreement of most interest was that of surgical site infections 
diagnosed by the cardiac registry and the HPA SSI surveillance. It was surprising that the HPA SSI 
surveillance data collection missed surgical site infections that the cardiac registry had reported, as 
the whole purpose of the HPA SSI surveillance was to detect these infections. Conversely, the 
registry data had a very low sensitivity for recording surgical site infections, although it improved 
with the severity of the infection, with 43% of organ space infections detected but only 14% of 
superficial infections recorded by registry. An element of this may be a reflection of the variables 
which the cardiac registry uses to record surgical site infections, only having space for deep sternal 
wound infections and infections requiring re-operation.   
The HPA SSI surveillance was based on clinical observation of patients and their notes, not 
necessarily looking at the microbiology or radiology results. This means that if something was 
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reported in the patient notes incorrectly, or omitted from the notes, this would be reflected in the 
surveillance data. Anecdotally, on a data collection round which I attended there was a patient who 
had been diagnosed as having an SSI upon re-admission by the IPC nurses. However, the patient 
notes written by the attending surgeon indicated that patient had a hospital acquired pneumonia, 
using this diagnosis as the indication for antibiotic treatment. The clinical examination of the patient 
confirmed that the correct diagnosis was in fact a surgical site infection.   
This example highlights limitations in surveillance, firstly explaining some discrepancies observed 
between the ICD-10 codes in the PAS data and those SSI reported by the HPA SSI surveillance. 
Secondly it raises the issue of how differences in diagnoses arise, depending on where you obtain 
the data from. Finally, there is the delicate issue of potentially purposeful misreporting of 
information. The recording of SSI in the cardiac registry data is dependent on a surgeon diagnosis or 
a re-operation for wound debridement, meaning the positive diagnoses which are present are likely 
accurate, but they may not be comprehensive.  
Ideally an ICD-10 code indicative of a surgical site infection would have 100% sensitivity, specificity, 
PPV and NPV for identifying patients with a clinical diagnosis of an SSI. However these analyses have 
demonstrated that this was not the case. The codes with the best balance were chosen with a trade-
off between finding all the possible surgical site infections and ensuring that the identified patients 
do in fact have an SSI, especially as many of the ICD-10 codes are non-specific.   
An enquiry made to the Coding Clinic [Appendix 6] about what codes are appropriate for use in 
surgical site infections formed the basis of the codes used. This provided an evidence base for the 
codes which I used, but did not remove the issue in the quality of the coding, and quality of patient’s 
records. The numbers of patients with an SSI in the 2009/2010 CABG cohort identified using the ICD-
10 codes, had a similar incidence to that obtained from the traditional surveillance sources.   
When the patients with positive ICD-10 coding but no clinical SSI diagnosis were investigated further, 
two of the 25 patients had originally been diagnosed as having a surgical site infection in the HPA SSI 
surveillance but were corrected during the standardised HPA cleaning process.  This would explain 
details of an SSI being in the patient notes and hence having ICD-10 codes, with both these patients 
having the T814 code recorded. Despite these patients not meeting the HPA definition for SSI, based 
on the routine electronic data they appeared to be infections.  
Previous studies investigating the utility of administrative data for detecting SSI have reported 
diverse results (496-498); seeing as the ‘gold standard’ to which the PAS data were compared, was 
itself questionable, the sensitivities and specificities of the ICD-10 codes locally were relatively high.  
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Another interesting discrepancy in reporting between the cardiac registry and PAS data was that of 
post-surgical deaths. The registry reported 12 deaths out of the 534 patients it captured, a death 
rate of 2.3%. PAS on the other hand reported 19 deaths amongst these patients, a rate of 3.6% 
Taking the whole cohort of 617 patients into account, PAS recorded 25 deaths following CABG, 
giving an overall rate of 4.1%. This demonstrates that the registry not only under-reports infections, 
but it also under-reports deaths following CABG. This may reflect the lack of follow-up by the cardiac 
registry in patients that are re-admitted, highlighting a major advantage of both the HPA SSI 
surveillance and administrative data.  
 
Post – discharge surveillance 
 
As has been touched upon in chapter 2 (section 2.2.1), one of the main elements of surgical site 
infection surveillance that distinguishes it from other HCAI surveillance is the aspect of long term 
active community follow-up of patients.  
Much of the advantage of the HPA SSI surveillance data was the post-discharge follow-up carried out 
once the patients have been discharged from the hospital and the detail this added. The registry 
recorded 32% of the inpatient infections, but not one of the outpatient infections. There is a 
significant added value of having the post-discharge surveillance when monitoring rates of infection, 
especially in light of shorter inpatient stays following elective surgery (457).  
An issue in the analysis of ICD-10 codes and the comparison of utility of the different databases was 
the decision to only use the ‘inpatient cases’. The infections recorded by the HPA SSI surveillance 
and cardiac registry were meant to represent the best estimate of true SSI, including those 
diagnosed post discharge. A true assessment of the utility of electronic hospital data versus 
traditional surveillance data should take these extra cases diagnosed through active patient follow 
up into consideration. However, the sensitivities, specificities, PPV and NPV would be much worse if 
they were kept, as no codes or microbiology information would reasonably be expected. The 
decision to exclude these self-reported, post-discharge cases is justified in that it is unreasonable to 
test for the accuracy of diagnosis codes against an infection that didn’t exist at the time of data 
collection. As discussed previously, active patient follow up is an advantage of traditional 
surveillance systems over automated surveillance based on hospital data, and in this case it will 
remain as an advantage over an electronically developed syndromic surveillance system, unless it 
can be linked to primary care data.  
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An interesting factor to consider was the potential effect that awareness of infections due to 
surveillance being undertaken could have had on the way notes were kept, known as the Hawthorne 
effect. This effect could have impacted on data quality in both directions, as surgeons are less 
inclined to write that a patient has had a surgical site infection if they are under surveillance. Or the 
opposite effect, as more awareness of the issue results in a concerted effort to record this 
information better. Change in behaviour under surveillance is hard to measure from looking at the 
coding alone. However what should be noticeable is that during the period of surveillance, the 
incidence of SSI decreased, so the prevalence could be expected to be lower in 2011 than 
2009/2010.The SPC chart demonstrated that in the routine ICD-10 coding there was no distinctive 
change in the rate of SSI after the HPA SSI surveillance had started.   
A general limitation in this analysis, as the wide confidence intervals throughout suggest, was the 
small sample size. Only 35 cases of SSI were used to assess the utility of the ICD-10 codes so the 
results that have been reported here need to be treated with caution. However, basing the ICD-10 
codes that I used on previously reported studies and the having comparable results suggests that the 
analysis had an acceptable degree of accuracy.  
 
5.3.2 Syndromic Surveillance 
 
The second aim of this chapter was to investigate ways in which laboratory and radiology data could 
be used for syndromic surveillance of surgical site infections after coronary artery bypass graft 
surgery. Two syndromic algorithms were generated, both of which had relatively high sensitivities 
and specificities when detecting those patients who had been clinically diagnosed with an infection 
either by the IPC nurses of cardiac surgeons. However when these algorithms were investigated for 
early detection or compared to the surgical site infections defined by ICD-10 codes in the 
administrative data they proved inconsistent.  
Selecting the combinations of markers and proxies of infection with the best balanced sensitivity and 
positive predictive values may sacrifice finding all the true positives, in order to reduce 
overestimating the incidence by finding too many false positives. For a system focussing on 
supporting clinical care and not the reporting of incidence and trends, it would be wiser to use an 
algorithm with a poor PPV as long as it has a high sensitivity. The reason for this is to ensure that all 
patients who potentially have a surgical site infection are diagnosed and treated, even if several 
uninfected patients have ‘alerts’.  
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For the analyses in this chapter I focussed on those marker and diagnostic test combinations with 
the highest AUC values, favouring population level surveillance. This was highlighted when the time 
to diagnosis was investigated. Only 2 of the 17 patients investigated were diagnosed earlier by the 
syndromic algorithms than they were clinically, mostly due to the requirement of having at least two 
wound culture requests. However, when an adjusted approach was taken, using any three markers 
or proxies, then eight patients would have been diagnosed before the clinical diagnosis.  
However, when plotting the marker timelines, some of the recorded dates of surgical site infection 
onset seemed questionable. For example, patient 10 was diagnosed with a deep chest infection on 
day two post-surgery (Figure 5.28). This is a very short period of time for a serious infection to be 
diagnosed and the markers would suggest that the infection was more likely to have presented after 
day seven. However, without having the reasons for diagnosis or the source of information (i.e. 
patient notes or direct wound observation) it was hard to make a judgement on the data accuracy.  
 
Biological Markers of Infection 
 
Prior studies have investigated biological markers as indictors of surgical site infection and their 
potential for early diagnosis of infection. There were some unexpected results in this chapter, 
namely the initial statistical significance of eosinophils and basophils.  
This result was surprising as both of these white blood cells are generally associated with allergic 
reactions and not bacterial infections (Table 4.0). Whilst eosinophils levels prior to surgery were not 
significantly different between those with and without infections; the median values did differ and 
were 0.25 and 0.20 respectively. The same pattern was observed for basophils, with the pre-
operative mean values slightly increased in those patients who developed inpatient SSI (0.015 vs. 
0.010). The fact that the pre-operative levels were slightly elevated in the patients who went on to 
develop infections could suggest that the post-operative increases were not a reflection of the acute 
infection itself.  
Some research has demonstrated that atopic conditions such as asthma and chronic rhinosinusitis 
(in which these types of white cells would be elevated) increase the risk of certain infections (499-
502). This research has generally been based around respiratory infections and respiratory 
conditions. However, the principles could potentially apply to surgical site infections, with patients 
that have atopic conditions being at higher risk of infection. Another theory, based on the fact that 
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eosinophil levels were raised considerably higher in superficial (0.32 x109/L) versus other SSI types 
(0.26 x109/L), was misdiagnosis. An allergic reaction following surgery could have several of the same 
clinical signs as a superficial surgical site infection, such as redness or swelling.  Finally, there have 
been papers which demonstrate eosinophils and basophils play a role in bacterial infections (503, 
504).  
 
Table 5.28: Summary of findings from published studies relating to biological markers and infection 
diagnosis following surgery  
Marker(s) Patient group Finding  
CRP (505) Sepsis following surgery 
Increased CRP values were seen up to 3 days prior to clinical 
symptoms. A reduced post-operative decline in CRP was seen in 
septic patients 
CRP (506) 
Infectious 
complications 
following lower limb 
arthroplasty 
Two CRP thresholds (25 and 18mg/L) were investigated, with 
sensitivities of 58.3% and 66.7% respectively. PPV was high using the 
higher threshold but concluded that CRP was a poor indication of 
infection 
CRP (507) 
General infectious 
complications 
following TKR 
Pre-operative CRP was investigated and found that having a pre-
operative CRP of >0.5mg/L was a good predictor of post-operative 
infection 
CRP (488) 
Incisional SSI 
following colorectal 
surgery 
A raised CRP on day 7 post surgery was a good indicator of incisional 
SSI, compared to day 3 post-surgery; the threshold value of 36mg/L 
was used 
PCT, WBC, 
CRP (508) 
SIRS following CABG 
procedure 
Procalcitonin was significantly different between non-infectious 
inflammation patients and those without SIRS. CRP and WBC were 
no different between the two groups.  
PCT (509) 
Infectious fevers 
following 
orthopaedic surgery 
Found that only PCT was a good differentiator for infectious versus 
non-infectious fevers occurring within 10 days of surgery (AUC 0.71 
on day 3 post op) 
CRP, WBC, 
ESR (489) 
Endocarditis 
following in 
pacemaker insertion 
Elevated CRP was seen in 92.8% of the patients with endocarditis; 
ESR was also elevated in 92.8% of patients, while white blood cell 
count was only raised in 50% of patients 
CRP, ESR (490) Infection following TKR 
Using threshold values of 22.5mm/hr for ESR and 13.5mg/L for CRP, 
these two markers together had an AUC of 0.92 in detecting post-
operative infections. 
CRP, ESR (487) SSI following spinal surgery 
Followed up patients for 7 days and used threshold values of 4mg/L 
for CRP and 9 – 15mm/hr for ESR. These markers detected SSI with a 
sensitivity of 83.3% and 100% , respectively 
CRP, 
albumin, 
WBC (486) 
SSI following 
resection for 
oesophageal cancer 
A threshold of 180 mg/L for CRP on days 3 and 4 post-operation had 
a good predictive value for SSI. Persistently low albumin was also 
significant. WBC had the worst predictive value for SSI. Stated that 
prior studies on SSI following cancer surgeries found CRP to have 
sensitivities ranging between 61%-93% and infection thresholds 
ranging from 125-190 mg/L. 
CRP: c-reactive protein; PPV: positive predictive value; WBC: white blood cell count; PCT: procalcitonin; ESR: 
erythrocyte sedimentation rate; SIRS: systemic inflammatory response syndrome; TKR: total knee 
replacement 
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Several prior studies have investigated the utility of different biological markers in identifying 
infections, and some specifically for surgical site infections. A key finding from the literature has 
been the efficacy of procalcitonin (PCT), and comparisons with have shown PCT to be a more 
discerning marker of bacterial infection (510, 511). One study, carried out in France, investigated the 
use CRP, white blood count cell counts and PCT for distinguishing between infectious and non-
infectious systemic inflammatory responses following CABG procedures (508).  This paper concluded 
that only procalcitonin was an adequate marker for identifying infectious events. This test is not 
currently available routinely at ICHNT.  
Another marker found important in surgical site infection detection was the erythrocyte 
sedimentation rate (490) (Table 5.28). This test is available at ICHNT; however it was not routinely 
carried out with only a few CABG patients having this test performed. Adding this and procalcitonin 
tests to the routine blood tests that are carried out post-operatively in this patient could enhance 
the potential for syndromic surveillance of surgical site infections.  
In this study, the best marker for distinguishing patients with and without SSI was elevated platelet 
levels, followed by elevated fibrinogen levels. Whilst these are key components of the inflammatory 
response (464), a search of the literature did not present any studies which have previously 
demonstrated their potential in syndromic surveillance as markers of infection for surgical site 
infections.   
One of the main issues in the analysis of the markers for surgical site infections was that other 
infections had not been taken into account. Some of the uninfected patients had markers over the 
set thresholds for infection, indicating that they may have other infections; this was supported by 
the fact that they had an extended stay in hospital. The standard patient pathway is to be discharged 
on post-operative day five, so those patients that are still in hospital on day 20 or day 30 post 
surgery were likely to have had some form of serious complications, potentially including post-
operative pneumonias, bloodstream infections or further surgery. In these patients you would 
expect to see raised markers, like those patients with surgical site infections, so the fact that some of 
the potential markers were not as different as expected does not indicate that the markers were not 
significant in the SSI patients, but that the makers were also raised in the ‘uninfected’ patients. The 
same rationale can be applied to the radiology data, as again patients that were having diagnostic 
imaging requests 20 days after their surgery were likely to have had a post-operative complication; 
one example of this would be post-operative pneumonias and chest x-ray requests.  
An interesting factor among this patient group was that the patients with deep surgical site 
infections did have any particularly distinctive increases in biological markers; this was contrasting 
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with the organ space infections where CRP had a very distinctive increase or eosinophils in 
superficial infections. This calls into question the accuracy of the clinically diagnosed deep infections.  
 
Limitations 
 
The lack of full microbiology results was a considerable limitation when trying to define patients as 
having surgical site infections in the 2009/2010 data. A positive microbiology result from an 
uncontaminated wound swab would support the presence of an ICD-10 code. However, the clinical 
and microbiological definitions for surgical site infections need to be considered with some caution 
as there is not necessarily a test that can confirm with complete certainty the presence of an 
infection. SSI in this chapter were based solely on the presence of a set of ICD-10 diagnostic codes or 
a clinical diagnosis. These codes are only ever as good as the paper medical records and for SSI 
specifically the coding is not clear cut, with several non-specific codes available.  
However, microbiology culture requests reflect the intentions of a patient’s doctor. In order for a 
physician to order a wound culture, there should be some indication or symptomology of infection, 
such as fever or swelling of the wound site. In this chapter the number of wound swabs carried out 
was highly correlated with having an inpatient SSI diagnosis. I therefore did not consider this to have 
affected the results of the analyses carried out, but instead it limited the investigations which I was 
able to do.   
A similar limitation in the diagnostic imaging data were the lack of indication of the findings of the 
investigation or the purpose of the request. X-rays are requested for several reasons, such as 
checking a chest drain has been inserted correctly, or looking to diagnose a respiratory infection. In 
CABG patients, one of the operative incisions is in the chest and it is plausible that several chest x-
rays would be taken without any intention of looking for an infection. Even though there was an 
association between SSI and the number of x-ray and CT requests, these proxies eventually proved 
the least useful data sources for syndromic surveillance of SSI. Adding a simple variable of ‘indication 
for request’ could have the potential to greatly increase the utility of this data source for developing 
syndromic surveillance.  
This chapter is missing a stage of intended analysis, the testing and validation of the syndromic 
algorithms. This analysis would have involved taking those algorithms generated based on the 
January – June 2011 HPA SSI surveillance and cardiac registry data and comparing them to the 
inpatient SSI recorded in the July 2011 – March 2012 data.  
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There were two reasons this analytical stage was not carried out, the availability of the laboratory 
data and the availability of the HPA SSI surveillance data. Firstly, the first quarter of data from the 
HPA SSI surveillance from 2012 (January – March 2012) had not been returned to ICHNT from the 
HPA cleaning process by the time the analysis for this chapter was carried out (June 2012). Secondly, 
the clinical biochemistry and haematology data were only available up to the end of July 2011 in the 
form it was used for this chapter. A different extract of laboratory data, taken from the ‘live system’, 
contained data from September 2011 – March 2012. However, this second extract contained only 
microbiology and virology data, so could not be used for testing the syndromic surveillance 
algorithms.  
I decided not to split the six months of HPA SSI surveillance and cardiac registry data, which was fully 
linked, into two datasets of three months as the numbers were already relatively small and I did not 
want to weaken the results. Prediction models (or in this case a case algorithm) generally perform 
better in the dataset in which they were created (512). As different patient cohorts will have slightly 
different baseline characteristics, the model will adjust to these; hence not testing the syndromic 
algorithms in a second group of patients potentially reduced the generalisability of the syndromic 
algorithms for SSI following CABG procedures.  
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5.4 Conclusion 
 
Creating a single linked dataset from the HPA SSI surveillance data, the cardiac registry data and PAS 
data from Imperial College NHS Healthcare Trust highlighted the overlap in data collected and stored 
by these datasets, along with the discrepancies relating to surgical site infections.  This chapter 
emphasised the lack of a true ‘gold standard’ data sources, not only when addressing infection rates, 
but also for recording the numbers of procedures. The purpose of the three data sources are 
different, as are the organisations and audiences for which they are intended. The current system 
used for the collection of data relating to CABG patients is inefficient and could be much improved 
by streamlining the surveillance and registry data into a single comprehensive system incorporating 
inherent validation checks.  Taking the active follow up of patients performed by the infection 
prevention and control nurses, both in the wards and post-discharge, and adding this to the data 
collected by cardiac surgeons would produce a simpler, cheaper and comprehensive database for 
CABG patients.   
The second conclusion for this chapter was that there was a wide range of potential data from the 
electronic routine laboratory data that could be used in the syndromic surveillance of surgical site 
infections. The development of syndromic algorithms with the potential to identify all the organ 
space infections and 90% of all surgical site infections following CABG, demonstrates the utility of 
this data source. However, whether this type of surveillance will add value in early detection of 
surgical site infections for clinical support was less clear.  
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Chapter 6: Syndromic Surveillance of Surgical Site Infections following Caesarean Section 
 
 
Summary 
 
This is the second chapter to investigate the use of routine laboratory data for the creation of 
syndromic surveillance of surgical site infections. This chapter looks at patients who underwent 
caesarean sections at Imperial College Healthcare NHS Trust, taking advantage of an intervention 
study which carried out surveillance of SSI in this patient group.  Syndromic algorithms were 
explored for their utility in these patients.  
 
 
 
 
  
Chapter 9: 
Discussion 
 Chapter 2: 
Surveillance 
of HCAI 
Chapter 3: 
Risks of 
HCAI 
 
Chapter 8: 
Risk 
Modelling 
Chapter 7: 
Automated 
case 
detection 
Chapters 5 & 
6: Syndromic 
surveillance 
Chapter 4: 
Introduction 
to the 
databases 
 183 
 
6.0 Introduction 
 
A caesarean section is a surgical procedure in which a baby is delivered through an incision in the 
mother’s abdominal wall (513). Caesarean procedures date back to ancient civilisations and have 
been practiced across many cultures; the first procedure typical of the surgery carried out frequently 
today was performed in the late 1800’s (514). There are two approaches which can be taken, a lower 
uterine segment caesarean using a transverse incision, the more common of the procedures, and an 
upper caesarean with a vertical incision (513).  
Indications for a caesarean section relate to the baby’s and mother’s condition, and any threat to 
either life through complications. Caesarean sections are performed on 23% of women giving birth 
in the UK (515, 516), marginally higher than the European average of 19% (517).  In 2010 / 2011 this 
accounted for 162,512 procedures performed in hospitals in England, with Imperial College 
Healthcare NHS Trust having one of the highest rates of births by caesarean section in the UK (516).  
The rate of caesarean sections being performed has increased over the past decades (515), despite 
efforts by the WHO to set guidelines for the appropriate rate of delivery by caesarean section. The 
WHO released a report in 1985 suggesting that the rate of caesarean should be between 10 – 15% of 
births (518), a range which the majority of developed countries currently exceed, along with several 
developing nations (517). Suggestions have been made that rates of caesarean sections in first time 
mothers can be partly explained by the increasing age at which mothers have their first child 
compared to 50 years ago. There could also be an element of increasing BMIs and larger babies 
causing longer, more complicated labours (519, 520). With these rates either levelling off or 
continuing to increase, caesarean sections are likely to become even more common surgical 
procedures (515), especially in light of a recent policy change in the UK.  
In late 2011, the National Institute for Health and Clinical Excellence (NICE) released new guidelines 
for caesarean sections. These state that if a woman has requested a caesarean section, without any 
medical indication, and their current obstetrician refuses to carry out the procedure they are to be 
referred to another who will comply with the request (521). This sparked a public debate, with 
headlines such as: 
“Too posh to push?” (522) 
“The madness of Caesarean on demand” (523) 
“Caesareans should be life-saving, not a lifestyle choice” (524) 
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One of the outcomes that should be considered since the release of these guidelines in November 
2011 is the possibility that post-caesarean infections will increase and how this would be monitored 
and reported. Published rates of post-caesarean SSI range from 1.9% (525) to 11.2% (150). In these 
two papers, the first did not routinely carry out post-discharge surveillance, whereas the second 
performed post-discharge surveillance routinely on all patients. This suggests that the prevalence of 
1.9% is an underestimation of the number of SSI in this patient population.  
Results from the most recently published surveillance of post-caesarean SSI in England showed an 
infection rate of 9.6%; however only 36% of the study population were followed-up for a full 30 days 
post-surgery (526). Having a high BMI was the largest risk for developing an SSI following caesarean 
according to this study. The general female population in the UK has an ever increasing BMI, with a 
10% increase in the prevalence of obese adults in the UK over the last 15 years (527). Combining 
these two factors, it could be expected that this rate of infection will rise if this trend in BMI 
continues.  
As one of the most commonly performed surgical procedures in the UK, the morbidity and costs 
associated with post-caesarean infections are significant. The potential increase in the number of 
women opting for this procedure, the high rates of infection and the current lack of routine SSI 
surveillance, make this an important patient group to investigate for sustainable surveillance.  
 
6.0.1 Aim and Objectives 
 
The aim of this chapter was to utilise administrative data to develop syndromic surveillance for 
surgical site infections in caesarean section patients. 
In fulfilling this aim, several objectives needed to be met and several steps of analysis were carried 
out to accomplish these. The first objective was to understand and assess the data sources currently 
collected and available for caesarean section patients. The second was to understand the effect of a 
caesarean section procedure and any subsequent surgical site infections on biological markers of 
infection.  Finally, to develop syndromic algorithms for SSI in this patient group and investigate these 
perform within routinely collected health data.  
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6.1 Methods 
 
6.1.1 Data Cleaning, Linkage and Management  
 
Similar to the methods described in Chapter 5.1.0, the first stage of analysis was to link, clean and 
organise the data into a usable format. All linkages were deterministic and anonymisation was based 
on hospital number and date of birth. This was performed on NHS servers by the CIPM Database 
Manager, in accordance with the project’s ethics approval. The datasets being used for this chapter 
and the time periods which they were available for were presented in Table 6.0.  
 
Table 6.0: Overview of the data sources used in chapter 6 
2009 2010 Dec 2010 – June 2011 
PAS 
Laboratory 
PAS 
Laboratory 
PAS 
Laboratory 
Caesarean surveillance 
 
The data was received in two parts, one with the caesarean section data linked to the PAS data, and 
another with PAS linked to the laboratory data. The two data extracts were linked using the ‘joinby’ 
function, which forms all pairwise links between the two datasets within the anonymised patient ID. 
This allowed for irrelevant laboratory tests or patient episodes in these raw extracts to be taken into 
account by retaining all the possible combinations.  
Relevant episodes for each patient consist of all the episodes in which a caesarean section procedure 
was carried out and any subsequent episodes starting within 30 days of the surgery. For the 
microbiology, clinical biochemistry and haematology data all tests performed within 35 days of the 
surgery were kept, for the same reasoning as stated in section 5.1.0. Similarly, pre-operative tests 
for haematology and clinical biochemistry tests were considered in the 12 days prior to the surgery. 
The derived variables used for keeping and removing the relevant episodes are presented in Table 
6.1. 
The data were re-shaped into a wide format, using the same methodology as presented in section 
5.1.0. The PAS data were cleaned using standardised codes, removing any free text and duplications. 
The caesarean section surveillance data were further cleaned, by removing any data values that 
were obviously incorrect. These were determined as values that were outside plausible ranges, such 
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as a BMI of over 2,000, an age of 1, being of male gender or having a gestation period of 155 weeks.  
These values were replaced with ‘missing’.  
 
Table 6.1: Definitions of the derived variables  
Variable Name Definition 
Operation episode 
Binary variable indicating the episode in which the caesarean section took place; 
generated using the date of operation, date of episode start and date of episode 
end 
30 day post-Caesarean Date variable indicating the date 30 days after the caesarean section took place; generated using the date of operation variable 
Re-admission 
Binary variable indicating whether the episode was during a re-admission or the 
operative admission; generated using date of admission, date of discharge, 
district spell number and operation episode 
 
 
6.1.2 Descriptive Analysis of the Caesarean Surveillance data 
 
Firstly, I carried out a simple descriptive analysis of the information collected by the caesarean 
surveillance, defining the patient population, the surgical features and post-operative complications. 
This stage of analysis used only the caesarean surveillance data from December 2010 to June 2011 
and included all potential patients.  
 
6.1.3 Extracting Caesarean Patients from the Administrative Data 
 
In order to compare the caesarean surveillance data with the administrative PAS data, both in terms 
of patients and surgical site infections, all the caesarean patients needed to be extracted and the 
ICD-10 codes for SSI identified. This stage of analysis used the PAS data from January 2009 – June 
2011.  
All procedure codes were taken into account, not just the primary procedure, to ensure all possible 
patients were captured. The codes I used for extracting caesarean section patients at Queen 
Charlotte’s Hospital are presented in Table 6.2. All the relevant episodes and laboratory tests 
relating to patients with a caesarean section code were included. 
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Table 6.2: OPCS codes used for extract caesarean section patients 
OPCS code Definition 
R17.1 Elective upper uterine segment caesarean delivery 
R17.2 Elective lower uterine segment caesarean delivery 
R17.8 Elective caesarean delivery, other specified 
R17.9 Elective caesarean delivery, unspecified 
R18.1 Upper uterine segment caesarean delivery 
R18.2 Lower uterine segment caesarean delivery 
R18.8 Caesarean delivery, other specified 
R18.9 Caesarean delivery, unspecified 
R25.1 Caesarean hysterectomy 
 
 
‘Cases’ were defined using ICD-10 codes. All those caesarean section patients not classified as ‘cases’ 
were classified as ‘controls’. Firstly, in order to assess which ICD-10 codes are used in the PAS data 
for coding surgical site infections, relevant ICD-10 codes were identified. I chose relevant codes in 
three ways:  
 
o Keyword search of ICD-10 codes using the WHO online search tool 
o Codes that have been used in the published literature for diagnosing SSI 
o Codes specified by a communication with the Coding Clinic [Appendix 6]  
 
I also searched through all the diagnosis codes of those patients with an SSI diagnosed by the 
caesarean surveillance. This was done to identify any further potential codes that may be used at a 
local level. Binary variables were created for all the potential ICD-10 codes, with all the diagnostic 
codes for any post-operative episode within 30 days being considered in generating these variables. 
The identified codes are presented in Table 6.3. 
 The number of procedures and the rate of infection, along with the demographic makeup of the 
patient population extracted were compared to the caesarean surveillance patients. This was done 
in order to assess the similarities and differences between the two patient cohorts and highlight if 
there was any pronounced differences.  
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Table 6.3: ICD-10 codes for diagnosing SSI following caesarean section 
ICD-10 
Code ICD-10 code Translation Evidence 
T813* Disruption of operation wound, not elsewhere classified CC, KW 
T814 Infection following a procedure, not elsewhere classified CC, , KW, L (492-495) 
O860 Infection of obstetric surgical wound CC, KW 
O900 Disruption of caesarean wound KW 
Y83* Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without misadventure as the time of procedure CC, L 
(494) 
O85 Puerperal sepsis, including endometritis M 
O864 Other puerperal infection: pyrexia of unknown origin following delivery M 
O908 Other complications of the puerperium, not elsewhere specified M 
R104 Other and unspecified abdominal pain or abdominal tenderness M 
*These codes are only to be used in combination with B95 (Streptococcus & staphylococcus as the cause of diseases 
classified to other chapters); B96 (Other specified bacterial agents as the cause of diseases classified to other chapters) 
or B97 (Viral agents as the cause of diseases classified to other chapters). CC: coding clinic; L: established literature; 
KW: keyword search of ICD-10 codes; M: manual code search of those patients with a SSI diagnosed by the caesarean 
surveillance 
 
 
6.1.4 Comparing Administrative and Surveillance Data 
 
The next stage of analysis was to investigate the utility of administrative data for identifying surgical 
site infections. This stage of analysis was based on the caesarean surveillance data and PAS data 
from December 2010 – June 2011. 
They were investigated as individual codes and in combinations and sensitivities, specificities, 
positive predictive values, negative predictive values and c-statistics (AUC) were used to determine 
the optimal code combinations. The same method was used as presented in section 5.1.3.  
For this analysis, only ‘inpatient surgical site infections’ from the caesarean surveillance data were 
used, consisting of only those SSI diagnosed upon re-admission and during the operative admission. 
The reasoning is the same as it was the CABG patients, that there would not be any ICD-10 codes 
relating to events that occur outside of the hospital and therefore would not be comparing like with 
like.  
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6.1.5 Creating Syndromic algorithms of SSI 
 
The next stage of analysis was the development of syndromic algorithms (or ‘syndromic case 
definitions’) for those inpatient SSI diagnosed by the caesarean surveillance data. The syndromic 
algorithms were based on data from the following three laboratory departments: clinical 
biochemistry, haematology and microbiology. This used the caesarean surveillance and laboratory 
data from December 2010 – June 2011. This stage of analysis included: 
 A description of how the markers changed due to surgery (both in those with infections 
and without) 
 The justification of the markers that were used for developing syndromic algorithms and 
the thresholds that were applied 
 An investigation of  culture requests as proxies for SSI  
The same steps were taken in this analysis as were presented in section 5.1.4, so the method will 
only be described briefly. To determine the routine blood tests requested in caesarean section 
patients, both pre and post-surgery, I looked at the number test requests. Specific markers were 
then chosen from the routine panel of tests based again on scientific principles, having been used in 
the published literature or identified as significant by the systematic literature review (chapter3). In 
addition, those markers which proved to have a significant relationship with SSI in the CABG cohort 
were selected for investigation.  Based on the results of the trend graphs, published local guidelines 
and established literature, thresholds for infection were defined. A summary of the methods (both 
graphical and statistical) used for creating the syndromic algorithms are presented in Table 5.3.  
Again, the full microbiology results were not available for this analysis, so microbiology data were 
used as binary variables indicating if there was a request for a culture. The binary variables that I 
generated based on the defined marker thresholds for infection and culture requests were 
investigated for their sensitivity, specificity, PPV and NPV as individual variables, as well as in 
combinations. The syndromic algorithm for detecting SSI was then defined using the best 
combinations of markers and culture requests, based on the AUC values and balance between the 
sensitivity and specificity.   
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6.1.6 Applying the Syndromic Algorithms in Administrative Data 
 
The caesarean patient cohort from January 2009 to December 2010 was used for this stage of 
analysis. The syndromic algorithms were applied to the ‘cases’ and ‘controls’ generated using the 
ICD-10 codes. The sensitivity, specificity, PPV, NPV and area under the ROC curve were calculated to 
test the accuracy with which the laboratory data could be used to detect SSI as defined by ICD-10 
codes.   
Variables for other common healthcare associated infections (i.e. pneumonia, C. difficile, 
bloodstream infections and urinary tract infections) were created using ICD-10 codes (Table 5.5). A 
simple epidemiological description of these additional HCAI was done.  
 
Figure 6.0: Overview of the methodological steps used in chapter 6 
 
  
PAS, Laboratory and Caesarean Surveillance data: 
 
Linked and cleaned in preparation for analysis 
Caesarean Surveillance data (Dec 10 – Jun 11): 
 
Descriptive analysis of the data collected by the 
caesarean surveillance  
Laboratory + Caesarean surveillance data (Dec 
10 – Jun 11): 
Syndromic algorithm development, 
investigating marker patterns and infection 
thresholds 
PAS + Caesarean surveillance data (Dec 10 – Jun 
11): 
Assessing ICD-10 codes for identifying SSI 
diagnosed by the caesarean surveillance and 
comparing these with the caesarean 
surveillance data 
PAS + Laboratory data (Jan 09 – Dec 10): 
Applying syndromic algorithms within the 
administrative data 
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6.2 Results 
 
6.2.1 Descriptive Analysis of the Caesarean Surveillance data 
 
A total of 1,375 patients were included in the caesarean surveillance, from both Queen Charlotte’s 
Hospital and St. Mary’s hospital, across a six month period (December 2010 to June 2011). The 
number of surgical site infections diagnosed by this caesarean surveillance study was 72, an 
incidence of 5.2 SSI per 100 caesarean sections.   
As these data look at caesarean section surgery, the entire patient population is inevitably female 
and of a reproductive age (Figure 6.1). The majority of patients had a body mass index in the normal 
range (18 – 25) and only 1.4% of the patients were classified as underweight. It was not specified in 
the study methodology whether or not the height and weight measurements were taken at the 
point of data collection (i.e. giving the women’s pregnant weight) or were based on recalled pre-
pregnancy values. The pattern of BMI in the population (Figure 6.2) matches that of women of 
childbearing age in the UK population (527). In light of this, I have assumed that the weight recorded 
by this dataset was representative of pre-pregnancy weight.  
 
Figure 6.1: Age distribution of caesarean section patients 
 
Figure 6.2: BMI distribution of caesarean section patients 
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The average pre-caesarean length of stay was 0.6 days, meaning most women were admitted the 
day of their surgery. The longest pre-operative length of stay was recorded as 59 days and the 
longest for a patient who went on to develop an SSI was 13 days.  
 
Surgical features 
 
The average length of surgery was 48 minutes, with the longest reported as 265 minutes (4hrs 
25mins) and the shortest as 14 minutes. Unlike for CABG operations, there is no established T-time 
for caesarean sections, however the average length of surgery recorded by this study was similar to 
that reported by the national ‘KISS’ surveillance programme in Germany (525). Patients that had 
longer surgery were more likely to develop an SSI when compared to the group of patients with 40 – 
60 minute caesareans (OR: 3.2; 95% CI: 1.3 – 8.1; p-value: 0.012) (Figure 6.3). 
Of the 1,375 women who had caesareans performed, labour was induced in 143 (12%). Almost 60% 
of these women had no previous caesareans, although this information was missing in 22% of the 
records. The highest number of prior caesareans was 5 and for 236 (17%) patients, this was their 
second delivery by caesarean section.  In this cohort, 40% of women had the reason for caesarean 
recorded as ‘timed to suit woman or staff’ and 28.5% had caesareans carried out as there was an 
immediate threat to their lives or the life of the foetus (this being classed as the most urgent reason 
for a caesarean). The remaining women were either compromised but with no immediate threat to 
their lives (22%) or were not compromised but still in need of an early delivery (10%).  
 
Figure 6.3: Percentage of patients with an SSI according to duration of caesarean section 
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Closure of the surgical incision was done almost exclusively using continuous suturing (93%), with 
the remaining 90 women having either interrupted sutures (4.5%), staples (1%) or an unspecified 
closure (1.5%); most of the non-continuous suture closures were performed when the lead surgeon 
was a specialist registrar. In two thirds of surgery the lead surgeon was of a consultant grade, 
however in 262 (19%) procedures the lead surgeon was a specialist registrar. Two procedures were 
performed by FY2 doctors (2nd foundation year), meaning that the main surgeon was only in their 
second year out of medical school.  
 
Infection features 
 
Surgical site infection was recorded twice, as two separate variables, with discrepancies between 
these variables in 14 patients (1%). Any positives from either variable were taken to create an overall 
SSI variable, with 72 cases in total. Similarly, the way in which the infection was detected was 
recorded twice; I created a variable taking re-admission or current admission detection as the 
correct result if there was a discrepancy recorded between these two variables.  
Most infections were diagnosed after discharge in the community (73%), either self-reported or 
through active follow up of the patient by a midwife or through GP contact. A fifth were detected 
when the patient was re-admitted to hospital and only five patients (7%) had their SSI diagnosed in 
the same admission as the caesarean section surgery (Figure 6.4). Of those patients with SSI 
reported, four did not have the type of infection recorded. The majority of infections were 
superficial (80%), with only seven deep infections and three organ space infections, all of which were 
endometritis (inflammation of the inner uterine lining).  
 
Figure 6.4: Method of Surgical Site Infection Identification 
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There were a range of criteria on which an infection could be diagnosed, including clinical symptoms, 
positive microbiology and antibiotic prescriptions. However, none of the patients with SSI had any 
data on organisms detailed and only six patients had a wound swab recorded as part of the 
diagnosis. As most infections were diagnosed in the community, wound swabs would not be 
expected for any of those patients. A summary of the ways in which the SSI were diagnosed are 
presented in Figure 6.5.  
 
Figure 6.5: Symptoms present in patients diagnosed with SSI following caesarean section 
 
 
The most common method of identifying an SSI was having a clinician’s diagnosis, with almost three 
quarters of the patients with SSI having this as the diagnostic criteria. The next most common 
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redness and heat around the wound site.  The average number of criteria met in patients diagnosed 
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6.2.2 Comparing ICD-10 Codes with Inpatient SSI 
 
The results of comparing ICD-10 codes with those surgical site infections recorded by the caesarean 
surveillance are presented, followed by a description of those caesarean patients extracted from the 
PAS data in 2009 and 2010.  
When the caesarean surveillance data were linked to PAS, 10% of the patients recorded by the 
caesarean surveillance did not link to a PAS record. Therefore 1,233 patients remained for this 
analysis, using six months of linked PAS and caesarean surveillance data. Among this cohort there 
were 18 inpatient surgical site infections; one inpatient SSI detected by the caesarean surveillance 
was not included in this analysis as it occurred in one of the patients which did not link to the PAS 
data. The sensitivity, specificity, PPV and NPV of the ICD-10 codes investigated for identifying the 
inpatient SSI identified by the caesarean surveillance are presented in Table 6.4.  
 
Table 6.4:  Sensitivity analyses of ICD-10 codes in detecting inpatient SSI 
ICD-10 Code Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
T813 0 99.9 (99.5, 100) 0 98.5 (97.7, 99.1) 0.5 
O860 55.6 (30.8, 78.5) 98.5 (97.7, 99.1) 35.7 (18.6, 55.9) 99.3 (98.7, 99.7) 0.77 (0.65, 0.88) 
O860 + org 38.9 (17.3, 64.3) 99.5 (98.9, 99.8) 53.8 (25.1, 80.8) 99.1 (98.4, 99.5) 0.69 (0.58, 0.81) 
O900 11.1 (1.38, 34.7) 99.2 (98.5, 99.6) 16.7 (2.09, 48.4) 98.7 (97.9, 99.2) 0.55 (4.8, 6.2) 
O900 + or 0 99.8 (99.4, 100) 0 98.5 (97.7, 99.1) 0.5 
O85 5.56 (0.14, 27.3) 99.5 (98.9, 99.8) 14.3 (0.36, 57.9) 98.6 (97.8, 99.2) 0.53 (0.47, 0.58) 
O85 + org 5.56 (0.14, 27.3) 100 (99.7, 100) 100 (2.5, 100) 98.6 (97.8, 99.2) 0.53 (0.47, 0.58) 
O864 5.56 (0.14, 27.3) 98.1 (97.2, 98.8) 4.17 (0.11, 21.1) 98.6 (97.8, 99.2) 0.52 (0.46, 0.57) 
O908 5.56 (0.14, 27.3) 98.4 (97.6, 99.1) 5 (0.13, 24.9) 98.6 (97.8, 99.2) 0.52 (0.47, 0.58) 
R104 5.56 (0.14, 27.3) 98.8 (98, 99.3) 6.25 (0.16, 30.2) 98.6 (97.8, 99.2) 0.52 (0.47, 0.58) 
O860 / O900 61.1 (35.7, 82.7) 97.7 (96.7, 98.5) 28.2 (15, 44.9) 99.4 (98.8, 99.8) 0.79 (0.68, 0.91) 
O860 + org / O900 50 (26, 74) 98.7 (97.9, 99.2) 36 (18, 57.5) 99.3 (98.6, 99.7) 0.74 (0.63, 0.86) 
O860 / O900 / O85 + 
org 
61.1 (35.7, 82.7) 97.7 (96.7, 98.5) 28.2 (15, 44.9) 99.4 (98.8, 99.8) 0.79 (0.68, 0.91) 
O860 + org  / O900 / 
O85 + org 50 (26, 74) 98.7 (97.9, 99.2) 36 (18, 57.5) 99.3 (98.6, 99.7) 0.74 (0.63, 0.86) 
+: indicates that both markers are present; /: indicates that either marker is present, but does not need to be both. 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve; org: organism code (B95, B96 or B97) 
 
In isolation, the O860 code identified over half the inpatient SSI and had an AUC of 0.77, making it 
the best code in isolation (Table 6.5). The T813 code (which was successfully used to identify SSI in 
CABG patients) and the O900 code when combined with an organism code, both failed to identify 
any inpatient SSI. On the whole, individually ICD-10 codes performed poorly in terms of sensitivities.  
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Table 6.5: number of patients correctly identified as having with SSI by the O860 code 
O860 No inpatient SSI Inpatient SSI 
No ICD-10 Code 1,197 8 
ICD-10 Code 18 10 
 
When combined the sensitivities increased to a maximum of 61%, however the PPV remained poor 
(28%). Two combinations of codes came out as the best, with both of which had an AUC value of 
0.79. I chose to use the combination that included the most possible ICD-10 codes, to maximise the 
potential of finding patients with infections.   
I searched the ICD-10 diagnosis codes for those patients diagnosed as having an SSI by the caesarean 
surveillance but no previously identified relevant ICD-10 code. No further codes were found that 
could indicate a post-caesarean complication or infection, other than the codes already investigated. 
The ICD-10 code combination I used to define a surgical site infection in the administrative data was: 
 
Any of the following: O860, O900, O85 + organism code 
 
6.2.3 Comparing Administrative and Surveillance Data 
 
As there was no laboratory data available from St. Mary’s, from this point forward all the analyses 
utilised data from Queen Charlotte’s Hospital only. This resulted in 709 patients from the caesarean 
surveillance, and 14 inpatient surgical site infections. When the caesarean surveillance and PAS data 
were linked, 4% of the caesarean patients from Queen Charlotte’s Hospital specifically were lost 
(reducing from 739 to 709 patients). Linkage was based on hospital number and date of birth, and 
further linkage based on date of surgery or demographic features were not attempted due to data 
quality issues.  
A total of 4,352 patients had OPCS codes for caesarean sections at Queen Charlotte’s Hospital 
between January 2009 and December 2010. Of these unique patients, 36 had two caesareans 
recorded during these two years, with the shortest time between the two procedures being 380 
days (almost 13 months). On closer inspection of the data, 67 (1.5%) of these “caesarean” patients 
were actually neonates, despite having the primary procedure code recorded as either R172 or R182 
(see Table 6.2 for translation), and I removed these patients from the cohort.   
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This left 4,321 caesarean sections amongst 4,285 unique patients to be investigated in this cohort. 
Of these, 131 (3.0%) had one of the appropriate ICD-10 codes used to define SSI within the 
administrative data. A summary of the patient characteristics and number of infections according to 
year are presented in Table 6.6. There were 1,716 episodes associated with these patients, occurring 
within the seven days prior to the caesarean procedure and starting within 30 days of the surgery. 
The highest number of episodes for a single patient was six and the average was 1.4 episodes per 
patient. Within this cohort, 148 patients were re-admitted to hospital within 30 days of their 
caesarean section.  
 
Table 6.6: Summary of the Caesarean Section patients from 2009 – June 2011 
 2009 2010 
PAS, Laboratory 
and Caesarean 
Surveillance data 
Number of patients 1,725 2,597 709 
Average age  33.5 33.2 33.5 
Age range 17 – 58 15 – 52 19 – 49  
Patients with any wound culture 111 (6.4%) 103 (3.9%) 56 (7.9%) 
Patients with ≥ 2 wound cultures 10 (0.6%) 15 (0.6%) 9 (1.3%) 
Maximum number of wound cultures 4 3 4 
Number of wound cultures (av. per patient) 0.07 0.05 0.09 
SSI patients 38 (2.2%) 93 (3.6%) 18 (2.5%) 
 
The most caesareans were performed in women aged 30 – 40 years old (Figure 6.6); however no one 
age group appeared to have more patients with SSI codes. This was similar to the pattern seen in the 
caesarean surveillance data. There were a third less caesarean sections carried out in 2009 
compared to 2010, with the number of patients detected in the caesarean surveillance being more 
similar to the numbers found in 2009. The 2010 data had a higher number of infections according to 
the ICD-10 codes, however considerably fewer patients with a wound culture request.  
When the number of patients identified by both the caesarean surveillance and the PAS data were 
compared, 84% of the total possible patients were identified by both data sources. However, there 
was an element of non-linkage which could account for the 30 patients from the caesarean 
surveillance not being available in PAS. However the caesarean surveillance failed to identify a large 
portion of patients that PAS had recorded during the corresponding time period (Figure 6.7).  
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Figure 6.6: Proportion of patients with an SSI code following caesarean section, according to age group  
 
 
Figure 6.7: Venn diagram of the number of caesarean patients in the surveillance PAS data 
 
 
Figure 6.8: Venn diagram of the number of SSI diagnosed after a caesarean in the surveillance PAS data 
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Fourteen of the patients from the caesarean surveillance had an inpatient SSI, consisting of nine 
superficial infections, four deep and one organ space infection. Using the ICD-10 codes, 27 patients 
were recorded as having had a SSI following caesarean section. Only 28% of all the possible surgical 
site infections were identified by both sources, with nine infections recorded by both the caesarean 
surveillance and PAS data.  
The number of cases, as defined by the ICD-10 codes in the PAS data, were plotted as a statistical 
process control chart (SPC chart) from January 2009 till June 2011 (Figure 6.9). The lower control 
limit cannot be less than 0, and if this is the case, the lower limit is automatically set to zero. For this 
SPC chart, the lower limit was negative and thus I set it to zero.  This SPC chart demonstrates that in 
August 2009 an alert would have been triggered, as the number of patients with an ICD-10 code for 
a SSI following caesarean sections exceeded the upper control limit. 
The general rule with SPC charts is that 8 consecutive values above or below the mean line causes a 
shift in the control limits. In this SPC, this condition was not met at any point, although it was close 
from April 2010 onwards. The arrow indicates when the caesarean surveillance began and it did not 
appear to have had an effect on the number of SSI recorded in the ICD-10 codes.  
 
 
Figure 6.9: Statistical Process Control chart of SSI diagnoses based on ICD-10 codes within PAS data, January 
2009 - June 2011. The upper and lower limits represent 3 standard deviations distance from the mean. 
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6.2.4 Creating Syndromic Algorithms of SSI 
 
When the linked PAS and caesarean section surveillance data were linked to the laboratory data, 
15% of patients had no corresponding laboratory data during their entire admission, or where 
relevant re-admission. This meant that 601 of the 709 linked patients had any haematology, 
microbiology or clinical biochemistry data on which to develop the syndromic algorithms for surgical 
site infections. Within this cohort, there were 14 patients with inpatient SSI, of which two patients 
did not have any laboratory data.  
In this patient group there were no laboratory investigations carried out beyond 25 days post-
caesarean, despite following up patients in the laboratory data for 35 days post-surgery. 
Furthermore, only two patients had any haematology or clinical biochemistry investigations carried 
out more than 14 days after their caesarean section.  
 
Haematology and Clinical biochemistry 
 
For developing syndromic algorithms for surgical site infections in this patient group, I considered all 
those markers which were found to be useful for developing syndromic surveillance in the CABG 
cohort. The frequency of the tests, results of t-tests, box plots and graphs of the median values were 
all used to determine the relevant markers of infection in this patient population. Table 6.7 
summarises the different markers, both in patients with an SSI diagnosed by the caesarean 
surveillance and those without, pre and post-operatively. A single result for INR was recorded, and 
therefore this marker was not included.  
The results of the t-tests showed that only mean post-operative platelet levels were significantly 
different between the infected and uninfected patients. The median post-operative eosinophil levels 
appeared to be elevated in the patients with SSI; however this relationship was not statistically 
significant.   
When plotted as box plots, WBC showed no real difference between the SSI patients and controls, as 
would be expected from the results presented in Table 6.7. CRP, platelets and eosinophils on the 
other hand all appeared to have visibly higher post-operative levels in the SSI patients, despite the 
ranges overlapping with the uninfected patients (Figures 6.10, 6.11, 6.12).  
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Table 6.7: Summary of Routine Blood Tests Being Investigated for Developing Syndromic Surveillance 
 Pre Caesarean Post Caesarean 
Marker (reference 
‘normal’ range) SSI No SSI SSI No SSI 
C-reactive Protein 
(0 – 10 mg/L) 
3.3 – 8.8 (range) 
6.05 (mean) 
6.05 (median) 
2 (14%) (patients) 
0.9 – 195.9 
25.6 
7.5 
29 (4%) 
32.3 – 166.4 
102.2 
103.3 
9 (64%) 
1.3 – 299.7 
85.7 
70.9 
135 (19%) 
Full White Blood 
Cell Count 
(4 – 11 x109/L) 
5.0 – 11.7 
8.6 
8.9 
4 (29%) 
5.3 – 25.6 
11.0 
10.3 
135 (19%) 
7.4 – 18.6 
12.1 
11.9 
12 (86%) 
5.1 – 27.0 
12.2 
11.7 
562 (81%) 
Lymphocytes  
(1.0 – 3.5 x109/L) 
1.65 – 2.5 
2.2 
2.3 
4 (29%) 
0.5 – 3.0 
1.8 
1.9 
135 (19%) 
0.85 – 2.5 
1.9 
2.0 
12 (86%) 
0.4 – 4.6 
1.7 
1.6 
562 (81%) 
Neutrophils 
(2.0 – 7.5 x109/L) 
2.7 – 8.2 
5.7 
6.0 
4 (29%) 
2.7 – 20.8 
8.3 
7.5 
135 (19%) 
5.2 – 16.0 
9.3 
9.0 
12 (86%) 
3.0 – 24.9 
9.7 
9.2 
562 (81%) 
Basophils 
(0.0 – 0.1 x109/L) 
0 
0 
0 
4 (29%) 
0 – 0.05 
0 
0 
135 (19%) 
0 
0 
0 
12 (86%) 
0 – 0.08 
0 
0 
562 (81%) 
Eosinophils 
(0.0 – 0.4 x109/L) 
0.05 – 0.10 
0.09 
0.10 
4 (29%) 
0 – 0.30 
0.07 
0.10  
135 (19%) 
0 – 0.25 
0.14 
0.16 
12 (86%) 
0 – 0.6 
0.10 
0.10 
562 (81%) 
Platelets* 
(120 – 400 x109/L) 
205 – 257 
233.6 
236.2 
4 (29%) 
46 – 441.4 
215.9 
201.0 
135 (19%) 
169.8 – 500 
293.5 
288.3 
12 (86%) 
82.8 – 544 
205.5 
195.0 
562 (81%) 
Fibrinogen 
(1.5 – 4.0 g/L) 
4.6 
4.6 
4.6 
1 (7%) 
2.1 – 7.4 
4.4 
4.3 
27 (4%) 
3.2 – 5.1 
4.5 
4.6 
5 (36%) 
1.6 – 8.1 
4.1 
4.3 
76 (11%) 
Creatinine 
(60 – 110 µmol/L) 
41 – 55 
48.7 
50.0 
3 (21%) 
37 – 90 
57.1 
56.8 
44 (6%) 
37.9 – 74.6 
56.7 
56.8 
9 (64%) 
20 – 97 
56.9 
55.0 
138 (19%) 
Haematocrit 
(0.37 – 0.47 %) 
0.33 – 0.36 
0.34 
0.34 
4 (29%) 
0.25 – 0.44 
0.36 
0.36 
135 (19%) 
0.27 – 0.35 
0.32 
0.31 
12 (86%) 
0.22 – 0.42 
0.33 
0.33 
562 (81%) 
Serum Albumin 
(33 – 47 g/L) 
22.5 – 26.0 
24.3 
24.3 
2 (14%) 
18.3 – 31.0 
25.4 
26.0 
41 (6%) 
17 – 26 
22.6 
23.0 
7 (50%) 
16.4 – 34 
23.6 
23.9 
98 (14%) 
*Significant in a t-test comparing the average post-operative values between infected and uninfected patients, 
with a p-value <0.0001 
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Figure 6.10: Box plots of CRP levels 
pre and post caesarean, according to 
SSI diagnosis  
Figure 6.11: Box plots of Platelet 
levels pre and post caesarean, 
according to SSI diagnosis  
Figure 6.12: Box plots of 
Eosinophil levels pre and post 
caesarean, according to SSI 
diagnosis  
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Figure 6.13: Box plot of platelet 
levels following caesarean, 
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Figure 6.14: Box plot of 
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Figure 6.15: Box plot of CRP 
levels following caesarean, 
according to SSI severity 
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Splitting the patients according to the severity of SSI revealed that platelets and eosinophils appear 
to be correlated with the severity of infection (Figures 6.13, 6.14 and 6.15). CRP on the other hand 
had no clear pattern corresponding to the type of SSI. 
Taking these initial investigations into account, I investigated the following markers for their 
relationship with surgical site infection: CRP, platelets and eosinophils. The next step was to 
determine marker patterns as a result of surgery and infection. The median values on each day post 
caesarean of the infected and uninfected patients were graphed over time (Figure 6.16 and Figure 
6.17). The median was used as opposed to the mean as this will reduce the influence of any 
extremes on the overall pattern. The graph for eosinophils did not demonstrate any post-operative 
pattern, or any pattern to distinguish between infected and uninfected patients.  
 
Figure 6.16: Median CRP level after caesarean section, according to SSI status 
 
Figure 6.17: Median Platelet level after caesarean section, according to SSI status 
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The thresholds of infection were initially based on the Imperial College Healthcare NHS Trust 
laboratory guidelines. However, a CRP value exceeding the threshold was only deemed relevant 
after five days post-surgery to account for the effect of surgery. The threshold used to distinguish 
infected from uninfected patients are presented in Table 6.8.  
 
Table 6.8: Summary of marker thresholds for SSI following caesarean 
Marker Threshold for ‘Infection’ 
C-reactive protein >50mg/L after day 5 post-surgery >100mg/L after day 5 post-surgery 
Platelets >400x109/L any day post-surgery 
Eosinophils >0.4 x109/L any day post-surgery 
 
The sensitivities, specificities, PPV, NPV and area under the ROC curve (AUC) values for the different 
markers investigated are presented in Table 6.9. There were no occurrences of eosinophils 
exceeding the threshold values of >0.4 x109/L among the patients with surgical site infections. This 
was to be expected as Figure 6.12 demonstrated that the average post-operative eosinophil level 
was less than 0.2. Investigating the markers in isolation, having any occurrence of CRP >50 mg/L had 
the highest sensitivity (57.1%), whereas platelets only had a sensitivity of 35.7% and PPV of 23.8% 
indicating it was relatively poor at distinguishing infected from uninfected patients.  
 
Table 6.9: Sensitivity analysis for the different marker thresholds for identifying SSI following caesarean  
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Any occurrence of CRP >50 after 5 days post- caesarean 
One or more occurrence 57.1 (28.6, 82.3) 97.4 (95.9, 98.5) 30.8 (14.3, 51.8) 99.1 (98.1, 99.7) 0.77 (0.64, 0.91) 
Two or more occurrences 7.14 (0.18, 33.9) 97.8 (96.5, 98.8) 6.25 (0.16, 30.2) 98.1 (96.8, 99) 0.53 (0.46, 0.60) 
Three or more occurrences 7.14 (0.18, 33.9) 99 (97.9, 99.6) 12.5 (0.32, 52.7) 98.1 (96.8, 99) 0.53 (0.46, 0.60) 
Any occurrence of CRP >100 after 5 days post- caesarean 
One or more occurrence 28.6 (8.39, 58.1) 98 (96.6, 98.9) 22.2 (6.41, 47.6) 98.6 (97.4, 99.3) 0.63 (0.51, 0.76) 
Any occurrence of Platelets >400 any day post- caesarean 
One or more occurrence 35.7 (12.8, 64.9) 97.7 (96.3, 98.7) 23.8 (8.22, 47.2) 98.7 (97.5, 99.4) 0.67 (0.54, 0.80) 
Two or more occurrences 14.3 (1.78, 42.8) 99.1 (98.1, 99.7) 25 (3.19, 65.1) 98.3 (97, 99.1) 0.57 (0.47, 0.66) 
Three or more occurrences 14.3 (1.78, 42.8) 99.6 (98.7, 99.9) 40 (5.27, 85.3) 98.3 (97, 99.1) 0.57 (0.47, 0.66) 
Any occurrence of Eosinophils >0.4 any day post-caesarean 
One or more occurrence 0 99.1 (98.1, 99.7) 0 98 (96.7, 98.9) 0.50 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
The number of times the markers exceeded these thresholds of infection were plotted as a ROC 
curve to compare how well this predicted a patient with an SSI diagnosed by the caesarean 
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surveillance (Figure 6.18). From this analysis, the best indicator of SSI was having a CRP exceeding 50 
x109/L, with an AUC value of 0.77. However, if the number of occurrences was increased, the 
sensitivity and PPV both decreased dramatically and the AUC dropped to 0.53 (Table 6.9). 
 
Figure 6.18: ROC curve of the number of times different markers exceed defined thresholds  
  
 
As these thresholds did not yield results with high sensitivities or positive predictive values, I 
investigated several different thresholds for each marker (Table 6.10).  
 
Table 6.10: Further marker thresholds investigated for SSI following caesarean 
Marker Threshold for ‘Infection’ 
C-reactive protein 
>10 after day 5 post-surgery 
>50 after day 5 post-surgery 
>100 after day 5 post-surgery 
Platelets 
>250 any day post-surgery 
>300 any day post-surgery 
>400 any day post-surgery 
Eosinophils 
>0.15 any day post-surgery 
>0.25 any day post-surgery 
>0.4 any day post-surgery 
 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
si
tiv
ity
0.00 0.25 0.50 0.75 1.00
1-Specificity
Platelets >400 (AUC: 0.67) Eosinophils >0.4 (AUC area: 0.50)
CRP >50 (AUC: 0.77) CRP >100 (AUC area: 0.63)
 207 
 
  
 
 
0.
0
0
0.
2
5
0.
5
0
0
.7
5
1
.0
0
S
e
n
si
ti
v
it
y
0.00 0.25 0.50 0.75 1.00
1-Specificity
CRP>50 (AUC: 0.77) CRP >100 (AUC: 0.63)
CRP >10 (AUC: 0.77)
0.
0
0
0.
2
5
0.
5
0
0.
7
5
1.
0
0
S
e
n
si
ti
v
ity
0.00 0.25 0.50 0.75 1.00
1-Specificity
Platelet >400 (AUC: 0.67) Platelet >300 (AUC: 0.75)
Platelet >250 (AUC: 0.76)
0.
0
0
0.
2
5
0.
5
0
0.
7
5
1.
0
0
S
e
n
si
ti
v
ity
0.00 0.25 0.50 0.75 1.00
1-Specificity
Eosinophil >0.4  (AUC: 0.50) Eosinophil >0.15 (AUC: 0.67)
Eosinophil >0.25 (AUC: 0.57)
Figure 6.19: ROC curve of 
different CRP thresholds for 
identifying SSI after caesarean 
Figure 6.20: ROC curve of 
different platelet thresholds for 
identifying SSI after caesarean 
Figure 6.21: ROC curve of 
different eosinophil 
thresholds for identifying SSI 
after caesarean 
 208 
 
I plotted ROC curves for each marker, comparing the different thresholds of infection (Figure 6.19, 
6.20 and 6.21). Based on these ROC analyses, the marker thresholds of infection for both platelets 
and eosinophils were altered. A threshold of >250 x109/L was used for platelets and >0.15 x109/L for 
eosinophils. The best threshold for CRP in this patient group remained at >50 mg/L.  The markers at 
their new thresholds were investigated in isolation for their relationship in identifying SSI and the 
results are presented in Table 6.11. Despite the sensitivities at the new thresholds increasing in both 
eosinophils and platelets, the PPVs were still poor for both markers.  
 
Table 6.11: Sensitivity analysis for the alternative marker thresholds for identifying SSI following caesarean 
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Any occurrence of Platelets >250 any day post- caesarean 
One or more occurrence 64.3 (35.1, 87.2) 81.9 (78.8, 84.7) 6.67 (3.09, 12.3) 99.1 (98, 99.7) 0.73 (0.60, 0.86) 
Two or more occurrences 42.9 (17.7, 71.1) 92.4 (90.1, 94.2) 10.2 (3.82, 20.8) 98.8 (97.6, 99.5) 0.68 (0.54, 0.81) 
Any occurrence of Eosinophils >0.15 any day post-caesarean 
One or more occurrence 50 (23, 77) 75.5 (72.2, 78.7) 3.95 (1.6, 7.98) 98.7 (97.3, 99.5) 0.63 (0.49, 0.77) 
Two or more occurrences 35.7 (12.8, 64.9) 94.2 (92.2, 95.9) 11.1 (3.71, 24.1) 98.6 (97.4, 99.4) 0.65 (0.52, 0.78) 
CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
Next, the markers were combined to determine if combinations of markers acted as more reliable 
indicators of infection, than using them in isolation. The results of these combinations are presented 
in Table 6.12. The best combination of markers for identifying SSI recorded by the caesarean 
surveillance was having any occurrence of CRP >50mg/L and platelets >250x109/L, with a sensitivity 
of 57.1% and specificity of 97.8% (AUC: 0.78). This was a slight improvement over using CRP in 
isolation in terms of a balanced result. A higher sensitivity were achieved using platelets in isolation 
(64.3%), however the PPV in this instance was extremely low (6.7%).  
 
Table 6.12: Sensitivity analysis for combinations of markers for identifying SSI following caesarean 
Marker Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
CRP / Platelets 64.3 (35.1, 87.2) 81.4 (78.3, 84.3) 6.52 (3.03, 12) 99.1 (98, 99.7) 0.73 (0.60, 0.86) 
CRP / Eosinophils 71.4 (41.9, 91.6) 74.7 (71.3, 77.9) 5.38 (2.61, 9.66) 99.2 (98.1, 99.8) 0.73 (0.61, 0.85) 
Platelets / Eosinophils 71.4 (41.9, 91.6) 66.6 (63, 70.1) 4.13 (2, 7.47) 99.1 (97.8, 99.8) 0.69 (0.57, 0.81) 
CRP / Platelets / Eosinophils 71.4 (41.9, 91.6) 66.3 (62.7, 69.8) 4.10 (1.98, 7.41) 99.1 (97.8, 99.8) 0.69 (0.57, 0.81) 
CRP + Platelets 57.1 (28.9, 82.3) 97.8 (96.5, 98.8) 34.8 (16.4, 57.3) 99.1 (98.1, 99.7) 0.78 (0.64, 0.91) 
CRP + Eosinophils 35.7 (12.8, 64.9) 98.3 (97, 99.1) 29.4 (10.3, 56) 98.7 (97.5, 99.4) 0.67 (0.54, 0.80) 
Platelets + Eosinophils 42.9 (17.7, 71.1) 90.8 (88.4, 92.8) 8.57 (3.21, 17.7) 98.7 (97.5, 99.5) 0.67 (0.53, 0.80) 
CRP +Platelets + Eosinophils 35.7 (12.8, 64.9) 98.4 (97.2, 99.2) 31.3 (11.0, 58.7) 98.7 (9.75, 99.4) 0.67 (0.54, 0.80) 
+: indicates that both markers are present; /: indicates that either marker is present, but does not need to be both. CI: 95% 
confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating characteristic 
curve 
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Microbiology 
 
Overall 177 of the 709 (25%) patients had a microbiology culture request following caesarean 
section (Table 6.13). The maximum number of culture requests for a single patient was 15. There 
were 56 patients with a wound culture request specifically after the caesarean section (7.9%) and of 
these only eight had been diagnosed as having a SSI by the caesarean surveillance.   
 
Table 6.13: Summary of Culture Requests in caesarean patients 
Culture Request Maximum number per patient 
Number of patients (% 
with SSI) 
Blood 6 96 (8.3%) 
Body Fluid 1 1 (0%) 
MRSA 1 11 (9.1%) 
Tissue 1 5 (0%) 
Urine 5 91 (6.6%) 
Vaginal  3 72 (5.6%) 
Wound 4 56 (14.3%) 
Other 2 12 (8.3%) 
 
ROC curves for the number of wound culture requests, and for the number of other common culture 
requests against the SSI diagnosed by the caesarean surveillance were plotted (Figure 6.22 and 
Figure 6.23). The AUC value for wound culture requests was 0.75, and the AUC value for blood 
culture requests was 0.74, indicating that both of these were relatively good proxies for SSI in this 
patient group.  
The results of the sensitivity analyses for wound culture requests, any culture request and a 
combination of blood culture and wound culture requests are presented in Table 6.14. The best 
combination of culture requests for identifying patients with a surgical site infection according to the 
caesarean surveillance was having either a wound culture or a blood culture requested (AUC: 0.78). 
This had a sensitivity of 71.4%, but the positive predictive value was extremely poor at only 8.2%. 
This indicates that of the patients with either a wound or blood culture request, only 8.2% would 
have been diagnosed as having an SSI by the caesarean surveillance. Only eight of the 14 patients 
with an SSI diagnosis had any wound cultures requested during their post-operative admissions, and 
six patients without an SSI had two wound culture requests.  
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Figure 6.22: ROC curve of the number of wound cultures for identifying SSI after caesarean 
 
 
Figure 6.23: ROC curve of the number of different cultures for identifying SSI after caesarean 
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Table 6.14: Sensitivity analysis of culture requests for identifying SSI following caesarean 
Infection Proxy Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Any wound culture 57.1 (28.9, 82.3) 93.1 (90.9, 94.9) 14.3 (6.38, 26.2) 99.1 (98, 99.7) 0.75 (0.62, 0.89) 
>1 wound culture 21.4 (4.66, 50.8) 99.1 (98.1, 99.7) 33.3 (7.49, 70.1) 98.4 (97.2, 99.2) 0.60 (0.49, 0.71) 
>2 wound cultures 7.14 (0.18, 33.9) 100 (99.5, 100) 100 (2.5, 100) 98.2 (96.9, 99) 0.54 (0.47, 0.61) 
Any culture 71.4 (41.9, 91.6) 76 (72.6, 79.1) 5.65 (2.74, 10.1) 99.2 (98.1, 99.8) 0.74 (0.61, 0.86) 
>1 culture (any) 64.3 (35.1, 87.2) 87.9 (85.3, 90.2) 9.86 (4.52, 17.6) 99.2 (98.1, 99.7) 0.76 (0.63, 0.89) 
>2 cultures (any) 57.1 (28.9, 82.3) 92.5 (90.3, 94.4) 13.3 (5.94, 24.6) 99.1 (98, 99.7) 0.75 (0.61, 0.88) 
Wound / Blood culture 71.4 (41.9, 91.6) 83.9 (80.9, 86.5) 8.2 (4.0, 14.6) 99.3 (98.3, 99.8) 0.78 (0.65, 0.90) 
>1 wound/blood culture 57.1 (28.9, 82.3) 96.1 (94.4, 97.4) 22.9 (10.4, 40.1) 99.1 (98.1, 99.7) 0.77 (0.63, 0.90) 
Wound + Blood culture 42.9 (17.7, 71.1) 96.5 (94.9, 97.8) 20 (7.71, 38.6) 98.8 (97.7, 99.5) 0.70 (0.56, 0.83) 
+: indicates that both markers are present; /: indicates that either marker is present, but does not need to be both. CI: 
95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver operating 
characteristic curve 
 
 
Haematology, Clinical biochemistry and Microbiology 
 
Combining the haematology and clinical biochemistry results with the microbiology requests 
generally increased the area under the ROC curve values (Table 6.15). The highest possible PPV was 
36.8%, which was achieved when using any wound culture request and any occurrence of CRP 
>50mg/L. The sensitivity for this marker and infection proxy combination was only 50%.  
 
Table 6.15: Sensitivity analysis of markers and proxies of infection for identifying SSI following caesarean 
Markers and 
proxies Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) ROC area 
Any wound culture request 
Any CRP 50 (23, 77) 98.3 (97, 99.1) 36.8 (16.3, 61.6) 99 (97.7, 99.6) 0.74 (0.61, 0.88) 
CRP / Platelet 57.1 (28.9, 82.3) 96.3 (94.6, 97.5) 23.5 (10.7, 41.2) 99.1 (98.1, 99.7) 0.77 (0.63, 0.90) 
CRP + Platelet 50 (23, 77) 98.6 (97.4, 99.3) 41.2 (18.4, 67.1) 99 (97.9, 99.6) 0.74 (0.61, 0.88) 
Any culture request 
Any CRP 57.1 (28.9, 82.3) 97.6 (96.1, 98.6) 32 (14.9, 53.5) 99.1 (98.1, 99.7) 0.77 (0.64, 0.91) 
CRP / Platelet 64.3 (35.1, 87.2) 90.9 (88.6, 93) 12.5 (5.88, 22.4) 99.2 (98.2, 99.7) 0.78 (0.65, 0.91) 
CRP + Platelet 57.1 (28.9, 82.3) 98 (96.6, 98.9) 36.4 (17.2, 59.3) 99.1 (98.1, 99.7) 0.77 (0.64, 0.91) 
Any wound or blood culture request 
Any CRP 57.1 (28.9, 82.3) 97.7 (96.3, 98.7) 33.3 (15.6, 55.3) 99.1 (98.1, 99.7) 0.77 (0.64, 0.91) 
CRP / Platelet 64.3 (35.1, 87.2) 93.4 (91.3, 95.1) 16.4 (7.77, 28.8) 99.2 (98.2, 99.8) 0.79 (0.66, 0.92) 
CRP + Platelet 57.1 (28.9, 82.3) 98 (96.6, 98.9) 36.4 (17.2, 59.3) 99.1 (98.1, 99.7) 0.78 (0.64, 0.91) 
+: indicates that both markers are present; /: indicates that either marker is present, but does not need to be 
both. CI: 95% confidence interval; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver 
operating characteristic curve 
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The best combination of markers and proxies of infection for identifying the SSI diagnosed by the 
caesarean surveillance was:  
 
Any occurrence of: CRP >50mg/L or platelets >250x109/L  
AND either a wound or blood culture 
 
Time to Diagnosis  
 
To assess whether the syndromic algorithm would be useful in the early diagnosis of surgical site 
infections in this patient group, the time to diagnosis was investigated. This was to determine, if in 
practice, syndromic algorithms could have clinical benefits and applications. Of the 14 patients with 
an inpatient SSI diagnosis, two did not have any corresponding laboratory data and two had no date 
of clinical diagnosis recorded.  Therefore only ten patients could be investigated.  
I plotted the days on which a patient had a marker exceed the threshold value, or a wound or blood 
culture request. These are timelines, and provide a visualisation of the patterns in markers and 
proxies of infection. 
For the superficial infections, the average time till a clinical diagnosis of infection was made was 
seven days, although all but one infection were diagnosed within five days of the caesarean. Using 
the syndromic algorithm of SSI, the average time to diagnosis was 9.5 days and one patient would 
not have been detected as having an infection (Figure 6.24).  
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Figure 6.24: Time lines of superficial SSI diagnosis using proxies and markers of infection 
The SOLID vertical line indicates the day on which the SSI algorithm would have diagnosed the infection  
1 (ORANGE) = CRP >50; 2 (YELLOW) = Platelets >250; 3 (GREEN) = wound culture; 4 (BLUE) = blood culture 
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For the deep infections, one patient had only one occurrence of the white blood cell count 
exceeding the infection threshold, and therefore would not have been diagnosed using the 
syndromic algorithm. The average time to clinical diagnosis for patients with this type of infection 
was nine days. Using the syndromic algorithm this reduced to 8 days, demonstrating a one day 
advantage over the clinical diagnoses (Figure 6.25).  
 
Figure 6.25: Time lines of deep SSI diagnosis using proxies and markers of infection 
The SOLID vertical line indicates the day on which the SSI algorithm would have diagnosed the infection  
1 (ORANGE) = CRP >50; 2 (YELLOW) = Platelets >250; 3 (GREEN) = wound culture; 4 (BLUE) = blood culture 
 
 
 
 
 
For the single patient who had an organ space infection and laboratory data, they were clinically 
diagnosed on day 5 post-caesarean. They were classified as a re-admission case; however Figure 
6.26 would suggest that the patient had not been discharged from hospital prior to this diagnosis. 
Using the syndromic algorithm, the patient would have been diagnosed the day after their surgery, 
demonstrating a four day advantage over the clinical diagnosis.  
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Figure 6.26: Time lines of organ space SSI diagnosis using proxies and markers of infection 
The SOLID vertical line indicates the day on which the SSI algorithm would have diagnosed the infection  
1 (ORANGE) = CRP >50; 2 (YELLOW) = Platelets >250; 3 (GREEN) = wound culture; 4 (BLUE) = blood culture 
 
 
 
6.2.5 Applying the Syndromic Algorithms in Administrative Data 
 
Using the linked PAS and laboratory data from 2009 – 2010, I investigated how the syndromic 
algorithms fared in identifying those cases of SSI defined by ICD-10 codes. Again, as laboratory data 
were used, all these patients were based at Queen Charlotte’s Hospital. Of the cohort of 4,285 
patients, 1,235 (29%) of the patients had no laboratory data relating to them; the proportion of 
patients with no laboratory data was similar in those patients with and without ICD-10 codes for SSI 
(27%). The results of a comparison of the mean values for markers before and after caesarean and 
between patients with and without infection codes are presented in Table 6.16.  
 
Table 6.16: Summary of Routine Blood Tests Being Investigated for Developing Syndromic Surveillance 
 Pre caesarean Post caesarean 
Marker SSI No SSI SSI No SSI 
C-reactive 
Protein** 
(0 – 10 mg/L) 
5.1 – 28.1 (range) 
11.8 (mean) 
8.9 (median) 
8 (6%) (patients) 
0.2 – 145 
18.9 
12.0 
201 (5%) 
3.2 – 365.5 
105.4 
86.0 
43 (33%) 
1.5 – 325 
83.6 
61.3 
534 (13%) 
Eosinophils 
(0.0 – 0.4 x109/L) 
0 – 0.3 
0.08 
0.10 
33 (25%) 
0 – 0.8 
0.08 
0.10 
814 (19%) 
0 – 0.38 
0.11 
0.10 
93 (71%) 
0 – 1.2 
0.11 
0.10 
2839 (68%) 
Platelets* 
(120 – 400 x109/L) 
105 – 306 
210.6 
213.0 
33 (25%) 
32 – 489 
218.0 
211.0 
816 (19%) 
75.8 – 980 
242.7 
217.5 
93 (71%) 
60 – 564.9 
209.6 
203.6 
2841 (68%) 
*Significant in a t-test comparing the average post-operative values between infected and uninfected patients, 
with a p-value <0.0001 
**Significant in a t-test comparing the average post-operative values between infected and uninfected patients, 
with a p-value <0.05 
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Again the mean post-operative platelets had a highly statistically significant relationship with surgical 
site infections. In this group of caesarean patients, the mean post-operative CRP was also statistically 
significant between the infected and uninfected patients. On the whole, when compared to the 
mean values in the patients from the caesarean surveillance, these marker values were generally 
lower.  
The sensitivity, specificity, PPV and NPV when comparing the SSI cases created from the ICD-10 
codes with the syndromic algorithm were 22.1%, 96%, 14.6% and 97.5% respectively. The AUC for 
the syndromic algorithm in this patient population was 0.59 (0.56, 0.63).   
The syndromic case definitions did not perform as well in this cohort as they did when identifying 
the patients from the caesarean surveillance with an SSI. The number of patients identified using a 
combination of either CRP >50mg/L or platelets >250 x109/L and either a blood culture or wound 
culture request are summarised in Table 6.17.   
 
Table 6.17: Number of patients identified by the syndromic algorithms with an ICD-10 code  
 Algorithm negative Algorithm positive 
No ICD-10 Code 4,012 102 
ICD-10 Code 169 29 
 
 
Other HCAI within the administrative data 
 
ICD-10 codes were investigated for other common HCAIs in this patient group, to investigate how 
frequent other infections were following a caesarean section at Imperial College Healthcare NHS 
Trust (Table 6.18). 
  
Table 6.18: Summary of other HCAI codes in caesarean patients 
Infection Number of patients (%) Number with SSI codes 
Urinary tract infection 30 (0.69%) 2 
Pneumonia 6 (0.14%) 1 
C. difficile 1 (0.02%) 0 
Bloodstream infection 0 (0%) 0 
Sepsis 77 (1.8%) 8 
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There were 77 patients recoded with ‘sepsis’ codes, which included codes for infections with 
unspecified origins. UTI infections were relatively common in this patient group, with almost 1% of 
the patient cohort having a code for this condition, which would have been diagnosed during their 
admission. Other common HCAI however were extremely rare with only six pneumonia codes and 
one C. difficile code. Two patients of the 4,285 had the Y95 code indicating a nosocomial condition; 
both of these were in patients with a pneumonia code, suggesting the other 4 pneumonia diagnoses 
could have been community acquired.  
The results of comparing the syndromic case definition taking into consideration those patients with 
other HCAI diagnosed slightly improved the effectiveness of the syndromic algorithm definitions in 
detecting coded SSI (AUC 0.60). The PPV increased from 14.6% to 18% when patients with ICD-10 
codes for other infections were removed from the ‘uninfected’ group of patients.  
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6.3 Discussion 
 
In this chapter I have described the data from a surgical site infection surveillance study following 
caesarean section, investigated how administrative hospital data performs in identifying these 
infections and generated an algorithm from laboratory data for diagnosing these infections. During 
this process, several limitations and points of discussion were raised and these are set out below.  
 
Caesarean Surveillance Data 
 
The first point of discussion regarding the caesarean section surveillance data was the quality of the 
data. There were several examples of poor data quality, suggesting either the collection itself was of 
a low standard or the later transcription onto the electronic database introduced errors. It was more 
likely to have been the first explanation, due to the nature of the errors, such as recording the date 
of birth as the date of caesarean section (and thus as the new-born baby’s date of birth). Despite the 
cleaning of extreme values to remove all the obvious errors, it created doubt as to whether the data 
utilised for analyses was accurate. Unknown data quality is a hazard of working with secondary data 
that has not undergone rigorous validation and double entry and may as a consequence be a source 
of bias in my results. The main cause for concern for this chapter was the discrepancies in the 
duplicated variables regarding surgical site infections and the potential this had to reduce the 
accuracy of the findings from false classifications.    
The caesarean surveillance was carried out as part of an intervention study assessing the 
effectiveness of pre-operative antimicrobial wash cloths. As such, this was not a standardised 
national surveillance study, like the HPA SSI surveillance following coronary artery bypass graft, and 
the study protocol lacked some of this rigour. The post-discharge surveillance did not have a 
prescribed follow-up period for each patient but instead specified that surveillance would end with 
the community mid-wife’s final visit to the patient. Without a standard follow up time for each 
patient it was likely that late-onset infections or complications were not picked up. Again the issue of 
reliability of clinical diagnosis for surgical site infections also needs to be considered, as the lack of a 
definitive test for infection may have led to incorrect diagnoses.  
This was supported by the relatively low rate of SSI at ICHNT (5.3%) compared to a prior study 
carried out in the UK which included a longer post-discharge follow up (11.2%) (150). The overall SSI 
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rate from the entire intervention study (across the 14 showcase hospitals) was 9.6% (526). In this 
study, only 34% of women were followed up for the full standard duration of 30 days, with the 
ability to read English and ethnicity being significantly different in those women with short 
compared to long post-discharge follow up . At ICHNT, 25% of the surgical site infections diagnosed 
by the caesarean surveillance study occurred during the surgical admission or upon re-admission; in 
the overall study this dropped to 11% (526). This supports the suggestion that the rate of SSI seen at 
Imperial College Healthcare NHS Trust was underestimated, through incomplete or poor patient 
follow up in the community.  
The collection of the surveillance data relating to SSI was generally in the hands of the community 
midwife team and relied upon good communication and follow up between the hospital and the 
community healthcare teams. Anecdotally, it was noted that this process of patient follow up in the 
community was at times chaotic as several patients were not local to the area and were therefore 
being cared for by community midwives outside of the hospital’s normal catchment area. The 
method for diagnosing SSI was based on clinical criteria, such as fever or redness and swelling at the 
wound site. These data were collected either by the midwives or the nurses in the hospital, which 
may have affected the consistency of the diagnoses. The different types of data collectors would 
have had different degrees of medical training and experience with collecting surveillance data. 
There was no validation activities carried out for this study locally; therefor accurate SSI diagnoses 
were reliant on there being inherent consistency between the different data collectors.  
The caesarean surveillance, despite its various flaws, provided a clinically based data source with SSI 
diagnoses, taking post-discharge cases into account. This active follow up in the community is an 
inherent advantage of traditional surveillance systems which currently the electronic systems in NHS 
hospital could not compete with.  
 
Administrative data 
 
When the caesarean surveillance data were linked to the PAS data, several of the records were lost 
as they had no corresponding data in PAS. This comes back to the discussion that has been 
presented before in this thesis, of the lack unique and consistent patient IDs. In this chapter, the 
accuracy of the caesarean surveillance data were questionable, so it was possible that the hospital 
numbers or date of birth were recorded incorrectly and therefore the patients could not link. This 
explanation was supported by the fact that there were 110 patients in the PAS data with no 
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caesarean surveillance record, whereas there were only 30 patients with a caesarean surveillance 
record but no PAS record (Figure 6.7). However, there was also the possibility that the PAS data 
missed patients and so these unlinked patients may well have been unrecorded in the administrative 
data.  
There were two obvious issues with missing data once the datasets had been linked, firstly the lack 
of laboratory data relating to those patients at St. Marys hospital (SMH). At ICHNT, caesarean 
sections are performed at both SMH and Queen Charlotte’s Hospital. Approximately half of the 
caesarean surveillance patients were admitted to SMH and I could not include these in the analyses. 
The SMH laboratory data, despite being processed in the same laboratory as that from the other 
Imperial College Healthcare NHS Trust hospitals, is still entered and stored on a separate IT system, 
and as yet has not been synchronised with the rest of the ICHNT data. This limited the analyses as 
the power of the study was reduced by half. Increasing the number of patients in the study may 
have generated a more accurate syndromic algorithm.  Although interestingly, only four of the 18 
inpatient SSI recorded by the caesarean surveillance were diagnosed in patients from SMH, so only a 
small proportion of infections were lost as a result of this limitation.  
The second instance of missing data was the lack of radiology data. Following from the CABG 
analysis, which found radiology requests to be related to SSI diagnosis but ultimately poor proxy 
indicators of infections, it could be presumed that it would not be useful for this patient group 
either. However, as the nature of the procedures, the patient pathways and underlying condition of 
the patients were very different; the radiology data may have been a valuable proxy of SSI for this 
patient group.   
A quirk in the data for this group of patients was that some neonates were coded as having had a 
caesarean section. These patients were investigated further to determine if they were in fact women 
who had caesarean sections with the wrong date of birth recorded (such as was seen in the 
caesarean surveillance data). This was not the case as their method of admission was ‘babies born in 
the hospital’ and there were several males among this group. This highlights a potential problem in 
terms of the publicly reported numbers of procedures carried out each year, especially as ICHNT has 
one of the highest reported rates of caesarean sections in England (516). 
An interesting observation from the administrative data was a large increase in the number of 
caesarean procedures being carried out from May 2010 onwards. Possible oddities in the data were 
looked for however I could not find any explanations. This may be a reflection of improvements in 
the data recording or a change in local policy. This did not appear to have any effect on the number 
of SSI coded for each month in the ICD-10 codes (Figure 6.9), despite the incidence increasing by 1.4 
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infections / 100 procedures from 2009 to 2010. This sort of surveillance tool shows the advantages 
of using the administrative data for monitoring changes in practice or the effects of caseloads over 
time. 
  
Syndromic Surveillance 
 
The syndromic algorithms I generated for identifying SSI following caesarean section did not perform 
as well as those in the CABG patients, with the final algorithm having a sensitivity of 64% and 
specificity of 93%. The first limitation in this patient group was the lack of laboratory requests and 
results for all patients. As the majority of the procedures were emergency and length of stay in 
hospital following the surgery was generally very short (average of 3 days), fewer patients had fewer 
laboratory results to investigate. Added to the fact that most infections were diagnosed after 
discharge, the utility of syndromic surveillance in this patient population is questionable.  
Prior uses of biological markers for the diagnosis and early detection of surgical site infections has 
been discussed previously (section 5.3.2). Briefly, markers have been successfully used to identify 
post-surgical infectious complications following several different procedure types (Table 5.27); 
however none of these studies investigated pregnant women or caesarean sections. A search of the 
literature for articles relating to SSI following caesarean section and biological markers of infection 
returned no results.  
A factor that may have caused difficulties in using markers of infection in this patient group was the 
effect of pregnancy on biological markers. A published laboratory guideline for pregnancy suggested 
that the normal ranges for CRP (0.4 – 8.1 mg/L) and eosinophils (0.0 – 0.6 x109/L) do not change a 
large amount in pregnancy, but platelet levels are slightly increased (126 – 429 x109/L) (528). The 
results in this chapter did not necessarily reflect these ranges as the best threshold value for 
infections in platelets was >250 x109/L, lower than that used in the general patient population. 
Similarly, for eosinophils the threshold used was >0.15 x109/L, again lower than the general patient 
population, despite the wider normal range seen for pregnant women. The use of biological markers 
to indicate infections for this patient group may not have been appropriate, both due to the lack of 
available information and the unclear relationships between the markers, pregnancy, surgery and 
infection.  
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Further work in developing innovative surveillance for surgical site infections in this patient group 
may be better spent investigating antibiotic prescription data, both within the hospital and primary 
care settings. An example in the UK where primary care records have been electronically linked to 
hospital data is the Hampshire Health Record (529), and this data resource has been used to 
investigate post-operative infections in the community using general practice records, antibiotic 
prescriptions and hospital data (530). This system would be more appropriate for the surveillance of 
surgical site infections in caesarean section patients than syndromic surveillance based on hospital 
laboratory data, as the majority of these infections occur and are managed in the community.  
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6.4 Conclusion 
 
In the UK currently, there is no permanent surveillance programme in place for monitoring surgical 
site infections following caesarean sections. In light of the increasing numbers of these procedures 
being carried out and the recent changes in the NICE guidelines, this group of patients warranted 
investigation for novel electronic surveillance tools. However, the majority of SSI were diagnosed 
during post-discharge follow up and were treated in the community, reducing the potential for 
administrative hospital data to be used for comprehensive surveillance. Due to the nature of this 
patient group being mostly emergency procedures and lacking routine laboratory tests, syndromic 
surveillance was not necessarily appropriate as a surveillance method. However, tools such as the 
SPC chart provided an electronic method for monitoring changes in trends, and generating alerts 
based on the administrative data.  
Investigating the potential for linking hospital administrative data with primary care data, especially 
antibiotic prescriptions, could yield an efficient, sustainable surveillance system for this patient 
group.   
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Chapter 7: Electronic, Automated Surveillance of Urinary Tract Infections 
 
 
Summary 
 
This chapter investigates the use of routine electronic laboratory data (specifically microbiology 
data) for automated case detection of healthcare associated urinary tract infections. It is the second 
type of innovative surveillance method to be investigated within the routine hospital data available 
for this study. It has the potential to generate passive electronic surveillance for the healthcare 
associated infection with the largest associated burden at ICHNT.  
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7.0 Introduction 
 
Urinary tract infections (UTIs) constitute all infections occurring in the urinary tract, including cystitis 
(lower urinary tract) and pyelonephritis (kidney infection). UTIs are one of the most common 
bacterial infections occurring both within the community and the hospital environment. Whilst most 
infections are uncomplicated and can be treated with a short course of antibiotics, complications 
such as secondary bacteraemias can occur as a result of a UTI. In a recent point prevalence survey of 
healthcare associated infections, 20% of non-venous catheter related bloodstream infections in 
England were a result of a urinary tract infection (3).  
Within the healthcare setting, healthcare associated urinary tract infections (HCA UTI) result in 
longer hospital stays and thus exposing a patient to further risks of HCAI. The traditional surveillance 
definitions used for HCA UTI in Europe require the patient to have clinical symptoms (2). The 
reasoning for this is that asymptomatic bacteruria (the presence of bacteria in the urine in the 
absence of any infection symptoms), can occur despite the patient not having a clinically relevant 
infection. The CDC definition on the other hand includes asymptomatic bacteruria as a third category 
of UTI infection (531). In this chapter, when I talk about urinary tract infections in the methods and 
results, this technically refers to bacteruria, as there is a lack of clinical information to distinguish an 
infection from the presence of bacteria in the urine.  
HCA UTI constitute a significant burden to healthcare services globally (532) with the NHS incurring 
an estimated 66,160 cases every year, costing £68 million in excess bed days (533). In the 2006 UK 
and Republic of Ireland prevalence survey of healthcare associated infections, UTI accounted for 
19.9% of HCAI, second in frequency only to gastrointestinal infections (20.6%) (8). In the most recent 
European point prevalence survey (refer to Chapter 4), 3% of the whole patient population surveyed 
locally at Charing Cross Hospital had a HCA UTI (Figure 7.0). It was the most commonly diagnosed 
healthcare associated infection, accounting for 37% of the HCAI locally. However, nationally the 
proportion of HCAI accounted for by UTI was 17.2% (3), a decrease on that found in 2006 and half 
that of the local survey.  
At Imperial College Healthcare NHS Trust, the point prevalence survey found that a quarter of the 
patient population (24.5%) had a urinary catheter on the day of data collection (Figure 7.1). The high 
rate of UTI within hospitals is commonly attributed to the use of urinary catheters, and the review 
presented in chapter 3 confirmed urinary catheterisation as the HCA UTI risk factor with the highest 
associated PAR% (section 3.2.1). In 2006 it was found that 18.8% of the patient population in 
England have a urinary catheter on a given day (277); this figure remained  the same in 2011 (3).  
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Figure 7.0: Types of healthcare associated infections diagnosed at Charing Cross Hospital, September 2011 
 
 
Despite the key role of catheters in healthcare associated urinary tract infections, only half the HCA 
UTIs at Charing Cross were associated with a urinary catheter. Similarly for the England prevalence 
data, only 43% of HCA UTI were attributed to a urinary catheter (3).  This suggests that while urinary 
catheters have been the focus of interventions for reducing HCA UTI, there needs to be further 
investigation into those patients with non-catheter associated infections.  
 
Figure 7.1: Proportion of patients with invasive devices at Charing Cross Hospital, September 2011 
 
 
Surveillance of catheter associated urinary tract infections in England is now performed as part of 
the ‘Safety Thermometer’, an initiative launched by the UK Department of Health in January 2011 to 
reduce patient harm (469). However, despite the high burden that HCA UTI represents to the NHS, 
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this surveillance scheme is voluntary, focuses exclusively on CA-UTI and is still in its infancy. At 
ICHNT, a pilot was carried out for this system in April 2012 with a full roll out of the safety 
thermometer scheme panned to begin across the Trust in July 2012. The potential utility of 
innovative HCA UTI surveillance tools is apparent. Recently published literature relating to HCA UTI 
surveillance has focussed on developing automated systems to identify UTI using traditional clinical 
surveillance definitions (92). 
 
7.0.1 Aim and Objectives 
 
The aim of this chapter was to examine the utility of routine electronic laboratory data for the 
development of an automated urinary tract infection case detection surveillance tool. 
There were three specific objectives for this chapter, firstly to refine the definitions of a healthcare 
associated UTI ‘case’ (including catheter associated infections) and assess how they would be 
diagnosed within the routine electronic data in the absence of clinical information. The second was 
to describe the data and provide a basic epidemiological analysis using the information which was 
readily available. Finally, to compare and contrast an automated case detection surveillance tool for 
HCA UTI based on the laboratory data, with other administrative data. 
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7.1 Methods 
 
7.1.1 Data Cleaning, Linkage and Management 
 
The data I used for this chapter consists of six months of the full microbiology data (including culture 
results) from 1st September 2011 – 6th March 2012, linked to the PAS data. The PAS and microbiology 
data were linked using a deterministic approach, with no restriction by date. Once linked, the 
incorrect matches (i.e. those where the date of sample collection fell outside of the dates of 
admissions and discharge) were removed.   
I received both the PAS and microbiology data in a ‘long’ format, with each individual microbiology 
culture having up to 10 records. Each microbiology record contained a different aspect of the result 
(i.e. sample type, organism, and colony count). I re-shaped the data into a wide format, where a 
single record included all relevant episodes for one admission and all the corresponding 
microbiology cultures for that patient.  
In order to determine if a patient and their corresponding urine culture could be classified as 
‘healthcare associated’, a series of variables were generated (Table 7.0). These determined whether 
a urinary tract infection could be attributable to healthcare or the community.  
 
Table 7.0: Derived variables used to determine attributability of urinary tract infections  
Variable Definition 
Re-admission 
Binary variable indicating whether the patient had been discharged from ICHNT 
within the previous 48 hours, or had been admitted from healthcare (using the 
‘method of admission’ variable in the PAS data  
>72 hour admission Using the date of admission and date of culture sample collection, a binary variable was creating indicating if a urine culture was collected after 72 hours of admission 
Catheter 
 Using the ‘sample type’ from the microbiology data and ICD-10 and OPCS codes 
from the PAS data, a binary variable was created indicating if any catheters had been 
recorded for that patient during their admission (see Table 7.3) 
Healthcare associated The three variables above were combined to create a binary variable indicating if any of the three criteria had been met.  
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7.1.2 Defining and Extracting Patients with UTI 
 
The case definitions currently used in the UK for diagnosing HCA UTI are those set by the European 
Centre for Disease Control (Table 7.1) (2).  As standard with healthcare associated infections, a 
positive diagnosis cannot be made until the third day of the patient’s admission, unless they have an 
invasive device in place or qualify as a re-admission. The guidelines produced for the recent 
European-wide point prevalence survey classified re-admission for urinary tract infections as a 
patient that had been discharged from hospital within the previous 48 hours, and I used this for my 
initial draft definition.  
 
Table 7.1: ECDC definition of HCA UTI  (2) 
Infection Type Clinical Symptoms Pathology  Other 
UTI-A: 
microbiologically 
confirmed 
symptomatic UTI 
At least ONE of: fever 
(>38°C), urgency, 
frequency, dysuria, 
suprapubic tenderness 
Positive urine culture with ≥105 
microorganisms /ml of urine and 
no more than 2 species 
 -  
UTI-B: not 
microbiologically 
confirmed 
symptomatic UTI 
At least TWO of: fever 
(>38°C), urgency, 
frequency, dysuria, 
suprapubic tenderness 
ONE of: positive dipstick for 
leukocyte esterase and/or nitrate 
OR pyuria specimen with ≥10 
WBC/ml OR organisms seen on 
gram stain OR two urine cultures 
with the same pathogen with 
≥102 colonies/ml 
Or ONE of: Physician 
diagnosis 
Physician prescription 
of antimicrobial for UTI 
 
A third classification, UTI-C – asymptomatic bacteriuria, was excluded from the point prevalence 
survey, as only symptomatic infections were considered as positive. However, as I do not have 
access to clinical information I cannot distinguish between this and UTI-A. Based on the standardised 
definitions set out above and the limits of the data which were available for this project, the starting 
point for a definition of UIT for classifying patients with HCA UTI are presented in Table 7.2. These 
are draft definitions, which were refined or amended, based on the information routinely stored and 
collected in the microbiology database.  
In order to distinguish those infections which could be ‘catheter associated’, a catheter variable was 
generated using both PAS and microbiology data. In the microbiology data, the sample description is 
recorded which captures whether the urine sample was from a urine drainage bag or urinary 
catheter; this was turned into a binary code. Similarly for the ICD-10 and OPCS codes, the presence 
of a relevant catheter code was turned into a binary variable (Table 7.3).  
 
 230 
 
Table 7.2: Draft automated electronic HCA-UTI case definitions 
Probable Case 
Positive urine culture with ≥105 microorganisms /ml of urine and no 
more than 2 species 
Possible Case 
Positive dipstick for nitrate 
OR 
Urine specimen with ≥10 WBC/ml 
OR 
Organisms seen on gram stain 
OR 
Two urine cultures with the same pathogen with ≥102 colonies/ml 
OR 
Identified named pathogen with no colony count 
 
 
Table 7.3: ICD-10 and OPCS codes for urinary catheterisation 
ICD-10 codes 
T830 Mechanical complication of urinary (indwelling) catheter 
Y846 Urinary catheterisation 
OPCS codes 
M471 Catheterisation of bladder: urethral irrigation 
M472 Catheterisation of bladder: change of urethral catheter 
M473 Catheterisation of bladder: removal of catheter 
M478 Catheterisation of bladder: other specified 
M479 Catheterisation of bladder: unspecified 
 
Classifying urine cultures and patients both as having a positive culture and this being healthcare 
associated was done in three stages. First, urine cultures were classified as positive or negative. 
Then, patients were classified as having positive or negative cultures, taking into account whether 
they had been appropriately linked to a PAS record. Finally, positive patients were classified into 
healthcare (and a further category of catheter-associated) or community associated categories.  
 
7.1.3 Descriptive Analysis  
 
An epidemiological analysis of patients with HCA UTI, community acquired UTI and the general 
patient population using simple descriptive statistics was carried out. This included looking at the 
causative organisms of infection, methods of admission, demographic characteristics and specialty. 
Odds ratios and rates of infections were calculated for different patient characteristics, such as 
gender and specialty. A comparison of the incidence of infections diagnosed with the automated 
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case detection and the prevalence of HCA UTI identified in the PPS was done to quantify the 
accuracy of using automated case detection as a method of surveillance.  
 
7.1.4 Comparing Microbiology and Administrative Data  
 
The number of HCA UTI detected using automated case detection in the microbiology data were 
compared to the number of cases identified using ICD-10 codes from the PAS data. The codes used 
to define a urinary tract infection from the diagnosis codes are presented in Table 7.4.  
 
Table 7.4: ICD-10 codes used to define UTI from the PAS data 
ICD-10 code ICD-10 translation 
N10 Acute tubule-interstitial nephritis 
N11 Chronic tubulo-interstitial nephritis 
N12 Tubulo-interstitial nephritis, not specified as acute or chronic 
N15 Other renal tubule-interstitial diseases 
N30 Cystitis 
N34 Urethritis and urethral syndrome 
N390 Urinary tract infection, site not specified 
 
These codes were considered as relevant for a HCA UTI when they occurred in any diagnosis field, 
except the primary diagnosis. The primary diagnosis is meant to indicate the condition with which 
the patient was admitted, therefore a UTI code in this field should indicate a community acquired 
urinary tract infection. The exception to this was for re-admissions. I deemed the primary diagnosis 
field in a re-admission episode as relevant for a HCA UTI diagnosis in the PAS data. Any patient that 
had the Y95 ICD-10 code, indicating a nosocomial condition, was also classified as having an HCA UTI 
instead of a community acquired infection.  
 
 
 
 
 
 
 232 
 
Figure 7.2: Summary of the methodological steps in chapter 7 
 
  
PAS + Microbiology data (Sept 2010– Mar 
2011): 
Linkage & Cleaning 
PAS + Microbiology data (Sept 2010– Mar 
2011): 
Refining ‘cases’ definitions and extracting 
cases within microbiology 
PAS + Microbiology data (Sept 2010– Mar 
2011): 
Epidemiological description of the data 
PAS + Microbiology data (Sept 2010– Mar 
2011): 
Comparing microbiology based ‘cases’ to 
ICD-10 codes based ‘cases’ 
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7.2 Results 
 
7.2.1 Refining the UTI Case Definition and Extracting Patients 
 
Within six months of microbiology data (from September 2011 – March 2012) a total of 11,406 urine 
cultures were ordered for 6,480 patients. There were 37,662 admission records in the PAS data 
during the corresponding time period.  
 
Identifying Positive Cultures 
 
After investigating the electronically available microbiology data, I refined the case definitions for 
HCA UTI (Table 7.5). The major alteration was removing the criterion of a positive dipstick for 
nitrates as this was not reported in the microbiology data. However, the presence of frank pus in the 
urine was reported, which could also indicate an infection and so this was included in the case 
definitions.  
 
Table 7.5: Revised UTI ‘case’ definitions for use at ICHNT 
Probable Case 
Positive urine culture with ≥105 microorganisms /ml of urine and no 
more than 2 species 
Possible Case 
Urine specimen with ≥10 WBC/ml 
OR 
Organisms seen on gram stain 
OR 
Two urine cultures with the same pathogen with ≥102 colonies/ml 
OR 
Identified named pathogen with no colony count 
OR 
Frank pus seen on microscopy 
 
There were several other types of results reported from the WBC gram stains and direct microscopy 
which were not used for the case definitions. These included casts (tube shaped structures made up 
of cells), the presence of red blood cells and crystals (e.g. calcium oxalate). These were not included 
in the definitions as they were either too rare to add much value or could be easily misinterpreted. 
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For the positive urine cultures with ≥105 microorganisms per ml, up to two named organisms was 
considered positive, despite the mixed growth. However only those results with one named 
organism were classified as a positive where the quantity of isolated organisms was between 102 – 
105 organisms/ml. The overlap between the different methods of diagnosing a positive culture is 
represented in Figure7.3.  
 
Figure 7.3: Venn diagram of the number of positive urine cultures identified using the various criteria 
 
 
Additional notes could also be stored as free text, such as details of antibiotic resistance or the 
inappropriateness of the sample. I categorised and coded these notes and took them into 
consideration when classifying a urine culture as positive or negative. This step adds a level of 
complexity to the system of automation. When all the results relating to individual cultures were 
taken into account, several contradictions were observed within the results for individual urine 
cultures (Table 7.6).  
Further to this, 144 cultures (1.3% of the samples) did not have any result to report, be it negative or 
positive, due to clerical errors relating to the samples (e.g. unlabelled or leaking).  These were 
recorded as ‘negative’ for the analyses.  
 
 
≥105 organisms/ml 
(total 1,507)
10
≥102 
organisms/ml
(total 2,042)
478
>10 WBC/ml 
(total 1,224)
866
277 
7 
74 
1,213 
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Table 7.6: Discrepancies in Positive and Negative indications 
Negative result 
indication ≥10
5 organisms /ml ≥102 organisms /ml >10 WBC /ml 
No growth 1 2 - 
Mixed growth 17 26 - 
Colonisation 4 5 - 
Gram stain negative - - 11 
<10 WBC/ml - - 10 
 
 
Identifying Positive Patients 
 
There were 6,480 patients who had a urine sample sent to the laboratory during a six month period. 
The most urine cultures performed for one patient during this time period was 22, with the average 
being 1.8 per patient; 63% of patients in this cohort only had one urine culture taken.   
To take into consideration the length of stay in hospital, catheters and re-admissions (to determine if 
the culture qualified as being ‘healthcare associated’), the microbiology data had to be linked to a 
relevant PAS record.  In this process, 1,934 of the original 11,406 urine culture requests could not be 
linked to a patient in the PAS system (17%). This corresponded to 1,474 patients and therefore the 
total number of patients with a PAS record and urine culture was 5,006. Removing those PAS records 
which had been incorrectly linked left 3,443 patients with a urine culture and correctly linked PAS 
record. There were 3,964 admissions related to these patients, during which 5,948 urine cultures 
were requested. The most cultures in one admission reduced to 19 for a single patient. There were 
29,134 patients in the general patient population for this time period, who had not had a urine 
culture.  
Amongst those correctly linked patient admissions with a urine culture, there were 1,197 patients 
with a positive urine culture.  
 
Identifying Positive Healthcare Associated Infection Patients 
 
 The patients were then categorised into ‘community’, ‘healthcare associated’ and ‘catheter’ 
categories for the subsequent analyses. Of the patients with urine cultures 54% (1,852) qualified as 
having a healthcare associated urine cultures, as they were either in hospital for three or more days, 
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had been in hospital in the prior 48 hours, or had a catheter. This left 1,591 patients with community 
related urine cultures. Figure 7.4 presents the number of patient admissions associated with the 
different HCA criteria.  
 
Figure 7.4: Flow chart of patients with urine cultures included for analysis. Patients could be included in more 
than one HCA criteria, and this included both positive and negative urine cultures. 
 
 
Of those patients with urine cultures, who met the various HCA or community acquired criteria for a 
urinary tract infection, 1,158 had at least one positive urine culture. There were 636 patient 
admissions with HCA UTI and 522 with community acquired UTI during a six month period at ICHNT. 
Almost 2/3 of these positives were diagnosed with the criteria of a named organism with >105 
colonies/ml.  
 
7.2.2 Descriptive analysis 
 
Of the 3,443 patients with urine cultures, 57% were women. Age was only recorded for 18% of the 
patients; of those with age, the youngest was 17 and the eldest 98. Almost two thirds of patients 
were white (63%), with black (13%) and Asian (12%) ethnicities being the next most common. This 
was not reflective of the general population within the borough of Hammersmith and Fulham, as the 
general population has a higher proportion of white people (www.lbhf.gov.uk). Over half the 
patients were married and a third were single. 82% of patients classified themselves as Christian, 
followed by Muslim (6%).  
Below are comparisons between the types of patients who were found to have positive urine 
cultures versus negative urine cultures, those with community and healthcare associated infections, 
Urine Cultures: 11,406
Patient admissions with relevant PAS for the Urine Culture: 3,964
Patient admissions with urine cultures meeting HCA 
requirements : 1,996
Catheters: 996 Re-admissions: 46 Admission for ≥72 hrs: 1,489
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those with catheters and without and finally between those patients with urine infections and the 
general patient population. A summary of the number of patient admissions in each comparison 
group is presented in Table 7.7.  
 
Table 7.7: Number of patient admissions according to infection and patient type 
Patient type Positive Culture Negative Culture No Culture 
Healthcare Associated 636 1,360 n/a 
       Catheter Associated 346 650 n/a 
Community 522 1,446 n/a 
General population n/a n/a 29,134 
 
Positive versus Negative HCA Urine Cultures 
 
More women than men had urine cultures taken, however there was no difference in the proportion 
of these that were positive according to the patients’ sex (Figure 7.5).  
 
Figure 7.5: Patients with positive and negative healthcare associated urine cultures, according to sex 
 
  
The type of admission was recorded for all patients, with the most common admission type in this 
patient group being emergency admissions (Figure 7.6). A few ‘day case’ patients qualified as being 
‘healthcare associated’ (1.5%), as they either had a catheter in place or had been in the hospital 
within the previous 48 hours of their current admission. The proportion of patients with positive 
urine cultures was significantly higher for emergency patients (OR: 1.85; CI: 1.42, 2.41; p-value: 
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<0.001), day case patients (OR: 3.10; CI: 1.40, 6.88; p-value: 0.005) and non-elective patients (OR: 
1.60; CI: 1.06, 2.41; p-value: 0.025), when elective admission was the reference group.  
 
Figure 7.6: Proportion of patients with positive healthcare associated urine cultures, according to admission 
type 
 
 
Out of this group of patients, 2.7% were private or overseas patients. There was no difference in the 
likelihood of a culture being positive between private or NHS patients.   
The average length of stay for patients with a positive urine culture was 34 days, compared to 20 
days for those patients with a negative urine culture. The maximum stay was 311 days and this was 
for a patient with a negative urine culture. This difference in total length of stay was significant, with 
the odds of having a positive culture increasing by 1.06 for every extra day the patient was in 
hospital (p-value: <0.001). Length of stay however is also an outcome, not just a risk, therefore this 
relationship needs to be interpreted with caution.   
Whether the patient had died during their hospital admission was also recorded in the PAS data; this 
can be considered an outcome variable, related to HCA UTI, although not exclusively causative. 
Among the 1,852 patients who qualified as ‘healthcare associated’, 313 (17%) died. The number of 
patients with positive urine cultures who died was higher than those with negative cultures (Table 
7.8). The odds of dying were 1.4 times higher in those with a positive urine culture compared to a 
negative urine culture (p-value: 0.009).  
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Table 7.8:Number of patients who died and had a positive culture 
Urine Culture Died Survived 
Positive 113 482 
Negative 200 1,198 
 
Clinical Programme Group, or CPG (a local variable indicating the patient’s broad specialty), and 
admission method had very limited information collected, as with age. Instead, procedure codes 
were used to classify patients into groups of specialties. A third of the patients had no procedure 
codes, suggesting they were medical patients instead of surgical. 15% of the patients’ main 
procedure codes were for diagnostic imaging, 8% were miscellaneous procedures and 7% were 
urinary operations.  Of those with positive cultures, the most common classes of procedure were 
urinary, diagnostic imaging and heart procedures (Figure 7.7).  
 
Figure 7.7: Primary Procedure for patients with a positive healthcare associated urine culture  
 
 
The most commonly isolated organisms among the positive healthcare associated urine cultures 
were: E. coli (28%), unspecified species of yeast (19%) and unspecified Enterococcus species (12%). A 
total of 557 of the 636 patients with an HCA UTI (88%) had a named organism. Six patients had three 
different organisms named, all of which had >105 colonies /ml. There was one culture from which 
MRSA was isolated, from a catheterised male who was admitted to the hospital for over a month.  
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Community versus Healthcare Associated 
 
There were 1,158 patient admissions with positive urine cultures, 55% of which were healthcare 
associated and 45% community associated. In this section I have investigated whether the patients 
with community acquired infections were different from those who had a healthcare associated 
infection. In the analyses healthcare associated urinary tract infection was the outcome (or 
dependent) variable, with community acquired UTI acting as the control.  
There was a statistical difference in the sex of the patients, with females less likely to have a HCA UTI 
than a community acquired UTI (OR: 0.67; CI: 0.52, 0.83; p-value: 0.001) This means that men were 
at a higher risk of contracting healthcare associated infections, despite having less infections overall 
than women (Figure 7.8). This is a reflection of the fact that in the community UTI are much less 
frequent in men than women.  
 
Figure 7.8: Percentage of patients with HCA and community UTI, according to sex 
 
 
Unsurprisingly there were lots more patients with community infections amongst the day case 
patients (Table 7.9). Elective patients also had very few community infections, but were the 
admission group with the second highest proportion of healthcare associated urinary tract 
infections. A reason for this may be that elective patients would not come in for an elective 
procedure if they were unwell as it would put them at a higher risk of operative and post-operative 
complications.  
 Using elective admissions as the reference category in a logistic regression, being a day case (OR: 
0.05; CI: 0.02, 0.09; p-value: <0.001) or non-elective admission (OR: 0.35; CI: 0.21, 0.58; p-value: 
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<0.001) both decreased the likelihood of having a healthcare associated UTI compared to a 
community acquired infection. However, there was no difference for emergency admission patients.  
 
Table 7.9: Type of admission according to UTI type 
Admission Type Community UTI Healthcare Associated UTI 
Day case 117 12 
Elective 91 131 
Emergency 243 469 
Non-elective 68 54 
 
As patients with community acquired urinary tract infections are likely to present at hospital 
because of the infection, or related conditions (e.g. falls are associated with having a UTI), the main 
procedure codes of these patient groups would be expected to differ. Table 7.10 presents the 
number of patients according to their main procedure code, and the percentage of which had HCA 
UTI. Urinary procedures were more common amongst patients with community acquired infections; 
respiratory and bone procedures were far more prevalent in patients with HCA UTI.  
 
Table 7.10: Primary procedure codes for all patients with positive urine cultures 
Main Procedure Number of patients (% with HCA UTI) 
Neural 26 (77%) 
Respiratory 25 (92%) 
Digestive System 41 (73%) 
Heart 34 (74%) 
Arteries & Veins 33 (55%) 
Urinary 200 (33%) 
Pregnancy 41 (56%) 
Skin & Soft tissue 31 (84%) 
Diagnostic imaging 157 (66%) 
Bone 27 (89%) 
Miscellaneous 102 (44%) 
Other 23 (61%) 
No procedure 418 (52%) 
All patients with positive urine cultures 1,158 (55%) 
 
The length of stay was very different for those patients with community associated versus HCA UTI, 
with average stays of 3.3 days and 31 days respectively (p-value: <0.001). Of the inpatient deaths 
amongst those patients with a positive urine culture, 90% occurred in those patients with HCA UTI. 
Patients with healthcare associated urinary tract infections were 9.1 times more likely to die in 
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hospital than those patients with a community acquired urinary tract infections (CI:5.07, 16.35 ; p-
value: <0.001). 
Of the 1,158 positive urine cultures in the community and healthcare associated patients, 81.5% 
(944) had a named organism. Only healthcare associated cultures had more than one organism 
grown with sufficient colony counts not to be considered contamination. This relationship was 
significant, with the odds of an infection being HCA instead of community acquired increasing by 
1.67 (95% CI: 1.46, 1.92; p-value: <0.001) with the growth of a second organism grown.  
Whilst E. coli was the most common organism isolated from both community (36%) and healthcare 
associated cultures (25%), the proportion was much higher for community associated infections and 
this difference was significant (OR:0.60; 95% CI: 0.47, 0.77; p-value: <0.001). Similarly, Enterococcus 
infections were more common in the community associated patients, than healthcare associated. Of 
interest were the large numbers of fungal infections amongst the healthcare associated patients 
(21%) compared to the community associated infections (5%). The odds of an infection being 
healthcare associated if a fungal pathogen was isolated were 5.80 times higher (95% CI; 3.70, 9.11; 
p-value: <0.001). An overview of the pathogens isolated for both patient groups is presented in 
Figure 7.9. 
 
Figure 7.9: Isolated organisms for healthcare associated (HCA) and community associated (CA) UTI 
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Catheter associated versus non-catheter associated HCA UTI 
 
Of the 636 patient admissions with an HCA UTI, 346 (54%) had a urinary catheter code. Again, similar 
to the relationship between infection and sex seen in the community versus HCA UTI, being female 
reduced the likelihood that the HCA UTI was associated with a catheter (OR: 0.59; CI: 0.43, 0.81; p-
value: 0.001). Despite there being more infections among females overall, having a catheter was not 
a risk for women, in men however, as they are less prone to UTI, they were 1.69 times more likely to 
have a catheter related infection than a non-catheter related infection.   
 
Figure 7.10: Number HCA UTI patients with and without catheters, according to type of admission 
 
 
There was no statistical difference in the types of admission between patients with catheters and 
those without catheters (Figure 7.10). There appear to be more emergency admissions among those 
patients with catheters, but this was not significant (OR: 1.27; CI: 0.81, 1.99; p-value: 0.295).  
A third of these patients had no procedure recorded; the most common procedure type was 
diagnostic imaging for both catheterised and un-catheterised patients. The only procedure types 
with a significant difference between patients with and without catheters were neural procedures 
(OR: 4.11; CI: 1.33, 12.7; p-value: 0.014) and urinary procedures (OR: 2.01; CI: 1.12, 3.58; p-value: 
0.018).  
Despite all the patients having a healthcare associated infection, their outcomes (length of stay and 
death) were significantly different in those with and without catheters. The average length of stay 
was 26 days for patients without catheters and 38 days for those with a catheter (p-value: <0.001). 
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There were 120 (19%) deaths among the patients with HCA UTI; of the patients that died 64% had 
catheters (Figure 7.11). This was understandable as the number of patients with catheters is much 
higher on ICU and HDU wards, where the number of deaths would be expected to be higher than on 
general wards. The odds of dying in hospital were 3.9 times higher in those patients with catheters, 
than those un-catheterised patients with a HCA UTI (CI: 2.67, 5.60; p-value: <0.001).  
 
Figure 7.11: Number of patients with HCA UTI that died, according to catheterisation status 
 
 
Again, the most common pathogen was E. coli, with 21% of catheter associated infections and 29% 
of non-catheter infections being attributable to this organism; this difference was not significant.  
 
Figure 7.12: Isolated organisms for catheter associated and non-catheter associated HCA UTI 
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Different species of yeast, including C. albicans, were more common in patients with catheters (24%) 
than those without (16%). This was statistically significant relationship, with an odds ratio of 1.73 
(95% CI: 1.17, 2.55; p-value: 0.006). Having an infection caused by a pseudomonas species, including 
P. aeruginosa, was 2.34 (95% CI: 1.31, 4.19; p-value: 0.004) times more likely in a patient with a 
catheter than one without. This type of organism was responsible for 5.9% of infection in patients 
without catheters, but 11% of infections in those with catheters. Of those patients with a catheter 
related infection, only 10% of patients did not have a named causative organism.  
 
HCA UTI versus general patient population 
 
This section compares those patients with HCA UTI to the general patient population, specifically 
those patients that did not have a urine culture performed, and are thus assumed to not have a UTI 
or at least any symptomatic indication for a urine culture. The number of patient admissions in the 
general patient population during this time period was 29,134.  
Men were 1.18 times more likely to have an HCA UTI at ICHNT (p-value: 0.041), than women. In the 
general patient population, 57% were women compared to the 53% of HCA UTI patients; therefore 
despite females having more infections than men, the proportion amongst men was higher (Figure 
7.13).  
Figure 7.13: Number of HCA UTI according to gender in the general patient population 
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In the general patient population, the most common type of admission was a ‘day case’ admission 
(34%), which was unsurprisingly the least common in HCA UTI patients. Using elective admissions as 
the reference category, both emergency and day case admissions had a significant relationship with 
having an HCA UTI. Being a day case patient was protective (OR: 0.06; CI: 0.03, 0.11; p-value: 
<0.001), while emergency admissions increased the risk of HCA UTI (OR: 3.53; CI: 2.81, 4.34; p-value: 
<0.001).  
Having a code for either diagnostic imaging procedures or urinary tract procedures were the only 
two procedure types in which the percentage of HCA UTI patients increased (Table 7.11). In this 
patient cohort, 4.2% of patients were private and 0.1% was classified as overseas patients; the 
remaining 95.7% of patient’s received standard NHS care. When compared, being a private patient 
was protective against contracting a healthcare associated urinary tract infection, with  NHS patients 
2.1 times more likely to contract this type of  infection (OR: 0.47; 95% CI: 0.27, 0.82; p-value: 0.007).  
 
Table 7.11: Primary procedure code for all patients 
Main Procedure Number of patients (% with HCA UTI) 
Neural 603 (3.3%) 
Endocrine 342 (0.8%) 
Respiratory 836 (2.8%) 
Digestive System 1,345 (2.2%) 
Heart 1,310 (1.9%) 
Arteries & Veins 963 (1.9%) 
Urinary 1,524 (4.3%) 
Female genital tract 1,206 (0.7%) 
Pregnancy 1,570 (1.5%) 
Skin & Soft tissue 760 (3.4%) 
Diagnostic imaging 1,831 (5.7%) 
Bone 1,128 (2.1%) 
Miscellaneous 8,941 (0.5%) 
Other 313 (0.6%) 
No procedure 7,098 (3.1%) 
All patient admissions 29,770 (2.1%) 
 
The length of stay for the general patient population was only two days on average, compared to the 
31 days of a patient with a HCA UTI (p-value: <0.001). If the day case patients were removed from 
this cohort, the average length of stay increased from two to six days for the general patient 
population, and to 32 days for those with an HCA UTI. This remained a statistically significant 
difference. The inpatient death rate amongst the general patient population was 4%, much lower 
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than the 19% seen in those patients with HCA UTI. The odds of dying were 5.48 (CI: 4.45, 6.75; p-
value: <0.001) higher in patients with a HCA UTI.  
 
Prevalence and Incidence 
 
Based on the results from the point prevalence study carried out at Charing Cross Hospital in 
September 2011, the prevalence of HCA UTI was 3.2% and catheter associated UTI was 1.1%. In this 
chapter however, the rate of HCA UTI was presented as an incidence, with the incidence for all HCA 
UTI being 1.9/100 admissions, and 1.1/100 admissions for catheter associated UTI. 
In order to compare these two values, so a judgement can be made on how well an automated 
microbiology based system would be at capturing cases, the prevalence value was converted to 
incidence. The methodology used was published by Gastmeier et al. for this specific purpose in order 
to compare the results of different studies more effectively (534). The formula used to convert 
prevalence to incidence, and vice versa, is as follows: 
 
I = P *[LA / (LN – INT)] 
P = I*[(LN-INT)/LA] 
I = incidence; P = prevalence; LN = mean length of stay in patients with an HCA UTI; INT = mean interval 
between admission and HCA UTI onset; LA = mean length of stay for all patients 
 
The formula parameters were derived from the point prevalence survey and the PAS data. The date 
of HCAI onset was recorded in the point prevalence survey, so this was used to determine the 
average duration from admission to UTI diagnosis. The values used are presented in Table 7.12.  
 
Table 7.12: Parameters used for the calculation of incidence and prevalence  
Parameter Value 
Prevalence (P) 3.2% 
Incidence (I) 1.9 
Mean length of stay for patients with HCA UTI (LN) 31 days 
Mean interval between admission and HCA UTI onset (INT) 11 days 
Mean length of stay for all patients (LA) 5 days 
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The values obtained using these parameters underestimated the incidence and overestimated the 
prevalence. This means that the surveillance based on the electronic microbiology data would result 
in the prevalence being over double that obtained from the point prevalence survey (7.6% vs. 3.2%). 
However the parameters used for this calculation estimates that the average length of healthcare 
associated urinary tract infection to be 20 days, which is a long duration of infection.  
The standard duration of antibiotic treatment for an HCA UTI at ICHNT is 7 days, and this increases 
up to 14 days if the infection is unresponsive. Once a patient has finished their treatment for an 
infection it can be assumed that the infection has been cured, thus the minimum duration of 
infection using this parameter is 7 and the maximum is 14. I replaced the ‘LN – INT’ term in the 
equation with ‘duration of antibiotic treatment’ and the incidence and prevalence estimates were 
re-calculated:  
 
Using the minimum antibiotic treatment duration: 
   
Using the maximum antibiotic treatment duration:  
    
 
Using the shortened duration of antibiotic treatment, which assumes all the HCA UTI were 
uncomplicated, the automated laboratory method underestimates the prevalence of infections. 
Using the longer duration of treatment however means the automated system over estimates the 
P= 1.9*[(31-11)/5] 
P = 1.9*4 
P=7.6 
I = 3.2 * [5 / (31 – 11)] 
I = 3.2 * 0.175 
I = 0.56 
P= 1.9*[7/5] 
P = 1.9*1.4 
P=2.66 
I = 3.2 * [5 /7] 
I = 3.2 * 0.714 
I = 2.29 
P= 1.9*[14/5] 
P = 1.9*2.8 
P =5.32  
I = 3.2 * [5 /14] 
I = 3.2 * 0.357 
I = 1.14 
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prevalence, with a figure of 5.32% compared to 3.2%. Reasons for differences to be expected are 
presented in the discussion section.  
 
7.2.3 Comparing Microbiology and Administrative Data 
  
In the PAS data, ICD-10 codes were used to classify patients as having a healthcare associated 
urinary tract infection and these were compared to those identified by the electronic microbiology 
data. The codes used to extract urinary tract infections were presented in Table 7.4 and as stated in 
the methods, the primary diagnosis code was only considered in patients that were classified as re-
admissions. 
Using the ICD-10 codes, 720 patients were classified as having a HCA UTI, which is an incidence of 
2.2/100 admissions. This is a very similar incidence (2.1/100 admissions) to that found using the 
electronic microbiology data. However, when the HCA UTI diagnosed using microbiology and ICD-10 
codes were compared, only 27% of those patients with an HCA UTI also had an appropriate ICD-10 
code (Table 7.13).  
 
Table 7.13: Comparison of microbiologically confirmed UTI and ICD-10 code positive UTI patients 
 HCA UTI Micro CA UTI Micro No positive micro 
ICD-10 code 169 56 495 
No ICD-10 code 467 466 29,134 
 
The sensitivity and specificity for the comparison between microbiology and ICD-10 codes were 
26.6% and 99%, respectively. The positive predictive value of the ICD-10 codes for identifying a 
positive healthcare associated urine culture was 36.4%, which was higher than several of the codes 
used for detecting SSI (chapter 5 and chapter 6). The negative predictive value was 98.4%.  
When the ICD-10 codes were used as a predictor variable in a logistic regression for microbiologically 
confirmed infections, the odds ratio was extremely high at 35.4 (CI: 28.7, 43.6; p-value: <0.001). This 
along with the high specificity and NPV indicates that the ICD-10 codes were discerning in terms of 
correctly identifying true negatives. However, the relatively low sensitivity and PPV means that the 
true positives are less clear. If all the positives from the electronic microbiology data and ICD-10 
codes were combined the incidence of HCA UTI would be 3.6/100 admissions. This corresponds to 
1,187 admissions within a six month period at ICHNT.  
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7.3 Discussion 
 
Table 7.14: Summary of key findings from chapter 7 
Patient Type Number of patient admissions Average Length of Stay 
Inpatient Mortality 
Rate 
Healthcare associated UTI 636 31 days 19% 
Catheter associated UTI 346 37 days 22% 
Community acquired UTI 522 3.3 days 2.5% 
General patient population 29,134 2.1 days 4.1% 
 
In this chapter I have used electronic microbiology data to develop the capacity to automate the 
detection of healthcare associated urinary tract infections, including those attributable to catheters. 
Using this method, the incidence of HCA UTI at Imperial College Healthcare NHS Trust was 1.9/100 
admissions and 1.1/100 admissions for catheter associated UTI. This rate was comparable to that 
found by the point prevalence study at Charing Cross Hospital, determined by converting the 
incidence and prevalence rates using the length of antibiotic treatment to convert the incidence to 
prevalence. When comparing the patient population with HCA UTI and the general patient 
population, I found that being an emergency admission and having a diagnostic imaging or urinary 
procedure were more common amongst the infected patients. The odds of dying were 5.48 higher in 
patients with HCA UTI compared to the general patient population.  
An interesting finding was the distribution of organisms. E. coli was the most commonly isolated 
organism for the positive urine cultures, a well-established trend; however it was less common in 
healthcare associated and specifically catheter associated infections than community acquired 
infections. The opposite trend was observed for UTI caused by fungal pathogens, with catheter 
associated infections having the highest portion of infections due to this type of organism. The 
difference in length of stay and mortality between catheter associated and non-catheter associated 
infections could have been due to these differing causative organisms.  
There are several discussion points which needed to be considered before a conclusion could be 
made about the practicality of using this automation method for surveillance. These revolve around 
the potential for over and underestimation of cases when using electronic microbiology data in 
isolation. Firstly however, the issue of data quality, linkage and availability was also present in this 
chapter as it has been in the prior two analyses chapters.  
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Data Issues 
 
This chapter utilised the complete microbiology data, which was unavailable for the previous 
analyses chapters. There was six months of complete data on all microbiology cultures carried out at 
Hammersmith and Charing Cross Hospitals, however during this time period data from haematology 
and clinical biochemistry were not available. This meant that syndromic algorithms could not be 
developed, along with the fact that no ‘gold standard’ surveillance data source was available for HCA 
UTI at ICHNT. This did not affect the results presented, but restricted the investigations that could be 
done.  
As the microbiology data came from a live IT system, it contained the most recent data. When this 
was linked to PAS, several of the records did not link and had missing data. This could have been 
because the patient was still in hospital. Also, the data may not have been processed internally, and 
the unique patient ID assigned in both datasets, meaning the patients could not be linked to their 
corresponding episode. This resulted in incomplete and non-existent PAS data for a large proportion 
of patients, for example with age and source of admission. This affected the analyses and possibly 
the results in two ways.  
Firstly, the lack of a complete age variable and unclear ward coding to determine ICU admission 
were major limitations as these factors have been shown to be highly correlated with urinary tract 
infections (section 3.2.1). Not taking age or ICU admission into account may have overestimated 
some of the relationships observed, namely that seen with HCA UTI and inpatient mortality. Patients 
with an HCA UTI were over five times more likely to die during their admission than a patient 
without an infection, however without taking into account the patients age or ICU admission the 
increased mortality cannot be attributed to the HCA UTI. Published rates of attributable mortality 
from catheter associated UTI have ranged between 5 – 10% (535, 536), however the unadjusted rate 
based on this study was 22%. A study by Clec’h et al. showed that when patients were matched, the 
mortality rate of patients with and without catheter associated UTI was no longer different (537). 
The process of multiple imputations was not carried out for this missing data as the data available 
would not have been appropriate to make meaningful estimations of age and ICU admission; 
therefore variables with a high level of missing data were not investigated.  
Secondly, the patients that did not link were not likely to have been missing at random. Those 
patients with urine cultures but no PAS record, whilst they may not have linked due to inconsistent 
patient identifiers, could also have still been in hospital. This may have underestimated the number 
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of complex patients, with extended lengths of stay, in both the infected and uninfected patients. I 
could not have imputed an entire patient record, based solely on their microbiology data; therefore 
these patients could not have been investigated.     
Finally, setting up the microbiology and PAS data into a usable format for this chapter was 
complicated and time consuming (e.g. coding free text), with the resulting data structure not 
necessarily lending itself to easy navigation. These factors limited the epidemiological analyses 
somewhat, and are a consideration in adopting an automated surveillance system. 
 
Prior Uses of Electronic Case Finding 
 
It has been noted by other studies addressing the use of existing electronic data to create 
automated surveillance of HCAI that the data available do not meet the minimum healthcare 
associated infection case definitions. However, this goes back to the  purpose of surveillance, and 
whether it is to implement improvement or produce accountability (11). If surveillance is used to 
monitor trends and not to support individual patient care, is the use of a reduced case definition 
cause for concern (82)?  The literature around the subject of electronic surveillance and case 
definitions shows high variability in the specificity and sensitivity of such systems.  
Reduced definitions have been successful in previous studies when investigating HCAI, including UTI, 
with the detection of bloodstream infections against the traditional surveillance method being 100% 
in one study (538, 539). Reduced case definitions have used positive microbiology in conjunction 
with concomitant antibiotic subscription, or in the case of pneumonia, positive radiology. Another 
study which employed antibiotic prescribing as a diagnostic method demonstrated its usefulness as 
a proxy indicator for infection (540). A microbiology only definition (which required two positive 
cultures of the same organism within 5 days) had a sensitivity of 64%, specificity of 98%, PPV of 90% 
and NPV of 91%, so performed fairly well (541). However, this method was applied only to 
bloodstream infections and the requirement of two blood cultures as standard means it not 
necessarily widely applicable, with local policies potentially affecting its applicability.  
For urinary tract infections specifically, a study by Choudhuri et al. found that their electronic 
catheter associated UTI detection method had a sensitivity of 86.4% and a specificity of 93.8% (92). 
This study used infection prevention and control nurse performed patient chart review as their ‘gold 
standard’ and the electronic case definition was based on positive microbiology and a recorded 
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catheter. The study population was small with only 60 patients identified by the electronic 
surveillance and 59 by the chart review; they concluded that the electronic system was a more 
efficient method for surveillance in their setting (92).  However, as has been established by previous 
chapters, active clinical surveillance cannot always be taken as a ‘gold standard’. For the analyses in 
this chapter specifically, there was no traditional surveillance data available, therefore the accuracy 
of the reduced case definitions created in this chapter could not be tested.  
Another study successfully used microbiology data to detect BSI, UTI, SSI and pneumonia cases in a 
large hospital group in New York (542). This study used linked hospital data systems and electronic 
algorithms to detect cases of healthcare associated infections. In this setting, they had access to 
electronic health records, and detailed information regarding catheters (including length of 
catheterisation) could be extracted from the text; a significant advantage over the data available in 
this project. However, the paper demonstrated a considerable weakness, it did not describe or 
define how infections were distinguished into healthcare or community acquired (excluding SSI). As 
urinary tract infections and pneumonias are relatively common in the community, this paper was 
likely to have overestimated the number of healthcare associated infections present in their 
hospitals. Applying their stratification system of ‘case’, ‘non-case/non-control’ and ‘control’ to this 
data, the following results in Table 7.15 were obtained. The ‘non-case/non-control’ group included 
those patients with administrative diagnostic codes but no confirmed microbiology.  
 
Table 7.15: Reliability stratification for electronically detecting HCA UTI 
Patient type Number (%) 
Case 636 (1.9) 
Non-case / non-control 551 (1.7) 
Control 31,911 (96.4) 
 
Over estimation 
 
The final point above touches on one cause of mis-estimation, the difficulty in assigning the 
attribution of positive urine cultures to healthcare or community. The way in which healthcare 
associated infections are defined and the method of data manipulation could have affected the 
numbers produced.  
In this chapter three methods for classifying a urinary tract infection as healthcare associated were 
used: presence of a catheter; re-admission or admission from healthcare; the current admission 
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lasting more than 72 hours. For catheter associated UTI, all patients with a catheter were included 
with no consideration of duration. The duration of catheterisation was not available, nor the date of 
catheter insertion. This means that a catheter may have been put in after the onset of infection, but 
the method I used to would have attributed the infection to the catheter.  
For re-admission cases, this included patients who had been in the hospital in the previous 48 hours 
and the primary diagnosis was considered in the ICD-10 codes for these patients. Again, however 
this method could overestimate the number HCA UTI as the patients prior stay in hospital could have 
been for a community acquired UTI which had not been resolved. As the data were complex, it was 
hard to account for all the possible scenarios in which patients would be classified as community or 
healthcare, as often the line is blurred. To minimise the potential for misclassification, the rules I 
used to define patients as healthcare associated or community acquired were based as closely on 
the standardised ECDC definitions for HCA UTI as possible.  
One area where the ECDC definitions could not be followed was the use of clinical symptoms to 
distinguish between asymptomatic bacteriuria and a clinically relevant infection. Between 10-20% of 
females are colonised by potentially infectious bacteria which can be positive on a urine culture 
despite the patient being asymptomatic (543).  The lack of symptomatic information could have led 
to overestimation of clinically relevant cases of HCA UTI.  
 
Under estimation 
 
Using electronic case definitions are unlikely to catch all the infected patients as there are those 
patients who have false negative test results and those who simply have no urine samples sent to 
the laboratory. A study by Brossette et al. stated those patients with infections but no microbiology 
accounted for 16% of the patient population (544). This could cause a large underestimation of the 
number of infections, when microbiology is taken in isolation.   
When the numbers of microbiologically diagnosed HCA UTI were compared to those using the ICD-
10 codes from PAS, the sensitivity was only 26.6%. The excess cases detected with the ICD-10 codes 
could be explained by patients with a clinical diagnosis but no microbiological data. One of the ECDC 
definitions for HCA UTI (UTI-B) does not require a patient to have microbiological confirmation of 
infection. Therefore the discrepancies between the laboratory and PAS data should be expected and 
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the efficacy of an automated system would therefore depend on local policies of microbiology 
testing.  
As the microbiology and urinalysis criteria are strict for the diagnosis of a UTI, with over 105 
colonies/ml required of a single pathogen, the potential for false negative results was large (2). As 
high as a third of females with a clinical definition of a UTI will not have a colony count this high 
(543). In this chapter I included those cultures with a colony count of over 102/ml with a named 
organism as positive, as well as samples with a WBC >10/ml. This would more likely have led to an 
overestimation from false positives (i.e. colonisation) than an underestimation from false negatives. 
However it needs to be repeated that without any clinical information, an infection cannot be 
distinguished from bacteruria.      
 
Prevalence and Incidence 
 
The purpose of comparing the incidence of HCA UTI according to the electronic microbiology data 
and the prevalence determined by the local point prevalence study was to assess whether this 
method produced a comparable result. Using the method where the duration of infection was 
estimated using post-diagnosis length of stay, the prevalence calculated based on the electronic 
microbiology cases was much higher than expected (7.6% vs. 3.2%). However, when the length of 
antibiotic treatment was used as a proxy for infection duration the calculated prevalence then 
ranged from 2.66 – 5.32%. The prevalence of HCA UTI across all hospitalised English patients 
however was 1.2%, lower than the local rate and those calculated from the microbiology data (3).  
I would have expected the prevalence based on positive laboratory results to be lower than that of 
the PPS as 42% of the HCA UTI identified in the local PPS were not laboratory confirmed cases. 
However, the PPS did not included the third category of HCA UTI, asymptomatic bacteriuria (2), 
which would have increased the number of UTI diagnosed with microbiology data in the PPS.  
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7.4 Conclusion 
 
While this chapter has demonstrated that routine electronic microbiology data within the NHS can 
be used to automate surveillance of healthcare associated urinary tract infections, the system as it 
stands has several limitations. Firstly, the data were complex and incomplete, requiring a lot of 
manipulation before it could be used, a task that unless pre-programmed and simplified would not 
be time efficient. Secondly, the lack of clinical data or electronic patient charts reduces the accuracy 
of the numbers that would be reported, due to both under and over estimation of true positives. 
Despite the challenges however, if the purpose of the system is to monitor trends over time and 
provide a benchmark of incidence, then this method has potential. With the recent launch of the 
national ‘safety thermometer’ initiative, it would be interesting to compare the results from this 
traditional active case finding and the automated electronic surveillance systems. This further work 
could provide an indication of the automated surveillance’s accuracy and efficiency, informing 
subsequent HCA UTI surveillance policy, both locally and nationally.   
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Chapter 8: Risk Modelling and Score Creation for Surgical Site and Urinary Tract Infections   
Summary 
 
This is the last of the analysis chapters in this thesis, investigating the using routine electronic data, 
to generate simplified risk scores with applications of bedside use. It is the third type of surveillance 
tool to be investigated in this thesis and uses the evidence base established by the literature review 
on risks for HCAI (chapter 3). The risk models are converted into simplified risk scores, and 
investigated for their utility in stratifying patient risk at the bedside.   
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8.0 Introduction 
 
Not all patients have the same likelihood of developing a healthcare associated infection. The risks 
associated with acquiring a HCAI can be classified as intrinsic, relating to features of the patient 
themselves, or extrinsic, relating to their treatment and exposures (135). Risks of infection can be 
quantified and chapter 3 presented a literature review of studies which have investigated risk factors 
for HCAI.  
As extrinsic risks will vary between different countries and between healthcare facilities within 
countries, the relative importance of risks may also vary. Risk models and the creation of indices to 
rank patients have been generated for HCAI in the past. However, this work has been limited in the 
NHS environment and has rarely taken advantage of routine electronic data (Table 3.2 and Table 
3.6).  
Applying these risk scores at the bedside has been done for several conditions and outcomes and 
has become common place in many clinical settings. Examples include the APACHE II (545), SOFA 
(546) and PRISM scores (547), which aim to support clinical decision making and therefore care. 
These scores are often calculated by hand, based on patient notes and clinical presentation. 
However, if the routine electronic data contains sufficient data to stratify patient risk, these scores 
could be automated and made available at the bedside, in settings which have electronic patient 
records. They could be dynamic to changes in the patient’s condition and aid clinical care. The utility 
of these scores however are dependent on the data available, especially in a real-time electronic 
format.  
The National Nosocomial Infection Surveillance (NNIS) risk score for surgical site infections is a good 
example of one such risk score that has been widely applied in healthcare associated infections 
(548). It is a simple three factor score, based on the patients American Society of Anaesthesiology 
(ASA) score, duration of surgery and wound class. However, this simplified score does not 
necessarily perform across all procedure types. Taking CABG as an example, the wound classification 
should always be clean and all patients will have similar ASA scores, therefore the score has no 
added value other than simply using the duration of surgery to stratify patient risk (549, 550). The 
Australian Clinical Risk Index on the other hand uses just diabetes and body mass index to stratify 
patient risk for SSI following CABG and found it to be a better predictor (233, 551).    
An example of an automated risk score was that developed by Smith et al. for nutritional status 
screening in surgical patients (552).  This was based on laboratory data and was made available at 
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the bedside, to screen for post-operative malnutrition. It performed comparatively well with other 
scores used to assess postoperative complications and nutrition status, with an AUC value of 0.78 
(552).  
Going a step further, using real time data capture of clinical observations at the patient bedside and 
electronically integrating this information with a risk score has been carried out in Manchester (553). 
This highlights the potential for electronic and dynamic risk alerts which could be applied at the 
bedside. Being able to stratify patients according to their risk of infection using routine data may 
enhance the surveillance of HCAI in the absence of efficient, sustainable active clinical surveillance.  
 
8.0.1 Aim and Objectives 
 
The aim of this chapter was to assess the utility of administrative data for generating risk models and 
subsequent risk scores. Three patient cohorts were investigated, caesarean section and coronary 
artery bypass graft procedure patients for their risks of SSI and the general patient population for 
their risks of developing a healthcare associated urinary tract infection.   
The risks factors for investigation have already been defined by chapter 3, so the first objective of 
this chapter was to describe the patient cohorts for surgical site infections and urinary tract 
infections. The second objective was to produce risk models to predict which patients would acquire 
infections. The final objective was to determine the applicability of patient risks, creating simplified 
risk scores and probabilities of infection.   
This differs to the analysis presented in chapter 7 for HCA UTI and chapters 5 and 6 on surgical site 
infections, as this analysis focuses on risks of infection and risk modelling as a method of 
surveillance. While previous chapters have described patient groups and their associated risks of 
infection recorded by different data sources, this method will be using solely administrative data to 
create predictive risk models, not describing the characteristics of different patient groups.  
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8.1 Methods 
 
The data being used in this chapter has already been cleaned according to the methods set out in 
chapters 5, 6 and 7 (sections 5.1.0, 6.1.0 and 7.1.0).  The data being used in this chapter was the 
linked PAS and laboratory data from January 2009 – December 2010. Three cohorts of patients were 
generated, one for CABG patients, one for caesarean section patients and a third made up of the 
general inpatient population for investigating healthcare associated urinary tract infections.  
 
8.1.1 Creating the Three Cohorts 
 
The three patient cohorts being investigated were: CABG patients; caesarean section patients; and 
the general patient population with a hospital stay of over 72 hours. The outcome under 
investigation in the two surgical cohorts (CABG and caesarean) was surgical site infections 
developing within 30 days of surgery. The outcome under investigation in the third cohort (general 
patient population) was healthcare associated urinary tract infection.  
The ICD-10 codes used to identify the patients that developed either SSI or HCA UTI are presented in 
Table 8.0. These codes were chosen based on those ICD-10 codes established as the most 
appropriate in prior chapters. 
 
Table 8.0: ICD-10 codes used to extract patients with SSI and HCA UTI 
Condition ICD-10 code ICD-10 code translation 
UTI N10 Acute tubule-interstitial nephritis 
UTI N11 Chronic tubulo-interstitial nephritis 
UTI N12 Tubulo-interstitial nephritis, not specified as acute or chronic 
UTI N15 Other renal tubule-interstitial diseases 
UTI N30 Cystitis 
UTI N34 Urethritis and urethral syndrome 
UTI N390 Urinary tract infection, site not specified 
SSI T813 Disruption of operation wound, not elsewhere classified 
SSI T814 Infection following a procedure, not elsewhere classified 
SSI T827 Infection and inflammatory reaction due to other cardiac/vascular device, implant / graft 
SSI O85 Puerperal sepsis, including endometritis 
SSI O860 Infection of obstetric surgical wound 
SSI O900 Disruption of caesarean wound 
SSI Y83 + org Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without misadventure as the time of procedure 
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The following conditions were used to define an ICD-10 code as being healthcare associated, and 
hence signify an infected patient within the cohorts: 
 Surgical Site Infections: 
o Any ICD-10 codes indicative of a SSI in any admission (spell) starting within 30 days 
of surgery 
 Urinary Tract Infections: 
o Any non-primary ICD-10 codes indicative of a UTI in an admission lasting >72 hours 
o Any ICD-10 codes indicative of a UTI in an admission starting within 48 hours of a 
discharge  
o Any ICD-10 codes indicative of a UTI in an admission with a corresponding urinary 
catheter code 
The un-infected patients in the CABG cohort were all those who underwent CABG surgery but did 
not have an ICD-10 code for SSI which met the above conditions. Similarly, the un-infected patients 
in the caesarean cohort consisted of all the patients who had a caesarean section performed but did 
not have an ICD-10 code for SSI recorded.  
Un-infected patients in the HCA UTI cohort consisted of all patients admitted for longer than 72 
hours during 2009 and 2010, who did not meet the conditions stated above. The decision to use a 
cohort study structure and not a matched case-control (which is a common method in risk 
modelling) was made because several commonly used matching variables, such as sex and age were 
variables of interest. Keeping the structure as a cohort study reduced the complexity of the analysis. 
For the HCA UTI cohort, only patients over the age of 18 were kept for analysis, because there were 
too few patients in the younger age category.  
 
8.1.2 Risk Variables 
 
The risk variables I used for these analyses were based on those identified in the literature review 
from chapter 3. The risk variables were extracted from the PAS and laboratory data and turned into 
binary and categorical variables or kept as continuous variables where appropriate. Not all the 
variables were investigated as they were deemed too specific or tailored to the study question which 
found them significant. A summary of the variables included in the analyses, the database it 
originated from and the codes I used to identify them are presented in Table 8.1.  
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Table 8.1: Risk variables used in the risk models for HCA UTI and SSI 
Risk variable Data origin Code / variable 
Both UTI and SSI 
Age PAS Age on admission 
Gender PAS Sex 
Diabetes mellitus PAS: ICD-10 E100 – E119, E129 – E149, O240 – O244, O249 
Length of stay PAS Date of admission, date of surgery, date of discharge 
Elective / emergency admission PAS Admission method 
Admission from healthcare PAS Admission type 
Urinary Tract Infection 
Urinary catheter PAS: ICD-10 / OPCS T830, Y846 / M471 – M473, M478 – M479 
Neurologic disease  PAS: ICD-10 G00 – G99 
Unresolved spinal injury PAS: ICD-10 P115, S141 – S143, S241 – S242, S341 – S344, T060 – T061, T093 – T094 
Previous stroke  PAS: ICD-10 G463 – G464, I64X, I694 
Unconsciousness PAS: ICD-10 R402 
General surgery PAS: OPCS / PAS G, H, J / Specialty code: 100 
Orthopaedic surgery PAS: OPCS / PAS V, W / Specialty code: 110 
Serum creatinine Laboratory Average in the first 5 days 
Deceased kidney donor  PAS: OPCS M013 
Bladder dysfunction  PAS: ICD-10 N310 – N319 
VUR  PAS: ICD-10 N137 
Invasive procedure  PAS: OPCS Any code 
Surgical Site Infections - CABG 
Congestive heart failure PAS: ICD-10 I110, I119, I130, I132, I500, I501, I509 
Renal impairment PAS: ICD-10 N250 – N259, M103, N170 – N179 
Liver disease PAS: ICD-10 K70 – K77 
Other infection PAS: ICD-10 See Table 5.4 
Surgical Site Infections – C-section 
Chlorioamnionitis PAS: ICD-10 O411 
Pre-eclampsia PAS: ICD-10 O13x, O140 – O149 
Surgical Site Infections – non surgery specific variables 
BMI / Obesity PAS: ICD-10 E650 – E680, F504, R635, Z713 
Weight loss (>10%) PAS: ICD-10 R634, F500 – F503 
Smoking PAS: ICD-10 Z587, Z720, F170 – F179 
Alcoholism PAS: ICD-10 Z133, G312, F100 – F109, Z502, Z714, Z721 
COPD PAS: ICD-10 J440 – J449 
Haematocrit Laboratory Average pre-operative value 
Albumin Laboratory Average pre-operative value 
Blood transfusion PAS: ICD-10 / OPCS Z51 – Z59 / X321 – X329, X331 – X339 
International normalised ratio Laboratory Average pre-operative value 
White blood cell count Laboratory Average pre-operative value 
Surgery on a Monday PAS Date of surgery 
 
The lengths of stay and biological marker variables (e.g. creatinine and WBC) were based on pre-
operative values in the CABG and caesarean section cohorts. This was in order to ensure that they 
were risks of infection and not an outcome of infection. In the HCA UTI cohort, there was no 
indication of the date of infection diagnosis, so the creatinine variable was based on results from 
tests in the first five days of admission to try and minimise any effect infection may have on the 
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markers. The length of stay however, was the total duration and therefore needs to be interpreted 
with caution. 
  
8.1.3 Risk Modelling and Score Creation 
 
Logistic regressions were used for the risk modelling as the dependent variable (of either SSI or HCA 
UTI) was binary. I used the ‘logit’ command in Stata to carry these out. The three cohorts were each 
divided, creating a dataset for the model development and a second for model validation in the 
three cohorts. I decided to divide the data according to year, with 2009 being the development 
dataset and 2010 the validation dataset. Assigning the datasets temporally is a common method in 
risk model creation (512) and I therefore deemed it appropriate for this study. Splitting the data 
reduces the power of the model; however I decided that including this methodological step of model 
validation was more important.  
 
Univariate Regression 
 
All the risk variables were tested against the binary outcome variables of either HCA UTI or SSI, 
depending on the cohort. Prior to using the continuous variables, I tested their normality and where 
appropriate transformed them to improve their normality, and assessed their linearity with the 
outcome (using the ‘lowess’ graphing command in Stata). I converted the continuous variables into 
categorical or binary where appropriate, using the ICHNT laboratory guidelines to create categories 
for the biological markers. Continuous variables are preferable to categorical as they hold more 
information (554); however their distribution needs to be normal and their relationship to the 
outcome variable needs to be linear for them to be used appropriately. Hence, I investigated the 
variables in both formats and made decisions on what format to include in the final models based on 
these investigations, the aim of the chapter, and interpretability.  
Those variables with a p-value of <0.1 were then included in the multivariate regression.  
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Multivariate Regression 
 
Including all the variables found to be relevant in the univariate analyses, a stepwise approach was 
taken in the multivariate regression to create the final models. A backward selection approach, 
meaning that all the independent variables are put in the model and then eliminated based on a 
specified significance level, was used. Royston et al. state that backwards selection is better than a 
forward selection method, hence the decision to use a backwards approach (554). There are 
however issues with using a stepwise approach to variable inclusion, which is addressed in the 
discussion section.  
I used three different significance cut-offs in developing the multivariate models: 1% (p-value <0.01), 
5% (p-value <0.05) and 10% (p-value <0.10). The model with the best performance based on the 
Hosmer-Lemeshow and c-statistic results (both in the development and validation datasets) was 
chosen as the final model. In cases where there was no difference or an unclear advantage, the most 
parsimonious model was selected.  
A model, including all the possible variables (a ‘full model’) was also run to compare with the model 
generated using the backward stepwise approach. This was done to check if the backward stepwise 
process of variable selection caused significant over estimation of the regression coefficients or any 
arbitrary variable retention.     
 
Model Validation  
 
I then tested the model equation (or regression equation) for the three different cohorts in the 2010 
data, with the calibration measured using a Hosmer-Lemeshow test and the discrimination with the 
c-statistic. The model equations follow the formula below, with each statistically significant variable 
from the multivariate analysis included: 
 
Log odds of the dependent variable = Intercept + (variable coefficient x variable) + ….. 
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I then regressed the binary indicator of infection on the ‘log odds of the dependent variable’ in the 
2010 data (i.e. an ‘out of sample’ prediction). The Hosmer-Lemeshow and c-statistics were 
calculated for this model fit. A high c-statistic indicates good model discrimination. A p-value over 
0.05 (instead of the conventional less than) in the Hosmer-Lemeshow test signifies a good model fit, 
as it is examining if there is a difference in the observed and predicted outcomes in the model.  
There are some issues with the Hosmer-Lemeshow test (addressed in the discussion), so the model 
residuals were also plotted against the model prediction and their distribution investigated. 
Residuals are the distance between the observed and the predicted values from the model, and 
represent the variation which is unexplained by the model. The assumptions are that the residuals 
will have a mean of 0 and a normal distribution, so investigating these premises gives an indication 
of the model performance.  
 
Model Application 
 
The patient’s log odds of the dependent variable, as derived from the model equation explained 
above was then converted into a probability. This gives the patients likelihood, based on the 
predictive model, that they are either infected or un-infected. A full worked example is presented in 
Box 6. The log odds were converted to a probability using the following formula: 
 
Odds = e patient’s log odds value 
Probability = [Odds / (1 + Odds)] x 100 
 
The models were then turned into a simple ‘risk score’. The methodology used was that presented 
by Sullivan et al. for developing risk scores based on log odds (555). In summary, the reference 
category for each variable is set (e.g. for sex male is 0 and female is 1), with continuous variables 
converted into categorical variables for ease of use. The distance, in terms of regression units (i.e. 
the regression coefficient), of categories from the reference category is then determined. A 
‘constant’ by which these are compared is set. The ‘constant’ is generally the variable with the 
lowest regression coefficient. The points which are then assigned to the different risks are based 
around this value. This methodology allows for weighting in the scores, as the relative relationships 
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of each variable with the outcome are taken into account. A range of scores are produced, and these 
were categorised in ‘low’, ‘medium’ and ‘high’, to stratify the patients according to their risks of 
infection. A worked example is presented in Box 4. 
 
Figure 8.0: Summary of the methodological steps used in chapter8 
 
PAS + Pathology data 09/10: 
Linked and cleaned according to previous 
chapters, creating three patient cohorts 
PAS + Pathology data 2009: 
Risk model development for SSI following CABG 
and caesarean and HCA UTI in the general 
patient population 
PAS + Pathology data 2010: 
Risk model validation for SSI following CABG and 
caesarean and HCA UTI in the general patient 
population 
PAS + Pathology data 09/10: 
Risk score creation and application for SSI 
following CABG and caesarean and HCA UTI in 
the general patient population 
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Box 4: Example of assigning the points in risk score creation 
Using hypothetical numbers and variables, the following example demonstrates how points would 
be assigned in a risk score, based on the results of a regression. Three variables (sex, catheter and 
elective admission) were found significant in predicting infection. All three are binary variables, 
with regression coefficients of: 
Sex: 0.05; Catheter: 0.25; Elective admission: -0.10 
 
The reference categories (male, not having a catheter and being a non-elective admission) are 
each given a value of 0. Each of the non-reference categories (female, catheter and elective 
admission) are then assigned a distance of 1 from the reference category, which is then multiplied 
by the regression coefficient to give the distance in regression units.  
The constant is the lowest positive regression unit, i.e. 0.05. Each non-reference category’s 
distance in regression units is then divided by this constant to determine the points associated 
with having this risk.    
Non reference category = distance in regression units from the reference / constant 
E.g. Catheter = (1 x 0.25) / 0.05 
Catheter = 5 
 
E.g. Elective admission = (1 x -0.10)/0.05 
Elective admission = -2 
 
This particular score has a range of -2 to 6, with -2 being the lowest possible risk of infection and 6 
being the highest possible risk of infection. In this example, a male patient admitted electively, 
with a catheter would have a risk score of 3 (male = 0, elective admission = -2, catheter = 5). A 
female, non-elective admission without a catheter on the other hand would have a score of 1 
(female = 1, non-elective admission = 0, no catheter = 0).  
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8.2 Results 
 
The total number of patients included in each cohort are summarised in Table 8.2. The results are 
presented for HCA UTI, followed by SSI following coronary artery bypass grafts and then SSI 
following caesarean section.  
 
Table 8.2: Summary of the patients included in each cohort 
Cohort Infected Un-infected TOTAL 
CABG SSI 82 1,020 1,102 
Caesarean section SSI 131 4,138 4,269 
UTI 2,601 28,336 30,937 
 
 
8.2.1 Healthcare Associated Urinary Tract Infections 
 
When all the risk variables were generated not all were available for analysis, either because the 
numbers were too few, or the creation of the variable wasn’t possible.  A summary of the variables 
being used and those excluded are presented in Table 8.3. I decided to include Clinical Programme 
Group (CPG) as a variable, to reflect the type of patient. CPG indicates the type of service that the 
patient falls under during their stay, with six groups at ICHNT (e.g. CPG 1 – medicine), and in this 
case acts a proxy of specialty. Specialty was not included as there were too many categories and too 
few records within each one to be included in analysis.  
 
Table 8.3: Variables used or excluded from the HCA UTI risk modelling 
Binary Categorical (ref) Excluded 
Sex 
Urinary catheter  
Diabetes 
Admission from healthcare 
Stroke 
General Surgery 
Orthopaedic Surgery 
Deceased kidney donor 
Any procedure 
Neurological disease 
Age group (45 – 60 years) 
Length of stay group (<7 days) 
Diabetes type (None) 
Admission type (Elective) 
Creatinine group (60 – 110 µmol/L) 
Clinical Programme Group (CPG:1 – 
medicine) 
VUR 
Bladder dysfunction 
Spinal injury 
Unconscious 
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The sample size for the model development was 980 infected and 11,409 uninfected patients; this is 
an incidence of 7.91 infections /100 admissions of longer than 72 hours. A summary of the variables, 
according to the dataset and infection status are presented in Table 8.4.  
 
Table 8.4: Summary of the risk variables in the development and validation datasets for HCA UTI 
Variable Development Dataset [N(infected)] Validation Dataset [N(infected)] 
Total 12,389 (980) 18,548 (1,621) 
Age (years) (mean) 
(range) 
59.1 (69) 
18-102 (19-100) 
58.5 (67.6)  
18-110 (18-102) 
Length of stay (days) 15.6 (29.7)  0-423 (0-368) 
13.0 (26.5)  
0-406  (0-406) 
Creatinine (µmol/L) 125 (127)  18-1412 (35-922) 
122 (136)  
25-1566 (25-1059) 
Sex (female) 6,635 (628) 10,406 (1,073) 
Urinary catheter 182 (52) 286 (100) 
Diabetes 2,153 (249) 3,299 (374) 
Admission from hospital 1,039 (56) 1,098 (103) 
Stroke 106 (16) 220 (43) 
General surgery 2,114 (141) 3,168 (245) 
Orthopaedic surgery 944 (45) 1,467 (88) 
Deceased kidney donor 77 (7) 61 (5) 
Any procedure 9,897 (679) 15,110 (1,230) 
Neurological disease 1,407 (181) 2,285 (349) 
Admission type: Elective 
                              Emergency 
                              Non-elective 
2,907 (64) 
7,995 (868) 
1,486 (48) 
4,166 (140) 
11,626 (1,353) 
2,755 (128) 
CPG: 1: Medicine 
          2: Surgery & Cancer 
          3: Specialist services 
          4: Circular & Renal 
          5: Women & Children 
          6: Investigative services 
4,480 (604) 
2,010 (133) 
1,847 (57) 
2,349 (120) 
1,422 (39) 
281 (27) 
6,740 (945) 
2,682 (208) 
2,751 (120) 
3,251 (182) 
2,838 (139) 
286 (27) 
 
Univariate Analysis 
 
The continuous variables were tested for their normality (results presented in Appendix 8) and 
relationship with the outcome. Length of stay was transformed with the square root function, 
reducing the skew resulting from extreme long lengths of stay. The creatinine variable was 
transformed using the inverse function, accounting for the extreme high values. However, the 
relationships with HCA UTI were not linear, thus the categorical versions of these variables were 
used in the subsequent analyses.  
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Table 8.5: Univariate analysis results for risks of HCA UTI  
Variable Odds ratio SE P-value 95% CI 
Binary Variables 
Sex (ref: male) 1.604 0.111 <0.001 1.400, 1.837 
Urinary catheter 4.862 0.815 <0.001 3.500, 6.752 
Diabetes 1.700 0.132 <0.001 1.461, 1.980 
Admission from hospital 0.643 0.091 0.002 0.487, 0.848 
Stroke 2.087 0.571 0.007 1.222, 3.567 
General surgery 0.804 0.076 0.021 0.668, 0.967 
Orthopaedic surgery 0.563 0.088 <0.001 0.414, 0.765 
Deceased kidney donor 1.165 0.463 0.700 0.534, 2.542 
Any procedure 0.536 0.039 <0.001 0.465, 0.619 
Neurological disease 1.882 0.165 <0.001 1.584, 2.234 
Categorical Variables 
Age (yrs)                       <30 
[ref: 46 – 60]                31-45 
                                       61-75 
                                       >75 
1.108 
0.789 
1.490 
3.754 
0.176 
0.115 
0.174 
0.401 
0.519 
0.103 
0.001 
<0.001 
0.812, 1.512 
0.593, 1.049 
1.185, 1.872 
3.044, 4.629 
Length of stay:             8-14 days 
[ref: <7 days]                15-21 days 
                                       22-28 days 
                                        >29 days 
1.543 
2.531 
3.162 
5.352 
0.148 
0.285 
0.424 
0.488 
<0.001 
<0.001 
<0.001 
<0.001 
1.279, 1.862 
2.030, 3.155 
2.432, 4.114 
4.476, 6.400 
Diabetes:                       Type 1 
[ref: not diabetic]         Type 2 
                                        Other / unspecified 
1.600 
1.730 
1.214 
0.428 
0.139 
0.482 
0.079 
<0.001 
0.626 
0.947, 2.704 
1.477, 2.025 
0.557, 2.643 
Admission:                    Emergency 
[ref: elective]                Non-elective 
5.410 
1.483 
0.711 
0.287 
<0.001 
0.042 
4.182, 7.000 
1.014, 2.167 
Creatinine:                    No creatinine test 
[ref: 60 – 110µmol/L]  <60 
                                        >110 
0.700 
0.987 
1.551 
0.075 
0.112 
0.122 
0.001 
0.904 
<0.001 
0.567, 0.864 
0.790, 1.231 
1.330, 1.808 
CPG:                         2: Surgery & Cancer 
[ref:1 – medicine]  3: Specialist services 
0.455 
0.204 
0.045 
0.029 
<0.001 
<0.001 
0.374, 0.553 
0.155, 0.270 
                                  4: Circular and renal 
                                  5: Women & Children 
                                  6: Investigative services 
0.345 
0.181 
0.682 
0.036 
0.030 
0.141 
<0.001 
<0.001 
0.065 
0.282, 0.423 
0.130, 0.251 
0.455, 1.024 
 
Based on this initial univariate analysis (Table 8.5) the following variables were included in the 
multivariate analysis: age; length of stay; sex; catheter; diabetes (categorical); admission from 
hospital; stroke; general surgery; orthopaedic surgery; any procedure; neurological disease; 
admission type (binary: elective and non-elective); CPG and creatinine. I decided not to include 
general surgery or orthopaedic surgery, as both these and having any procedure performed were all 
protective, I decided to reduce the complexity of the model and keep just ‘any procedure’.  
The categorical version of diabetes was chosen, because this was a better representation of the 
patients. The categorical variable carries more information and the univariate analysis demonstrated 
that only Type 2 diabetes was a risk for developing a HCA UTI.   
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Multiple Variable Analyses 
 
The model cut-off with the best balance of fit and parsimony was the 1% inclusion threshold model. 
The results of the multivariate analysis for this inclusion threshold are presented in Table 8.6; the 
results from the cut-off 5% and 10% models are presented in Appendix 8.  
 
Table 8.6: Multivariate analysis results for risks of HCA UTI with an inclusion threshold of 1% 
Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 2.178 (0.779) 0.167 <0.001 1.875, 2.531 
Urinary catheter 6.249 (1.832) 1.185 <0.001 4.309, 9.063 
Any procedure 0.605 (-0.502) 0.051 <0.001 0.513, 0.713 
Non-elective admission 2.396 (0.874) 0.334 <0.001 1.823, 3.150 
Neurological disease 1.400 (0.337) 0.134 <0.001 1.160, 1.689 
Diabetes:              Type 2 
[ref: not diabetic] 1.295 (0.258) 0.113 0.003 1.091, 1.537 
Age:                       >75 year 
[ref: 46 - 60] 1.741 (0.554) 0.131 <0.001 1.502, 2.018 
Length of stay:     7-14 days 
[ref: <7days]         14-21 days 
                                21-28 days 
                                >28 days 
1.505 (0.409) 
2.239 (0.806) 
2.653 (0.976) 
4.331 (1.466) 
0.151 
0.267 
0.378 
0.446 
<0.001 
<0.001 
<0.001 
<0.001 
1.236, 1.831 
1.773, 2.828 
2.006, 3.508 
3.539, 5.299 
Creatinine:            >110 
[ref: 60-110 µmol/L] 1.511 (0.412) 0.129 0.002 1.277, 1.786 
CPG:                       2: Surgery & Cancer 
[ref: 1: medicine] 3: Specialist services 
                                4: Circular and renal 
                                5: Women & Children 
0.713 (-0.339) 
0.336 (-1.089) 
0.507 (-0.680) 
0.369 (-0.996) 
0.078 
0.050 
0.059 
0.066 
<0.001 
<0.001 
<0.001 
<0.001 
0.576, 0.883 
0.251, 0.450 
0.404, 0.636 
0.260, 0.525 
Constant -4.716 0.208 <0.001 -5.124, -4.308 
 
Based on the results of this analysis, several variables did not make it into the final model. These 
variables were: stroke, having a deceased kidney donor and admission from hospital. Of the 
variables that were included in the final prediction model, both having had any procedure and being 
admitted to CPG 2, CPG3, CPG4 or CPG5 instead of either CPG 1 (medicine) or CPG 6 (diagnostic 
services) were protective against developing an HCA UTI.  
The risk factor with the highest odds ratio was the presence of a urinary catheter, with an odds ratio 
of 6.249. This risk would have been expected to have a high association with developing an HCA UTI. 
Similarly with being over 75 years old (OR: 1.741) and increasing length of stay have both been 
demonstrated as important risks previously. A high creatinine in the first five days of admission had 
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an odds ratio of 1.51 and could be a reflection of kidney impairment, a factor which could 
predispose a patient to a urinary tract infection.  
The results from the logistic regression in which all the risk variables were included (full model) are 
presented in Table 8.7. The regression coefficients did not differ greatly between this model and that 
using the stepwise approach, with the greatest differences seen in having an age of over 75 years 
and creatinine >110 µmol/L.  
 
Table 8.7: Multivariate analysis results for risks of HCA UTI from the ‘full model’ 
Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex (ref: male) 2.160 (0.770) 0.167 <0.001 1.856, 2.514 
Urinary catheter 6.192 (1.823) 1.178 <0.001 4.265, 8.991 
Admission from hospital 0.693 (-0.367) 0.112 0.023 0.505, 0.950 
Stroke 0.858 (-0.153) 0.254 0.606 0.481, 1.532 
Any procedure 0.603 (-0.505) 0.051 <0.001 0.512, 0.712 
Neurological disease 1.414 (0.347) 0.138 <0.001 1.168, 1.712 
Non elective admission 2.645 (0.973) 0.388 <0.001 1.984, 3.526 
Age (yrs)                   <30 
[ref: 46 – 60]           31-45 
                                  61-75 
                                  >75 
1.437 (0.364) 
0.925 (-0.78) 
1.190 (0.174) 
1.985 (0.686) 
0.246 
0.143 
0.145 
0.229 
0.034 
0.617 
0.153 
<0.001 
1.027, 2.011 
0.683, 1.254 
0.937, 1.511 
1.584, 2.489 
Length of stay:        8-14 days 
[ref: <7 days]          15-21 days 
                                  22-28 days 
                                  >29 days 
1.502 (0.407) 
2.206 (0.791) 
2.674 (0.984) 
4.375 (1.476) 
0.152 
0.266 
0.385 
0.459 
<0.001 
<0.001 
<0.001 
<0.001 
1.231, 1.833 
1.742, 2.794 
2.017, 3.546 
3.562, 5.374 
Diabetes:                 Type 1 
[ref: not diabetic]   Type 2 
                                   Other / unspecified 
1.836 (0.608) 
1.322 (0.279) 
1.690 (0.525) 
0.517 
0.118 
0.718 
0.031 
0.002 
0.217 
1.058, 3.188 
1.109, 1.575 
0.735, 3.887 
Creatinine:               No creatinine test 
[ref: 60 – 110]         <60 
                                   >110 
0.778 (-0.251) 
0.987 (-0.013) 
1.430 (0.357) 
0.090 
0.120 
0.128 
0.030 
0.916 
<0.001 
0.620, 0.976 
0.777, 1.254 
1.200, 1.704 
CPG:                         2: Surgery & Cancer 
[ref:1 – medicine]  3: Specialist services 
0.757 (-0.278) 
0.373 (-0.987) 
0.084 
0.057 
0.013 
<0.001 
0.609, 0.942 
0.276, 0.503 
                                  4: Circular and renal 
                                  5: Women & Children 
                                  6: Investigative services 
0.577 (-0.549) 
0.401 (-0.913) 
1.389 (0.329) 
0.073 
0.078 
0.316 
<0.001 
<0.001 
0.148 
0.451, 0.739 
0.275, 0.587 
0.890, 2.168 
Constant -4.895 0.231 <0.001 -5.348, -4.443 
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The final predictive model for developing an HCA UTI in patients admitted for >72 hours was: 
 
Log odds of HCA UTI = -4.716 + (0.554 x age >75 years) + (0.779 x sex) + (1.832 x catheter) + (-0.502 x 
any procedure) + (0.874 x non-elective admission) + (0.337 x neurological disease) + (0.412 x 
creatinine >110) + (0.258 x type 2 diabetes) + (-0.339 x CPG2) + (-1.089 x CPG3) + (-0.680 x CPG4) + (-
0.996 x CPG5) + (0.409 x length of stay 7-14 days) + (0.806 x length of stay 14-21 days) + (0.976 x 
length of stay 21-28 days) + (1.466 x length of stay >28 days) 
 
Model Validation  
 
Using the regression equation specified above, the model was tested in the 2010 data for its 
performance. The results of the Hosmer-Lemeshow test and the C-statistic from the regression 
models are given in Table 8.8 and Figures 8.1 and 8.2.  
 
Table 8.8: Model testing statistics for HCA UTI 
Dataset Hosmer-Lemeshow chi2 (p-value) C-statistic 
2009 – Development 12.11 (0.1466) 0.7899 
2010 – Validation 14.79 (0.0633) 0.7700 
 
The area under the ROC curve (C-statistic) was similar for the model in both the development and 
validation datasets, with it decreasing slightly in the validation cohort. However the Hosmer-
Lemeshow goodness-of-fit test showed that the model fit, whilst significant in both datasets, 
deteriorated in the validation dataset.  
When the residuals were investigated, the skewness was 1.201 and the Kurtosis was 5.898 for the 
model in the 2010 data. Figure 8.3 demonstrates the residuals plotted against the model prediction 
for the validation data. This graph demonstrates that the model performs less well when the 
patients have a low risk of infection, as there was a wider variation in the residuals when the model 
prediction was low. However, the running mean is close to 0 at all predictions and the skewness and 
kurtosis values indicate that while the distribution was not completely normal, it was not terrible 
either.  
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Figure 8.1: ROC curve of the predictive 
model for HCA UTI in the development 
data 
Figure 8.2: ROC curve of the 
predictive model for HCA UTI in the 
validation data 
Figure 8.3: Scatter plot of the 
residuals against the model 
prediction of HCA UTI 
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Box 5: Example of the regression equation and predicting HCA UTI 
Taking two real patients as examples, I demonstrate how the regression equation leads to a 
prediction. The first patient was a 26 year old male, with a procedure, a four day length of stay 
and non-elective admission to CPG 4.  
Log odds of HCA UTI = -4.716 + (0.554 x age >75 years) + (0.779 x sex) + (1.832 x catheter) + (-
0.502 x any procedure) + (0.874 x non-elective admission) + (0.337 x neurological disease) + 
(0.412 x creatinine >110) + (0.258 x type 2 diabetes) + (-0.339 x CPG2) + (-1.089 x CPG3) + (-0.680 
x CPG4) + (-0.996 x CPG5) + (0.409 x length of stay 7-14 days) + (0.806 x length of stay 14-21 days) 
+ (0.976 x length of stay 21-28 days) + (1.466 x length of stay >28 days) 
 
Log odds of HCA UTI = -4.716 + (-0.502 x 1) + (0.874 x 1) + (-0.680 x 1)  
Log odds of HCA UTI = -5.024 
Odds of HCA UTI = e-5.024 
Odds of HCA UTI = 0.0053 
Probability = [0.0053 / (1 + 0.0053)] x 100 
Probability = 0.53% 
The second patient was a 79 year old male, admitted into CPG 1. He was a non-elective 
admission with a procedure carried out during the admission and no neurological disease. He had 
an average creatinine level of over 300 and a catheter recorded during his 8 day stay.  
Log odds of HCA UTI = -4.716 + (0.554 x 1) + (0.409 x 1) + (1.832 x 1) + (-0.502 x 1) + (0.874 x 1) + 
(0.412 x 1)  
Log odds of HCA UTI = -1.137 
Odds of HCA UTI = e-1.137 
Odds of HCA UTI = 0.32077 
Probability = [0.32077/ (1 + 0.32077)] x 100 
Probability = 24% 
When the cut-off of a probability >20% is applied, the first patient is not considered to have an 
HCA UTI according to their risk factors, whereas the second patient was. In this instance, the 
model’s prediction was correct, with the second patient having a code for a urinary tract 
infection that met the criteria for being healthcare associated.  
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Model Application 
 
As the model equation does not produce a binary outcome (see box 6), the log odds of having an 
HCA UTI were converted into probabilities. This was done in the validation dataset, where there 
were 1,621 infected patients out of a total of 18,548 patients. The majority of patients had 
probability of infection of less than 10% according to the final risk model and only 4% had a 
probability of over 30%. Using the threshold of over a 20% probability to indicate infection, the 
model had a sensitivity of 4%, specificity of 99%, PPV of 57% and NPV of 92%.  
 
 Table 8.9: Risk score creation – reference categories, regression unit values and the associated points 
Variable Regression coefficient Categories 
Reference 
values Regression units 
Associated 
points 
Sex 0.779 Male [REF] Female 
0 
1 
0 
0.779 
0 
3 
Catheter 1.832 No catheter [REF] Catheter 
0 
1 
0 
1.832 
0 
7 
Any 
procedure -0.502 
No procedure [REF] 
Procedure 
0 
1 
0 
-0.502 
0 
-2 
Non-elective 
admission 0.874 
Elective admission [REF] 
Non-elective admission 
0 
1 
0 
0.874 
0 
3 
Neurological 
disease 0.337 
No neurological disease [REF] 
Neurological disease 
0 
1 
0 
0.337 
0 
1 
Diabetes: 
Type 2 0.258 
No Type 2 diabetes 
Type 2 diabetes 
0 
1 
0 
0.258 
0 
1 
Age 0.544 <75 years [REF] >75 years 
0 
1 
0 
0.544 
0 
2 
Length of Stay - 
0.409 
0.806 
0.976 
1.466 
<7 days [REF] 
7-14 days 
14-21 days 
21-28 days 
>28 days 
0 
1 
1 
1 
1 
0 
0.409 
0.806 
0.976 
1.466 
0 
2 
3 
4 
6 
Creatinine:  0.412 Creatinine <110 / no test >110 
0 
1 
0 
0.412 
0 
2 
CPG: - 
 -0.339 
 -1.089 
 -0.680 
 -0.996 
CPG1: medicine [REF] 
CPG 2: Surgery & Cancer 
CPG3: Specialist services 
CPG4: Circular& renal 
CPG5: Women & children 
0 
1 
1 
1 
1 
0 
-0.339 
 -1.089 
 -0.680 
 -0.996 
0 
-1 
-4 
-3 
-4 
 
Based on this methodology, the range of scores a patient could have was -6 to 25.  These were 
stratified into three categories, to classify patients as low risk, medium risk and high risk for 
acquiring a UTI during their hospital stay, based on recorded risk factors (Table 8.10).  
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Table 8.10: Risk Score Categories for HCA UTI 
Risk Score Infected Uninfected % Patient with HCA UTI 
Low risk (-6 – 3) 321 10,114 3% 
Medium risk (4 – 10) 951 6,225 13% 
High risk (11 – 22) 348 586 37% 
 
The next step was to create a risk score, based on the regression model for HCA UTI. The reference 
categories and their associated reference values and points presented in Table 8.9. The baseline 
constant was based on the increase in risk associated with having type two diabetes and thus the 
constant was 0.258. All the other regression unit values were then divided by this value and rounded 
the nearest whole integer to become the assigned points for that risk, which are weighted according 
to their relative importance in predicting HCA UTI in the general hospital population.  
The risk score, whilst having increasing accuracy as the score increased, did not perform particularly 
well.  
 
8.2.2 Surgical Site Infections following CABG 
 
Following the same steps as were carried out for the HCA UTI prediction modelling, the first step was 
to determine which variables would be used and then to describe them in the development and 
validation datasets. A summary of the variables used and those excluded are presented in Table 
8.11.  
 
Table 8.11: Variables used or excluded from the CABG SSI risk modelling 
Binary Categorical (ref) Excluded 
Sex 
Smoking 
COPD 
Diabetes 
Admission from healthcare 
Non-elective admission 
Congestive heart failure 
Other infection 
Age (<50 years) 
Length of stay pre-CABG (<1 day) 
WBC (4-11x109/L) 
Albumin (33-47g/L) 
Haematocrit (37-52%) 
Diabetes (non-diabetic) 
Admission type (elective) 
Weight loss 
Obesity 
Alcoholism 
Blood transfusion 
Liver disease 
INR 
Day of surgery 
 
 
The sample size for the model development was 34 infected and 412 uninfected patients and 48 
infected and 608 uninfected patients for the model validation; this was an overall incidence of 7.4 
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infections /100 coronary artery bypass graft procedures. A summary of the variables, according to 
dataset and infection status are presented in Table 8.12.  
 
Table 8.12: Summary of risk variables in the development and validation datasets 
Variable Development Data [N(infected)] Validation Data [N(infected)] 
Total 446 (34) 656 (48) 
Age (years) (mean) 
(range) 
67 (66)  
30-88 (49-85) 
67 (64)  
21-89 (28-85) 
Length of stay pre-CABG (days) 6 (10)  0-53 (1-51) 
4 (6) 
0-89 (0-38) 
WBC (x109/L) 7.6 (7.7)  3.2-23.5  (3.8-11) 
8.2 (7.2)  
2.7-204.3 (4.1-10.2) 
Albumin (g/L) 37.3 (35.6)  19-47 (28.0-46) 
36.6 (35.6)  
19.2-48 (21-45) 
Haematocrit (%) 0.38 (0.36)  0.26-0.48 (0.26-0.46) 
0.39 (0.38)  
0.23-0.52 (0.29-0.46) 
Sex (female) 95 (16) 134 (9) 
Smoking 52 (2) 107 (8) 
COPD 23 (3) 33 (1) 
Diabetes:  All 
                   Type 1 
                   Type 2 
                   Other 
151 (17) 
6 (0) 
142 (17) 
3 (0) 
231 (21) 
13 (2) 
217 (19) 
1 (0) 
Admission from healthcare 140 (16) 166 (15) 
Non-elective admission 262 (21) 223 (21) 
Congestive heart failure 70 (6) 40 (6) 
Other infection 28 (7) 40 (6) 
 
There were a few differences between the development and validation datasets, importantly the 
differences in infection distribution in patient sex and the difference in ‘other infections’.  
 
Univariate Analysis 
 
Length of stay prior to CABG was transformed with the square root function to take into account the 
extremely long stay values, and the full white blood count prior to surgery was transformed using 
the inverse square root function [Appendix 9]. However, the relationship of these continuous 
variables with developing an SSI was not linear so all the continuous variables were analysed as 
categoricals. The results from the univariate analysis are presented in Table 8.13. 
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Table 8.13: Univariate analysis results for risks of SSI following CABG 
Variable Odds ratio SE P-value 95% CI 
Binary Variables 
Sex (ref: male) 3.747  1.370 <0.001 1.830, 7.672 
Smoking 0.453 0.337 0.287 0.105, 1.946 
COPD 1.897 1.227 0.322 0.534, 6.737 
Diabetes 2.075 0.744 0.042 1.027, 4.191 
Admission from healthcare 2.065 0.743 0.044 1.020, 4.181 
Not elective admission 1.679 0.615 0.157 0.819, 3.444 
Congestive heart failure 1.165 0.548 0.745 0.464, 2.927 
Other infection 4.827 2.315 0.001 1.885, 12.359 
Categorical Variables 
Age                                     50 – 60 year 
[<50 years]                       60 – 70 years 
                                           70 – 80 years   
                                           >80 years  
0.616 
0.700 
0.668 
0.946 
0.432 
0.435 
0.410 
0.705 
0.490 
0.566 
0.511 
0.941 
0.156, 2.439 
0.207, 2.368 
0.201, 2.225 
0.219, 4.077 
Length of stay:                 2 – 5 days 
[<1 day]                             >5 days  
0.911 
1.932 
0.469 
0.771 
0.856 
0.099 
0.332, 2.500 
0.884, 4.222 
Diabetes type*:               Type 2 2.224 0.800 0.026 1.099, 4.499 
Admission type:              Emergency 
[Elective]                           Non-elective  
1.731 
1.615 
0.722 
0.729 
0.188 
0.288 
0.764, 3.920 
0.667, 3.914 
WBC pre-CABG:               No result 
[4 – 11 x109/L]                 >11   
0.424 
2.093 
0.263 
2.328 
0.166 
0.506 
0.126, 1.428 
0.237, 18.508 
Albumin pre-CABG:         No result 
[33 – 47g/L]                      <33 
0.597 
3.049 
0.379 
1.207 
0.417 
0.005 
0.172, 2.073 
1.403, 6.625 
Haematocrit pre-CABG: No result 
[37 – 52%]                        <37% 
0.592 
1.963 
0.383 
0.740 
0.417 
0.074 
0.167, 2.102 
0.938, 4.110 
 
Following from the univariate analysis, the variables included in the multivariate analysis were: 
length of stay prior to CABG; pre-operative albumin level; pre-operative haematocrit level; sex; 
diabetes (binary); admission from healthcare and other infection. For diabetes, the binary version 
was used in the multivariate analysis despite containing less information, as many of the categories 
contained too little data.  
 
 Multivariate Analysis 
 
Following multivariate regression at the three inclusion thresholds, the final model being used was 
that with a significance threshold of 10%. The results from this backward stepwise logistic regression 
are presented in Table 8.14 and those of the 1% and 5% threshold models are in Appendix 9.  
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Table 8.14: Multivariate analysis results for risks of SSI following CABG using a significance threshold of 0.10 
Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 3.614 (1.285) 1.381 0.001 1.709, 7.642 
Albumin pre-CABG: <33 g/L 2.634 (0.969) 1.094 0.020 1.168, 5.944 
Other infection 3.692 (1.306) 1.900 0.011 1.346, 10.126 
Admission from healthcare 2.125 (0.754) 0.827 0.053 0.991, 4.555 
Constant -4.860 0.634 <0.001 -6.102, -3.617 
 
The result of the multivariate regression showed that having an ICD-10 code for a non-SSI infection 
carried the highest risk for developing an SSI following a CABG procedure, with an odds ratio of 
3.692. This was followed closely by being female (OR: 3.614). These have both been found to be risks 
of SSI previously, with female sex specifically a risk in CABG procedures; whereas ‘other infection’ 
had not been shown as a risk in this particular patient group before (Table 3.5).  
Low pre-operative albumin (hypoalbuminemia) was retained as a significant risk of developing an 
SSI; this could represent the patient having comorbidities, putting them at higher risk of infection. 
None of the investigated predictors were found to be protective.  
The results from the logistic regression in which all the risk variables were included (full model) are 
presented in Table 8.15. The regression coefficients differed between the two models, but not by a 
large amount. The exception to this was for having an albumin level of less than 33 g/L pre 
operation, which changed from 0.969 in the stepwise model to 0.839 in the full model. Therefore 
the stepwise model was likely to have overestimated the importance of this variable.  
 
Table 8.15: Multivariate analysis results for risks of SSI following CABG using a ‘full model’ 
Variable Odds ratio SE P-value 95% CI 
Sex (ref: male) 3.339 (1.206) 1.300 0.002 1.556, 7.163 
Diabetes 1.258 (0.229) 0.239 0.227 0.867, 1.825 
Admission from healthcare 2.112 (0.748) 0.859 0.066 0.952, 4.686 
Other infection 3.511 (1.256) 1.879 0.019 1.230, 10.021 
Length of stay:                 2 – 5 days 
[ref: <2 days]                    >5 days  
0.666 (-0.406) 
0.965 (-0.035) 
0.369 
0.450 
0.464 
0.940 
0.225, 1.974 
0.387, 2.409 
Albumin pre-CABG:         No result 
[33-47 g/L]                         <33g/L 
0.662 (-0.414) 
2.315 (0.839) 
0.662 
1.052 
0.679 
0.065 
0.093, 4.700 
0.950, 5.639 
Haematocrit pre-CABG: No result 
[37-52%]                            <37% 
0.991 (-0.009) 
0.987 (-0.013) 
1.006 
0.422 
0.993 
0.975 
0.136, 7.250 
0.427, 2.279 
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Based on the stepwise regression, the model equation for predicting SSI following CABG was:  
 
Log odds of post-CABG SSI = -4.522 + (1.231 x sex) + (1.124 x Pre-CABG Albumin <33g/L)  
+ (1.196 x other infection) + (0.754 x admission from healthcare) 
 
 
Model Validation  
 
Using the regression equation specified above, the model was tested in the 2010 data for its 
performance. The results of the Hosmer-Lemeshow test and the C-statistic from the regression 
models are given in Table 8.16 and Figures 8.4 and 8.5. 
 
Table 8.16: Model testing statistics for SSI following CABG 
Dataset Hosmer-Lemeshow chi2 (p-value) C-statistic 
2009 – Development 0.54 (0.9696) 0.7368 
2010 – Validation 1.38 (0.7092) 0.5375 
 
The c-statistic decreased considerably in the validation data, dropping from 0.75 to 0.54, indicating 
poor model discrimination in the validation dataset. The Hosmer-Lemeshow test on the other hand 
showed a relatively high goodness-of-fit in both datasets, indicating good model calibration.  
I used the same variables and ran the stepwise regression in the 2010 data to investigate whether 
different variables would be significant. In this model, no variables were retained either at the 0.01 
or 0.05 inclusion thresholds, with only ‘other infection’ being retained at the 0.10 threshold (p-value: 
0.062). This helps to explain the poor model discrimination, demonstrated by the c-statistic.  
When the residuals were investigated, the distribution of residuals versus predicted likelihood of SSI 
appeared random; the residuals’ mean centred on 0 (Figure 8.6). The skewness for the residuals in 
the 2010 validation data was 0.998 and the kurtosis was 3.540, indicating good normality of 
distribution. 
 282 
 
 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
si
tiv
ity
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.7368
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
S
e
n
si
ti
v
ity
0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.5375
-1
0
1
2
R
e
si
d
u
a
ls
0 .2 .4 .6 .8
Model prediction
Figure 8.4: ROC curve of the predictive 
model for SSI in the development data 
Figure 8.5: ROC curve of the predictive 
model for SSI in the validation data 
 
Figure 8.6: Scatter plot of the residuals 
against the model prediction of SSI 
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Model Prediction 
 
The log odds of having an SSI were converted into probabilities. This was carried out in the 2010 
data, where there were 48 infected patients and 606 uninfected patients. The majority of patients 
had a probability of infection of less than 5% according to the model equation and only 5% of 
patients had a probability of over 20%. Using the threshold of over a 10% probability to indicate 
infection, the model had a sensitivity of 17%, specificity of 82%, PPV of 7% and NPV of 93%. 
Lowering this threshold to a probability of infection of over 5% according to the model equation, the 
sensitivity increased to 56%, but the sensitivity lowered to 53%.  
The next step was to create a risk score, with the reference categories and their associated reference 
values and points presented in Table 8.17. The constant was based on being admitted from 
healthcare, and was 0.754. 
 
 Table 8.17: Risk score creation – reference categories, regression unit values and the associated points 
Variable Regression coefficient Categories 
Reference 
values 
Regression 
units 
Associated 
points 
Sex 1.285 Male [REF] Female 
0 
1 
0 
1.285 
0 
2 
Other infection 1.306 No other infection [REF] Other infection 
0 
1 
0 
1.306 
0 
2 
Admission from 
healthcare 0.754 
Not admitted from healthcare [REF] 
Admission from healthcare 
0 
1 
0 
0.754 
0 
1 
Pre-operative 
albumin:  0.969 
Albumin >33 / no test [REF] 
Albumin <33 
0 
1 
0 
0.969 
0 
1 
 
Based on this methodology, the scores a patient could have ranged from 0 - 6.  These were stratified 
into three categories, to classify patients as low risk, medium risk and high risk for acquiring an SSI 
following a CABG procedure, based on recorded risk factors (Table 8.18). The risk score was 
extremely poor at distinguishing between patients who went on to develop infections from those 
who did not. 
 
Table 8.18: Risk Score Categories for SSI following CABG 
Risk Score Infected Uninfected % Patient with SSI 
Low risk (0) 21 319 6% 
Medium risk (1-2) 20 216 8% 
High risk (3-6) 7 73 9% 
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8.2.3 Surgical Site Infections following Caesarean Section 
 
Following the same process again, the first steps were to determine which variables would be used 
and describe them in the development and validation datasets. A summary of the variables used and 
those excluded are presented in Table 8.19.  
 
Table 8.19: Variables used or excluded from the caesarean SSI risk modelling 
Binary Categorical (ref) Excluded 
Diabetes 
Pre-eclampsia 
Chlorioamnionitis 
Married 
Non-white ethnicity 
Age (<25) 
Length of stay (0 days) 
Admission type (Elective) 
Day of surgery (Monday) 
Weight loss 
Obesity 
Alcoholism 
Smoking 
Blood transfusion 
COPD 
INR, Albumin, WBC 
Haematocrit 
 
Unlike for the CABG patients, routine blood tests were not necessarily carried out for caesarean 
section patients, meaning there was not enough information in the laboratory variables to include 
them in the analysis. The sample size for the model development was 43 infected and 1,674 
uninfected patients and 88 infected and 2,464 uninfected patients in the validation dataset. This was 
an overall incidence of 3.1 infections / 100 caesarean section procedures. A summary of the 
variables, according to the dataset and infection status are presented in Table 8.20.  
 
Table 8.20: Summary of risk variables in the development and validation datasets 
Variable Development Data [N(infected)] Validation Data [N(infected)] 
Total 1,717 (43) 2,552 (88) 
Age (yrs) (mean) 
 (range) 
33.5 (32.7)  
18-58  (19-46) 
33.3 (31.6)  
18-52 (18-45) 
Length of stay pre-Caesarean (days) 0.6 (1)  0-7 (0-4) 
0.5 (0.8)  
0-8 (0-6) 
Diabetes 62 (2) 134 (1) 
Chlorioamnionitis 11 (1) 24 (4) 
Pre-eclampsia 137 (5) 183 (8) 
Married 1,000 (16) 1,260 (37) 
Non-white ethnicity 752 (22) 1,010 (41) 
Day of surgery: Sunday 
                            Monday 
                            Tuesday 
                            Wednesday 
                            Thursday 
                            Friday 
                            Saturday 
149 (1) 
279 (6) 
293 (5) 
282 (6) 
264 (11) 
286 (9) 
164 (5) 
201 (9) 
417 (17) 
427 (13) 
417 (8) 
419 (17) 
458 (15) 
213 (9) 
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Univariate Analysis 
 
Length of stay prior to caesarean section was transformed with the square root function; however 
the relationship with developing an infection was not linear, and therefore the categorical version of 
the variable was used. The results from the univariate analysis are presented in Table 8.21. 
 
Table 8.21: Univariate analysis results for risks of SSI following caesarean section 
Variable Odds ratio SE P-value 95% CI 
Binary Variables 
Diabetes 1.312 0.966 0.712 0.310, 5.552 
Chlorioamnionitis 3.962 4.201 0.194 0.496, 31.659 
Pre-eclampsia 1.537 0.744 0.375 0.595, 3.971 
Married 0.416 0.133 0.006 0.222, 0.777 
Non-white ethnicity 1.335 0.412 0.350 0.728, 2.446 
Categorical Variables 
Age:                    <25 yrs 
[ref: 30-35]         25-30 
                              35-40 
                             >40     
3.243 
1.135 
1.530 
1.885 
1.518 
0.591 
0.650 
1.047 
0.012 
0.809 
0.317 
0.254 
1.296, 8.118 
0.408, 3.152 
0.665, 3.519 
0.635, 5.597 
Length of stay:  1 – 3days 
[ref: 0 days]       >4 days 
1.545 
3.801 
0.531 
1.646 
0.205 
0.002 
0.788, 3.029 
1.626, 8.882 
Day of surgery: Sunday 
[ref: Monday]   Tuesday 
                            Wednesday 
                            Thursday 
                             Friday 
                             Saturday 
0.307 
0.790 
0.989 
1.978 
1.478 
1.431 
0.334 
0.483 
0.577 
1.019 
0.789 
0.878 
0.277 
0.700 
0.985 
0.185 
0.464 
0.559 
0.037, 2.578 
0.238, 2.618 
0.315, 3.104 
0.721, 5.428 
0.519, 4.210 
0.430, 4.764 
 
The admission type was not included as there were too few patients that were not admitted non-
electively. Based on the results of the univariate analysis, only the following variables were included 
in the multivariate regression: length of stay, age and being married.  
 
Multivariate Analysis 
 
The multivariate backwards stepwise regression was performed at the three inclusion thresholds 
and the model from the 10% threshold for significance analyses was selected.  The models at the 1% 
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and 5% threshold are presented in Appendix 10. The results of this regression are presented in Table 
8.22.  
 
Table 8.22: Multivariate analysis results for risks of SSI following caesarean section 
Variable Odds ratio (coefficient) SE P-value 95% CI 
Length of stay: >4 days 2.932 (1.076) 1.195 0.008 1.319, 6.516 
Age:  <25 years 0.561 (-0.578) 0.180 0.072 0.299, 1.052 
Married 0.437 (-0.829) 0.140 0.010 0.233, 0.819 
Constant -3.131 0.244 <0.001 -3.610, -2.653 
 
Only one variable was retained in the model as a risk of developing an SSI following caesarean 
section. This was having a pre-operative stay of over 4 days, with an odds ratio of 2.932.  The other 
two variables retained in the model were both protective. Being less than 25 years of age and 
married, both reduced the likelihood of a patient developing a surgical site infection.  
The results from the ‘full’ logistic regression are presented in Table 8.23. The regression coefficients 
differed between the two models, with the effects of being young or a pre-operative length of stay 
of over 4 days both exaggerated by the stepwise model.  
 
Table 8.23: Multivariate analysis results for risks of SSI following Caesarean using a ‘full model’ 
Variable Odds ratio SE P-value 95% CI 
Married 0.483 (-0.728) 0.161 0.029 0.251, 0.928 
Age:                    <25 yrs 
[ref: 30-35]         25-30 
                              35-40 
                             >40     
0.447 (-0.806) 
0.706 (-0.348) 
1.503 (0.408) 
- 
0.196 
0.313 
1.66 
- 
0.067 
0.433 
0.713 
- 
0.187, 1.058 
0.296, 1.685 
0.172, 13.146 
- 
Length of stay:  1 – 3days 
[ref: 0 days]       >4 days 
1.414 (0.347) 
3.353 (1.210) 
0.494 
1.473 
0.321 
0.006 
0.713, 2.806 
1.417, 7.931 
 
The final model equation for SSI following caesarean section was:  
 
Log odds of post-caesarean SSI = -3.131 + (1.076 x length of stay >4 days) + (-0.578 x age <25 years) 
+ (-0.829 x married) 
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Model Validation  
 
The results of the different statistical tests for model fit are presented in Table 8.24 and Figures 8.7 
and 8.8. The model discrimination was relatively low in both the development and validation 
datasets, with the c-statistic less than 0.7 in the development dataset and decreasing to only 0.56 in 
the validation dataset. The Hosmer-Lemeshow test on the other hand indicated relatively good 
model fit, with p-values over 0.05 for both datasets. Therefore there was good calibration but poor 
discrimination.  
 
Table 8.24: Model testing statistics for SSI following CABG 
Dataset Hosmer-Lemeshow chi2 (p-value) C-statistic 
2009 – Development 2.90 (0.4066) 0.6598 
2010 – Validation 2.20 (0.5313) 0.5556 
 
When the residuals were then investigated, the skewness was -0.419 and the Kurtosis 2.234, 
demonstrating that there residuals had a relatively normal distribution. The graph of the residuals 
versus the model prediction shows a random distribution, however the running mean was not 
consistently centred on zero (Figure 8.9).  
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Figure 8.9: Scatter plot of the 
residuals against the model 
prediction of SSI 
 
Figure 8.7: ROC curve of the 
predictive model for SSI in the 
development data 
Figure 8.8: ROC curve of the 
predictive model for SSI in the 
validation data 
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Model Prediction 
 
Converting the log odds to a probability resulted in all but 1.5% of the patients having a probability 
of infection of less than 10%, according to the patient’s risk factors. The number of cases, based on 
ICD-10 codes for the 2010 data was 88 out of 2,552 patients (3.4 infections / 100 caesarean 
sections).  
The next step was creating the risk score, and the baseline constant was the only positive regression 
unit, indicating the increase in risk associated with being admitted for longer than 4 days (1.076). All 
the other regression unit values were then divided by this value and rounded the nearest whole 
integer to assign points (Table 8.25).  
 
Table 8.25: Risk score creation – reference categories, regression unit values and the associated points 
Variable Regression coefficient Categories 
Reference 
values 
Regression 
units 
Associated 
points 
Age: <25 years -0.578 >25 years <25 years 
0 
1 
0 
-0.578 
0 
-1 
Length of stay: 
>4 days 1.076 
Length of stay <4 days 
Length of stay >4 days 
0 
1 
0 
1.076 
0 
1 
Married -0.829 Not married Married 
0 
1 
0 
-0.829 
0 
-1 
 
Based on this methodology, the range of scores a patient could have ranged between -2 and 1.  
These were stratified into two categories, to classify patients as low risk, medium risk and high risk 
for acquiring an SSI following caesarean section, based on their recorded risk factors (Table 8.26).  
 
Table 8.26: Risk Score Categories for SSI following caesarean 
Risk Score Infected Uninfected % Patient with SSI 
Low risk (-2 to -1) 43 1,188 3% 
High risk (0 to 1) 39 1,048 4% 
 
The risk score for predicting surgical site infections following caesarean section performed extremely 
poorly in this patient group. Stratifying the score into high and low risk demonstrated almost no 
difference in the proportion of infected patients.   
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8.3 Discussion 
 
In this chapter I created three risk scores based on three predictive risk models, one for SSI following 
CABG, one for SSI following caesarean sections and one for healthcare associated urinary tract 
infections in the general inpatient population.  
The model for healthcare associated urinary tract infections performed the best out of the three 
cohorts, with AUC values of over 0.77 in both the development and validation datasets. However, 
they did not all perform as well as hoped when validated and used for infection prediction. There 
were several factors which limited their development. 
 
Defining infected and uninfected patients 
 
The first factor which may affected the potential for generating accurate risk models was 
inaccuracies in determining patients who were infected and uninfected. As has been discussed 
previously in this thesis, ICD-10 codes have been reported as having variable success at identifying 
true healthcare associated infections (496, 556). If the cases and controls were incorrectly defined, 
the relationship to risks of infections would have been biased in the analyses. I tried to minimise the 
effect of inaccurate cases by using the combinations of ICD-10 codes found to have the highest 
sensitivities and specificities in prior chapters when compared to traditional surveillance sources.  
Also, those patients defined as ‘uninfected’ in the three cohorts could in fact have had healthcare 
associated infections. As many of the risks for developing an HCAI are similar for the different 
conditions, not excluding those patients with a different infection from the ‘uninfected’ patient 
groups may have biased the relationships. ‘Other infection’ was included as a risk variable in the 
model for SSI following CABG procedures, and therefore those patients with other infection codes 
could not have been excluded from the cohort. These potentially infected uninfected patients were 
not excluded from the HCA UTI and SSI following caesarean analyses, as the accuracy of the patients 
being excluded may not have been high.  
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Model Creation and Validation 
 
The second area which could have affected the accuracy of the risk models was the methodology 
used to create them. The first issue for discussion was the choice to assign the development and 
validation datasets using a temporal method. There are several other methods available for 
assigning the development and validation datasets, namely internal (randomly assignment or basic 
splitting of data from the same location and time period) or external validation (data from a 
different location, e.g. a different hospital). External validation is seen as the best form of validation 
(512), however in this study external validation was not possible as only data from Imperial College 
Healthcare NHS Trust was available. Assigning the datasets temporally goes part way to becoming 
‘external’ as the two data sets are independent in time. Whilst I could have randomly assigned the 
patients to the different datasets, Altman et al. suggest that temporal validation is a more stringent 
method  than internal validation (512).    
The next cause for discussion was the use of a backwards stepwise method of variable selection for 
the final model. Backwards stepwise regression begins with all the variables in the model and 
variables are removed until all those variables remaining met the significance threshold. This 
methodology for variable inclusion has several reported issues, because multiple comparisons are 
made using a methodology which was only intended to make one comparison (557). This results in 
the standard errors and p-values being lower than they should be, and can lead to slightly spurious 
variable inclusions (558). In comparison with forward selection however, using a backward approach 
is favourable as it will only remove variables if they do not reduce model fit, whereas a forward 
approach may omit certain variable effects (554, 559). 
In this chapter, the variables had already been through a pre-selection process based on their 
previously established relevance as risk factors for SSI and HCA UTI. When all the potential variables 
identified at a univariate level were included in full models (not using a stepwise method) the 
regression coefficients did not change dramatically from the stepwise approach in the HCA UTI 
cohort. There were some noteworthy changes for the two SSI cohorts however, with the regression 
coefficients over-estimated in the stepwise models. This use of this method for variable selection 
was unlikely to have negatively impacted the model for HCA UTI, but may have had an effect on the 
two poorly performing SSI models.  Despite these limitations, a stepwise approach was appropriate 
as the purpose of the analysis was predictive and not explanatory.  
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Finally, the use of three thresholds for significance led to both of the SSI risk models having an 
inclusion threshold of significance of 10%, higher than the routinely accepted threshold for 
significance of 5%. This may have led to variables being retained in the final model that had a poor 
association with the outcome. However, the risk models for surgical site infections following both 
CABG and caesarean sections performed poorly at all three significance thresholds, and the models 
which used the 10% threshold had the most variance explained. The HCA UTI risk model on the 
other hand had the best performance using a significance threshold of 1%, lower than the standard 
5%. The lower threshold was chosen as it presented the most parsimonious model, whilst 
maintaining a good discrimination and reasonable fit.   
The final issue in the model creation and validation was the use of goodness of fit as a method for 
selecting and assessing the best model. Measures of calibration and discrimination are important, 
however there are known issues with the commonly used Hosmer-Lemeshow test for assessing 
goodness of fit (560). The Hosmer-Lemeshow tends to over-estimate the model fit in a small sample 
size, and under-estimate the model fit in a large sample size (561, 562). This pattern was seen in this 
chapter as the Hosmer-Lemeshow values were lower in the HCA UTI cohort than in the CABG and 
caesarean section cohorts. The utility and performance of the final models in this chapter were not 
based solely on the Hosmer-Lemeshow values. Aware of the issues in interpretability of this 
measure, I took into account the residuals and numbers of patients at varying risk scores before 
making any conclusions regarding their utility.  
 
Risk Factors 
 
As with the identification of infected and uninfected individuals, ICD-10 codes were used to create 
many of the risk variables.  And as has been discussed above, there may have been inaccuracies in 
this data, with under recording of conditions.  The coding clinic in the UK published guidance on how 
to code for different conditions, as well as a published list of conditions which must be coded for 
(475). This list contains several comorbidities, such as renal failure and diabetes, meaning that these 
variables should have been relatively complete. Other comorbidities however are less clearly 
defined. This may have caused bias, as certain risks with good coverage become overestimated, 
whilst those which are under-reported become under-estimated.  
This links to the limitation of several variables being left out of the analyses due to the lack of 
patients with the recorded risk. Take obesity or smoking for example, both of these risks are 
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relatively common in society, yet there were too few patients with these codes to be included in the 
caesarean analysis. Not having obesity reliably recorded posed a large limitation for SSI prediction. A 
previously published risk score for SSI following CABG found that using just BMI and diabetes could 
stratify patients at risk of developing infections (233, 551). For caesarean patients, BMI has been 
shown as the most significant risk for developing a surgical site infections (526), so including this 
single variable could have greatly improved the power of these two models.   
Similarly, there were several risk factors found to be relevant in chapter 3, which could not be 
investigated as they were not available electronically. A good example here is of the duration of 
surgery as a risk for surgical site infections. This information is manually collected in the HPA SSI 
surveillance, cardiac registry and the caesarean section intervention study; however it was not 
available in an electronic format for this project. In fact the three variables upon which the NNIS 
score is based were not electronically available, namely wound class, length of surgery and ASA 
score (548). This raises the question of whether, without more comprehensive data, a good enough 
risk model can be generated using solely administrative data.  
The risk factors that were included in the model creation had been identified as relevant by a 
literature review, with the exception of Clinical Programme Group (CPG) and marital status. CPG was 
included to act as a reflection of specialty or patient type in the HCA UTI prediction model and it 
demonstrated that being a non-medical patient was protective. Marital status was included in the 
SSI model for patients who had had caesarean sections; whilst this particular variable had not been 
investigated previously and found relevant, other social factors have been (183, 196). One possible 
explanation for this relationship (of being married as protective against developing an SSI) is that 
married women have better support at home, encouraging positive health behaviour and providing 
stability after childbirth. Another is that married people have better underlying levels of well-being 
and ultimately health outcomes (563).  
Validation of risk models is not always performed (512), and so the risk variables selected for the 
models may not actually have been as significant as previously thought as they were based on 
unvalidated findings. However, the variables found to be significant we all scientifically plausible as 
protectors or risks. 
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8.4 Conclusion 
 
Using predictive models to establish an individual’s risk of becoming infected is a common 
methodology for HCAI, with over 300 published papers included in the literature review from 
Chapter 3. However, relatively few were based in the NHS and none of those that were had used 
routine electronic data. The aim of this chapter was to assess whether this could be done and in 
addition whether it would be useful as a surveillance tool. Risk models were created for three 
patient cohorts, however when validated and the model fit investigated, the utility of the models 
were called into question. The subsequent risk scores, especially for risk surgical site infections, 
performed relatively poorly at distinguishing high risk from low risk patients.  Without more 
comprehensive data in the routine electronic data (such as obesity), risk scores for dynamic, 
electronic, bedside prediction is not possible for all patient groups.  
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Chapter 9: Discussion 
 
 
Summary 
 
This is the final chapter of the thesis, presenting the overall discussion and the conclusions of the 
thesis. The discussion draws on themes encountered throughout the project, and evaluates the 
results in light of the limitations and barriers encountered working in a real life context. The 
conclusion addresses whether the original hypothesis for the thesis could be accepted and 
recommendations based on the research conducted and suggestions for further work are provided.  
 
 
 
 
  
Chapter 9: 
Discussion 
 Chapter 2: 
Surveillance 
of HCAI 
Chapter 3: 
Risks of 
HCAI 
 
Chapter 8: 
Risk 
Modelling 
Chapter 7: 
Automated 
case 
detection 
Chapters 5& 
6: Syndromic 
surveillance 
Chapter 4: 
Introduction 
to the 
databases 
 296 
 
9.0 Summary of Results 
 
This thesis aimed to assess whether routinely collected electronic health data could be used to 
develop novel healthcare associated infection surveillance tools within the NHS environment. In the 
process of addressing this question several outputs were generated.  A summary of the key findings 
from each chapter are presented below: 
 
 Automated and syndromic surveillance are emerging as important methods within infection 
surveillance, but as yet are not widely applied for HCAI (chapter 2) 
 The use of routine data within the NHS for surveillance and risk modelling is currently lacking 
despite large amounts of potential data sources (chapters 2, 3, and 4) 
 A lack of true ‘gold standard’ data sources relating to CABG patients was found, with the 
implementation of a single integrated system having the potential to increase both data 
quality and sustainability of SSI surveillance (chapter 5) 
 Syndromic surveillance of surgical site infections based on laboratory data alone is plausible 
in certain patient groups, such as coronary artery bypass graft patients, but less so with 
caesarean section patients (chapters 5 and 6) 
 Whilst CRP and WBC were found useful in identifying surgical site infections in line with 
previous studies, fibrinogen and platelets were found to be better markers for surgical site 
infections (chapter 5) 
 Automated case finding is a plausible surveillance method for healthcare associated urinary 
tract infections, with the potential to complement traditional surveillance of catheter 
associated infections (chapter 7) 
 The generation of simplified risk scores for SSI and HCA UTI based on routine data 
demonstrated mixed success, with missing information a large limiting factor (chapter 8) 
 Throughout the this thesis, linked data sources have demonstrated improved data quality 
and utility, highlighting the benefits of an integrated electronic health data system 
 
The depth of analyses carried out, the population groups investigated and subsequently the results 
obtained were highly dependent on the databases available, the information they contain and the 
quality of this information. Discussions of these aspects are presented below, along with an 
assessment of the utility and applicability of the results.  
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9.1 Barriers and Limitations 
 
As stated in the Introduction (section 1.3), this project was carried out at Imperial College Healthcare 
NHS Trust, one of the largest NHS Trusts in England. The context of this real life setting was the basis 
for both limitations and strengths in the project.  
The complex organisational structure, and therefore complex, fragmented and unceasingly changing 
IT infrastructure, meant that there were barriers experienced in terms of data access, data coverage 
and data quality. There were several factors which explain the challenging circumstances of the 
study setting, firstly that of budget constraints. This is not unique to ICHNT, but is a challenge being 
faced throughout the NHS. Therefore recommendations relating to streamlining and developing 
sustainable surveillance have applications across the NHS. As a consequence of resource constraints, 
there were changes to personnel and redundancies, resulting in increased workloads and 
discontinuity in the staff responsible for IT and data management.    
Specific to ICHNT was the merger of two trusts in 2007; the remnants of this merger are still seen in 
the out-dated IT systems. A recent article published on BBC News, specifically regarding the 
management of patient data at Imperial College Healthcare NHS Trust, highlighted the role of 
“antiquated computer systems” in limiting patient care (564). Alongside the migration to Cerner, this 
meant that the IT department specifically has been facing several challenges in terms of data 
management, relocation, storage and harmonisation.  
The strength of this project has been to demonstrate that research can still be conducted and reveal 
interesting results, in spite of these real world complexities and barriers. The specific limitations of 
data access, data coverage and data quality are discussed below. These issues merit discussion for 
the bearing they have on the results presented, as well as being integral to in assessing whether 
surveillance can practically and efficiently be carried out using routine data.   
 
9.1.1 Accessing Databases 
 
The first challenge for conducting research with routine data within the NHS environment was 
gaining access to the routine data. There are over 750 databases stored at Imperial College 
Healthcare NHS Trust, providing a large pool of data to choose from (10). Conversely, this multitude 
of resources highlights the fragmented structure of the IT system at ICHNT, with data siloes arising in 
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the absence of a single centralised data warehouse.  Access to data proved to be the largest barrier I 
experienced in this project, with issues ranging from technical to organisational and individual 
resistance.  
Barriers to innovation within healthcare are a recognised issue; explanations for this include: limited 
financial resources; lack of support from key players; deficient policies to support innovations and a 
culture of accountability for meeting restrictive demands (566). In the case of this project, these 
barriers were present, with budget constraints and resistance amongst gate keepers to the data. 
This project eventually aims to provide efficiency and sustainability to surveillance activities through 
better use of administrative hospital data, which could subsequently lead to cost savings and 
improved clinical care. The technical capacity to link the different databases exists and support for 
this research was publicly expressed by key senior members of ICHNT. One of the crucial successes 
in the CIPM project was the initial ethics approval, allowing the use of all local administrative 
hospital data for research (Appendix 5). However, this top down support did not necessarily 
penetrate to the levels where collaboration was required. Reservations were experienced when 
trying to access some of the databases, despite having ethical and managerial approvals, as 
demonstrated by this quote: 
 
“People at the top level were fine with us having access but the middle tier wasn't that happy to co-
operate which made my life a bit complicated” (CIPM employee) 
 
The databases at ICHNT are generally not centrally managed by the IT department (with the 
exception of the patient administration system), but instead administered by individual 
departments. This meant that gaining access to each data source required approval from a different 
person or persons, each with varying protocols and policies of their own. This came with a variety of 
challenges, and different departments presented different complications.  
Firstly, there were concerns raised about the sharing of data with people from outside of 
departments for fear of misunderstanding specialised data. The types of data available at the Trust 
are vast and due to the expert nature of their content (such as antibiotic resistance data), not always 
self-explanatory for the person attempting to analyse them. This is understandably a large concern 
to the specialists who are in charge of the databases, as misinterpretation of the complex data could 
lead to incorrect results being published in the absence of expert input. This issue is not unique to 
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ICHNT, with a previous study on healthcare innovation adoption noting the need for siloes to be 
broken down and flexible ways of working in collaboration to succeed them  (567). 
CIPM is a multidisciplinary research initiative, working in partnership with Imperial College 
Healthcare NHS Trust, as well as experts from the HPA. Through collaborating with individual experts 
across several departments, this barrier to research was eventually broken down, facilitating 
discussion and feedback of the research outputs.  
Remaining residual resistance may have been related to the matter of data ownership, as this topic 
is wrought with misunderstandings. Whilst this project was granted ethical approval to use all 
routine electronic data stored at a local level from ICHNT in an anonymised format, the principles of 
data ownership were less straightforward amongst those holding the data. The ethics approval 
covered all routine data within the Trust, from large administration systems to small department 
level audits and these involve varied levels of personnel involvement. Certain databases are created 
by an individual staff member wanting to pursue a specific research question, require NHS staff to go 
through lengthy collection processes, or form part of a voluntary research network. In comparison, 
the Patient Administration System or the mandatory surveillance information are required and 
collected by Trusts as standard. These routinely go on to be used for research (in the form of 
Hospital Episode Statistics) or are publicly reported.  
These different underlying purposes for hospital data may have fostered different opinions of 
ownership and sharing practices between departments and database managers. There was no issue 
in gaining access to the PAS data, or infection prevention and control surveillance data, as these are 
collected for planned dissemination. On the other hand, the microbiology department for example, 
has a sense of ownership of the information as a large amount of time has gone into generating the 
data and the cultural ethos has supported this sentiment.   
However, the perception that contributing to the collection, generation or management of patient 
data provides justification for ownership is flawed. The NHS acts as a guardian of patient data, 
ensuring this information is only used when necessary and aims to produce benefits for patients. The 
ethical approval process which all researchers undergo is in place to ensure that these two 
conditions are met and the handling of any sensitive information is done so appropriately. The 
Department of Health has published guidelines relating to patient data, information governance and 
the legal arguments relating to data ownership (568-570). These state that: 
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“Under the Public Records Act all NHS employees are responsible for any records that they create or 
use in the course of their duties. Thus any records created by an employee of the NHS are public 
records and may be subject to both legal and professional obligations.” (568) 
 
However, this official standpoint is not necessarily well known or clear, either amongst researchers 
or NHS staff, as the following quote demonstrates:  
 
“Since the original working group’s report on the security of patients’ information in 1997, it has 
become clear that there is sometimes a lack of understanding about the rules and this can act as a 
barrier to exchanging information that would benefit the patient.” Dame Fiona Caldecott 
(Accessed from: http://www.dh.gov.uk/health/2012/02/dame-fiona-caldicott-to-lead-confidentiality-review) 
 
The perception of ownership, the specialised nature of the data and the attitudes of individual 
departments are important considerations in data access for a project such as this. Clearer, more 
widely disseminated instructions regarding data access protocols would be welcome within the NHS, 
removing a major barrier to conducting research within routine data. Whilst engaging with individual 
departments and their data managers is crucial for collaboration, it should not be misconstrued as 
asking for permission to use data for which approval has already been granted.  
In this project, there was some degree of technical issues. The amount of data that is stored locally 
at ICHNT is vast and done so in a fragmented fashion. The format of the data causes it to take up 
more space than necessary and overlapping systems containing the same information unnecessarily 
increase the storage space required. Hence, when attempting to link several of these data sources 
together, the problem of space and where to store it emerged. This led to delays in the project, and 
affected how the data could be extracted for research.  
Despite the challenges and barriers to data access, seven distinct types of data were exploited in this 
project, from the large centrally managed patient administration system, to the laboratory data and 
clinical surveillance. This range of data types allowed for insights into the relative strengths of 
different sources for developing novel surveillance systems.  
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9.1.2 Data Completeness  
 
The desired information was not always available for analysis. This limitation of coverage (or 
completeness) was relevant as missing information could have biased the results obtained in this 
study and shaped the range of analyses carried out. In this project there were three different 
limitations in completeness: missing datasets, unavailable variables and missing time periods in 
which the datasets could be accessed.  
 
Missing Datasets 
 
There are several datasets that could have been relevant in creating surveillance tools for healthcare 
associated infections, however constraints on time and technical barriers meant not all desired 
databases could be exploited. The creation of a comprehensive Trust wide data warehouse which 
once completed may greatly diminish this issue for future research projects, is underway at ICHNT 
but still on-going. This limitation mainly applies to two potentially important data sources, namely 
accident and emergency data and theatre data.  
‘Theatre Man’, the database containing information relating to surgical procedures had the potential 
to contain several variables relevant for risk score creation for surgical site infections. As the 
literature review on risks for HCAI (chapter 3) demonstrated, several of the most important risks for 
developing surgical site infections relate to specific features of the surgery, e.g. the number of 
surgeon contacts (196, 209). These risks could not be included in the risk models as surgery specific 
features were not present in any of the routine administrative databases used. Considering the poor 
performance of the risk scores for surgical site infections, the addition of ‘Theatre Man’ data could 
have rendered considerably different predictive scores.   
As much of the syndromic surveillance which has been successfully implemented to date is based on 
accident and emergency (A&E) data (100, 107, 111), this data source could have provided greater 
insights and innovations for HCAI surveillance in the NHS. A specific example within the A&E data is 
that of re-admission, which presents opportunities when investigating syndromic surveillance and 
automated detection of HCA UTI. Whilst I generated re-admission variables in the different patient 
cohorts, this was based solely on the time between admissions.  The basis for classifying an 
individual as being re-admitted within the A&E data may have been based on more sophisticated 
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criteria. Another example of where this data could have added information is if a patient presents to 
A&E after being discharged from a surgical admission, and not subsequently admitted. For example, 
if they are prescribed antibiotics for a superficial wound infection, before being referred to their GP, 
this patient would not be recorded by the routine administrative data I had available for this project.  
However, in the specific example of CABG patients, Hammersmith Hospital is a tertiary referral 
centre. If patient’s are not local then they may seek care at a hospital closer to home in the event of 
a post-operative complication. Therefore it is unclear how much extra information this source from a 
single Trust would add. 
 
Unavailable Variables 
 
Within Imperial College Healthcare NHS Trust there are variables which are currently not stored 
electronically, or are done so inconsistently. The lack of specific variables could have weakened 
analyses, both for the risk modelling and syndromic surveillance. Again, the poorly performing risk 
models for surgical site infections are likely to have suffered from certain variables not being 
routinely stored electronically.  
Body mass index is the best example of a variable which was found significant as a risk for surgical 
site infections by previous studies and can be recorded for in the routine data, yet it could not be 
used in any meaningful way within the data I was using. This is in light of the results from the 
traditional surveillance (which collects this information) that demonstrated 27% of CABG patients 
and 19% of caesarean patients were obese. The NHS Coding Clinic prescribes that a set of specific 
comorbidities always be coded for if they are present, whether they are the reason for admission or 
not. At present, obesity is not one of these (475). Including obesity in this list of essential 
comorbidities to be consistently coded for has the potential to improve the utility of administrative 
data for surveillance activities.  
The lack of electronic antibiotic prescribing data or of any electronic drug prescriptions or therapies 
(including blood transfusions or administration of fresh frozen plasma) posed a major limitation in 
terms of both risks of and proxies for infection. Antibiotic data has been used at ICHNT previously as 
a proxy in infection surveillance (116); however this was based on an actively collected biannual 
prevalence survey. Implementing an electronic system for prescriptions could greatly enhance the 
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potential for syndromic surveillance at ICHNT, seeing as a system using manual data collection for 
antibiotics has already demonstrated surveillance benefits.  
Finally, the markers identified by the literature as being effective at identifying surgical site 
infections but not exploited for syndromic algorithms of SSI in this project included procalcitonin, 
international normalised ratio and the erythromycin sedimentation rate. These markers were not 
used as procalcitonin is not currently measured at ICHNT, and INR and ESR were rarely tested. PCT 
has been shown on multiple occasions to be good at distinguishing bacterial infections from viral 
infections and non-infectious inflammation (509, 571), including for surgical site infections (572).  
The NICE guideline relating to febrile illness in children conducted a cost-effectiveness analysis of 
CRP versus procalcitonin. This guideline concluded that CRP should not be replaced by the more 
expensive PCT test, as the benefit in diagnostic accuracy was not enough and the evidence base was 
too weak to justify a change (573). Whilst this is not directly relevant to surgical site infections, it 
could explain why procalcitonin is not used routinely in the NHS. Trialling the use of procalcitonin as 
a marker for bacterial infections is currently in discussion at ICHNT, and coronary artery bypass graft 
patients would constitute an appropriate patient group.  
 
Missing Time Periods 
 
An aspect of data coverage which restricted analyses was the duration for which certain data were 
available. This limited the power of analyses and in specific cases prevented steps of analysis which 
were originally planned. Examples to highlight are that of the laboratory data, radiology data and the 
HPA SSI surveillance. 
There were two types of extracts of laboratory data extracts used in this project. The first, 
incomplete data from a back-up system and the second was an extract from the ‘live system’, which 
only ever contains the most recent six months’ worth of data. The back-up data covered January 
2009 to July 2011, and the live system data covered the time period of September 2011 to March 
2012. As a result, there was a time period in which no laboratory information was available. The 
development of syndromic surveillance in CABG patients was the analysis which suffered most from 
this lost time period as there were several months of HPA SSI surveillance data with no 
corresponding laboratory data.  
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The radiology data for this project was available from January 2010 and extracts were obtained until 
the end of 2011. However, due to the IT system changing at the start of 2010, any data before this 
was not available. This meant that x-ray requests could only be investigated as a proxy for surgical 
site infections in part of the available data for CABG patients. Despite there being a significant 
relationship between x-ray requests and SSI following CABG, they did not appear to increase the 
accuracy of the syndromic algorithms. It is possible that with more data this could have changed, 
however this was not likely to have caused a serious limitation.   
The HPA SSI surveillance data I used in the project had undergone the standardised HPA cleaning 
process, which is carried out centrally at the HPA every quarter. This process causes delays in 
accessing the data, and in this project meant that only one year’s worth of CABG surveillance data 
could be used. The data pertaining to January – June 2012 was requested; however as of 6th June 
2012 the first quarter of data from 2012 was still not available for local use. This represents a 
considerable delay in feedback of results at a local level and highlights a negative aspect of the 
national voluntary SSI surveillance run by the HPA. Efficient feedback demonstrates an advantage 
that local electronic surveillance could have over traditional surveillance systems. Despite limitations 
to the investigations that could be carried out, the quantity of data that was obtained for this project 
was sufficient to address the study question.  
 
9.1.3 Data Quality 
 
The final overarching issue relating to data in this project was that of the quality of NHS data. 
Different data types have inherent advantages and disadvantages which cannot be avoided and so 
part of this project was to address the utility of the administrative data in light of these expected 
limitations.  
 
Uniquely Identifying a Patient 
 
The first cause for concern relating to data quality in this project was the difficulty in determining 
whether an individual patient was in fact unique. This was twofold, with the potential for two 
patients to have the same identifiers, or for one patient to have multiple identifiers. NHS numbers 
are unique and assigned for life in England, and this variable is collected and stored by several of the 
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databases. In the local PAS data, approximately 20% of patients did not have an NHS number 
recorded and for this reason, other identifiers were needed to link patients between databases and 
produce the encrypted anonymised CIPM ID for research.  
At ICHNT patients are assigned a hospital identifier for their admission and should be re-used for any 
subsequent admissions. However, the trust consists of five hospitals and often a patient can have a 
different hospital number for each site. This causes problems in determining if a patient has been re-
admitted or transferred between the hospitals. The IT department is aware of this problem within 
the PAS system and has developed an algorithm for creating a genuinely unique patient identifier, 
therefore improving the quality of the data. This variable was not present on the extracts of data 
used for this project however.  
The CIPM ID was created using the hospital number and patient’s date of birth. The addition of date 
of birth served to reduce the likelihood that two different patients had been assigned the same 
CIPM ID, even if there were duplicate hospital numbers. On the other hand, this made the 
assumption that there were no errors in the recording of patient’s date of birth between databases 
and admissions. Variables such as address, postcode and name were not used as they were deemed 
to be too unreliable with potential misspellings and patients moving homes.  
This aspect of data quality had the potential to affect the results by underestimating the number of 
patients that were re-admitted, and thus classified as exposed to healthcare. For surgical site 
infections, this may have led to an underestimation of infections, as a patient who was re-admitted 
would not be picked up. Similarly, in instances of urinary tract infections prior admission to hospital 
within 48 hours of the current admission would classify patients as being exposed to healthcare. If a 
different ID was generated, then the estimates of exposure would be reduced. However, the rates of 
infections were not unexpectedly low and those patients classified as re-admission cases from 
tradition surveillance were also found to be re-admissions using administrative data. This suggests 
that the issue of unique identifiers did not cause any real inaccuracies in the analyses.  
 
Patient Administration System 
 
In the case of using diagnostic codes only, some concerns may be raised regarding the reliability of 
the assigned codes and the lack of distinctions in the codes between community and healthcare 
associated infections. A study found that the PPV of healthcare associated infection definitions 
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based on diagnostic data only (using ICD-9 codes) was only 20%, despite the sensitivity being similar 
to that of using clinical chart review (556). In Italy, it was found that the sensitivity of using 
administrative data only was as low as 10% for SSIs (495). On the other hand, a study by Bouam et al. 
found that an automated system (lacking clinical data) performed better than the traditional 
laboratory and clinical chart review surveillance in terms of sensitivity, specificity, PPV and NPV 
(574).   
A literature review on the sensitivity of microbiology based, administrative based and a combination 
of both confirms this lack of consensus in the literature regarding the efficacy of reduced definitions 
of HCAI (77). This review demonstrated that there did not appear to be a large advantage gained 
from using combined data sources (sensitivity range of 71-94.3%) versus solely microbiology data 
(sensitivity range of 63-91%) (77).  For administrative data only, the range was wider (59-96%) (77), 
only somewhat supporting conclusions from other papers that using solely administrative data is 
unreliable in HCAI surveillance (495, 556). A second review demonstrated a similar range of results 
for the sensitivity (65-94%) and specificity (72-99%) of electronic surveillance, but also highlighted 
the time saving benefits of this type of surveillance (80). 
In this project the sensitivity and specificity for identifying SSI following CABG using ICD-10 codes 
was 76.5% and 95.6%, respectively. This was similar for caesarean section patients, with a sensitivity 
of 61.1% and specificity of 97.7%. These values are consistent with those published by prior studies; 
although the PPV for using codes to identify SSI in caesarean patients was low at 28.2%.  However, 
this assumes that the HPA SSI and caesarean surveillance, to which the administrative data were 
compared, was accurate.  
The quality of PAS data can only ever be as good as the patient’s clinical notes and the interpretation 
of the coders that translate them. Presuming the coders follow the correct protocols and are trained 
to an appropriate standard, flaws in the data may be as much the fault of the clinical staff. This issue 
would remain if patient records were made electronic, unless stricter record keeping procedures and 
protocols were in place.  
 
Laboratory Data 
 
Laboratory data were received in two different formats, one originating from the back-up storage 
system and the other from the ‘live system’ (containing microbiology only). The data from these 
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distinct data storage systems were different not only in their structure, but also in the data content 
they stored; there were quality issues with both. A large portion of this project was spent re-
formatting and cleaning the laboratory data as the formats in which they were received was 
unusable for analysis. During this process I identified several problems within the data. The following 
three highlighted issues relate solely to the microbiology department’s data.  
The first difficulty in using the microbiology data for research purposes was the use of free text. The 
‘notes’ field contained information that could not be coded, for example stating that an infection 
was likely to be due to a catheter and would not be resolved without its removal. Information such 
as this is extremely useful when trying to generate rules for automated case finding, however the 
un-coded format and inconsistent use of language makes it hard to exploit without the use of 
complex free-text mining methods. In this free text column there were also patient identifiable 
details, where the microbiologist has used a patient’s name or date of birth in their entry. This poses 
a problem in using this variable for research outside of the NHS. The time to clean and remove this 
information prior to anonymisation is likely not worth the effort for the information gained.  
The second of these was missing data in the microbiology back-up storage dataset. Each 
microbiology culture has several pieces of information relating to it, including the sample origin (e.g. 
nose for MRSA swab, or catheter for a urine culture), any organisms, the quantification (i.e. colony 
count), any directly observed microscopy and whether it is to be repeated. All these elements can 
have more than one (with the exception of sample origin) result per culture and several cultures 
have results reported at multiple time points. However, a peculiarity of the data system causes 
corruption when the data are moved from the live system to the backup system. In the backup 
system only one record is ever retained for each of the result types, therefore a significant portion of 
information is lost during data migration (Figure 9.0). 
 
Figure 9.0: Hypothetical example of a corrupted urine culture record in the microbiology data 
*DIRMIC: directly observed microscopy; RBC: red blood cells; WBC: white blood cells 
Live system  Backup System 
Culture Result type Result Culture Result type Result 
Urine Sample Catheter Urine Sample Catheter 
Urine Repeat No Urine Repeat No 
Urine Culture Mixed growth, predominantly Urine Culture 
Mixed growth, 
predominantly 
Urine Culture E. coli Urine DIRMIC RBC <10/cm 
Urine Culture >100,00/ml 
Urine DIRMIC RBC <10/cm 
Urine DIRMIC WBC >50/cm 
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In the theoretical patient presented in Figure 9.0, the full microbiology results would indicate that 
this is a positive urine culture, with not only a high white blood count, but a significant colony count 
of E. coli despite some mixed growth. The patient in the backup system however would not be 
classified as having an infection as the positive indications of infection were lost during the data 
transfer; instead they appear to have mixed bacterial growth, no named organism and no white 
blood cell count result. This was particularly an issue in urine cultures as the standard definitions 
require colony counts to rule out contamination. In wound cultures, results are generally reported 
daily for up to five days, meaning that a result of ‘no growth’ on day one may appear negative but 
this is not necessarily the case at day five.  
To mediate this issue, I decided not to use any of the results from the back-up system (except the 
sample type). Instead binary variables of culture request were used in analyses which used this 
database system. Therefore, despite this limitation the data could still provide useful insights for 
surveillance as culture requests proved to be successful proxies for surgical site infections both in 
caesarean and CABG patients.  
The third concern specific to the microbiology data were the inability to uniquely identify which data 
corresponded to a single microbiology culture in the back-up data. As these data are stored in a long 
format (meaning there are several records for each test), all the records relating to a single culture 
needed to be identified. I used the date of sample collection and cultures type to distinguish 
between unique cultures in a patient. However, this method was inappropriate when multiple 
cultures of the same type were collected on the same day. Take MRSA screening swabs as an 
example. Two swabs are taken, one from the nose and one from the groin on the same day. In these 
cases, it was unclear which result belonged to which sample.  
The data obtained from the live system was presented in a more user friendly format, in which all 
the data relating to a single test could be identified. However, this only ever contains the most 
recent six months of data and only for microbiology. This meant that at any one time period during 
this project haematology, clinical biochemistry and complete microbiology data did not coincide. 
This limited investigations into causative organisms and how these could have affected markers and 
the potential for validation of the syndromic algorithms using laboratory confirmed infections.  
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Traditional Data Sources 
 
The main concern with data quality in the traditional data sources (cardiac registry, HPA SSI 
surveillance and caesarean surveillance) was data accuracy. Taking the HPA SSI surveillance and 
cardiac registry to begin with, a comparison of these datasets demonstrated that only 77% of 
patients were included in both sets. Furthermore, within these linked patients 12% had 
discrepancies in sex or date of surgery. In the caesarean cohort, 84% of the total potential patients 
were recorded by both the caesarean surveillance and PAS data, with the PAS data recording 80 
more patients than the surveillance.  
These inconsistencies and missing patients call into question the quality of information that was 
recorded at a local level. As these traditional data sources form widely reported statistics and are 
used to monitor trends in infection rates nationally, these sorts of data quality issues could impact 
policy recommendations and guidelines.   
As has been discussed in Chapters 4, 5 and 6, the use of SSI identified by the HPA SSI, cardiac registry 
and caesarean SSI surveillance as a ‘gold standard’ for the analyses needs to be interpreted with 
caution considering the demonstrable data quality issues. However, without performing a clinical 
validation exercise (such as chart review) these data constituted the best clinical reflection of the 
patients’ infection status. Inaccurate data had the potential to affect the results obtained in this 
thesis, as misclassifying patients with infection as not having infections and vice versa would have 
diluted the comparisons between these groups. However due to the nature of the research 
questioned being asked, the quality of the data being undetermined was an accepted risk.  
The caesarean SSI surveillance had several issues, the first being the lack of a standardised follow-up 
time. The community midwives had the discretion to determine when follow-up of the patient was 
completed. The average duration of follow-up was only 12 days, less than half the standardised 30 
day post-surgical surveillance used in the HPA protocol.  Along with the difficultly that was noted in 
collating all the post-discharge information from the midwives and GPs, the rate of infection was 
likely to be underestimated. Previous studies in the UK have shown infection rates as high as 11.9% 
(150, 526) and ranging between 2.9% - 17.9% (averaging 8.8%) (149). The SSI rate of 5.2% at 
Hammersmith Hospital falls within this range, but is on the lower end of the spectrum. This is 
consistent with the possibility that infections were missed.   
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9.2 Utility and Applicability 
 
Despite the expected limitations of working with routine data in a complex NHS environment, the 
scope for generating novel surveillance tools was still possible. Three types of surveillance tool were 
developed within the routine data: syndromic surveillance, automated case finding and risk scores. 
These tools had varying success depending on the patient groups investigated (Table 9.0).  
Classifying the tool as ‘successful’ or ‘unsuccessful’ was based on the relative strength of the results 
(e.g. AUC values or model fit) and the potential applicability of this surveillance method.  
 
Table 9.0: Summary of the success of the surveillance tools investigated in this thesis 
Patient Population Syndromic surveillance 
Automated Case 
finding Risk Modelling 
Urinary tract infections n/a √ √ 
Surgical site infections – CABG  √ n/a X 
Surgical site infections – Caesarean section X n/a X 
n/a: not investigated; √: successful; X: unsuccessful 
 
Syndromic Surveillance 
 
There can be several motivations for surveillance, either long term monitoring of patterns, 
investigating interventions, setting benchmarks or to provide early warning systems. In this case, 
developing syndromic algorithms for surgical site infection surveillance could have different 
applications. Firstly to generate alerts at an individual patient level, in order to inform timely 
treatment and support clinical care. Or for detecting and monitoring changes in infection rates at a 
population level over time.  
Syndromic surveillance in caesarean section patients was classed as unsuccessful. Despite the 
methodology working in principle, this patient group was not ideal due to lack of routine laboratory 
tests and short pre and post-operative lengths of stay. Caesarean section patients overall did not 
lend themselves to surveillance within the administrative data. In comparison to the CABG patients, 
they had relatively few microbiology culture requests, diagnostic imaging requests and blood tests 
sent to the laboratory with only 85% of patients having any sort of laboratory test during their entire 
stay. As most SSI following caesarean are detected in the community (149, 150), efforts would be 
better spent integrating primary care data with the hospital data.  
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There are examples in the UK where linkage of primary care data with hospital data has been 
implemented, two good examples being the Hampshire Health Record (529, 530) and 
comprehensive electronic patient records in Scotland (575, 576).  Both of these examples have 
demonstrated the potential for integrated patient records across primary, secondary and tertiary 
care and the potential for innovative surveillance for caesarean section patients in such systems 
could be greatly increased.  
Coronary artery bypass graft patients on the other hand have regular blood tests, a longer length of 
stay following their surgery and a clearer patient pathway. This made this patient group better for 
developing syndromic surveillance, as most patients had the relevant biological marker information 
available. Considering the high rate of surgical site infections that were observed over 2011 at 
Hammersmith Hospital (11%), and the duplicated, inefficient systems currently employed for 
surveillance, this makes a fitting patient population for such novel surveillance tools.  
The difference in utility of syndromic surveillance between caesarean and CABG patients could help 
to shape which patient groups are potential targets for automated, electronic surveillance. To 
demonstrate the benefits of using routine administrative data over traditional data sources for 
infection surveillance, the utility and applicability in a real world sense would need to be 
demonstrated.     
Syndromic surveillance has generally been used for early outbreak recognition in the past. In this 
setting, of surgical site infections, the concept of ‘outbreaks’ does not necessarily apply, however 
early infection detection in an individual with syndromic algorithms is plausible and could lead to 
improved clinical care. This could be a useful tool to have automated at the bedside, providing alerts 
of patients with a likely infection. Applying this algorithm in reality would need extra research and 
work, both in terms of the clinical utility and technical aspects.  
 
Automated Case Finding 
 
The automated case finding for healthcare associated urinary tract infections was successful. This 
was based on the comparisons of incidence and prevalence rates and the ability to this method 
within the routine data. With the recent implementation of surveillance for catheter associated 
urinary tract infections, as part of a national patient safety initiative (469), methods to embed and 
streamline this system would be welcome. The ‘safety thermometer’ utilises antibiotic prescribing 
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for the surveillance of catheter associated UTI and not positive microbiology. Using linked 
microbiology and PAS data to automate case detection for catheter associated UTI is possible and 
could provide opportunities to support active traditional surveillance. However, the laboratory data 
as it is currently stored would struggle to produce any usable outputs without considerable 
restructuring. In this project, I focussed on HCA UTI as they were the most prevalent healthcare 
associated infection at ICHNT; however the principle of automated detection could have wider 
applications in infection surveillance.  
 
Risk Modelling and Score Creation 
 
Of the three risk models that I generated, one was a success in terms of practical utility, with a 
reasonable model fit in both the development and validation datasets. The two models for surgical 
site infections, in CABG and caesarean section patients on the other hand, performed poorly. When 
validated and a simplified risk score created, the two scores were ineffective at distinguishing 
between a patient with a code for an SSI and a patient without. However, this has formed a basis 
from which improved scores could be built upon as more databases become available for research.  
The risk score for HCA UTI had a reasonable performance and could be automated in routine data. 
However, in the absence of an electronic patient record system, it could not be automated in real 
time. As ICD-10 codes are only assigned in the PAS data at discharge, a patient’s risk of developing 
an HCA UTI cannot be quantified automatically during their stay. With an electronic patient chart, 
risk factors would be available real time and therefore a risk score could be responsive to changes in 
a patient’s circumstance. Based on the systematic literature review, these were the first risk scores 
created for surgical site infections and HCA urinary tract infections using routine electronic NHS 
data.  
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9.3 Recommendations and Further Work 
 
Based on the analyses carried out and experience of working with local routine administrative 
hospital data, I have several recommendations and suggestions for further work to support these.   
The first recommendation is to re-structure the local laboratory data and ensure the system for 
backing up this information is functioning correctly. Within the linked data warehouse, changing the 
structure of the data could be widely beneficial, removing duplicate information and ensuring single 
cultures are uniquely identifiable. With the microbiology data organised more effectively, the 
practicalities of running automated case finding and syndromic surveillance could then be 
addressed.  
The second recommendation is to implement a single, integrated and linked surveillance system for 
surgical site infections following CABG procedures. Taking the advantages post-discharge HPA SSI 
surveillance and combining this with the extensive information that is collected by the cardiac 
registry would produce an effective surveillance system. Linking this to the patient administration 
system would increase the completeness and could help to introduce internal validation. The cardiac 
registry database can be customised and altered at a local level (e.g. including additional variables), 
making it a good database on which to base an integrated system. There is already local support for 
this change to be made from the cardiac surgery department.   
The third recommendation is to investigate the potential for streamlined surveillance in other 
disciplines, such as orthopaedics. This surgery also has a national registry and mandatory HPA SSI 
surveillance and therefore the analyses performed on CABG patients could be emulated for this 
patient group. This research could demonstrate whether the discrepancies and duplications 
between data sources were unique to CABG procedures or widespread amongst national registries 
and national infection surveillance schemes.  
The fourth recommendation is to add obesity as an essential comorbidity to be recorded for all 
patients. Of all the information that was desired but not available in this project, this variable was 
the most important. Including this information routinely, either as an ICD-10 code or as a separate 
variable of BMI in the PAS system could add to the predictive power of the data held routinely in the 
NHS.  
The fifth recommendation is to enhance and complement the local surveillance of catheter 
associated UTI as part of the ‘safety thermometer’ using automated cases detection based on linked 
PAS and microbiology data. This could add information at a local level, such as patterns in organisms 
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and the types of antibiotic prescribed. This links to a further recommendation of making antibiotic 
prescribing data electronic. If this was implemented, then the surveillance of catheter associated UTI 
could be completely automated, saving time and money, as well as introducing the potential uses of 
this data source for syndromic surveillance.  
I also have several suggestions for further work that could build on that presented in this thesis and 
provide further insight into the use of routine NHS data for healthcare associated infection 
surveillance.  Based on the understanding that certain limitations experienced in this project had 
been resolved, I would recommend the following:  
 Investigate the utility of the ‘Theatre Man’ database for surveillance for surgical site 
infections, looking specifically at the potential for real-time intra-operative risk monitoring 
and the variables being stored to enhance predictive models.  Also, investigate the utility of 
the accident and emergency data for improving the recording of re-admission. This could 
impact on the accuracy and efficacy of innovative surveillance tools.  
 
 Trial the use of procalcitonin as a marker for surgical site infections in CABG patients and 
compare the accuracy of this single test with the syndromic algorithms presented in this 
project. Prior studies have shown procalcitonin to be highly sensitive to bacterial infections 
and not to act as a general marker of inflammation. Therefore this marker could increase the 
sensitivity and specificity of syndromic algorithms for infection detection.  
 
 Investigate the potential for alerts to be generated at the patient’s bedside for early 
diagnosis of surgical site infections, based on patterns of markers and proxies of infection.  
This thesis demonstrated mixed results on the temporal advantages of syndromic 
algorithms; therefore a more formal assessment needs to be conducted. The clinical utility 
and acceptability to the ward staff would also need to be investigated before any novel 
surveillance tools are implemented.   
 
 Explore the possibility of linking hospital records with primary care data, specifically 
targeting information relating to antibiotic prescriptions in surgical patients. Caesarean 
section patients would make a good patient group in which to investigate the potential for 
automated post-discharge surveillance based on primary care data. The ease with which this 
could be done, in terms of technical processes and the ethical and organisational 
implications would need to be investigated.   
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Conclusion of Thesis 
 
 
The hypothesis for this project was that existing routine electronic hospital data can be used more 
effectively to create innovative surveillance tools for healthcare associated infections. Through 
conducting this research study, I conclude that the hypothesis can be accepted, but with caveats.  
Whilst in principle, the answer to the thesis title is ‘yes, routine data can be exploited for 
surveillance of healthcare associated infections’.  In reality, the practicalities mean that the answer 
must be ‘not immediately’. The technical, organisational and practical challenges encountered 
throughout the project limit the real world application of such surveillance tools in the current NHS 
environment.  However, with improved database linkage and concerted efforts in enhancing routine 
data quality, the application of automated case finding, syndromic algorithms for clinical support 
and dynamic risk stratification should be feasible. 
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Abstract: 
Multiple national and local data sources collected by healthcare systems across Europe contain 
information regarding coronary artery bypass grafts (CABG). Currently surveillance for surgical site 
infections (SSI) in this patient group is voluntary in the UK. We aimed to investigate and compare the 
currently available data sources in England for SSI surveillance in CABG patients.  
We took local data extracts of the National Cardiac registry, the Health Protection Agency SSI 
surveillance and the patient administration system (PAS). These data were deterministically linked 
using patient identifiers and then anonymised. We performed a descriptive analysis of the data.      
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From 1st January 2011 – 30th June 2011, 306 patients were recorded in at least one dataset as having 
undergone CABG. Of these, 76% were recorded by all three data sources being investigated. Of the 
discordant patients, 5% were recorded by both the local cardiac registry and PAS and 18% by both 
the HPA surveillance and PAS. A total of 28 surgical site infections were recorded, of which 21% were 
identified by all the data sources.  
Currently, the databases which collect and store data relating to CABG patients suffer from 
duplications and discrepancies. We would recommend integration of the discordant systems, to 
create a streamlined, sustainable electronic surveillance system.  
 
Introduction: 
Coronary artery bypass grafts (CABG) remain one of the most commonly performed surgical 
procedures, with 114,300 procedures carried out in England between 2003 and 2008 (1). Post-
surgical wound infection rates for this procedure range from 0.49% - 18.8% (2-5), with the surgical 
site infection (SSI) rate in the UK specifically being 4.4% (6).  
Surgical site infection surveillance is routinely carried out across Europe and the USA (7, 8). In the 
UK, certain orthopaedic procedures have mandatory surveillance with public reporting, however for 
CABG the surveillance is voluntary (9).  In its current form, the surveillance data are collected in a 
paper format and periodically submitted to the Health Protection Agency (HPA) for cleaning, 
processing and dissemination. This system entails a large amount of time and effort, usually from 
the Infection Prevention and Control team, and has a long time delay between data collection and 
feedback.  
The National Cardiac Registry in the UK collects copious amounts of information about CABG 
surgeries. Despite submission of data to the National Cardiac Registry being close to comprehensive, 
it has been acknowledged that reporting of post-operative complications can have up to 15% 
missing data (10). Re-operation, for which one of the indications is a deep sternal wound infection, 
showed an SSI incidence of 0.5% in 2008, however this variable had 14% missing data (1).   
The UK is not alone in having a long running, widely used Cardiac Registry and national initiatives for 
surgical site infection surveillance. The National Cardiovascular Data Registry (NCDR) in the USA has 
been established since 1997 (www.ncdr.com), considerably shorter than the UK register maintained 
by the Society for Cardiothoracic Surgeons since 1977 (www.ic.nhs.uk). According to Taylor (11), 
Sweden and the UK are the only two countries worldwide with all centres reporting to a national 
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cardiology registry. The Swedish register is now completely electronic and has been linked to other 
national data sources, allowing for long term patient follow-up (11). This registry, like that in the UK, 
collects data on post-operative complications and specifically re-operation for mediastinitis (12, 13).   
Hospitals consistently collect and store a wealth of administrative data, including information on 
admissions, microbiology, diagnoses and procedures (14). Even though this wealth of data has not 
been widely exploited for the support of healthcare associated infection surveillance, integrative 
approaches towards the more effective use of administrative data are being pioneered (14-16). 
Utilising SSI surveillance data, alongside cardiac registry data and administrative hospital data allows 
a unique opportunity to investigate these data sources for sustainable SSI surveillance. We aimed to 
assess the current data sources available within the English NHS which relate to CABG patients, to 
evaluate their potential for surgical site infection surveillance.   
 
Methods: 
This study was carried out Imperial College NHS Healthcare Trust (ICNHT), a group of hospitals with 
1,540 beds. Ethical approval for the use of linked anonymised local patient data for research was 
granted by St. Mary’s Research Ethics Committee [REC: 09/H0712/85].  
We used three data sources in this study: the National Cardiac Registry, the voluntary HPA SSI 
surveillance data and local administrative hospital data from the patient administration system 
(PAS).  
The Health Protection Agency surgical site infection surveillance data were collected weekly by 
Infection Prevention and Control (IPC) nurses. The data collection followed a standardised national 
protocol which has been previously described (17) and is available from ww.hpa.org.uk. These data 
are submitted quarterly to the HPA through an online reporting system, where it is cleaned, collated 
and then reported back to individual hospitals. As part of the standard protocol, 30 day post-surgical 
follow up is carried out, with patients contacted and asked to fill in a post discharge questionnaire 
relating to wound infections. In this study, we used a local extract of the HPA surveillance data once 
it had undergone the cleaning process performed by the HPA.  
The National Cardiac Registry data are collected and reported by cardiac surgeons, and all hospitals 
in the UK which perform cardiothoracic surgery submit data. Data are collected and stored locally on 
a specialised cardiac database system and then uploaded to a central data-repository (CCAD) which 
is part of the NHS Information Centre. The data are cleaned at this stage and an anonymised form is 
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linked to the Office of National Statistics (ONS) data on mortality (1).  In this study, we used a local 
extract of the cardiac registry data; this extract had not undergone any cleaning or data-checks 
according to the standard methods used by the CCAD.  
The patient administration system (PAS) contains information on patient admissions, discharge 
diagnoses and procedures during their stay. This system feeds into the national Hospital Episode 
Statistics (HES) dataset, which is used widely for research purposes, and is made up of administrative 
data from all hospitals in the UK.  Procedures are recorded as Operation and Procedure Codes 
(OPCS) version 4.4, and discharge diagnosis codes are recorded using the International Classification 
of Diseases version 10 (ICD-10). Patients who had undergone CABG were classified as those with any 
of the following OPCS codes: K40, K41, K42, K43, K44 and K45.   
The HPA surveillance, local cardiac registry and PAS data were deterministically linked using NHS 
number, a local hospital identifier and the patient’s date of birth. For patient’s that did not link 
based on these criteria we then looked at their date of admission, date of surgery and gender in 
attempt to validate these patients as separate individuals. The data extracts covered all coronary 
artery bypass graft surgeries carried out between the 1st January 2011 and 30th June 2011 at ICNHT.  
We performed descriptive analysis on the data from the different databases. Sensitivities, 
specificities, positive predictive values and negative predictive values were calculated for the cases 
of surgical site infections diagnosed from the different data sources. All analyses were carried out 
using Stata SE 11.  
 
Results:  
A total of 306 patients were recorded as having undergone coronary artery bypass graft surgeries 
between the 1st January 2011 and the 30th June 2011. Of these patients, 76% (232) were recorded by 
all three databases we investigated. Figure 1 demonstrates how many patients were identified by 
the different databases and how they overlap. The patient administration system documented the 
most patients, with 303 of the 306 patients having a record. The fewest patients were recorded by 
the local cardiac registry, which contained 249 patients (82%).   
The variables collected by both data sources can be split into themes, with varying levels of detail 
associated to the different data sources (Table 1). All the databases collected information relating to 
patient demographics, but there was a discrepancy in gender for 2% of the patients which occurred 
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in all three databases. The date of surgery was recorded for all patients in all the databases, but 8% 
of those patients with data in all three databases had incongruities in this variable.  
 
Table 1: Summary of the Variables Collected by  the HPA surveillance, cardiac registry and PAS systems 
Variables collected HPA Surveillance  
Cardiac 
Registry  PAS 
Patient Information (identifiers, age and sex) +++ +++ +++ 
Patient History (risks, co-morbidities & operative history) + +++ +++ 
Pre-operative features (drug administration & support) + ++ + 
Operative features (surgeons, type, duration & technical details)  ++ +++ + 
Post-operative complications (SSI, stroke, renal complication, death) ++ ++ ++ 
+ Less than 25% of the potential variables collected by all the databases; ++ Between 25 – 75% of the potential 
variables collected by all the databases; +++ Over 75% of the potential variables collected by all the databases. HPA: 
Health Protection Agency; PAS: Patient Administration System 
 
In order to compare surgical site infections in the PAS database, the codes for SSIs needed to be 
assessed first. All those ICD-10 codes identified as relevant to SSI are presented in Table 2.  
 
Table 2: ICD-10 codes assessed for detecting surgical site infections following Coronary Artery Bypass Graft 
ICD-10 Code Definition 
→ T813* Disruption of operation wound, not elsewhere classified 
→ T814    Infection following a procedure, not elsewhere classified 
     T826 Infection and inflammatory reaction due to cardiac valve prosthesis 
→ T827 Infection and inflammatory reaction due to other cardiac / vascular device, implant and grafts 
     T857 Infection and inflammatory reaction due to other internal prosthetic device / implant and graft 
     Y83* Surgical operation and other surgical procedures as the cause of abnormal reaction of the 
patient, or of later complication, without misadventure as the time of procedure 
     Y840 Cardiac catheterisation, as the cause of abnormal reaction of the patient or of later complication 
*These are to be used in combination with the following ICD-10 codes: B95 (streptococcus & staphylococcus as 
the cause of diseases classified to other chapters); B96 (Other specified bacterial agents as the cause of diseases 
classified to other chapters); B97 (Viral agents as the cause of diseases classified to other chapters). → Indicates 
codes we used to extract SSI from the PAS data. ICD-10: International Classification of Diseases version 10. 
 
These ICD-10 codes were compared to those SSI diagnosed by the HPA surveillance and local cardiac 
registry. The combination of T813 or T814 or T827, had a sensitivity of 74.3% and specificity of 96.3% 
and an area under the Receiver Operating Characteristic (ROC) curve of 0.86. This set of codes was 
used to extract surgical site infection cases from the PAS data. Including either Y83 or Y840 reduced 
the sensitivity for detecting patients with SSI according to the HPA surveillance and local cardiac 
registry data and T826 and T857 were not assigned to any patients in this study and were thus not 
assessed further. 
A total of 28 surgical site infections were diagnosed in inpatients by the three databases, giving a 
prevalence of 9.2% when combining all three databases. The HPA surveillance data in isolation 
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produced a prevalence of 6.6% for inpatient infections; this increased to 11.6% when considering 
post-discharge infections. Figure 2 illustrates the number of surgical site infections diagnosed by 
different databases and how they overlap.  The local cardiac registry diagnosed the fewest SSI, with 
only eight infections; the HPA surveillance and PAS data diagnosed 20 and 23 infections, 
respectively. Of the six infections diagnosed by all the databases, one was superficial, three were 
deep and two were organ space infections.    
 
   
 
 
The local cardiac registry collected information on SSI, either with the binary ‘sternal wound 
infection’ variable or through a reoperation variable, with deep sternal wound as a reason for 
reoperation. The cardiac registry data had a sensitivity of 43% and specificity of 98%, when 
considering organ space infections only.  
The statistical process control chart (Figure 3), demonstrates the number of SSI and CABG patients 
according to the PAS data, from January 2009 to the end of June 2011. The average number of 
infections per month across this time period was 7.6% and there were no months which exceeded 
the control limits.  
 
 
 
HPA Surveillance 
Data: 2
[Total 290]
PAS Data: 
[Total 303]
Cardiac Registry 
Data:
[Total 249]
HPA Surveillance 
Data: 3
[Total 20]
PAS Data: 8 
[Total 23]
Cardiac Registry 
Data: 0
[Total 8]
Figure 1: Number of patients recorded as 
having a CABG 
Figure 2: Number of patients recorded as 
having an inpatient SSI following CABG 
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Discussion: 
In creating a dataset which has linked the standardised HPA surveillance data and the cardiac 
registry data we have been able to highlight the overlap in data collected by these datasets, along 
with the discrepancies in data recorded.  The duplication in data between the cardiac registry and 
HPA surveillance data relates not only to the basic administrative information, but to surgical 
features and surgical site infections. Alongside this, the comparison of these purposeful, traditional 
data sources to the administrative data demonstrates the potential inconsistencies between rates 
that are publicly reported and those data which are used for financial, organisational and research 
purposes. There are several factors which warrant discussion before any recommendations 
regarding the creation of a streamlined, sustainable and continuous method for SSI surveillance 
following CABG can be made.  
Important facets of data quality include the coverage (i.e. the number of patients and variables 
included), the completeness (i.e. missing data) and the validity (i.e. the data collected is correct). 
This study has found that there were questions concerning the validity of certain data. In some of 
the variables that were collected by multiple databases, such as date of surgery or gender, we found 
discrepancies. Some level of error is to be expected when data collection is in a paper format and 
involves single manual entry. However in the case of variables that are routinely collected 
electronically, inconsistencies could be reduced or removed by linking to the available 
administrative data.  
0%
5%
10%
15%
20%
25%
SSI prevalence Average
Upper Natural Process Limit Lower Natural Process Limit
Figure 3: Statistical Process Control Chart of SSI diagnosed with ICD-10 codes within PAS 
data, January 2009 – June 2011 
Start of HPA surveillance  
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In terms of coverage, there were inconsistencies seen in the patients that were picked up by the 
databases, with almost a quarter of those patients captured being present in only two of the three 
databases. It is possible that some of the patients were double reported as different patient 
identifiers were used for one patient. However when we attempted to link the patients further 
based on dates of admission and surgery, it was not possible to make any additional matches. The 
HPA surveillance data are collected by Infection Prevention and Control nurses, whereas the local 
cardiac registry data are collated by the cardiac surgeons. It is likely that they are obtaining their 
information from disparate sources, such as patient notes versus direct observation. However, an 
incongruity of 24% remains disturbing. Implementing a streamlined system would have the 
potential to flag data quality issues regarding coverage, between the different databases.   
Conversely, the cardiac registry demonstrated the highest coverage in terms of variables collected. 
The one area in which the cardiac registry collected fewer variables than the HPA surveillance was 
that of surgical site infections, notably the absence of post- discharge surveillance. 
This paper is specifically interested in surgical site infections, and we have highlighted the variation 
between the numbers of cases of SSI diagnosed by the various data sources.  The rate was relatively 
high compared to the national SSI rate of 4.4% (6); however the rate of inpatient infections fell to 
3.1% in the second half of the year with the implementation of a multidisciplinary improvement 
programme lead by the cardiac surgeons.  
It was not surprising that the cardiac registry does not pick all cases of SSI as it lacks post-discharge 
surveillance, however the converse was unexpected. Active prospective case finding is generally 
regarded as the ‘gold standard’, in terms of surveillance, but in this case we saw that 29% of the 
possible 28 SSI were not recorded by the HPA active clinical surveillance. This could be a reflection 
of the quality of the clinical coding, as PAS reported the most SSI. However, prior studies have found 
administrative codes to have high sensitivities for diagnosing surgical site infections, with one study 
of CABG patients reporting a sensitivity of 86.4% (18). Similar findings have been found relating to 
other surgical procedures, such an 87.5% sensitivity in breast reconstruction (19). A study relating to 
orthopaedic surgeries actually found that routine diagnosis codes were more sensitive to identifying 
true surgical site infections (as established by patient chart review) than the traditional surveillance 
(20).  
Much of the difference in SSI recorded by the HPA surveillance and the cardiac registry or PAS, is due 
to the active post-discharge surveillance once the patients have been discharged from the hospital. 
There is a huge amount of added value of having the post-discharge surveillance, with previous 
studies reporting that up to 67% of post-CABG infections occur within the community (21, 22). The 
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post-discharge surveillance carried out as part of the HPA surveillance was performed by Infection 
Prevention and Control and is a time consuming activity. However, in this study the active case 
finding from the community caused the SSI prevalence to increase by 5%, as 43% of the SSI 
diagnoses by the HPA surveillance were post-discharge. The standardised practice of using a 30 day 
cut off for patient follow up is questionable despite being adopted by most surveillance 
programmes. A study found that 32% more cases of SSI in CABG patients would be identified if 
patients were followed up for 60 days instead of 30 days (23). This would suggest that long term 
follow up of patients using administrative hospital data, in combination with an element of active 
post-discharge surveillance would be an efficient and accurate method for identifying SSI following 
CABG. 
The manners in which the cardiac registry and the HPA surveillance data are collected and stored 
differ. The cardiac registry is an electronic system, whereas the HPA surveillance data, despite 
having an electronic online submission tool, is collected in a paper format and then manually 
entered to a local database. This traditional form of surveillance is time consuming in comparison to 
an electronic data collection system. However, the HPA surveillance is currently limited by the fact 
that it is a nationally standardised system for data collection, making local innovations difficult. 
Added to this, the criteria for SSI diagnosis used involve a clinical assessment of the patient, 
information which is not currently available electronically at a local level, such as post-operative 
antibiotics. These two elements relating to the collection and dissemination of the HPA surveillance 
data make it difficult to adapt to an automated system whilst using the current methodology. 
Once the data has been collected and processed, the cardiac registry and HPA surveillance both have 
reporting of pooled results, at a hospital level. Surgical site infection surveillance in the UK is 
reported regularly and available online (www.hpa.org.uk). The National Cardiac Registry also publicly 
disseminates results, which demonstrated a decrease in mortality following surgery in accordance 
with the public reporting of mortality data (24); however these reports are not published annually.  
Despite both the cardiac registry and HPA publishing information online, the rate of surgical site 
infections  following CABG are not directly comparable as they stand.  
Currently in Sweden, the National Cardiac Registry (SWEDEHEART) has gained the ability to link 
other national data sources such as information on hospital admissions and deaths (11). This 
development allows for the long term follow up of patient outcomes; however it is still in its infancy.  
In the UK, this would also be possible, with electronic Hospital Episode Statistics collected for every 
patient and stored electronically.  
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Conclusion and recommendations: 
The current overlap in data collection for CABG patients suggests that a more streamlined approach 
could be taken for information gathering, storage and dissemination in this patient group. We have 
shown that by harmonising the HPA surveillance, the National Cardiac Registry and the hospital 
patient administration system, improvements in the data coverage and validity can be achieved. 
Current trends in the surveillance of surgical site infections are moving towards better use of existing 
electronic data to support and enhance traditional surveillance and there is potential here for this to 
be done. Based on this study and previously reported conclusions (25), we would recommend 
adopting an integrated electronic surveillance system, exploiting the advantages of the different 
databases. The potential for automated electronic linkage to the patient administrative system and 
the ability to update and support the cardiac registry database at a local level provide a good 
opportunity for embedding sustainable surveillance.  Integrating the surgical site infection data 
collected by the Infection Prevention and Control team, namely the post-discharge follow up of 
patients, would further improve efficiency. Insights from this work could lead to a viable and 
continuous electronic surveillance system for surgical site infections in cardiac patients, and offer 
valuable lessons for the development of EU wide cardiac surgery SSI surveillance. 
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Appendix 4: Point Prevalence Survey Extra Data Collection Form (Chapter 4) 
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Appendix 7: Markers Excluded from Syndromic Algorithm Creation (Chapter 5) 
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Appendix 8: HCA UTI Risk Modelling (Chapter 8) 
 
Table I: Summary of the Normality of Continuous Variables 
Variable (transformation) Skewedness Kurtosis 
Age  -0.209 1.936 
Length of stay 5.994 65.82 
Length of stay (Sqrt) 2.443 12.00 
Creatinine 3.734 19.49 
Creatinine (Inverse) -0.304 3.040 
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Table II: Multivariate analysis results for risks of HCA UTI with an inclusion threshold of 5% 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 2.180 (0.767) 0.167 0.000 1.877, 2.533 
Catheter 6.209 (1.836) 1.180 0.000 4.277, 9.012 
Any procedure 0.604 (-0.505) 0.051 0.000 0.512, 0.712 
Non-elective admission 2.509 (0.920) 0.355 0.000 1.901, 3.311 
Neurological disease 1.390 (0.330) 0.134 0.001 1.151, 1.678 
Admission from healthcare 0.708 (-0.345) 0.114 0.032 0.517, 0.970 
Age:                   <30 years  
                           >75 years 
1.380 (0.322) 
1.808 (0.592) 
0.202 
0.140 
0.028 
0.000 
1.036, 1.839 
1.553, 2.104 
Length of stay: 7-14 days 
                           14-21 days 
                           21-28 days 
                           >28 days 
1.513 (0.414) 
2.257 (0.814) 
2.745 (1.010) 
4.500 (1.504) 
0.153 
0.271 
0.394 
0.469 
0.000 
0.000 
0.000 
0.000 
1.241, 1.845 
1.784, 2.856 
2.072, 3.638 
3.668, 5.518 
Creatinine:       No creatinine test 
                           >110 
0.779 (-0.249) 
1.450 (0.372) 
0.088 
0.128 
0.028 
0.000 
0.624, 0.973 
1.220, 1.723 
CPG:                 2: Surgery & Cancer 
                          3: Specialist services 
                          4: Circular and renal 
                          5: Women & Children 
0.736 (-0.307) 
0.359 (-1.024) 
0.559 (-0.582) 
0.373 (-0.986) 
0.081 
0.055 
0.069 
0.133 
0.005 
0.000 
0.000 
0.000 
0.593, 0.912 
0.267, 0.483 
0.483, 0.713 
0.260, 0.536 
Diabetes:         Type 1 
                          Type 2 
1.742 (0.555) 
1.341 (0.293) 
0.488 
0.119 
0.048 
0.001 
1.005, 3.016 
1.127, 1.594 
Constant -4.761 0.212 0.000 -5.176, -4.346 
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Table III: Multivariate analysis results for risks of HCA UTI with an inclusion threshold of 10% 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 2.148 (0.765) 0.165 0.000 1.850, 2.498 
Catheter 6.194 (1.824) 1.178 0.000 4.267, 8.992 
Any procedure 0.603 (-0.505) 0.051 0.000 0.512, 0.712 
Non-elective admission 2.514 (0.922) 0.356 0.000 1.904, 3.318 
Neurological disease 1.392 (0.331) 0.134 0.001 1.153, 1.681 
Admission from healthcare 0.703 (-0.352) 0.113 0.029 0.513, 0.964 
Age:                   <30 years  
 
                           >75 years 
1.494 (0.401) 
1.212 (0.192) 
2.004 (0.695) 
0.229 
0.128 
0.194 
0.009 
0.069 
0.000 
1.105, 2.018 
0.985, 1.490 
1.658, 2.424 
Length of stay: 7-14 days 
                           14-21 days 
                           21-28 days 
                           >28 days 
1.507 (0.410) 
2.233 (0.803) 
2.714 (0.999) 
4.440 (1.491) 
0.153 
0.268 
0.390 
0.463 
0.000 
0.000 
0.000 
0.000 
1.234, 1.837 
1.765, 2.826 
2.048, 3.598 
3.619, 5.448 
Creatinine:       No creatinine test 
                           >110 
0.779 (-0.250) 
1.434 (0.361) 
0.088 
0.126 
0.027 
0.000 
0.624, 0.973 
1.207, 1.704 
CPG:                 2: Surgery & Cancer 
                          3: Specialist services 
                          4: Circular and renal 
                          5: Women & Children 
0.740 (-0.301) 
0.362 (-1.014) 
0.564 (-0.572) 
0.392 (-0.936) 
0.081 
0.055 
0.070 
0.073 
0.006 
0.000 
0.000 
0.000 
0.597, 0.918 
0.269, 0.488 
0.442, 0.720 
0.272, 0.565 
Diabetes:         Type 1 
                          Type 2 
1.804 (0.590) 
1.317 (0.276) 
0.506 
0.117 
0.035 
0.002 
1.041, 3.127 
1.106, 1.568 
Constant -4.848 0.218 0.000 -5.275, -4.421 
 
Table IV: Model testing statistics for HCA UTI 
Dataset Hosmer-Lemeshow chi2 (p-value) C-statistic 
Cut-off of 0.05 
2009 – Development 14.31 (0.0740) 0.7928 
2010 – Validation 20.19 (0.0096) 0.7696 
Cut-off of 0.10 
2009 – Development 14.30 (0.0742) 0.7930 
2010 – Validation 19.12 (0.0142) 0.7702 
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Appendix 9: SSI following CABG Risk Modelling (Chapter 8) 
 
Table I: Summary of the Normality of Continuous Variables 
Variable (transformation) Skewedness Kurtosis 
Age  -0.5066591 2.938244 
Length of stay pre-CABG 3.695032 22.08842 
Length of stay pre-CABG (Sqrt) 1.800379 6.611993 
WBC pre-CABG 23.49594 633.9601 
WBC pre-CABG (1/sqrt) 0.2786125 5.552849 
INR pre-CABG 12.027 177.212 
INR pre-CABG (1/cubic) -0.4069776 4.615366 
Albumin pre-CABG -0.6851503 3.943001 
Haematocrit pre-CABG -0.3502014 2.842245 
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Table II: Multivariate analysis results for risks of SSI following CABG using a significance threshold of 0.01 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 3.728 (1.316) 1.386 0.000 1.799, 7.727 
Albumin pre-CABG: <33 3.307 (1.196) 1.309 0.003 1.522, 7.186 
Constant -4.514 0.581 0.000 -5.652, -3.375 
 
Table III: Multivariate analysis results for risks of SSI following CABG using a significance threshold of 0.05 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Sex 3.424 (1.231) 1.294 0.001 1.632, 7.183 
Albumin pre-CABG: <33 3.077 (1.124) 1.236 0.005 1.401, 6.760 
Other Infection 3.306 (1.196) 1.657 0.017 1.238, 8.831 
Constant -4.522 0.591 0.000 -5.680, -3.365 
 
Table IV: Model testing statistics for SSI following CABG, at a cut-off of 0.01 
Dataset Hosmer-Lemeshow chi2 (p-value) C-statistic 
1% 
2009 – Development 1.10 (0.5766) 0.6820 
2010 – Validation 0.73 (0.3943) 0.4995 
5% 
2009 – Development 0.19 (0.9111) 0.7068 
2010 – Validation 0.60 (0.7396) 0.5234 
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Appendix 10: SSI following Caesarean Section Risk Modelling (Chapter 8) 
 
Table I: Summary of the Normality of Continuous Variables 
Variable (transformation) Skewedness Kurtosis 
Age  -0.2415178 2.89608 
Length of stay pre-caesarean 9.130872 122.2298 
Length of stay pre-caesarean (Sqrt) 2.229198 11.51901 
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Table II: Multivariate analysis results for risks of SSI following caesarean section at a significance threshold of 
0.01 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Length of stay: >4 days 2.999 (1.098) 1.219 0.007 1.352, 6.651 
Married 0.431 (-0.842) 0.138 0.009 0.230, 0.808 
Constant -3.386 0.212 0.000 -3.802, -2.970 
 
Table III: Multivariate analysis results for risks of SSI following caesarean section at a significance threshold of 
0.05 
Risk Variable Odds ratio (coefficient) SE P-value 95% CI 
Length of stay: >4 days 2.999 (1.098) 1.219 0.007 1.352, 6.651 
Married 0.431 (-0.842) 0.138 0.009 0.230, 0.808 
Constant -3.386 0.212 0.000 -3.802, -2.970 
 
Table IV: Model testing statistics for SSI following caesarean section 
Dataset Hosmer-Lemeshow chi2 (p-value)2 C-statistic 
Cut-off of 0.01 
2009 – Development 
2010 – Validation  
0.03 (0.8531) 
0.17 (0.6812) 
0.6453 
0.5609 
Cut-off of 0.05 
2009 – Development  
2010 – Validation 
0.03 (0.8531) 
0.17 (0.6812) 
0.6453 
0.5609 
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Appendix 11: Conference Abstracts and Planned Papers 
 
Presentations: 
King C, Aylin P, Holmes A, Thomas C, McCabe I, Chukwuemeka A, Garcia Alvarez, L (2012). 
“Developing electronic syndromic surveillance for surgical site infections: an example of coronary 
artery bypass graft patients.” HPA, Warwick 
King C, Garcia Alvarez L, Hasnat R, Johnstone C, Holmes A, Aylin P (2011). “Use of routinely collected 
hospital data to develop innovative prediction models for Healthcare Associated Infections.” IPS, 
Bournemouth 
King C, Hasnat R, Garcia Alvarez L, Holmes A, Aylin P (2011). “Linking of routine administrative 
databases within an English Academic Health Science Centre to support the creation of a syndromic 
surveillance tool for healthcare associated infections.” SHIP, St. Andrews 
 
Posters: 
King C, García Álvarez L, Hasnat R, Holmes A, Aylin P (2011). “Developing proxy indicators of 
healthcare associated infections to support syndromic surveillance in a UK Academic Health Science 
Centre.” ICPIC, Geneva  
King C, Aylin P, Holmes A, Thomas C, McCabe I, Chukwuemeka, Garcia Alvarez, L (2012). “Utilising 
routine electronic data to develop syndromic surveillance for surgical site infections in coronary 
artery bypass graft patients.” ICAAC, San Francisco [Unable to attend] 
 
Planned Papers: 
Risk score creation for healthcare associated urinary tract infections, using routine electronic 
administrative health data. 
Syndromic algorithms for the surveillance of surgical site infections: an example in coronary artery 
bypass graft patients  
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